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How does the advance in science happen? Is it a sudden phenomenon like an unex-
pected illumination or a result of collective addition of many small facts?
This book is based on the 8th Takao International Symposium on Molecular 
Mechanism of Cardiopulmonary Disease—New Insight into the Development of 
Pulmonary Circulation and Ductus Arteriosus—in October 2017 in Matsue, Japan.
The Takao International Symposium was first held in 1978 by Dr. Atsuyoshi 
Takao who was a professor and the chief of Pediatric Cardiology at the Heart Institute 
of Japan in Tokyo Women’s Medical University from 1972 to 1990 (passed away on 
August 8, 2006, at the age of 81). In the 1970s, Dr. Takao wanted to facilitate basic 
science in pediatric cardiology by holding international conferences, putting 
researchers together in a small place, and letting them discuss the etiology of con-
genital heart diseases (CHD). Since the success of the first symposium, it has been 
held every 4–5 years and after he passed away, twice in recent 5 years. The proceed-
ing books were published after each symposium in 1980, 1984, 1990, 1995, 2000, 
2005, 2015, and this time in 2020. It is amazing that so much advance in science has 
been accomplished since the first Takao symposium, with path-breaking changes 
occurring in fields ranging from experimental teratology to molecular biology.
At this time of the 8th Takao symposium, we, organizers, thought that it might be 
a good time to change the field of discussion somewhat from cardiac morphogenesis 
to lung development. Pulmonary circulation consists of airway, lung parenchyma, 
and pulmonary vessels, and each component can have diseases closely related with 
CHD. Development of the lung in the embryonic stage may have a common path-
way of heart development. Researchers in the field of cardiac morphogenesis may 
be interested to talk with researchers in the field of pulmonary circulation. Also, 
between the heart and lung, there is a ductus arteriosus, which has unique character-
istics, although it is so close to the pulmonary artery. Thus, the 8th Takao sympo-
sium focused on new insights into the development of pulmonary circulation as well 
as basic science of pulmonary hypertension (PH) and ductus arteriosus. The aim of 
the meeting was to mix old friends studying cardiac morphogenesis with new 
friends studying pulmonary circulation and ductus arteriosus.
Although PH in the field of pediatric cardiology shares common features of adult 
PH, it is associated with diverse diseases with onset at any age. The etiology of 
pediatric PH is quite different to that of adults, including idiopathic pulmonary arte-
rial hypertension, PH associated with CHD, and/or developmental lung diseases. 
vi
Recently, medical and surgical treatment of CHD has been well established, and the 
associated PH and/or pulmonary arterial disorders have become important causes of 
morbidity and mortality in children. The management of such children remains 
challenging as treatments are basically dependent on evidence-based studies in 
adult and/or the clinical expertise of pediatric cardiologists. Moreover, there is still 
a lack of data on treatment strategies, effectiveness, pharmacokinetics as well as 
basic science of pulmonary vascular development and disorders.
The ductus arteriosus is an essential fetal structure, which provides a fetal arterial 
shunt between the main pulmonary artery and the descending aorta. Normally, the 
ductus arteriosus begins to close immediately after birth, but in some cases, it 
remains patent after birth and results in severe complications including PH, right 
ventricular dysfunction, and respiratory failure. On the other hand, patent ductus 
arteriosus after birth is required for patients with some complex CHD in which the 
systemic or pulmonary circulation is dependent on the blood flow through the duc-
tus arteriosus. Understanding of the precise molecular mechanism underlying duc-
tus closure is, therefore, important in the field of pediatric cardiology. The final step 
of ductus closure is as a result of vascular remodeling events driven by the cascade 
of signaling pathways that have not been fully elucidated.
In this proceedings book, many interesting results in the field of “Basic Science of 
Lungs and Pulmonary Circulation,” “Clinical/Translational Science of Pulmonary 
Hypertension,” “Basic and Clinical Science of Ductus Arteriosus and Vessels,” as 
well as “Development and Regeneration of Cardiovascular System” are presented. 
These interactive chapters must contribute to an enthusiastic and exciting advance in 
science. We hope to shed light on the basic mechanisms of PH by studying basic sci-
ence in the development of the lung, pulmonary vessels, ductus arteriosus, and heart.
Finally, we would like to note that the Takao symposium and its publications have 
been supported by the Akemi-chan Fund from The Sankei press since its inception. 
The Akemi-chan Fund was set up over 50 years ago to save the life of Akemi-chan 
who was a Japanese girl with ventricular septal defect. Since that time, the fund has 
been supported by the donation from many persons from all over Japan. Also, we 
would like to appreciate the support from the Japanese Society of Pediatric Cardiology 
and Cardiac Surgery, Japan Research Promotion Society for Cardiovascular Diseases, 
and the Cardiovascular Development Forum in Japan. The purpose of this Forum is 
to study the etiology and management of CHD, from both basic and clinical aspects, 
as well as to exchange the results among the members in order to contribute to the 
development of medicine which totally overlaps with the concept propounded by Dr. 
Takao. We do hope that this book would shed light on the direction in which we 
should proceed in the research field in the next 5 years, to ultimately save the lives of 
those who suffer from congenital and acquired heart and lung diseases.
Tokyo, Japan Toshio Nakanishi 
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The lungs are the primary organs of the respiratory system in vertebrates, other than 
fish, that function as an efficient gas exchanger. This respiratory system is physi-
cally and physiologically connected to the cardiovascular system to extract oxygen 
from the atmosphere and transfer it into the bloodstream and to release carbon diox-
ide from the bloodstream into the atmosphere. The normal pulmonary circulation, 
in contrast to the systemic circulation, has low pressure because of a low-resistant 
vascular bed that enables highly efficient gas exchange between the millions of 
alveoli and capillaries. Pulmonary hypertension (PH) is a rare pulmonary arterial 
disease with a high mortality and morbidity although treatment options have 
improved in the last decades. PH is defined by a mean pulmonary artery pressure 
(mPAP) greater than or equal to 20 mmHg at rest and is classified into five main 
subgroups based on the etiology and hemodynamic criteria. Because PH is hetero-
geneous at the genetic and molecular levels, a deeper understanding is required for 
the development of more effective therapies.
In Part I, the basic science for the development of the lungs and the pathogenesis 
of PH is discussed towards a better understanding of the etiology and pathophysiol-
ogy of PH. Drs. Hogan and Morimoto overview the morphogenesis and epithelial 
development of the lung. Each alveolus in lungs is composed of epithelial and mes-
enchymal populations. Dr. Hogan (Chap. 2) focuses on the interesting function of 
Type 2 epithelial cells, as epithelial stem cells for the alveoli, capable of long-term 
self-renewal and differentiation into Type 1 epithelial cells that are extremely large 
and thin to be specialized for gas exchange. The relative contribution of the WNT, 
FGF, EGF, and BMP signaling pathways as well as cytokines produced by immune 
4
cells to alveolar homeostasis, repair and regrowth is discussed. Dr. Morimoto 
(Chap. 3) focuses on Notch signaling as a reciprocal mesenchymal-epithelial inter-
action that controls the development of the airway branching structure. Notch-
mediated cell fate selection is utilized to organize three epithelial cell types during 
the bronchial tree is extending. As for the mesenchymal population that gives rise to 
endothelial cells, pericytes, several different fibroblast subpopulations, and immune 
cells, Dr. Uchida et al. (Chap. 8) suggest that the expression of a transcription factor 
Tbx4 in the lung mesenchyme may be involved in the formation of both airways and 
vessels in the lungs using animal experiments. It is also known that mutations of the 
TBX4 gene lead to PH in human. Dr. Ishizaki et al. (Chap. 9) demonstrate that pul-
monary arterial smooth muscle layers, probably derived from mesenchyme of the 
mesodermal origin, may elongate gradually from the proximal pulmonary arterial 
trunk to bilateral peripheral pulmonary arteries by using a transgenic mouse line 
harboring the LacZ reporter gene in the specific locus. This observation supports the 
“distal angiogenesis” model for pulmonary arterial development.
PH is also known as a progressive pulmonary vascular remodeling disease. 
Histopathological changes in PH include an increase in smooth muscle cells in the 
pulmonary vasculature with muscularization of normally non-muscularized distal 
pulmonary arterioles. Dr. Greif’s team (Chap. 4) identified novel smooth muscle 
cell progenitors located at the muscular-unmuscular arteriole border that have a 
unique molecular signature and are the source of the vast majority of pathological 
distal arteriole smooth muscle cells in PH.  Molecular mechanisms underlying 
induction, proliferation, migration, and differentiation of these specialized progeni-
tor cells are discussed. In addition to the above-described fashions to increase 
smooth muscle cells in the pulmonary vasculature of PH, recent studies have dem-
onstrated that a part of smooth muscle cells from intimal and plexiform lesions has 
an endothelial origin through the process of endothelial-mesenchymal transition 
(EMT). Dr. Ranchoux et al. (Chap. 6) describe how EMT appears to play a crucial 
role in PH progression including the underlying molecular mechanisms. As another 
advanced understanding for pathogenesis of PH, Drs. Chen and Raj (Chap. 7) focus 
on extracellular vesicles. Subsets of extracellular vesicles are microvesicles, exo-
somes, and apoptotic bodies. They are released from a variety of cell types and carry 
cargo such as proteins and microRNAs that may play an important role in the patho-
genesis of PH.
Utilizing animal models, three important findings about the pathogenesis of PH 
are also discussed in Part I. Dr. Nakanishi et al. (Chap. 11) show morphological 
changes of pulmonary microvasculature in the mouse model of bronchopulmonary 
dysplasia (BPD). As BPD is often associated with PH, their study may provide 
insights into secondary PH due to pulmonary diseases. Dr. Zhang et al. (Chap. 12) 
identify significant increased expression of chemokine receptor type 4 (CXCR4) 
and some stem cell markers in PH model rats as putative mediators of pulmonary 
vascular remodeling. Dr. Shibata et  al. (Chap. 13) demonstrate that Ca2+ signal 
through the inositol trisphosphate receptor (IP3R) may be involved in the patho-
physiology of PH using IP3R knockout mice. CXCR4 or IP3R might be a potential 
candidate for new therapeutic targets of PH.
H. Yamagishi
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Finally, Dr. Clapp’s group (Chap. 5) discuss about basic science for the treatment 
of PH. Although there were no treatments available for PH 20 years ago, current 
therapies come from four drug classes, namely, prostanoid analogs, endothelin 
receptor antagonists, phosphodiesterase type 5 inhibitors, and soluble guanylate 
cyclase stimulators, and through focused research, there are more in development. 
Intravenous prostacyclin, as a prostanoid analog, remains the most efficacious treat-
ment for PH, and several prostacyclin analogs are approved for use via different 
administration routes. They act as vasodilators but potently inhibit platelet aggrega-
tion, cell proliferation, and inflammation. Dr. Clapp et al. discuss how prostacyclins 
might rescue BMPR2 and TASK-1 dysfunction and the importance of prostanoid 
EP2 receptors as negative modulators of vascular tone, proliferation, and fibrosis. 
BMPR2 is known as the most important genetic cause of PH, and TASK-1 is a 
TWIK-related acid-sensitive potassium channel that, they believe, is likely to be a 
key target for prostacyclins. As basic research for future stem cell therapy of PH, Dr. 
Maeda et al. (Chap. 10) suggest that stem cell antigen-1 in the pulmonary endothe-
lium may potentially make progenitor cell populations stay resident in adult murine 
lungs.
The field of pulmonary vascular biology continues to capitalize on advances in 
basic science. Part I includes a number of exciting advances in basic science and 
how these advances are impacting the patient with PH. This knowledge should be 
required for physicians and scientists to be translated into future clinical practice.
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2The Alveolar Stem Cell Niche of the Mammalian Lung
Brigid L. M. Hogan
Abstract
The alveolar region of the mammalian lung evolved to enable highly efficient gas 
exchange between the millions of air-filled sacs known as alveoli and blood cir-
culating through the pulmonary vessels. Each alveolus is composed of epithelial 
and mesenchymal populations; Type 1 (AT1) and Type 2 (AT2) epithelial cells 
line the sacs while the mesenchymal compartment is composed of endothelial 
cells, pericytes, several different fibroblast subpopulations, and immune cells. 
Compared with organs such as the intestine and skin, there is normally little cell 
turnover in the adult lung. However, if the alveolar epithelium is damaged, for 
example, by toxic agents or viral infections, or if a lung lobe is removed, there is 
extensive repair or compensatory regrowth (neoalveolarization) of the tissue. It 
is now well accepted that AT2s function as epithelial stem cells for the alveoli, 
capable of long-term self-renewal and differentiation into AT1s. However, many 
important questions remain, in particular, about the functional heterogeneity of 
AT2s and how the different components of their local environment or niche inter-
act to regulate their proliferation and differentiation. Known signaling factors 
include ligands and antagonists of the WNT, FGF, EGF and bone morphogenetic 
(BMP) signaling pathways as well as cytokines produced by immune cells. The 
relative contribution of these factors to alveolar homeostasis, repair and regrowth 
is discussed.
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2.1  Introduction: The Alveolar Type 2 Epithelial  
Stem Cell Niche
Our current understanding of the alveolar stem cell niche of the mammalian lung is 
schematized in Fig. 2.1 [1–4]. Each alveolus contains two kinds of epithelial cells: 
Type 2 cells (AT2s), specialized for producing, secreting and recycling surfactant 
lipids and proteins, and Type 1 cells (AT1s) that are extremely large and thin and 
specialized for gas exchange [5]. It is now well accepted AT2s that express surfac-
tant protein C (Sftpc) can function as stem cells during homeostasis and repair by 
self-renewing and giving rise to AT1s. However, the rate at which AT2s proliferate 
and differentiate depends on local “demand.” At steady state the rate is very low. If 
lungs are experimentally depleted of only AT2s then their proliferation increases but 
differentiation is still minimal [6]. However, if AT1s are also damaged or if whole 
new alveoli need to be generated in response to partial (left lobe) pneumonectomy 
(PPnx), then AT2s both self-renew and show robust AT1 differentiation [7–9]. How 
AT2s detect the absence of AT1s is unclear; perhaps they sense denuded basal lam-
ina or a reduction in cellular contacts with AT1s or, in the case of PPnx, an increase 



















Fig. 2.1 Schematic representation of the alveolar region of the mouse lung. The Type 2 stem cell 
niche (boxed) includes fibroblasts known as TASCs that have long cytoplasmic extensions, AT1 
cells, capillary endothelial cells and pericytes as well as alveolar macrophages and interstitial 
immune cells. Alveolar septae contain myofibroblasts, and other fibroblast cell types (matrix fibro-
blasts) are present in the stroma
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2.2  Evidence for Heterogeneity in the AT2 Population
An important unanswered question is whether all AT2s have the same stem cell 
potential or whether this is a property of a privileged few. Significantly, two groups 
have recently shown that at steady state a minority of AT2s express a reporter for 
Axin2, a downstream target of canonical Wnt signaling. One group [11] found that 
only 1% of the AT2s were positive although more cells became active in response to 
injury. By contrast, a second group [12] reported that 20–30% of AT2s were positive 
at steady state and constituted a stable subpopulation which they termed alveolar 
epithelial progenitors (AEPs). In both cases evidence was presented that the Wnt 
ligand responsible for upregulating Axin2 and promoting AT2 proliferation is pro-
duced by niche fibroblasts in close proximity to AT2s, termed MANCs (mesenchy-
mal alveolar niche cells). These cells can also produce Wnt antagonists, which 
reduce AT2 proliferation and promote differentiation, and may, therefore, fine tune 
the dynamic response of the stem cells during repair [13].
In the light of these studies, one may ask whether AT2 subpopulations have been 
detected by single-cell transcriptomic analysis. One recent study does show a minor 
AT2 subpopulation in the steady state lung, defined as “alveolar bipotential progeni-
tors” [14]. However, these cells are distinguished by co-expressing markers of AT2s 
and AT1s but not by Axin2 levels. In support of the single-cell RNA-seq data, a 
recent report [8] identified by immunohistochemistry a small subpopulation (less 
than 1%) of AT2s co-expressing Sftpc and Ager (advanced glycosylation and end 
product-specific receptor, a marker for AT1s). The proportion of these dual-positive 
cells increases to 20% by 7 days after PPnx when compensatory cell proliferation is 
active. In addition, when isolated AT2 cells are placed in 3D organoid culture under 
conditions in which single cells give rise to structures known as “alveolospheres” 
containing both AT2s and AT1s, all of the cells initially and transiently become dual 
positive for Sftpc and Ager [8]. This behavior may indicate a reversion of mature 
AT2s to a more plastic, bipotential state under conditions promoting repair. New 
genetic tools are clearly needed to test the in vivo significance of the dual-positive 
cells and their relation, if any, to Axin2+ epithelial cells [11, 12].
2.3  Signaling Pathways in the Stem Cell Niche
Besides WNTs and their antagonists, a number of other signaling factors have been 
identified as playing a role in the mouse lung alveolar stem cell niche. Pathways 
include those regulated by Fgfs (largely produced by fibroblast populations), Vegf 
(secreted by AT2s), Bmps and Egfs. Egf signaling is thought to be mediated both by 
the ligand itself and by peptides released from the extracellular matrix after injury. 
This latter mechanism has been proposed for the proliferation of AT2s after PPnx 
[15]. Specifically, it appears that in response to PPnx pulmonary capillary endothe-
lial cells (PCECs) activate the expression of the matrix metalloproteinase MMP14. 
This degrades laminin and releases peptides with a cryptic Egf domain that can bind 
to Egf receptors in the AT2 cells. Changes in PCECs and perivascular macrophages 
2 The Alveolar Stem Cell Niche of the Mammalian Lung
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have also been implicated in the response of the alveolar region to damage by bleo-
mycin or HCL [16]. In this case, it is argued that the notch ligand Jagged1 is upregu-
lated in the damaged PCECs, affecting the behavior of adjacent fibroblasts. Given 
the recent finding that lung microvasculature is a major site of platelet biogenesis 
and a reservoir for hematopoietic progenitors [17] there are likely many other ways 
in which cytokines and angiocrine factors produced by the vascular compartment 
influence the stem cell niche.
BMP signaling in the alveolar niche has not received much attention until 
recently since most research has focused on the pathway in the etiology of pulmo-
nary hypertension. However, immunohistochemistry with antibodies to phosphoS-
mad1/5/8 shows that BMP signaling is active in both epithelial and stromal cells of 
the alveolar region. Signaling is transiently downregulated after PPnx when AT2s 
are proliferating and preparing to differentiate into AT1s. This transient downregu-
lation is likely brought about by the upregulation of BMP antagonists, including 
follistatin and follistatin-like 1 by stromal cells rather than downregulation of BMP 
ligands [8].
2.4  The Role of Immune Cells and Stromal Cells in Alveolar 
Repair and Regeneration
One of the major roadblocks to our understanding of the alveolar stem cell niche is 
the precise identification of the different mesenchymal/mesoderm-derived cell types 
in the region. This population includes lipofibroblasts (cells with varying numbers 
of lipid inclusion), myofibroblasts (cells rich in smooth muscle actin) and “matrix 
fibroblasts” and their progenitors [13, 14, 18]. The lung also contains a rich and 
varied population of resident immune cells with multiple subclasses of dendritic 
cells and innate lymphoid cells, and interstitial and alveolar macrophages. Immune 
cells are recruited to the alveolar niche after injury and can play important roles in 
repair and regrowth. Recent studies have shown a role for bone marrow–derived 
macrophages in compensatory regrowth after PPnx [9]. Genetic deletion of the bone 
marrow-derived macrophages, or the innate immune cells thought to activate them, 
results in reduced AT2 proliferation and regrowth. In the future, it will be important 
to determine the precise mechanism by which the macrophages promote repair, for 
example, whether they produce cytokines acting directly on AT2s or function indi-
rectly through other components of the niche.
Progress in defining the precise physiological function of the different stromal 
populations in the alveolar region has been hampered by the relative paucity of tools 
for genetically manipulating and lineage tracing specific cell types. We, therefore, 
generated a new Pdgfra-CreEr knock-in allele (Jackson Lab stock number 032770) 
to test the function of genes expressed in fibroblasts expressing the Pdgf receptor 
alpha. This is a heterogeneous population but includes cells intimately associated 
with AT2s that we have called Type 2 associated stromal cells, or TASCs [8]. These 
cells have a very distinct morphology with long cellular extensions and may be the 
same as the MANCs described by others [13]. They likely represent the mouse 
B. L. M. Hogan
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equivalent of cells described in the human lung that make contact with AT2, AT1 
and endothelial cells [19] and are, therefore, well positioned to integrate signaling 
pathways within the niche.
2.5  Future Directions and Clinical Implications
This review highlights recent advances in our understanding of the cells and sig-
naling pathways that regulate AT2 proliferation and differentiation in the alveolar 
niche of the mouse lung. In the long term, this information may inspire new clini-
cal strategies for promoting alveolar repair from remaining endogenous stem cells 
in damaged human lungs. A major challenge is to translate techniques used with 
mouse cells to primary cells isolated from the human lung. For example, the 
“alveolosphere” organoid culture system that has been used so successfully to 
screen for factors that regulate AT2 stem cell behavior is much less efficient with 
human AT2 cells for reasons that are currently unclear [20]. Nevertheless, prog-
ress is being made and we should expect to see important advances in the near 
future.
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3Lung Development and Notch Signaling
Mitsuru Morimoto
Abstract
The respiratory system is connected to the cardiovascular system physically and 
physiologically. This chapter overviews the morphogenesis and epithelial devel-
opment of the lung. The airway branching structure is formed as development 
progresses and is controlled by reciprocal mesenchymal-epithelial interactions. 
During the branching process, the distal terminal buds are thought to contain a 
population of multipotent epithelial progenitors that are more proliferative than 
proximal cells. This predominant proliferation in the distal tip leads to the lung 
bud extension toward the distal end. As the bronchial tree extends further, descen-
dants of these multipotent cells give rise to lineage-restricted progenitors in the 
conducting airways. Notch signaling is used repeatedly to organize three epithe-
lial cell types: Club, ciliated, and neuroendocrine (NE) cells. The Notch-mediated 
fate selection of Club/ciliated cells and of the size of NE cell clusters is regulated 
by different mechanisms. The Club/ciliated cell fate decision is mediated exclu-
sively by Notch2 in response to Jag1. In contrast, all three Notch receptors con-
tribute to robustly regulate the NE cell-cluster size. High-resolution whole-mount 
imaging of the developing lung revealed that the NE cell cluster appears at the 
stereotypic positions at the bifurcating area of the branching airways. Moreover, 
the 4D imaging, 3D plus live-imaging, method for developing lung epithelial 
cells discovered dynamics of NE cell clustering in which NE cells appear at 
inter-bifurcation area as solitary cells and migrate toward the branching points to 
form clusters. Further analyses determined that Notch signaling regulates the 
number of solitary NE cells in a lateral-inhibition fashion.
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3.1  Introduction
The lung facilitates gas exchange by maximizing ventilation efficiency and the sur-
face area of interface to the capillaries. The developing lung forms an intricate, but 
stereotypic, branching airway structure and arrayed epithelial cells (Fig. 3.1). Air 
from the external environment includes viruses, bacteria, and toxic chemical com-
pounds, which means that the airways may become damaged and need to be repaired 
rapidly. For these reasons, the lung is a useful model organ for studying cellular 
events that are conserved between organogenesis in the embryo and tissue regenera-
tion in the adult.
3.2  Morphogenesis and Epithelial Progenitors
For the last two decades, extensive studies using mouse models have revealed bio-
logical processes and genes that regulate lung development. Although there are sig-





Basal Goblet Ciliated Club Neuroendocrine Type II Type I
Fig. 3.1 The structure of the lung airways and their epithelial components
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histology and pathology [1], suggesting that the mouse lung may be a useful model 
system for investigating organ biology and human disease. Lung development relies 
on reciprocal mesenchymal-epithelial interactions orchestrated by temporal and 
spatial expression waves of multiple secreted factors and their downstream effectors 
[2]. Airway branching morphogenesis takes place at E11.5–16.5 in the mouse and 
at 5–17 weeks in human embryo (known as pseudoglandular stage, during which 
most of airway branching morphogenesis takes place); it is thought that the terminal 
buds contain a population of multipotent epithelial progenitors (Fig. 3.2) [3]. While 
the buds extend and branch in a genetically coordinated stereotypic pattern [4], the 
progenitors give rise to lineage-restricted descendants that produce at least seven 
major cell types in the ‘stalk’ region [3, 5]. Thus, the early stalks form the proximal 
airway, then the distal airways, and finally the alveoli [6]. In the proximal airway, 
the tracheal epithelium consists of the basal, goblet, Club (secretory), and ciliated 
cells. Smaller bronchi contain the latter two cell types and pulmonary neuroendo-
crine (NE) cells. The distal-most airway, the alveolus, is lined with thin layers of flat 
Type I cells and cuboidal Type II cells (Fig. 3.1).
3.3  Notch Signaling Controls Both Epithelial Cell Fates 
and Distributions
One of the outstanding questions in the field is how epithelial cells interact and 
exchange information to generate and maintain the appropriate balance in their 
respective cell numbers and distributions. Using genetic engineering methods, we 
have performed stepwise removal of the components of Notch signaling, a key sig-
naling in cell fate decisions in developing lung epithelium, and revealed that Notch 




Fig. 3.2 The distal tip 
stem cells and proximal 
differentiated cells in 
developing airways during 
pseudoglandular stage
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ciliated, and NE cells [7, 8]. We also identified significant differences between the 
selection of Club/ciliated cells and the size regulation of NE cell clusters. The Club/
ciliated cell fate decision is mediated exclusively by Notch2  in response to Jag1 
with negligible contributions from Notch1 and 3 (Fig. 3.3a). In contrast, all three 
Notch receptors respond to Dll1 and contribute in an additive manner to regulate NE 
cell cluster numbers and size (Fig. 3.3b). These results indicate that two distinct 
Notch signaling pathways, involving Jag1-Notch2 and Dll1-Notch123 signaling, 
respectively, coordinate the number and distribution of the major epithelial cell 
types of the conducting airway in lung organogenesis. However, at the time we were 
unable to clarify the Notch-mediated mechanism by which the NE cell number and 
cluster size are regulated.
3.4  Development of NE Cell Clusters on Bifurcating Area 
of Branching Airways
The pulmonary NE cells are thought to function as chemoreceptors and as a compo-
nent of the stem cell niche and are also the cells of origin in small-cell lung cancer. 
NE cells often localize at bifurcation points of airway tubes, forming small clusters 
called neuroepithelial bodies (NEBs). These are referred to as “nodal” NEBs [9] 
whereas NEBs in inter-bifurcation regions are called “internodal” (Fig. 3.4). Despite 
a
b
Fig. 3.3 Loss of Notch signaling phenotypes within airway epithelium. (a) Immunostainings for 
Club (CC10, Red) and ciliated (Foxj1, Green) cells of epithelial Notch1 or 2 conditional KO lung. 
(b) Schematic diagrams of the proposed regulatory mechanisms involved in Notch-mediated cell 
fate determination during bronchial epithelial development. In the pseudoglandular stage, epithe-
lial progenitors (purple) located at the distal tip produce descendants that differentiate into Club 
(pink), ciliated (green), SPNC (red) and NE (blue) cells
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the functional importance of NE cells and NEBs, their developmental course 
remains unclear in part because of technical limitations in obtaining high-resolution 
images and quantitative analysis of the behavior of epithelial cells in the context of 
a 3D branching morphology. We have established methods for 3D mapping of lung 
epithelial cells and ex vivo 4D imaging of the developing lung [10].
To accurately map the positions of all NEBs throughout the entire respiratory 
tree, we used two-photon microscopy to image whole-mount lungs in a transgenic 
mouse strain, RetEGFP/+; SHHCre/+; R26RH2B-mCherry mice visualizing NE cells in the 
epithelium (EGFP+; mCherry+) and neuronal cells in the mesenchyme (EGFP+; 
mCherry−). Lungs were collected at E14.5, E15.5, and E16.5 and cleared using 
clear, unobstructed brain imaging cocktail (CUBIC) solution [11]. The 3D architec-
ture of mCherry+ lung epithelium was extracted computationally from 3D image 
stacks by removal of mesenchymal signals, and data on the positions of all epithelial 
and NE cells were recorded (Fig. 3.5a). These 3D imaging and quantitative analyses 
revealed that nodal NEBs are significantly larger than internodal NEBs at each 
stage. We redefined the localization of nodal NEBs by close examination of their 
positions within the entire geometric architecture of the airway tubes (Fig. 3.5b). 
These geometric analyses revealed that nodal NEBs are located at stereotypic posi-
tions in airway branching structures.
3.5  Notch-Hes1 Signaling Is Required for Restricted 
Differentiation of Solitary NE Cells
To determine the mechanisms of Notch-mediated NEB development, we geneti-
cally ablated Hes1 gene, which is the target of Notch signaling and a regulator of 
NE cell development [12], from endodermal epithelium by generating SHHCre/+; 
Fig. 3.4 Immu-
nohistochemistry of the NE 
cell marker CGRP (brown) 
for E18.5 mouse lung. The 
arrowheads indicate the 
NEBs on bifurcation points 
(black) or inter-bifurcation 
region (gray)

























































































































































































































































































































































Hes1f/f mice. Ascl1-positive primordial NE cells were examined at E13.5. Compared 
with normal epithelium, the Hes1-deficient epithelium showed abundant NE cells 
that tended to adjoin each other at the proximal region in Hes1-deficient epithelium 
(Fig. 3.6a). The punctate distribution of NE cells in the normal E13.5 lung and the 
disruption of this pattern in Hes1 mutants suggest that Notch-Hes1 signaling sup-
presses NE cell fate in a classical lateral inhibition fashion (Fig. 3.6b). To analyze 
the effect of Hes1 depletion in NEB formation, we performed NEB 3D mapping by 
generating SHHCre/+; R26RH2B-mCherry; RetEGFP/+; Hes1f/f embryos and imaged the cra-
nial lobes at E16.5. In contrast to the wide distribution of NE cells at E13.5, we 
noted markedly enlarged NEBs throughout the proximal to distal airways (Fig. 3.6c).
3.6  Directional Migration of NE Cells Toward Bifurcation 
Points Creates Nodal NEBs
We hypothesized that NE cells emerge as solitary cells and, subsequently, migrate 
toward a bifurcation point to form NEBs. To test this hypothesis, we established a 
4D imaging method for the developing lung, involving 3D plus time-lapse imaging 
of living tissue. We cultured E13.5 cranial lobes at the air-liquid interface on a mem-
brane filter that becomes transparent in liquid (Fig. 3.7a). In these 4D images, NE 
cells initially appear as individual cells, in line with our expectations. These cells 
subsequently migrated toward a bifurcation point located in a more distal region and 
accumulated there to form an NEB (Fig.  3.7b). Some NE cells also clustered at 
inter-bifurcation areas. These observations support the idea that NE cells emerge as 
solitary cells via Notch-mediated cell fate selection and, subsequently, migrate 
toward bifurcation points on the basement membrane to form nodal NEBs (Fig. 3.8). 
Internodal NEBs may be generated by a population of cells that are arrested during 
this migration. In this study, we described a spatial relationship between 3D branch-
ing morphology and nodal NEB localization. We also provided direct evidence 
showing that cell-autonomous Notch-Hes1 signaling inhibits NE cell differentiation 
in a classical lateral inhibition fashion, giving rise to a limited number of NE cells. 
Our results suggest the presence of at least three factors (or combinations of factors) 
that control NE cell clustering, working to attract them to the distal trap at bifurca-
tion points and induce their aggregation [10]. We are now investigating molecular 
mechanisms explaining directional migration and clustering at the bifurcating area 
of the developing airways.
Given that NE cells are thought to be the cells of origin in highly malignant 
small-cell lung cancers, investigating the molecular mechanisms of NE cell migra-
tion may provide important clues toward the development of new therapeutic 
approaches to mitigate this malignancy.
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4Specialized Smooth Muscle Cell Progenitors in Pulmonary Hypertension
Fatima Zahra Saddouk, Aglaia Ntokou, and Daniel M. Greif
Abstract
The accumulation of excessive and ectopic smooth muscle cells (SMCs) is inte-
gral to the pathogenesis of diverse cardiovascular diseases, including atheroscle-
rosis, restenosis and pulmonary hypertension. Unfortunately, underlying 
mechanisms are poorly understood which markedly limits therapeutic options. 
In the idiopathic form of pulmonary hypertension, reduced pulmonary artery 
compliance is a strong independent predictor of mortality (Mahapatra et al. J Am 
Coll Cardiol 47(4):799–803, 2006). Distal arteriole endothelial tubes in the nor-
mal lung lack a SMC coating, and pathological distal arteriole muscularization 
contributes to the reduced compliance. Recently, we identified specialized pro-
genitors that are located at the muscular-unmuscular border of each arteriole in 
the normal lung and express markers of SMCs and the undifferentiated mesen-
chyme marker platelet-derived growth factor receptor-β (Sheikh et al. Cell Rep 
6(5):809–17, 2014; Sci Transl Med 7(308):308ra159, 2015). Upon exposing 
mice to hypoxia, these “primed” SMC progenitors are induced to express the 
pluripotency factor Kruppel-like factor 4 (Sheikh et  al. Sci Transl Med 
7(308):308ra159, 2015). Subsequently, one of these primed cells migrates dis-
tally and in a cell autonomous hypoxia-inducible factor (HIF)1-α-dependent 
manner and clonally expands, giving rise to distal arteriole SMCs (Sheikh et al. 
Sci Transl Med 7(308):308ra159, 2015; Cell Rep 23(4):1152–65, 2018). 
Additionally, endothelial cell HIF1-α-dependent signaling contributes in a non- 
cell autonomous manner, regulating induction, proliferation and differentiation 
of primed cells (Sheikh et al. Cell Rep 23(4):1152–65, 2018).
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4.1  Introduction
Physiologically, pulmonary hypertension (PH) is defined by a mean pulmonary 
artery pressure greater than or equal to 25 mm Hg at rest. PH encompasses hetero-
geneous entities that the World Health Organization has classified into five groups 
by etiology as follows: Group 1—pulmonary arterial hypertension (PAH); Group 
2—PH due to left heart disease; Group 3—PH due to lung disease and/or chronic 
hypoxia; Group 4—PH due to chronic thromboembolism; and Group 5—PH with 
unclear multi-factorial mechanisms [1]. Overall, PH is a grave complication of 
other pathologies as well as a devastating disease in its own right: indeed, within 
seven years of initial diagnosis of PAH, one-half of patients have died [2].
Histopathological changes in PH include an increased SMC burden in the pulmo-
nary vasculature with muscularization of normally non-muscularized distal pulmo-
nary arterioles. Reduced compliance of the pulmonary arterial vasculature is an 
independent predictor of mortality in idiopathic PAH [3], and the distal extension of 
SMC coverage to normally unmuscularized distal arterioles contributes to this 
reduced arterial compliance. Treatments for PAH are largely limited to therapies that 
primarily induce vascular dilation, but these approaches do not ameliorate the hyper-
muscularization. The lack of therapeutic options that combat hypermuscularization 
is striking but perhaps not surprising given our limited understanding of the molecu-
lar and cellular processes underlying distal arteriole muscularization. To begin to 
delineate these mechanisms, our group utilized a reductionist approach and investi-
gated in-depth, the process of hypoxia-induced distal muscularization of select arte-
riole beds in the murine lung. We identified novel SMC progenitors located at the 
muscular-unmuscular arteriole border that have a unique molecular signature and are 
the source of the vast majority of pathological distal arteriole SMCs in PH. During 
the muscularization process, these progenitors and their daughter cells undergo a 
stereotyped program of gene expression, migration and proliferation, which is sub-
jected to intricate cell autonomous and non-cell autonomous regulation.
4.2  Hypoxia-Induced Distal Pulmonary Arteriole SMCs 
Derive from Specialized SMC Progenitors
Chronic hypoxia is a common cause of PH in humans and is widely used in a rodent 
model of PH, resulting in muscularization of distal pulmonary arterioles [4, 5]. At 
each arteriole muscular-unmuscular transition zone in the normal lung, we identi-
fied a pool of cells that express SMC markers (α-smooth muscle actin [SMA], 
smooth muscle myosin heavy chain [SMMHC]) and the undifferentiated mesen-
chyme marker platelet-derived growth factor receptor (PDGFR-β) [6, 7]. Because 
F. Z. Saddouk et al.
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of their gene expression and position, we assessed if these cells give rise to distal 
pulmonary arteriole SMCs during PH through fate mapping in mice carrying the 
ROSA26R-mTmG Cre reporter and either Acta2-CreERT2 to induce recombination 
in SMCs (Acta2 is the gene encoding SMA) or Pdgfrb-CreERT2 [6–9]. Treatment of 
these mice with hypoxia revealed that more than 80% of the distal pulmonary arte-
riole SMCs derive from primed SMCs [6, 7]. Thus, we termed these PDGFR- 
β+SMA+SMMHC+ progenitors as “primed” cells by virtue of their head start on 
other SMCs with regard to muscularizing the distal arteriole due to their location 
and PDGFR-β expression.
4.3  Stereotyped Program of Distal Muscularization
During the distal muscularization process, the primed SMC-derived lineage 
undergoes stereotyped steps of dedifferentiation (downregulation of SMMHC and 
maintenance of PDGFR-β expression) and migration beyond the muscularized-
unmuscularized arteriole border and finally differentiation (upregulation of 
SMMHC and downregulation of PDGFR-β) [6]. In addition, analysis of bromode-
oxyuridine (BrdU) incorporation indicates that proliferation of distal arteriole 
SMCs peaks at day 7 of hypoxia with remarkably ~2/3 of distal arteriole SMCs 
staining for BrdU, four hours after a single BrdU injection (100 mg/kg) [6].
4.4  Monoclonal Expansion of SMCs in PH
Furthermore, we analyzed the clonal relationship of hypoxia-induced distal arteri-
ole SMCs. For these studies we used Acta2-CreERT2 mice also carrying the multi- 
color Rainbow (Rb) Cre reporter; a ROSA26R(Rb/+) cell that has undergone 
Cre-induced recombination will randomly and permanently express a specific fluo-
rophore—Cerulean, mCherry or mOrange—and all of the cell’s progeny will 
express this same fluorophore [10, 11]. Remarkably, for each distal arteriole, almost 
all of the pathological distal SMCs are marked by a single color (Fig. 4.1) and thus 
derive from clonal expansion of a single SMA+ cell and based on the fate mapping 
studies described above, from a single primed SMC [6, 7].
4.5  Signaling Pathways Regulating Primed Cells
The expression of the pluripotency factor Kruppel-like factor 4 (KLF4) in primed 
cells is essential for their initial migration in response to hypoxia, but KLF4 is dis-
pensable for subsequent steps of SMC proliferation [7]. Interestingly, the hypermu-
scularized arterioles of human PH patients have a marked upregulation of KLF4 [7]. 
Platelet-derived growth factor (PDGF)-B is integral in primed cell KLF4 expression 
and distal muscularization as Pdgfb(+/−) mice are protected against these hypoxia- 
induced changes and do not develop PH [7].













































Fig. 4.1 The vast majority of hypoxia-induced SMCs in each pulmonary arteriole derive from a 
single pre-existing SMC. Acta2-CreER mice also carrying the multi-color Rainbow (Rb) Cre 
reporter ROSA26R(Rb/+) were induced with tamoxifen, rested and then exposed to normoxia or 
hypoxia (FiO2 10%) for 21 days. (a) Potential patterns of Rb colors in pulmonary arteriole SMCs. 
Middle (M) arteriole SMCs are present in normoxia and marked by different Rb colors [i.e., 
Cerulean (blue), mOrange (yellow) or mCherry (red)]. Hypoxia-induced distal (D) arteriole SMCs 
will be a single color if they derive from a single pre-existing SMC. Instead, distal arteriole SMCs 
will be of multiple colors if they derive from multiple SMCs. (b), Lung sections from a normoxic 
mouse and two hypoxic mice and imaged for Rb colors. Middle arteriole SMCs are polyclonal 
whereas distal arterioles are almost entirely monoclonal. Alveolar myofibroblasts are also marked 
(arrowheads). (c) Quantification of arteriole SMCs by size (M, D) and color. n = 4 lungs, 2–3 arte-
rioles per lung (Adapted from reference [7])
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Hypoxia-inducible factors (HIFs) are key transcription factors in PH. Deletion of 
Hif1a in SMMHC+ cells attenuates hypoxia-induced pulmonary vascular remodel-
ing [12]. In contrast to KLF4, our studies suggest that HIF1-α in PDGFR-β+ cells is 
not required for initial primed cell migration but is needed for the subsequent clonal 
expansion. In ECs, HIF1-α is upstream of PDGF-B, and EC deletion of either of 
these genes non-cell autonomously attenuates hypoxia-induced primed cell KLF4 
expression, distal muscularization and PH [7, 13].
4.6  Future Direction and Clinical Implications
A number of questions are raised by these findings. From a developmental perspec-
tive, it is interesting to consider what is the role of primed cells in morphogenesis of 
the pulmonary vasculature and when do primed cells form. It remains to be deter-
mined whether the primed SMCs clonally expand in models of PH other than the 
hypoxia model and whether primed cells are present in the pulmonary arterioles of 
other animals beyond mice and in humans. Yet, the clonal expansion of SMC 
marker+ progenitors in pathological settings is not limited to hypoxia-induced PH as 
a series of recent studies demonstrate marked expansion of rare SMCs during ath-
erogenesis in mice [14–16]. The need for effective and safe treatments for PH is 
dire, and further studies that investigate the role of primed cells and underlying 
signaling pathways in pathogenesis are critical and likely to provide key steps in the 
development of novel therapeutic approaches.
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Pulmonary arterial hypertension (PAH) is a progressive vascular remodelling 
disease where patients ultimately die from heart failure. Increased production of 
vasoconstrictors (endothelin-1 and thromboxane  A2) accompanied by loss of 
prostacyclin, nitric oxide (NO), bone morphogenetic protein receptor type 2 
(BMPR2) and TASK-1 combine to cause endothelial apoptosis, smooth muscle 
hyperactivity and thickening of the blood vessel wall. Prostacyclin remains the 
most efficacious treatment for PAH, and several prostacyclin analogues are 
approved for use via different administration routes. They act as vasodilators but 
potently inhibit platelet aggregation, cell proliferation and inflammation. The 
pharmacology of each prostacyclin (IP) receptor agonist is distinct, with other 
targets contributing to their therapeutic and side-effect profile, including pros-
tanoid EP1, EP3, EP2 and DP1 receptors, alongside peroxisome proliferator- 
activated receptors (PPARs), to which prostacyclin and some analogues directly 
bind. To improve selectivity, selexipag, a non-prostanoid was developed, whose 
only significant biological target is the IP receptor, but is a partial agonist in 
cyclic AMP assays and has no anti-aggregatory properties in vivo. Prostanoid 
receptor expression profiles in the normal and diseased lung demonstrate loss of 
the IP receptor and upregulation of EP2 and EP3 receptors in PAH, affecting the 
action of prostacyclin mimetics in different ways. We discuss how prostacyclins 
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might rescue BMPR2 and TASK-1 dysfunction and the importance of EP2 recep-
tors as negative modulators of vascular tone, proliferation and fibrosis. Alongside 
DP1 and EP4 receptors, they have specific roles in veins and airways. Whether 
drugs selective for the IP receptor confer a superior or reduced therapeutic ben-
efit remains an important clinical question as do the role of platelets in PAH.
Keywords
Prostanoid receptors · Prostacyclin mimetics · Vascular smooth muscle · 
Pulmonary hypertension · Cell proliferation
5.1  Introduction
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease. Patients 
suffer from elevated pulmonary artery pressure (PAP) and right ventricular (RV) 
heart failure [1]. Without treatment, adults have a median life expectancy of 
2.8 years from diagnosis, while children have less than 10 months [2, 3]. Narrowing 
of the small pulmonary arteries involves proliferation of endothelial cells, smooth 
muscle cells and fibroblasts and is associated with inflammatory cell infiltration and 
the formation of thrombotic lesions [4, 5]. The highly proliferative phenotype is 
driven by elevated levels of mitogens (endothelin-1, thromboxane A2 and 5-HT) and 
growth factors (platelet-derived growth factor, transforming growth factor β1 and 
fibroblast growth factor) concomitant with a reduction in the endogenous levels of 
nitric oxide (NO) and prostacyclin, agents which have potent anti-proliferative and 
anti-inflammatory properties in many different cell types [6].
Pulmonary hypertension (PH) is classified by the World Health Organization 
(WHO) into five clinical groups, with patients diagnosed as having PAH belonging 
to Group I [5, 7]. PAH is further classified as being idiopathic (of no known cause), 
heritable (genetic component) or secondary to other lung or systemic diseases, 
including connective tissue disease (CTD), congenital heart disease (CHD) and 
HIV [5, 7]. It is estimated that around 10% of all patients are described as having 
heritable PAH (HPAH). From this, a significant proportion of patients (~70–80%) 
have a mutation in the bone morphogenetic protein receptor type 2 (BMPR2), a 
member of the transforming growth factor beta (TGF-β) receptor family [7, 8]. The 
consequence of such mutations is to lead to a pro-proliferative phenotype in pul-
monary arterial smooth muscle cells (PASMCs) and a high vascular permeability in 
endothelial cells leading to apoptosis [9, 10]. It is also important to note that down-
regulation of the BMPR2 protein occurs in around 25% of patients with idiopathic 
PAH (IPAH) [8, 11].
Additional and rarer heterozygous germline mutations in the TGF-β pathway 
have also been implicated, with studies confirming activin-like kinase-type (ALK- 
1), endoglin and various members of the SMAD (SMAD 9, 4, 5, 1) family contrib-
uting to the pathogenesis of HPAH [8]. ALK is a type-1 receptor phosphorylated 
when BMPR2 is  activated by a BMP ligand and endoglin encodes a type III or 
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accessory receptor to BMPR2, while phosphorylation of SMAD 1,5 and 8(9) leads 
to their association with the nuclear chaperone SMAD4, resulting in translocation 
of the SMAD complex to the cell nucleus to regulate transcription [8]. Furthermore, 
loss of function mutations in the potassium channel KCNK3 (TASK-1) have been 
described in patients with either HPAH or IPAH, representing a mechanistically 
novel cause of PAH [12]. This parallels the downregulation of Kv channels that has 
been implicated to underlie hypoxic-induced vasoconstriction and abnormal prolif-
eration of smooth muscle cells from patients with IPAH [12].
5.2  Development of Prostacyclin Mimetics and Their 
Diverse Pharmacology
Prostacyclin, a prostanoid produced in endothelial and smooth muscle cells by the 
cyclooxygenase (COX) pathway, was discovered in 1976 by a group of scientists 
led by John Vane as a potent vasodilator and anti-thrombotic agent of the vascula-
ture [13, 14]. It was the first treatment to routinely be used in PAH, with the primary 
clinical benefit resulting from a reduction in PAP and resistance thereby improving 
cardiac output [15]. Shortly thereafter, chemically stable analogues of prostacy-
clin with a longer half-life in the blood were synthesised, including beraprost, ilo-
prost, treprostinil and cicaprost. Apart from cicaprost, these analogues have been in 
use for PAH since the early to mid-1990s, with iloprost and treprostinil receiving 
FDA approval in 2002 and 2004, respectively, whereas beraprost is currently only 
licensed in Asia. Initial work presumed prostacyclin drugs produced their effects via 
binding to the Gs-coupled prostacyclin (IP) receptor leading to the activation of ade-
nylate cyclase and the cellular accumulation of intracellular cyclic-3′,5′-adenosine 
monophosphate (cAMP) [16]. Consistent with this notion, the blood pressure–low-
ering, vasodilatory and anti-aggregatory properties of cicaprost were abolished in 
IP receptor null mice [17]. Indeed the IP receptor appears to largely account for the 
pharmacological properties of prostacyclins in humans, including vasodilator [18, 
19] and anti-proliferative effects [20–22] in normal pulmonary smooth muscle as 
well as inhibition of platelet function in healthy individuals [23, 24]. However, early 
on in their development, prostacyclin and its analogues were found to regulate gene 
transcription via peroxisome proliferator-activated receptors (PPARs), which would 
concur with the strong perinuclear expression of prostacyclin synthase [13] with 
cyclooxygenase enzymes [25], both the enzymes required for prostacyclin synthe-
sis. Some analogues (but not cicaprost) were shown to bind and activate PPARα and 
PPARβ, an effect reported to be independent of the IP receptor and cAMP genera-
tion [26, 27]. Such a mechanism might help to explain the enigmatic observation 
(at the time) that abolition of the iloprost-induced elevation in cAMP by adenylate 
cyclase inhibition had no significant effect on vascular relaxation by this agent in 
guinea-pig aorta [28]. However, it was not until a decade later did evidence emerge 
for the explicit role of PPARs in mediating some of the functional effects of pros-
tacyclin analogues on vascular tone, cell proliferation and endothelial cell integrity 
(reviewed in [6]). Indeed, studies in genetically modified mice show that distinct 
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phenotypes are generated when the IP receptor and the prostacyclin synthase gene 
are deleted; the former are normotensive but do show an increased susceptibility to 
thrombosis, while the latter are hypertensive and show fibrosis and vascular remod-
elling in the kidney [6]. This strongly suggests that PPARs are involved in regulat-
ing blood pressure and is consistent with the known vasodilatory effects of ligands 
activating all three PPAR (α, β, γ) isoforms [29, 30].
At the same time as the discovery of signalling through PPARs, prostacyclin 
and its analogues were found to activate multiple prostanoid receptors, including 
EP1, EP3, EP4, TP and FP [16, 31]. Given that all (bar EP4) are contractile recep-
tors linked to either calcium elevation or inhibition of cAMP generation (Fig. 5.1), 
and thus their activation might promote unwanted side effects or physiologically 
oppose IP receptor signalling, prompted the search for more selective IP receptor 
agonists. Based on this rationale, selexipag, a novel non-prostanoid moiety with 
a high selectivity for the IP receptor was developed [32, 33] and subsequently 
approved in 2015 for the treatment of PAH [34]. Selexipag, which is structurally 
different from prostacyclin, is broken down in the liver to form MRE-269 (known 
also as ACT 333679), a metabolite with a significantly increased affinity for the 
IP receptor but with essentially weak or no activity at other prostanoid receptors 


















Fig. 5.1 Synthesis of prostanoids and their downstream receptors. Oxidation of arachidonic acid 
by cyclooxygenase (COX-1 and COX-2) enzymes converts it to an unstable intermediate, prosta-
glandin H2, the common precursor for five principal bioactive derivatives. Thromboxane A2 
(TXA2), prostaglandin F2α, (PGF2α), prostaglandin E2 (PGE2), prostacyclin and prostaglandin D2 
(PGD2) are then generated by the action of individual prostaglandin synthase enzymes (TxAS, 
PGFS, PGES, PGIS and PGDS). Once generated, the different prostanoids exert their biological 
effects by binding to and activating specific membrane bound G-protein-coupled receptors. TP, FP, 
EP1 and EP3 receptors are contractile receptors coupled to Gq and Gi that either elevate intracel-
lular Ca2+and/or reduce cAMP, respectively. EP2, EP4, IP and DP1 receptors are vasorelaxant recep-
tors coupled to Gs that will activate adenylate cyclase and elevate intracellular cAMP 
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selective IP receptor agonists were recently synthesised, with ralinepag (APD811) 
in clinical development as a next generation, once a day oral for the treatment of 
PAH [35]. Other novel approaches are being taken, including the development of 
ONO-1301, a non-prostanoid with a dual function of activating the IP receptor and 
inhibiting TXA2 synthase [24]. The latter property of the molecule appears to pro-
tect the IP receptor from undergoing desensitisation, which is often observed with 
repeated prostacyclin or analogue administration. This suggests a major role for the 
TP receptor in promoting IP receptor desensitisation.
All prostacyclin mimetics used clinically display high affinity binding to the 
human IP receptor. Potency varies, with those having a Ki of 2–4 nM (prostacy-
clin, iloprost and ralinepag) and those having a tenfold lower affinity with a Ki of 
20–38 nM (MRE-269, treprostinil and beraprost), or lower still, with selexipag 
having a Ki of 250 nM [6, 35]. Esuberaprost (beraprost-314d), a reformulated 
single isomer of beraprost, may be the most potent IP agonist developed so far 
for therapeutic use [36] and is now in a phase III clinical trial as an oral with 
inhaled treprostinil. It remains to be determined whether high selectivity towards 
the IP receptor, which typifies the two non-prostanoid IP receptor agonists, will 
give rise to therapeutically superior effects and/or a better side-effect profile 
compared to prostacyclin mimetics that can act at other membrane and nuclear 
receptors.
Mechanistic and functional differences between prostanoid and non-prostanoid 
IP agonists are now beginning to emerge that need to be carefully considered 
in a clinical context. Both ralinepag and MRE-269 behave as partial agonists in 
cAMP assays in CHO cells stably expressing the human IP receptor and in human 
PASMCs from PAH patients [35, 37, 38]. Partial agonism may in part explain why 
MRE-269 was about 65-fold less potent than iloprost at inhibiting contractions in 
human pulmonary arteries [19] and why selexipag has little overall effect on platelet 
aggregation in vivo [39]. The latter might suggest the inability of the active metabo-
lite to raise cAMP levels sufficiently to oppose platelet aggregation by endogenous 
mediators like thromboxane A2 (TXA2), which in itself can lower cAMP levels 
through IP receptor desensitisation, Gi coupling to adenylate cyclase or Ca2+ activa-
tion of cAMP-dependent phosphodiesterases [6, 24]. High EP3 receptor activity is 
also likely to have a similar effect as this receptor is negatively coupled to adenylate 
cyclase.
The role of platelets as a disease-modifying process in PAH is neither well under-
stood nor the nature of the benefit derived from anti-coagulant therapy [40, 41]. This 
is an issue that needs to be further investigated as activated platelets produce and 
release vasoactive substances such as TXA2, 5-HT and platelet-derived growth fac-
tor [41, 42], which may cause harmful vasoconstriction and vascular remodelling 
in PAH. However, as internal bleeding is a potential risk factor for all prostacyclin 
analogues [41], and thrombocytopenia a complication of long-term use with epo-
prostenol (synthetic prostacyclin) in some PAH patients [43], the ability to switch 
to an IP agonist devoid of anticoagulation properties might be considered beneficial 
in some patients.
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There are also key mechanistic differences in how prostacyclin analogues and 
non-prostanoid IP agonists inhibit pulmonary arterial smooth muscle proliferation 
in cells derived from PAH patients. The anti-proliferative responses to treprostinil 
and iloprost show weak effects of IP receptor inhibition with RO1138452 [22, 44] 
whereas the same antagonist completely reversed the effects to both MRE-269 and 
ralinepag, suggesting inhibition of cell proliferation was fully IP receptor- dependent 
[37, 44]. These results suggest that non-IP receptor targets play a significant role in 
mediating the effects of some prostacyclin analogues in PAH whereas the IP recep-
tor is likely to be the only significant biological target for MRE-269 and ralinepag. In 
the search for an explanation to the original 2010 observation, radioligand-binding 
assays against human prostanoid receptors demonstrated unexpectedly that trepro-
stinil had a tenfold higher affinity for the DP1 and EP2 receptor (Ki 4.4 and 3.6 nM, 
respectively) than the IP receptor [45]. On the other hand, iloprost had a ≥240-fold 
lower affinity for DP1 and EP2 but was equipotent at the IP and EP1 receptor [45]. A 
similar potency pattern was observed in functional assays (cAMP and calcium) in 
the same study, confirming the unique pharmacology of treprostinil [6], which was 
subsequently independently verified [46]. It is known that receptor affinities can 
differ significantly between species for natural ligands as well as for their agonists 
[6] and antagonists [47] so future experiments should be directed towards obtaining 
the binding affinity profile of treprostinil at mouse and rat prostanoid receptors (and 
for that matter some prostacyclin drugs) and how different models of PAH affects 
receptor expression in relevant tissues and cells.
The receptor selectivity of prostacyclin and its mimetics could greatly impact 
on their control of pulmonary haemodynamics and vascular remodelling in PAH as 
well influence their side-effect profile. It is presumed that the IP receptor-selective 
agonists will have fewer adverse events than those agents which activate multi-
ple receptors although this remains to be determined clinically. For the remainder 
of this chapter, the physiological and pathophysiological context of these distinct 
membrane receptor profiles for the different prostacyclin mimetics will be evalu-
ated. Comparative prostanoid receptor expression profiles in normal and diseased 
lung will be described and how this has the propensity to affect the mode of action 
of prostacyclin mimetics in arteries and veins and other cell types in PAH. We will 
also focus on the importance of EP2 and EP4 receptors as negative modulators of 
pulmonary artery smooth muscle tone, cell proliferation and fibrosis, and how these 
receptors alongside DP1 receptors may have a specific role in the veins and the air-
ways. Other data suggests that limiting EP3 receptor activation will be beneficial in 
PAH as this receptor is upregulated by hypoxia and activates TGF-β signalling and 
may thus oppose signalling through BMPR2 receptors.
5.3  Prostanoid Synthesis and Receptor Expression
Prostanoids are derived from cyclooxygenase isoenzymes (COX-1 and COX-2), 
which convert arachidonic acid to an unstable intermediate, prostaglandin H2, the 
common precursor for five principal bioactive derivatives. TXA2, prostaglandin F2α, 
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prostaglandin E2 (PGE2), prostacyclin and prostaglandin D2 (PGD2) are then gen-
erated by the action of individual prostaglandin synthase enzymes. Once gener-
ated, the different prostanoids exert their pharmacological and biological effects 
by binding to and activating specific membrane bound G-protein-coupled receptors 
(Fig. 5.1). EP1, EP3, FP and TP receptors are contractile receptors coupled to Gq and 
Gi that either elevate intracellular Ca2+and/or reduce cAMP, respectively. EP2, EP4, 
IP and DP1 receptors are vasorelaxant receptors coupled to Gs that will activate ade-
nylate cyclase and elevate intracellular cAMP (Fig. 5.1). The DP2 (CRTH2) recep-
tor, which has no significant homology to other prostanoid receptors, recognises 
PGD2 as its endogenous ligand and is involved in allergic or T-helper 2 cell inflam-
mation, with antagonists currently being trialled as a novel therapy for asthma. As 
the receptor is not activated to any significant extent by prostacyclin mimetics [48], 
for this reason it will not be further discussed.
As mentioned already, prostacyclin analogues have diverse effects on prostanoid 
receptors, with different IP receptor agonists likely to activate EP1 (iloprost), EP3 
(prostacyclin) and EP2 or DP1 (treprostinil) receptors within their therapeutic dose 
range [6]. TP receptor activation by prostacyclin might come into play if either the 
plasma concentration is in excess of 50 nM (twice the reported plasma concentra-
tion in patients [49]), the receptor becomes primed by other vasoconstrictor agents 
(cross-sensitization), and/or its activity increases because the receptor becomes 
uncoupled from IP receptors, dimerization of which normally limits the deleterious 
effects of thromboxane [6]. Thus in order to understand the mode of action of these 
drugs in the therapeutic setting, it is important to assess the relative expression, 
function and impact of PAH on prostanoid receptors in small arteries and veins, the 
major sites of vessel disease. We have, therefore, sought to assess their expression 
in lung sections from control and PAH patients with end-stage disease using meth-
ods previously described [44]. For comparison, bronchial sections were examined 
and acted as a positive control since the staining for IP, EP1–4 and DP1 was strong to 
moderately strong for all of these receptors in the respiratory epithelium (Fig. 5.2).
5.3.1  Bronchial Smooth Muscle
IP, EP2 and EP3 receptor staining was strong in the bronchial smooth muscle, with 
EP2 being the strongest (Fig. 5.2a). DP1 staining was moderately strong, and EP4 
staining less uniform, but nonetheless the smooth muscle stained positively, while 
overall EP1 receptor expression was weak. In studies conducted nearly 20 years ago, 
IP, EP2 and to a lesser extent DP1 receptors, but not the EP4 receptor, were reported 
to be associated with human bronchus relaxation as assessed by prostacyclin ana-
logues, PGE2 and PGD2 [50]. Furthermore, PGE2 did not induce relaxation in tra-
cheal smooth muscle preparations from EP2 receptor knockout mice [51], consistent 
with these earlier observations of a dominant role for EP2 receptors in regulating 
airway smooth muscle tone. However, more recent studies using highly specific 
receptor agonists and antagonists suggest that the EP4 receptor is the main receptor 
subtype to promote relaxation to PGE2 in human small airways [52]. However, in 
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the same study, EP2 receptors were reported to inhibit mast cell-mediated broncho-
constriction, highlighting a novel and potentially important function of EP2 recep-
tors. Inhibition of mast cell function might be considered beneficial in the context 
of PAH. Increasingly mast cells are thought to promote vascular remodelling in lung 
disease, including in PAH, releasing a number of mediators like histamine, PGD2, 
leukotrienes, pro-inflammatory cytokines and growth factors like TGF-β [53].
With respect to contractile prostanoid receptors in the bronchus, TP receptors 
are the predominant functional contractile prostanoid receptor and appear to medi-
ate contractions induced by high concentrations of PGE2 [52, 54]. The latter would 
fit in with the relatively weak expression of EP1 receptors that we observed in the 
human bronchus muscle (Fig. 5.2a). Based on this pharmacology, and that neither 
treprostinil nor iloprost has significant activity at TP receptors, it is suggested that 
these agents will be effective bronchial dilators through the IP receptor. EP4 recep-
tors may contribute to iloprost-induced relaxation, though given iloprost has a Ki of 
212 nM at this receptor [45], the inhaled drug would have to reach concentrations in 
excess of 100 nM in order to do so. This is highly unlikely given the upper plasma 
concentrations of iloprost in patients is ~1  nM [6]. DP1 receptors are, however, 
likely to contribute to treprostinil-induced bronchial relaxation. As EP2 receptors 
were the most highly expressed prostanoid receptor in the bronchus smooth muscle, 
this might indicate a significant role for these receptors although further work is 
required to understand their function in small bronchi.
5.3.2  Pulmonary Blood Vessels
5.3.2.1  Endothelium
There was moderate to strong expression of all prostanoid receptors in the endo-
thelium of large and small pulmonary arteries (Fig. 5.2b, c) although the strongest 
expression was observed in small veins (Fig.  5.2d), suggesting the endothelium 
may be particularly important for maintaining the patency of blood vessels in 
the venous circulation. Few studies have investigated the involvement of human 
prostanoid receptors expressed on the endothelium and none in small pulmonary 
vessels. Moreover, studies have often assessed prostanoid effects on vascular tone 
in the presence of inhibitors of nitric oxide (NO) synthase and COX to prevent 
the release of endogenous prostanoids and NO (e.g. [55, 56]), thus masking the 
potential effect/role of the endothelium. Nonetheless, NO synthase inhibition was 
reported to augment the contractile function of PGE2 in rat pulmonary arteries [57]. 
Furthermore, a significant dependency on endothelial-derived NO for relaxation 
induced by beraprost and treprostinil in rat and human pulmonary arteries has been 
reported [58, 59], which is likely to be associated in part by activation of the IP 
receptor. Curiously, both MRE-269 and iloprost show no endothelial dependence 
to their vasorelaxant actions in pulmonary arteries [58, 59], demonstrating a dif-
ferential mechanism of these two prostacyclin mimetics compared to beraprost and 
treprostinil. The clinical significance of these findings is unclear but may suggest 
differences in the clinical efficacy of combination therapies based around potentia-
tion of NO signalling (e.g. phosphodiesterase type 5 inhibitors).
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5.3.2.2  Pulmonary Artery
There was expression of all prostanoid receptors in the medial layer of large arteries, 
though EP1 receptor expression was moderate to weak, as was EP2 receptor staining 
which was mainly confined to the outer medial layer (Fig. 5.2b). Our immunos-
taining data broadly support many of the previously published findings investigat-
ing receptor expression and contractile function in large (control) pulmonary blood 
vessels from humans. In arterial preparations, the IP receptor was found to be the 
predominant receptor involved in relaxation [55], while EP3 and TP receptors were 
the main contractile receptors to counteract this [60]. In other studies, EP4 and DP1 
receptors were found to be expressed in human pulmonary arteries whereas EP2 
and EP1 receptors were not [19, 56]. This would generally fit with the moderate to 
strong IP, EP3, EP4 and DP1 receptor staining, the generally weaker staining of the 
EP1 receptor we observed in larger arteries coupled with the overall weak staining of 
EP2 receptors that was recently reported in large and small pulmonary arteries [44].
5.3.2.3  Differential Prostanoid Expression in Distal Pulmonary 
Artery and Veins
There were some distinctive features of prostanoid receptor expression in small 
arteries (Fig. 5.2c) and veins (Fig. 5.2d) in control sections of lung tissue that are 
worth noting. Staining for EP2 receptors was weak in the medial layer of arteries, 
but strong in veins, with a broadly similar picture for DP1 receptors. By contrast, 
EP3 staining was observed throughout the media in arteries but was generally con-
fined to the outer layer of the vein juxtaposed with the adventitia although the endo-
thelium was, however, strongly stained. Likewise, the EP4 receptor antibody stained 
the medial layer of the distal artery, and greater staining was observed in the vein 
compared to EP3. With respect to the IP receptor, staining appeared stronger in the 
artery compared to the vein, while the EP1 receptor antibody moderately stained 
both small artery and vein.
5.3.2.4  Distal Pulmonary Veins
Previous experiments in human proximal veins have provided clear evidence that 
prostanoid IP, DP1 and EP4 receptors mediate relaxation to prostanoids whereas TP 
and EP1 receptors mediate constriction [55, 56, 61]. The particularly strong expres-
sion of EP2 and DP1 receptors in the endothelium and medial layer of small veins 
suggest a functional role of these two prostanoid receptors in regulating venous 
tone. Such an observation may explain why PGE2 and PGD2 are strong relaxants of 
human proximal pulmonary veins constricted with phenylephrine whereas they fail 
to cause relaxation in pulmonary arteries under similar experimental conditions [55, 
56]. DP1 receptors are expressed at the protein level in veins and reported to underlie 
in part the venorelaxation to treprostinil [19]. This is consistent with the observation 
of only a partial dependence of the IP receptor in mediating relaxation to treprostinil 
in both human [19] and rat pulmonary veins [62]. Furthermore, 40% of relaxation 
to treprostinil in human vessels still remained in the presence of both a DP1 and 
IP receptor antagonist, suggesting an additional mechanism contributing to relax-
ation [19], possibly via EP2 receptors. Indeed, functional EP2 receptors have been 
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reported in large human pulmonary veins, with the EP2 agonist, ONO-AE1-259, 
causing relaxation, albeit at relatively high concentrations [56]. The prediction is 
that EP2 receptors will play a greater role in small pulmonary veins, given its strong 
expression both in the endothelium and in the medial layers. To our knowledge, 
there have been no reports investigating the role of EP2 receptors in small pulmo-
nary vessels, so the functional consequence of these receptors requires investiga-
tion. Elsewhere in the vasculature, the main vasodilator response to PGE2 appears 
to be driven by the EP2 receptor as PGE2 produces hypotension in wild-type mice 
compared to substantial hypertension in EP2 null mice [63]. This suggests a major 
role for EP2 receptors in regulating vascular tone, at least in mice.
In terms of the function of other prostanoid receptors, EP4 receptor agonists (e.g. 
ONO-AE1–329) strongly relax human pulmonary veins, and these were partially 
inhibited by an EP4 antagonist as were PGE2-induced relaxations [56]. Surprisingly, 
iloprost relaxations in pulmonary veins (and also arteries) were insensitive to EP4 
receptor antagonists [19]. Thus the EP4 receptor as a proposed target for iloprost- 
mediated vasodilation during therapeutic use in human PAH [64] is so far not sup-
ported experimentally. Whether this relates to iloprost acting at various receptor 
targets (IP, EP4 and PPARs)  to cause relaxation, thus requiring the simultaneous 
treatment with multiple antagonists to inhibit functional responses is unclear, but 
supported by experimental observation in other vascular tissues [65]. EP4 activa-
tion may be thwarted by the potent actions of iloprost at EP1 receptors. Indeed 
EP1 antagonists enhance iloprost and PGE2 relaxation in human pulmonary veins 
and also underlie contractions seen by these two agents in the same tissue [55, 56, 
61]. Likewise, the presence of an EP1 antagonist was required before the relaxant 
effect of prostacyclin in pulmonary veins approached that in pulmonary arteries 
[66]. Furthermore, beraprost strongly relaxed human pulmonary arteries but not 
veins [19] whereas treprostinil was a stronger venorelaxant than an arterial relaxant 
in rat distal pulmonary blood vessels [62], presumably through its combined action 
at IP, DP1 and EP2 receptors. Such findings might provide a rationale for investi-
gating the effects of treprostinil in pulmonary hypertension (PH) associated with 
post-capillary disease, of which PH due to left heart dysfunction is characterised 
predominantly by venoconstriction and remodelling (see later).
5.3.3  Prostanoid Receptor Expression in PAH
In lung sections derived from a patient with PAH, prostanoid receptor expression 
in the bronchi remained largely unchanged, the exception being the DP1 receptor, 
expression of which went up in the bronchial smooth muscle (Fig. 5.3a). In contrast, 
there were marked changes to expression in pulmonary blood vessels (Fig. 5.3b–d). 
There was a reduction in the expression of all prostanoid receptor subtypes in the 
endothelium of arteries and veins, with IP and EP1 receptor staining barely evident 
in small arteries, while EP3 receptor expression appeared particularly reduced in 
the vein. Some loss of staining is undoubtedly due to endothelial damage which 
was apparent in many blood vessels. The pattern of prostanoid receptor expression 
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was somewhat different in smooth muscle. Prostanoid EP3 receptor staining was 
increased in the medial layer of large and small arteries and in the vein compared to 
control, while EP4 and EP2 receptor antibody staining was increased in small arteries 
and veins. Similar to EP2 and EP4 receptors, DP1 receptors were found to be strongly 
expressed in the small artery and vein. In contrast, IP receptor expression was weak 
in arteries and veins. Finally, the expression of EP2 receptors in the adventitial layer 
of both large and small arteries and veins was marked, being particularly strong in 
PAH lung sections as was the case for the EP4 receptor in small arteries (Fig. 5.3c). 
Staining in the adventitial layer is likely to come from fibroblasts, which preside pre-
dominately in this layer, undergoing proliferation in PAH and producing significant 
amounts of collagen to increase adventitial thickness [67, 68]. This was evidenced 
by the Van Gieson (EVG) stain which showed extensive collagen deposition (red 
staining). We cannot rule out the possibility that EP2 and EP4 receptor staining comes 
from inflammatory cell types, particularly monocytes and dendritic cells, which can 
be found in the adventitia of remodelled arteries in PAH [4, 67] and which express 
functional EP2 and EP4 receptors [60, 69]. Whether EP4 receptors can account for 
any of the IP receptor-independent effects of iloprost on cell growth in PASMCs 
from PAH patients, where EP4 function may be upregulated, requires investigation.
5.3.3.1  Downregulation of IP Receptors in PAH
It was not unexpected to find that IP receptor expression was downregulated in the 
arteries and veins in PAH, as previous studies have shown that mRNA and protein 
levels are substantially reduced both in the lungs and in PASMCs derived from 
PAH patients compared to controls [22, 64]. Furthermore, in a rat monocrotaline 
model of PAH, IP receptor mRNA levels were decreased while EP4 and EP2 receptor 
expressions were preserved [64], although in another study using the same model, 
no decrease in the IP receptor expression was found [33]. In a sugen/hypoxia model 
of severe PAH, the IP receptor was minimally expressed in whole lungs, and ilo-
prost did not reduce mean PAP despite improving cardiac output [70]. This might 
suggest that in severe disease IP receptor function in the pulmonary circulation may 
be limited or be curtailed by the activation of prostanoid vasoconstrictor pathways 
opposing signalling through this receptor. That IP receptors were still functional 
in cultured PASMCs from PAH patients and significantly contributed to the anti- 
proliferative effects of non-prostanoid IP agonists may, however, be counterintui-
tive. It might be expected that due to the substantive drop in IP receptor expression 
found even in cell culture, combined with cells having been exposed to long-term 
prostacyclin therapy (epoprostenol or iloprost) for several months prior to isolation 
[22, 44], this would lead to substantive receptor desensitisation. Because this did not 
happen, it might suggest either a large IP receptor reserve (redundancy) in the sys-
tem and/or that IP function recovers sufficiently well in culture before agonist treat-
ment. Other studies have suggested that partial agonism leads to limited β-arrestin 
recruitment and less  IP receptor internalisation, and hence a lower likelihood of 
receptor desensitisation with MRE-269 compared to other analogues [38]. Against 
this notion, MRE269 still remains the weakest anti-proliferative agent when com-
pared to other prostacyclin analogues in the same assay [37].
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5.3.3.2  Robust Expression of EP2 and EP4 Receptors in PAH: Key 
Anti-Fibrotic Targets
A striking difference in the pattern of prostanoid receptor mRNA expression was 
recently reported in human PASMCs derived from control versus PAH patients [44]. 
While prostanoid IP, EP2 and EP4 receptor mRNA levels were similarly expressed 
in control cells, the relative expression of EP2 or EP4 over the IP receptor was 
enhanced 84- and 15-fold, respectively, in PAH cells, suggesting that signalling 
through these receptors may be well-maintained or even upregulated in PAH [44]. 
Indeed, EP2 and EP4 receptors, as evidenced by the use of butaprost (selective EP2 
agonist) and iloprost, respectively, were functionally coupled to cAMP generation 
in PASMCs cells derived from either patients or rats with PAH [44, 64]. Moreover, 
using the selective EP2 receptor antagonist, PF-04418948 [71] as well as EP2 recep-
tor siRNAs, the anti-proliferative effects of treprostinil were found to be mediated 
by this receptor over a wide concentration range (0.1–1000 nM) in human PASMCs 
from PAH patients [44]. This corroborates with an earlier observation that an IP 
receptor- and adenylate cyclase-independent mechanism was largely responsible 
for the anti-proliferative effects of treprostinil in the same diseased cell type, and 
appeared also to be the case for iloprost [22]. With respect to treprostinil, PPARγ 
plays a significant role in mediating the anti-proliferative effects of treprostinil in 
human PASMCs isolated from PAH patients [22] and by inference involves the EP2 
receptor in its activation although this remains to be established. Other PPARs may 
contribute to the anti-proliferative effects of beraprost [72] though this has not been 
investigated in PASMCs.
From a pharmacological perspective, this switch towards signalling via the EP2 
receptor with treprostinil may with hindsight not be surprising. Based on the high 
relative EP2/IP receptor expression (84-fold) and that treprostinil has a tenfold 
greater affinity at the EP2 receptor compared to the IP receptor [45], it suggests that 
it is >800× more likely to activate the EP2 over the IP receptor in PAH cells. This 
does not necessarily mean that the IP receptor would not be activated by treprostinil 
at therapeutic doses as IP receptor activation could be observed under conditions 
of substantial EP2 antagonism [44]. The situation is in stark contrast to the mode 
of action of the non-prostanoid IP agonists, MRE-269 and ralinepag, where the IP 
receptor appears to be entirely responsible for their anti-proliferative properties in 
cells from PAH patients assessed under similar experimental conditions [37, 44]. At 
this stage it is unknown whether non-prostanoid IP agonists can bind to PPARs and 
act in concert with the IP receptor [73] to promote their biological effects, but this 
is key information to ascertain.
The observation that EP2 receptor expression was abundant relative to other pros-
tanoid receptors may imply that it is upregulated as a consequence of disease. In this 
respect, EP2 receptor expression can be enhanced in response to platelet-derived 
growth factor [74, 75] and transforming growth factor β [76], key drivers of smooth 
muscle proliferation in PAH [4]. Moreover, significantly more EP2 receptors per 
cell (but not EP4) were detected in asthmatic airway smooth muscle cells compared 
with non-asthmatic cells, and were found to be associated with enhanced sensitiv-
ity to the anti-proliferative effects of both PGE2 and butaprost but not to either 
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prostacyclin or forskolin [74]. Likewise, EP2 (and EP4) receptor expression was 
enhanced in lung fibroblasts derived from patients with chronic obstructive pulmo-
nary disease [77, 78]. Such observations are consistent with enhanced EP2 receptor 
function/activity in airway remodelling as well as in PAH. While the role of the EP2 
receptor in the context of remodelling in PAH is unknown, it should be noted that 
the activation of EP2 receptors has a range of inhibitory effects on fibroblast func-
tion that could have beneficial effects in PAH. Treatment of human lung fibroblasts 
with either PGE2 or butaprost inhibits migration [79]. In addition, PGE2 inhibits the 
transition of fibroblasts to myofibroblasts [80] and is capable of suppressing fibro-
blast proliferation and collagen synthesis through EP2 receptor-mediated pathways 
[81]. Indeed, anti-fibrotic properties of treprostinil have been reported both in vivo 
(bleomycin-induced pulmonary fibrotic model) and in vitro (inhibition of TGF-β- 
stimulated collagen production), though the receptor involved was not defined in 
these studies [82, 83]. It should also be mentioned that some of the above effects 
can be replicated by EP4 receptors [47, 84], suggesting some overlapping function 
of EP2 and EP4 receptors in regulating fibroblast function. Iloprost appears to ame-
liorate established cardiac fibrosis by preventing collagen synthesis and increasing 
collagen turnover, and though the receptor mechanism was not specifically estab-
lished in this study, evidence was presented that the IP receptor was probably not 
involved [70]. It is worth noting that in a high-throughput screen to assess the thera-
peutic potential of novel drugs in pulmonary fibrosis, drugs acting at either the EP2 
or EP4 receptor were identified as amongst the most effective agents at inhibiting 
TGF-β-induced myofibroblast differentiation via the SMAD2/3 pathway [85].
5.3.3.3  EP3 Receptors May Contribute to Disease Pathology in PAH
It is important to understand the role of contractile prostanoid receptors as these could 
limit the doses of prostacyclin mimetics given therapeutically or potentially give rise 
to unwanted side effects. Of note, EP3 expression went up in small arteries from PAH 
patients, as has been reported in the airway smooth muscle cells derived from asth-
matic patients compared to controls [74]. Likewise, enhanced EP3 expression was 
observed in rodent models of PAH [33, 86] and was associated with increased sensitiv-
ity to the EP3 agonist, sulprostone, suggesting a gain of function at this receptor [33]. 
Elevated EP3 receptor expression would be predicted to dampen cAMP signalling in 
cells and hence potentially reduce prostanoid-induced relaxation in pulmonary blood 
vessels as well as relaxation to non-prostanoid IP agonists. Prostacyclin action may be 
curtailed since it potently binds to the EP3 receptor (Ki of ~10–40 nM) and the plasma 
concentration in patients (~25 nM) would be in the range for receptor activation [6, 
49]. Many studies have provided evidence that the contractile effects of prostacyclin 
analogues are mediated through EP3 receptors [33, 58, 65, 87] and that their inhibi-
tion can enhance vasorelaxation induced by these agents [33, 65]. However, based 
on binding affinities, EP3 receptors are unlikely to be activated by prostacyclin ana-
logues in the clinical setting; the upper plasma concentration achieved in humans is 
~1 nM for iloprost and ~50 nM for treprostinil which is 50× the Ki for both drugs [6]. 
Consistent with this interpretation, the contractile effects of prostacyclin analogues 
are only observed at high concentrations (≥1000 nM) in distal rat pulmonary arteries 
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although priming of the tissue with phenylephrine was required before contractions to 
treprostinil were even observed [87]. Thus any counteracting effect of EP3 is likely to 
arise from basal activity of the receptor and not from direct activation by prostacyclin 
analogues. EP3-TP-induced vasoconstrictive synergism has been described in blood 
vessels where priming with a TXA2 mimetic markedly increases both the potency and 
size of contraction to EP3 agonists (see [87]). Enhanced synergy between EP3 and TP 
receptors could occur in PAH because of increased TXA2 levels [88] and because of 
enhanced activity of EP3 receptors. Such an interaction might provide an explanation 
of why iloprost showed far less relaxation and sensitivity in human pulmonary arteries 
when contracted with the TXA2 mimetic (U46619) as opposed to phenylephrine [87]. 
This might suggest that the vasodilatory responses of prostacyclin and iloprost in the 
lung may be more adversely affected in patients with high TXA2 levels compared to 
other IP receptors agonists which either have less sensitivity towards the EP3 receptors 
or do not activate them.
EP3 receptors may contribute to disease pathology in PAH as inhibition of 
EP3 receptors either pharmacologically or through deletion of smooth muscle 
EP3 receptors attenuated right ventricular systolic pressure (RVSP) and vascular 
wall thickness in rats with mild (chronic hypoxia), moderate (monocrotaline) or 
severe (sugen/hypoxia) PAH [86]. Interestingly, the mechanism appeared related to 
hypoxia-induced TGF-β activation via Rho-associated kinase, with the downstream 
activation of SMAD2/3 leading to extracellular matrix remodelling via upregulation 
of collagen 1, fibronectin and tenascin-C genes. Effects were, however, independent 
of cell proliferation [86], so this suggests that the main role for the EP3 receptor is 
to module vascular tone and stiffness in PAH through TGF-β-induced changes in 
extracellular matrix remodelling.
5.3.3.4  Role of the Veins in PAH and Other Classified Groups of PH
The extent to which venous remodelling contributes to the pathology in PAH is 
currently a subject of much debate [89] and is thwarted by the lack of good venous 
biomarkers and the difficulty in identifying veins that might masquerade as a remod-
elled artery. We can functionally distinguish distal arteries from veins on the basis of 
their differential response to PGD2 and PGE2 in blood vessels pre-contracted with 
U46619 (thromboxane mimetic). The former relaxes veins while having little effect 
on tone in arteries, contrasting with PGE2, which has potent contractile effect in 
arteries but is minimally contractile in veins under similar experimental conditions 
(unpublished observations). Whether this will be observed in remodelled veins and 
arteries is unknown but should be investigated. Strong expression of DP1 and EP2 
and EP4 receptors in veins suggests this pattern of response may be preserved.
Elucidating the role of venous remodelling in PH and what might be an effective 
treatment strategy is complicated by their being a spectrum of disease. This might 
be seen as a continuum from pure pre-capillary disease (perhaps defined as IPAH) to 
secondary causes giving rise to a mixed pre- and post-capillary disease (e.g. CTD) 
through to a predominantly post-capillary phenotype, epitomised by PH due pul-
monary venoocclusive disease or left heart disease. Interestingly, increased pulmo-
nary venous remodelling has recently been demonstrated in PAH patients harbouring 
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BMPR2 mutations compared to those without, showing a somewhat similar histo-
logical presentation to inoperable chronic thromboembolic pulmonary hypertension 
(CTEPH) with persistent PH, i.e. fibrotic lesions associated with bronchial to pul-
monary shunting [90, 91]. In the context of PH, targeting the veins is important as 
remodelled veins will significantly contribute to PVR, and mismatching (dilation 
in arterial but not venous side) will cause higher sheer stress in veins and increase 
PAP. Enhanced collagen deposition, which makes veins less distensible, would also 
contribute to the elevated pressure. In primary PH (IPAH), intimal and adventitial 
thickening of pulmonary veins <250 μm was estimated to be observed in ~50% of 
cases [92]. Given this study predates the discovery of BMPR2 mutations in the IPAH 
population [8, 11], and that the current definition of IPAH has a more stringent hemo-
dynamic definition (lower mean PAP and pulmonary artery wedge pressure), sug-
gests that this figure might be overestimated and should thus be re-evaluated [93].
In humans, pulmonary veins have a greater vasoconstrictor sensitivity towards 
ET-1, TXA2, leukotrienes and platelet activating factor (PAF) than in arteries, a 
finding reported in many animal species as well [94]. In addition, numerous stud-
ies have shown intense constriction of pulmonary veins in response to hypoxia in a 
variety of species which may involve the release of ET-1 and TXA2 [94]. The con-
sequence of venous constriction will be to increase pulmonary capillary pressure 
and thus promote pulmonary oedema. ET-1 is known to increase capillary perme-
ability via post-capillary vasoconstriction, which is also dependent on the presence 
of inflammatory cells [95]. Experiments in EP3 receptor null mice suggest that the 
EP3 receptor is responsible in part for oedema triggered by PAF in rat lungs [96] 
and, as discussed above, is also linked to enhanced collagen production [86]. It also 
suggests that hypoxia in the veins may be an underlying trigger for oedema via this 
prostanoid receptor.
The potential for the deleterious effects of prostacyclin (epoprostenol) in patients 
with severe congestive heart failure and POVD, and the failure of agents that 
increase cGMP (riociguat and sildenafil) to show significant improvement in the 
context of PH with left heart disease, has led to the belief that vasodilatory therapy 
is not appropriate or at least controversial in this setting [89, 97, 98]. Several fac-
tors may account for the problems faced with epoprostenol use in patients with 
diagnosed venous disease. Not only is this agent predicted to be a poor venodila-
tor in humans [19], due in part to its actions on the EP1 receptor in veins [66], but 
also the activation of the EP3 receptor is likely to cause oedema and perpetuate 
vasoconstriction [94]. The latter may help to explain why pulmonary oedema is 
commonly reported in POVD patients on epoprostenol therapy [98], particularly 
in those patients on higher doses of the drug, which would give rise to significant 
activation of the EP3 receptor. In severe venous disease, the hypoxic environment 
coupled with high TXA2 levels and low IP receptor function might actually be pre-
dicted to convert prostacyclin into a venoconstrictor, which would have detrimental 
consequences (c.f. [97]). For similar reasons, the use of iloprost and beraprost may 
also be contraindicated in PH-related venous disease. Both, particularly beraprost, 
are better arterial dilators than venodilators in human pulmonary blood vessels. 
Iloprost has potent actions on the contractile EP1 receptor [45] which is functionally 
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expressed in veins, while repeated administration with beraprost in mice has been 
reported to increase circulatory TXA2 levels [24]. Whether such an effect occurs in 
humans remains to be determined, but this might explain why beraprost is a particu-
larly poor venodilator and why effects may not be sustained in PAH patients [1]. In 
contrast, MRE-269, which is devoid of significant EP3 receptor activity, is surpris-
ingly a slightly better veno than an arterial vasorelaxant, the significance of which 
remains unclear but might suggest some usefulness in treating venous disease.
The pharmacological profile of treprostinil suggests it should be seriously con-
sidered as a treatment option in PH associated with venous remodelling. Its ability 
to activate IP, DP1 EP2 receptors coupled to the robust expression of the latter two 
receptors in PAH suggests that its use could provide a beneficial response both 
as a venodilator and as an anti-fibrotic agent even in the absence of the IP recep-
tor. As such, the efficacy of oral treprostinil, in a multi-centre randomised double 
blinded trial, is currently being investigated in patients with PH in heart failure 
with preserved ejection fraction (TDE-HF-301). On a cautionary note, in a retro-
spective analysis of a PAH cohort (1996–2006) with high rate of contamination 
from post-capillary disease (of different aetiologies), patients with a mean pulmo-
nary artery wedge pressure (PAWP) >12 did not show meaningful changes in PVR 
or PAP whereas those classified as having ‘pure’ pre-capillary disease did [93]. 
This occurred despite patients having a significant increase in cardiac output and a 
placebo- corrected improvement in 6-min walk test of 35 m compared to 23 m in the 
IPAH group. Interestingly, in another randomised study of non-operable CTEPH 
or persistent PH pulmonary hypertension, patients did respond to treprostinil with 
significant hemodynamic improvement, including in PVR and mean PAP [99]. The 
extent to which these patients had venous disease was not reported, but it is possible 
that venous improvement may have occurred.
5.4  BMPR2 and TGF-β Signalling in PAH and Impact 
of Prostacyclin Analogues
Since the original discovery of a loss-of-function mutation in the gene encoding 
for BMPR2 being associated with PAH, more than 300 disease-causing mutations 
have been described throughout the BMPR2 gene, including critical regions such 
as the kinase domain [8, 11]. BMPR2 is a transmembrane serine-threonine kinase, 
which serves as a receptor for bone morphogenetic proteins (BMPs). In associa-
tion with a co-receptor, usually BMPR1A, BMPR2 can signal through multiple 
pathways, including the canonical Smad1/5/8-dependent pathway (Fig. 5.4) [5, 6, 
8]. The impact of prostacyclin analogues on BMPR2 signalling was investigated by 
Yang and colleagues in 2010 [9]. They found that iloprost and treprostinil enhanced 
BMP-induced phosphorylation of Smad1/5 and caused induction of the inhibi-
tor of DNA-binding protein 1 (Id1), both of which are downstream effectors of 
BMPR2  in normal PASMCs (Fig. 5.4). The growth-suppressive effects of BMPs 
were re-established in PASMCs derived from patients harbouring BMPR2 muta-
tions without restoring BMPR2 protein levels, consistent with a mechanism that 
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bypasses the defective receptor. The prostanoid receptor involved remains undeter-
mined although prostacyclin analogue effects on BMPR2 signalling were shown to 
be cAMP/PKA-dependent. Likewise, the phosphodiesterase type 5 inhibitor, silde-
nafil, another PAH therapy, was able to enhance BMPR2 signalling either in normal 
or mutant cell PASMCs by acting through cyclic GMP-dependent protein kinase I 
[100]. Thus, prostacyclin drugs known to act by increasing NO (beraprost, epopros-
tenol and treprostinil) might be predicted to promote a more robust activation of this 
pathway, with or without sildenafil.
In addition to a deficit in Smad1/5 phosphorylation, heightened Smad2/3 phos-
phorylation and transcriptional activity have been demonstrated in BMPR2-mutant 
PASMCs, indicative of increased pro-proliferative TGF-β signalling unopposed 
by growth-suppressive BMPR2 signalling [101]. Moreover, in contrast to normal 
PASMCs, upon which TGF-β has growth-suppressive effects, TGF-β promotes the 
proliferation of BMPR2-mutant PASMCs. The prostacyclin analogue beraprost 
Fig. 5.4 Prostacyclin analogues can enhance bone morphogenic protein receptor type 2 (BMPR2) 
signalling and oppose cell growth induced via the transforming growth factor beta 1 (TGF-1β) 
receptor pathway. Upon ligand binding, the BMPR2 receptor phosphorylates a type I receptor 
(ALK1, ALK2, or ALK6) leading to the phosphorylation of SMAD 1/5/8. The subsequent phos-
phorylation of SMAD 4 causes translocation of the phosphorylated SMADs to the nucleus to 
modulate the expression of target genes that inhibit pulmonary artery smooth muscle cell (PASMC) 
growth and promote apoptosis. Iloprost and treprostinil enhance BMPR2-mediated SMAD 1/5/8 
phosphorylation and inhibitory DNA binding protein 1 (ID1) transcription by recruiting IP and EP2 
receptors and activating cAMP-dependent protein kinase A (PKA); induction of ID1 expression 
can also occur independently of SMADs. Activation of EP3 receptors by hypoxia in PASMCs 
pulmonary leads to Rho-dependent activation of metalloproteinase type 2 (MMP2), with the 
release of active TGF-1 β and the downstream activation of SMAD2/3 via TGF-1β type II receptor 
(TGFBR2), which phosphorylates a type I receptor, ALK5. The consequence will lead to enhanced 
proliferation and collagen deposition 
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inhibited TGF-β-induced Smad2/3-dependent signalling (Fig. 5.4) and was more 
effective at inhibiting the proliferation of BMPR2 mutant PASMCs than that of their 
wild-type equivalent. Beraprost, like iloprost and treprostinil, could, therefore, be 
rescuing the diminished BMRP2 signalling while inhibiting the augmented TGF-β 
signalling to reduce the proliferative capacity of BMPR2-mutant PASMCs. Such a 
mechanism may also be important in the heart where beraprost was shown to inhibit 
rat cardiac fibroblast proliferation by activating IP receptors and suppressing the 
TGF-β/Smad signalling pathway [102].
5.5  Regulation of TASK-1 By Prostacyclin Mimetics: 
Implications in PAH
Two-pore domain potassium channels of the KCNK gene subfamily, designated 
K2P channels, mediate leak or background potassium currents (IKN) and underlie 
the high-membrane permeability to K+ at physiological resting membrane poten-
tials [103]. KCNK3 encodes a TWIK-related acid-sensitive potassium channel, 
also known as TASK-1, and is the only TASK subunit to be expressed in either 
normal or PAH patient lungs [104]. In many cell types, including PASMCs, 
extracellular acidosis strongly and reversibly inhibits TASK-1 currents and 
causes membrane depolarisation whereas extracellular alkalosis enhances the 
currents mediated by TASK-1 to hyperpolarise the membrane. Several lines of 
evidence suggest a key role for TASK-1 in regulating pulmonary vessel diameter 
and, hence, vascular tone through its sensitivity to vasoactive mediators, pH, 
membrane stretch and hypoxia [105, 106]. TASK-1 currents are switched off by 
hypoxia in PASMCs and are proposed to contribute to standard terminology in 
the field [106].
In 2013, using whole-exome sequencing, novel heterozygous mutations in the 
KCNK3 gene were identified in patients with IPAH and HPAH [107]. Subsequently, 
homozygous KCNK3 mutations were later reported in patients with very aggres-
sive and early-onset forms of PAH [108]. All KCNK3 mutations have severely 
reduced whole-cell TASK-1 currents recorded from COS-7 as well as from 
PASMCs expressing both wild-type and mutant TASK-1 subunits to reproduce 
the heterozygosity observed in carriers of the mutations [104, 107]. Moreover, 
TASK-1 expression levels were found to be markedly reduced in the explanted 
lungs of patients with IPAH but lacking disease-causing KCNK3 mutations [109], 
suggesting more widespread dysfunction of TASK-1 in PAH. Consistent with this 
notion, rats chronically treated with A293, a selective blocker of TASK-1 channels, 
were shown to develop early manifestations of PAH, including muscularisation 
of distal pulmonary arteries (normally non-muscular) and elevated RVSP [109]. 
Histological analysis of pulmonary arteries from these A293-treated rats revealed 
marked proliferation of pulmonary arterial endothelial cells (PAECs), PASMCs 
and pulmonary adventitial fibroblasts [109]. Moreover, TASK-1 currents were 
also shown to be attenuated in PAECs and PASMCs derived from the lungs of 
patients with HPAH due to BMPR2 mutations, suggesting that TASK-1 channel 
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downregulation might represent a second hit required for PAH to manifest in car-
riers with BMPR2 mutations [109].
Activation of different potassium channel types represents an important mecha-
nism underlying the vasorelaxing properties of prostacyclin analogues, includ-
ing large-conductance calcium-activated, ATP-sensitive and TASK-1 potassium 
channels [6, 110]. TASK-1 appears to be a downstream target of the IP receptor 
where iloprost and treprostinil have both been shown to equipotently (EC50 1 nM) 
enhance IKN currents through TASK-1 channels in normal human PASMCs [110]. 
The effects of iloprost and treprostinil on TASK-1 currents were mimicked by 8-br-
cAMP, a membrane-permeant form of the second messenger cAMP, and blocked 
by the protein kinase A (PKA) inhibitor, KT5720 and the IP receptor antagonist, 
RO1138452, suggesting that in healthy human PASMCs prostacyclin analogues 
signal primarily via the IP/cAMP/PKA pathway to increase TASK-1 currents 
(Fig.  5.5) [106, 110]. Consensus PKA phosphorylation motifs were  also identi-
fied within TASK-1 and treprostinil was shown to promote the phosphorylation 




































Fig. 5.5 Opposing regulation of TASK-1 by prostacyclin analogues and by hypoxia. TASK-1 in 
pulmonary arterial smooth muscle cells (PASMCs) is activated by prostacyclin analogues via the 
IP or EP2 receptor, while EP3 receptors oppose this action either through lowering cyclic AMP 
(cAMP) or via activation of the Rho pathway. Hypoxia-induced synthesis of  thromboxane A2 
(TXA2) or endothelin-1 (ET-1) will inhibit TASK-1 though activation of Gq or G11/12. DAG diacyl-
glycerol, PKA protein kinase A, ROCK Rho-associated protein kinase 
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the forward trafficking of TASK-1 channel subunits from the ER (where they are 
synthesised) to the plasma membrane where they assemble to form functional, cur-
rent-conducting channels [111, 112]. Thus, treprostinil or iloprost could be increas-
ing TASK-1 currents in human PASMCs by promoting the forward trafficking of 
TASK-1 channel subunits from the ER to the sarcolemma. Whether iloprost and 
treprostinil can rescue the depressed TASK-1 currents in PASMCs from patients 
with PAH, and whether these channels contribute to the anti-proliferative effects of 
prostacyclin analogues, remain to be established. Downregulation of the IP recep-
tor in PAH could mean that iloprost becomes less effective at enhancing TASK-1 
currents than treprostinil, which is also able to recruit the EP2 receptor to enhance 
TASK-1 currents [113].
Several mechanisms may account for the depressed function of TASK-1  in 
PAH. Gq-coupled receptors, including those activated by ET-1, 5-HT and TXA2, 
suppress current through TASK-1 channels (Fig.  5.5) [103]. Given that all these 
mediators would be elevated in PAH [5, 88, 114], this may lead to a generalised 
inhibition of the channel. Prostacyclin analogues are potent inhibitors of ET-1 syn-
thesis, both in pulmonary endothelial and smooth muscle cells [6], so these agents 
could negate the inhibitory effects of ET-1 on TASK-1. The mechanisms by which 
hypoxia inhibits TASK-1 currents are unclear but may involve increased ET-1 pro-
duction, given that ET-1 expression and secretion have been shown to be induced 
by hypoxia in pulmonary endothelial, smooth muscle cells and fibroblasts [94, 
114]. ET-1 has been shown to reduce TASK-1 currents in PASMCs by recruiting 
the RhoA/Rho kinase pathway [115, 116]. EP3 receptors have been shown to be 
upregulated in PASMCs in response to hypoxia and are directly linked to activation 
of the RhoA/Rho kinase pathway [86], so may, like ET-1, inhibit TASK-1 currents 
through this pathway (Fig. 5.5). EP3 receptors also couple to Gi/o to inhibit cAMP 
production and so could counteract the effect of prostacyclin analogues on TASK-1 
currents, particularly under hypoxic conditions.
5.6  Prostacyclin Effects on Vascular Remodelling In Vivo: 
Outstanding Issues
The key question is whether prostanoid drugs used to treat PAH patients have posi-
tive effects on vascular remodelling associated with the abnormal proliferation of 
different cell types within the blood vessel wall. In vitro studies reported from a num-
ber of laboratories using vascular cells isolated from the lungs of patients with end- 
stage disease suggest that they should do so in vivo [9, 22, 83, 101]. Our own studies 
directly comparing the anti-proliferative properties of several clinically approved 
therapies in PASMCs from PAH patients showed hugely variable responses with 
the lowest dose to significantly inhibit cell proliferation varying some 10,000-fold 
from 0.1 nM for treprostinil up to 1 μM for the ET-1 receptor antagonist bosentan 
[117]. By inference, therapies are, therefore, likely to have vastly different effects 
on the remodelling process in vivo and pose challenges when designing protocols. 
Nonetheless, translation into positive effects on vascular remodelling has been 
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consistently reported in a monocrotaline model of PAH where treprostinil, bera-
prost and iloprost all significantly improved pulmonary haemodynamics as well 
as reducing muscularisation and the cell proliferation index of small blood vessels 
[9, 118–120]. This may in part be due to the analogue effects on inflammatory cell 
types like macrophages, dendritic cells and mast cells [6], which play a pivotal role 
in regulating pulmonary vascular remodelling in the monocrotaline model [121] 
and also in humans [53, 67, 89]. Dysfunctional BMPR2 signalling can also be res-
cued by prostacyclin analogues through their downstream enhancement of phosph- 
Smad1/5 and Id1 gene expression in monocrotaline-induced PAH in rats [9], which 
may act in concert with analogue effects on inflammatory cell types, particularly 
dendritic cells [6].
With respect to the Sugen 5416/hypoxia model of severe PH, which is a mixed 
model of group 1 (PAH) and group 3 (due to lung disease and/or hypoxia) PH, all 
analogues improved cardiac function either by reducing RVSP and RV hypertro-
phy (beraprost and treprostinil), by increasing exercise capacity and reducing car-
diac fibrosis (iloprost) or by improving the ultrastructure of the heart [70, 119, 122]. 
This would fit with data suggesting that prostacyclins have positive effects on RV 
function in the heart [123]. Beraprost, given at a high dose as an inhaled bolus in 
nanoparticles (150 μg/kg), was the only analogue to reduce the muscularisation of 
arteries, possibly suggesting under dosing may have occurred in the other two stud-
ies [70, 119, 122]. The interpretation and significance of the above results would be 
greatly enhanced if the impact of Sugen 5416/hypoxia on prostanoid receptor and 
PPAR expression was known, and if hypoxia is a confounding factor in limiting the 
ability of prostacyclin drugs to activate any of their downstream targets. This could 
occur, for example, through the excessive production of TXA2 and ET-1 within the 
blood vessel wall by hypoxia. This would lead to activation of TP receptors which 
may cause substantial IP receptor desensitisation and/or enhance EP3 receptor acti-
vation and may thus affect some analogues (iloprost and prostacyclin) more than 
others. Rats have the peculiar property in that prostacyclin analogues do not relax 
pulmonary arteries constricted with ET-1 at all whereas they strongly relax human 
arteries [47]. Whether this means that these agents are not, therefore, able to reverse 
the mitogenic effects of ET-1 in rats should be considered. Dysfunctional BMPR2 
signalling with depressed phospho-Smad1/5 and Id expression is a key feature of the 
monocrotaline-induced PAH model [9, 10] whereas surprisingly it does not appear 
to be a feature of the sugen/hypoxia model of PAH as reported in a recent study 
[122]. This represents a potentially key difference between how PAH is generated in 
these two classic models. Likewise, many drugs, including potent anti-cancer or anti-
angiogenic drugs, do not reverse remodelling in sugen/hypoxia either [124], possibly 
suggesting that enhanced drug resistance is occurring in this experimental setting, for 
example, from the inactivation of regulators of the tumour suppressor gene, p53. The 
use of simvastatin in PAH is not supported by clinical trial data in patients [125] but 
is one of the very few drugs shown to reduce the number of obliterated lung vessels 
in the Sugen 5416/hypoxia model. This demonstrates the unpredictability of translat-
ing results from animal models into the clinical area.
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Another reason why it may be difficult to translate prostanoid receptor function 
in rodents directly into humans is that, depending on the species, IP and EP2 recep-
tors can have pro- or anti-inflammatory actions in rat/mouse [126] and human [127] 
macrophages, respectively. This may confound the interpretation of prostacyclin 
action in animal models of PAH. The significance of the curious absence of peri-
vascular infiltration of inflammatory cell types in the sugen/hypoxia model [128] 
needs to be addressed. Moreover, the rat expresses an atypical IP receptor which 
has a relatively low affinity for the selexipag metabolite compared to the human 
receptor [32], making it difficult to assess the properties of MRE-269 with other 
prostacyclin analogues. The same may be true in mice, the other species regularly 
used to model PAH disease. In this respect, there is no published data on prostanoid 
receptor affinities in the rat and mouse for treprostinil or much knowledge about 
prostanoid expression in the lung of these species and whether/how this differs to 
the pattern of expression in the human lung.
5.7  Future Work and Clinical Implications
Studies suggest that TASK-1 is likely to be a key target for prostacyclins either through 
the IP or EP2 receptor. It will be important to understand the role of this channel in 
experimental PAH models, dysfunction of which is known to promote vasoconstric-
tion, cell proliferation and resistance to apoptosis in cells [12]. Whether prostacyclins 
can rescue such dysfunction, and thus become a treatment strategy for those patients 
harbouring TASK-1 mutations, remains to be determined. Along the same lines, upfront 
prostacyclin therapy should be considered for patients with dysfunctional TGF-β1 and 
BMPR2 signalling, and those with venoconstriction or remodelling the use of trepro-
stinil considered. Interestingly, in a small scale study in children, only epoprostenol 
appeared to provide significant improvement out of all the standard PAH therapies in 
patients habouring BMPR2 and ALK-1 mutations [129]. Furthermore, a number of 
patients were found to respond to oxygen therapy. It is tempting to speculate here that 
switching off of the hypoxic-sensitive EP3 receptor, which is linked to TGF-β receptor 
activation, may provide some clinical benefit as might activating the hypoxia-sensitive 
TASK-1 channel. This remains an interesting area for further research. 
We have little knowledge about prostacyclin signalling in human distal pulmonary 
vessels, and to our knowledge no studies have specially investigated vascular reac-
tivity and remodelling processes in small veins in PAH. Clearly future experiments 
should focus on bridging these gaps. The diverse pharmacology of prostacyclin, its 
analogues and the newly developed non-prostanoid selective IP agonists potentially 
give each one of them advantages and disadvantages in different clinical scenarios that 
should be exploited by patient stratification of PAH and PH subtypes as well as from 
a personalised medicine approach. These agents are not just vasodilators; they are 
potent anti-proliferative agents in smooth muscle, and increasing evidence suggests 
that they act to dampen down fibrosis through their actions on the pro-fibrotic TGF- β 
signalling pathway, and some of this may also translate into long-term improvements 
of heart function. The inhibitory action of prostacyclins on platelet function should 
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not be underestimated in PAH, and having a selective IP agonist like selexipag, which 
is seemingly devoid of in vivo action on platelets, may help to tease out their role. 
From a clinical standpoint, treprostinil through its potent action on EP2 and DP1 recep-
tors may provide another treatment option in those patients seen not to be responding 
well to IP receptor-selective agonists, who are subsequently identified with having 
low IP receptor expression or limited functional capacity of the receptor. Its pharma-
cological profile suggests it should also be a good venodilator and strong anti-fibrotic 
agent through its action on the EP2 receptor.
Acknowledgements Some of the research described in this article was funded by United 
Therapeutics (529389) and UCL and supported by the National Institute for Health Research 
University College London Hospitals (UCLH) Biomedical Research Centre. Jeries Abu-Hanna is 
funded by a UCL overseas PhD scholarship and Dr. Jigisha Patel is funded in part by a grant from 
the Biomedical Research Centre (BRC499/CM/LC/101320).
Declaration of Interest Statement L.H.C. has acted as a consultant for United 
Therapeutics Corp, Arena Pharmaceuticals and Bayer but has received no personal 
remuneration from these activities. She has also received educational grants from 
United Therapeutics and Lung Biotechnology PBC which supported part of the 
work described in this article. The funders had no input into the writing of this 
manuscript.
References
 1. Humbert M, Ghofrani HA. The molecular targets of approved treatments for pulmonary arte-
rial hypertension. Thorax. 2016;71:73–83.
 2. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hyper-
tension. Results from a national prospective registry. Ann Intern Med. 1991;115:343–9.
 3. Sandoval J, Bauerle O, Gomez A, et al. Primary pulmonary hypertension in children: clinical 
characterization and survival. J Am Coll Cardiol. 1995;25:466–74.
 4. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary 
vascular remodeling. J Am Coll Cardiol. 2009;54:S10–9.
 5. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 
2012;122:4306–13.
 6. Clapp LH, Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pul-
monary arterial hypertension: Role of membrane versus nuclear receptors. Prostaglandins 
Other Lipid Mediat. 2015;120:56–71.
 7. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary 
hypertension. J Am Coll Cardiol. 2013;62:D34–41.
 8. Liu D, Morrell NW. Genetics and the molecular pathogenesis of pulmonary arterial hyperten-
sion. Curr Hypertens Rep. 2013;15:632–7.
 9. Yang J, Li X, Al-Lamki RS, et al. Smad-dependent and Smad-independent induction of Id1 
by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells 
in vitro and in vivo. Circ Res. 2010;107:252–62.
 10. Long L, Ormiston ML, Yang X, et al. Selective enhancement of endothelial BMPR-II with 
BMP9 reverses pulmonary arterial hypertension. Nat Med. 2015;21:777–85.
 11. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension 
is associated with germline mutations of the gene encoding BMPR-II, a receptor member of 
the TGF-beta family. J Med Genet. 2000;37:741–5.
5 Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary…
56
 12. Boucherat O, Chabot S, Antigny F, et al. Potassium channels in pulmonary arterial hyperten-
sion. Eur Respir J. 2015;46:1167–77.
 13. Smith WL, DeWitt DL, Allen ML.  Bimodal distribution of the prostaglandin I2 synthase 
antigen in smooth muscle cells. J Biol Chem. 1983;258:5922–6.
 14. Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol Rep. 2008;60:3–11.
 15. Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation 
in primary pulmonary hypertension. Circulation. 1982;66:334–8.
 16. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and func-
tions. Physiol Rev. 1999;79:1193–226.
 17. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response 
in mice lacking prostacyclin receptor. Nature. 1997;388:678–82.
 18. McLaughlin VV, McGoon MD.  Pulmonary arterial hypertension. Circulation. 
2006;114:1417–31.
 19. Benyahia C, Boukais K, Gomez I, et al. A comparative study of PGI2 mimetics used clini-
cally on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor. 
Prostaglandins Other Lipid Mediat. 2013;107:48–55.
 20. Wharton J, Davie N, Upton PD, et  al. Prostacyclin analogues differentially inhibit 
growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation. 
2000;102:3130–6.
 21. Clapp LH, Finney PA, Turcato S, et al. Differential effects of stable prostacyclin analogues 
on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am 
J Respir Cell Mol Biol. 2002;26:194–201.
 22. Falcetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacy-
clin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 
2010;182:1161–70.
 23. Jones RL, Wise H, Clark R, et  al. Investigation of the prostacyclin (IP) receptor antago-
nist RO1138452 on isolated blood vessel and platelet preparations. Br J Pharmacol. 
2006;149:110–20.
 24. Kashiwagi H, Yuhki K, Kojima F, et  al. The novel prostaglandin I2 mimetic ONO-1301 
escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane 
A2 synthesis in mice. J Pharmacol Exp Ther. 2015;353:269–78.
 25. Parfenova H, Parfenov VN, Shlopov BV, et  al. Dynamics of nuclear localization sites for 
COX-2 in vascular endothelial cells. Am J Physiol Cell Physiol. 2001;281:C166–78.
 26. Hertz R, Berman I, Keppler D, et al. Activation of gene transcription by prostacyclin ana-
logues is mediated by the peroxisome-proliferators-activated receptor (PPAR). Eur J 
Biochem. 1996;235:242–7.
 27. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eico-
sanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl 
Acad Sci U S A. 1997;94:4312–7.
 28. Turcato S, Clapp LH. The effects of the adenylyl cyclase inhibitor SQ22536 on iloprost- 
induced vasorelaxation and cAMP elevation in isolated guinea-pig aorta. Br J Pharmacol. 
1999;126:845–7.
 29. Linz W, Wohlfart P, Baader M, et  al. The peroxisome proliferator-activated receptor-α 
(PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases sur-
vival in rats. Acta Pharmacol Sin. 2009;30:935–46.
 30. Jimenez R, Sanchez M, Zarzuelo MJ, et al. Endothelium-dependent vasodilator effects of 
peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 
kinase-Akt pathway. J Pharmacol Exp Ther. 2010;332:554–61.
 31. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors 
to determine the affinities and selectivities of prostaglandins and related analogs. Biochim 
Biophys Acta. 2000;1483:285–93.
 32. Kuwano K, Hashino A, Asaki T, et  al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]
butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prosta-
cyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007;322:1181–8.
 33. Morrison K, Studer R, Ernst R, et al. Differential effects of selexipag and prostacyclin ana-
logs in rat pulmonary artery. J Pharmacol Exp Ther. 2012;343:547–55.
L. H. Clapp et al.
57
 34. Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial 
Hypertension. N Engl J Med. 2015;373:2522–33.
 35. Tran TA, Kramer B, Shin YJ, et  al. Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)
carbamoyl)oxy)methyl)cyclohexyl)methoxy)a cetate (Ralinepag): an orally active prosta-
cyclin receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem. 
2017;60:913–27.
 36. Clapp LH, Shen L, Patel J, et al. The single isomer beraprost-314d has disproportionate and 
superior prostacyclin (IP) receptor and antiproliferative activity compared with beraprost. 
Am J Respir Crit Care Med. 2015;191:A1940.
 37. Shen L, Patel JA, Behan DP, et  al. APD811, a novel and highly selective non-prostanoid 
IP receptor agonist in smooth muscle cells from patients with pulmonary hypertension. 
Circulation. 2018;134:A16601.
 38. Gatfield J, Menyhart K, Wanner D, et al. Selexipag active metabolite ACT-333679 displays 
strong anticontractile and antiremodeling effects but low beta-arrestin recruitment and desen-
sitization potential. J Pharmacol Exp Ther. 2017;362:186–99.
 39. Bruderer S, Hurst N, Kaufmann P, et al. Multiple-dose up-titration study to evaluate the safety, 
tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selec-
tive prostacyclin receptor agonist, in healthy subjects. Pharmacology. 2014;94:148–56.
 40. Bazan IS, Fares WH.  Hypercoagulability in pulmonary hypertension. Clin Chest Med. 
2018;39:595–603.
 41. Robbins IM, Kawut SM, Yung D, et al. A study of aspirin and clopidogrel in idiopathic pul-
monary arterial hypertension. Eur Respir J. 2006;27:578–84.
 42. Willis AL, Smith DL, Vigo C. Suppression of principal atherosclerotic mechanisms by pros-
tacyclins and other eicosanoids. Prog Lipid Res. 1986;25:645–66.
 43. Chin KM, Channick RN, de Lemos JA, et al. Hemodynamics and epoprostenol use are asso-
ciated with thrombocytopenia in pulmonary arterial hypertension. Chest. 2009;135:130–6.
 44. Patel JA, Shen L, Hall SM, et al. Prostanoid EP2 receptors are up-regulated in human pulmo-
nary arterial hypertension: A key anti-proliferative target for treprostinil in smooth muscle 
cells. Int J Mol Sci. 2018;19:2372.
 45. Whittle BJ, Silverstein AM, Mottola DM, et  al. Binding and activity of the prostacyclin 
receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is 
a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012;84:68–75.
 46. Syed NI, Jones RL. Assessing the agonist profiles of the prostacyclin analogues treprostinil 
and naxaprostene, particularly their DP1 activity. Prostaglandins Leukot Essent Fatty Acids. 
2015;95:19–29.
 47. Lebender LF, Prunte L, Rumzhum NN, et al. Selectively targeting prostanoid E (EP) receptor- 
mediated cell signalling pathways: Implications for lung health and disease. Pulm Pharmacol 
Ther. 2018;49:75–87.
 48. Woodward DF, Jones RL, Narumiya S.  International union of basic and clinical pharma-
cology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. 
Pharmacol Rev. 2011;63:471–538.
 49. Desai UA, Deo SK, Hyland KV, et al. Determination of prostacyclin in plasma through a 
bioluminescent immunoassay for 6-keto-prostaglandin F1α: implication of dosage in patients 
with primary pulmonary hypertension. Anal Chem. 2002;74:3892–8.
 50. Norel X, Walch L, Labat C, et al. Prostanoid receptors involved in the relaxation of human 
bronchial preparations. Br J Pharmacol. 1999;126:867–72.
 51. Fortner CN, Breyer RM, Paul RJ. EP2 receptors mediate airway relaxation to substance P, 
ATP, and PGE2. Am J Physiol Lung Cell Mol Physiol. 2001;281:L469–74.
 52. Safholm J, Manson ML, Bood J, et al. Prostaglandin E2 inhibits mast cell-dependent bron-
choconstriction in human small airways through the E prostanoid subtype 2 receptor. J 
Allergy Clin Immunol. 2015;136:1232–9.
 53. Arthur G, Bradding P.  New Developments in Mast Cell Biology: Clinical Implications. 
Chest. 2016;150:680–93.
 54. Armour CL, Johnson PR, Alfredson ML, et  al. Characterization of contractile prostanoid 
receptors on human airway smooth muscle. Eur J Pharmacol. 1989;165:215–22.
5 Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary…
58
 55. Walch L, Labat C, Gascard JP, et al. Prostanoid receptors involved in the relaxation of human 
pulmonary vessels. Br J Pharmacol. 1999;126:859–66.
 56. Foudi N, Kotelevets L, Louedec L, et  al. Vasorelaxation induced by prostaglandin E2 in 
human pulmonary vein: role of the EP4 receptor subtype. Br J Pharmacol. 2008;154:1631–9.
 57. Jourdan KB, Evans TW, Curzen NP, et al. Evidence for a dilator function of 8-iso prostaglan-
din F-2 alpha in rat pulmonary artery. Br J Pharmacol. 1997;120:1280–5.
 58. Kuwano K, Hashino A, Noda K, et  al. A long-acting and highly selective prostacyclin 
receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-
N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with 
unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)
amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther. 
2008;326:691–9.
 59. Fuchikami C, Murakami K, Tajima K, et  al. A comparison of vasodilation mode among 
selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-
(methylsulfonyl)aceta mide]), its active metabolite MRE-269 and various prostacyclin recep-
tor agonists in rat, porcine and human pulmonary arteries. Eur J Pharmacol. 2017;795:75–83.
 60. Norel X.  Prostanoid receptors in the human vascular wall. ScientificWorldJournal. 
2007;7:1359–74.
 61. Walch L, de Montpreville V, Brink C, et al. Prostanoid EP1 and TP-receptors involved in the 
contraction of human pulmonary veins. Br J Pharmacol. 2001;134:1671–8.
 62. Orie NN, Ledwozyw A, Williams DJ, et al. Differential actions of the prostacyclin analogues 
treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small 
pulmonary arteries and veins. Prostaglandins Other Lipid Mediat. 2013;106:1–7.
 63. Kennedy CR, Zhang Y, Brandon S, et al. Salt-sensitive hypertension and reduced fertility in 
mice lacking the prostaglandin EP2 receptor. Nat Med. 1999;5:217–20.
 64. Lai YJ, Pullamsetti SS, Dony E, et al. Role of the prostanoid EP4 receptor in iloprost-mediated 
vasodilatation in pulmonary hypertension. Am J Respir Crit Care Med. 2008;178:188–96.
 65. Orie NN, Clapp LH.  Role of prostanoid IP and EP receptors in mediating vasorelaxant 
responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors. 
Eur J Pharmacol. 2011;654:258–65.
 66. Norel X, Walch L, Gascard JP, et al. Prostacyclin release and receptor activation: differential 
control of human pulmonary venous and arterial tone. Br J Pharmacol. 2004;142:788–96.
 67. Stenmark KR, Davie N, Frid M, et al. Role of the adventitia in pulmonary vascular remodel-
ing. Physiology (Bethesda). 2006;21:134–45.
 68. Tuder RM, Marecki JC, Richter A, et al. Pathology of pulmonary hypertension. Clin Chest 
Med. 2007;28:23–42.
 69. Poloso NJ, Urquhart P, Nicolaou A, et al. PGE2 differentially regulates monocyte-derived 
dendritic cell cytokine responses depending on receptor usage (EP2/EP4). Mol Immunol. 
2013;54:284–95.
 70. Gomez-Arroyo J, Sakagami M, Syed AA, et al. Iloprost reverses established fibrosis in exper-
imental right ventricular failure. Eur Respir J. 2015;45:449–62.
 71. af Forselles KJ, Root J, Clarke T, et al. In vitro and in vivo characterization of PF-04418948, 
a novel, potent and selective prostaglandin EP2 receptor antagonist. Br J Pharmacol. 
2011;164:1847–56.
 72. Lin H, Lee JL, Hou HH, et  al. Molecular mechanisms of the antiproliferative effect of 
beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol. 
2008;214:434–41.
 73. Falcetti E, Flavell DM, Staels B, et al. IP receptor-dependent activation of PPARγ by stable 
prostacyclin analogues. Biochem Biophys Res Commun. 2007;360:821–7.
 74. Burgess JK, Ge Q, Boustany S, et al. Increased sensitivity of asthmatic airway smooth muscle 
cells to prostaglandin E2 might be mediated by increased numbers of E-prostanoid receptors. 
J Allergy Clin Immunol. 2004;113:876–81.
L. H. Clapp et al.
59
 75. Zhu S, Xue R, Zhao P, et  al. Targeted disruption of the prostaglandin E2 E-prostanoid 2 
receptor exacerbates vascular neointimal formation in mice. Arterioscler Thromb Vasc Biol. 
2011;31:1739–47.
 76. Tian M, Schiemann WP. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on 
TGF-beta signaling during mammary tumorigenesis. FASEB J. 2010;24:1105–16.
 77. Dagouassat M, Gagliolo JM, Chrusciel S, et  al. The cyclooxygenase-2-prostaglandin E2 
pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts. Am J 
Respir Crit Care Med. 2013;187:703–14.
 78. Horikiri T, Hara H, Saito N, et al. Increased levels of prostaglandin E-major urinary metabo-
lite (PGE-MUM) in chronic fibrosing interstitial pneumonia. Respir Med. 2017;122:43–50.
 79. White ES, Atrasz RG, Dickie EG, et  al. Prostaglandin E2 inhibits fibroblast migration by 
E-prostanoid 2 receptor-mediated increase in PTEN activity. Am J Respir Cell Mol Biol. 
2005;32:135–41.
 80. Kolodsick JE, Peters-Golden M, Larios J, et al. Prostaglandin E2 inhibits fibroblast to myo-
fibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophos-
phate elevation. Am J Respir Cell Mol Biol. 2003;29:537–44.
 81. Moore BB, Ballinger MN, White ES, et al. Bleomycin-induced E prostanoid receptor changes 
alter fibroblast responses to prostaglandin E2. J Immunol. 2005;174:5644–9.
 82. Corboz MR, Zhang J, LaSala D, et  al. Therapeutic administration of inhaled INS1009, a 
treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. 
Pulm Pharmacol Ther. 2018;49:95–103.
 83. Lambers C, Roth M, Jaksch P, et al. Treprostinil inhibits proliferation and extracellular matrix 
deposition by fibroblasts through cAMP activation. Sci Rep. 2018;8:1087.
 84. Lai YJ, Chen IC, Li HH, et al. EP4 agonist L-902,688 suppresses EndMT and attenuates right 
ventricular cardiac fibrosis in experimental pulmonary arterial hypertension. Int J Mol Sci. 
2018;19:727.
 85. Sieber P, Schafer A, Lieberherr R, et al. Novel high-throughput myofibroblast assays identify 
agonists with therapeutic potential in pulmonary fibrosis that act via EP2 and EP4 receptors. 
PLoS One. 2018;13:e0207872.
 86. Lu A, Zuo C, He Y, et al. EP3 receptor deficiency attenuates pulmonary hypertension through 
suppression of Rho/TGF-beta1 signaling. J Clin Invest. 2015;125:1228–42.
 87. Benyahia C, Ozen G, Orie N, et al. Ex vivo relaxations of pulmonary arteries induced by 
prostacyclin mimetics are highly dependent of the precontractile agents. Prostaglandins 
Other Lipid Mediat. 2015;121:46–52.
 88. Christman BW, McPherson CD, Newman JH, et  al. An imbalance between the excretion 
of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 
1992;327:70–5.
 89. Tuder RM, Archer SL, Dorfmuller P, et al. Relevant issues in the pathology and pathobiology 
of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D4–12.
 90. Ghigna MR, Guignabert C, Montani D, et al. BMPR2 mutation status influences bronchial 
vascular changes in pulmonary arterial hypertension. Eur Respir J. 2016;48:1668–81.
 91. Dorfmuller P, Gunther S, Ghigna MR, et al. Microvascular disease in chronic thromboem-
bolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. Eur 
Respir J. 2014;44:1275–88.
 92. Chazova I, Loyd JE, Zhdanov VS, et al. Pulmonary artery adventitial changes and venous 
involvement in primary pulmonary hypertension. Am J Pathol. 1995;146:389–97.
 93. Gerges C, Gerges M, Skoro-Sajer N, et al. Hemodynamic thresholds for precapillary pulmo-
nary hypertension. Chest. 2016;149:1061–73.
 94. Gao Y, Raj JU. Role of veins in regulation of pulmonary circulation. Am J Physiol Lung Cell 
Mol Physiol. 2005;288:L213–26.
 95. Comellas AP, Briva A. Role of endothelin-1 in acute lung injury. Transl Res. 2009;153:263–71.
 96. Goggel R, Hoffman S, Nusing R, et al. Platelet-activating factor-induced pulmonary edema 
is partly mediated by prostaglandin E(2), E-prostanoid 3-receptors, and potassium channels. 
Am J Respir Crit Care Med. 2002;166:657–62.
5 Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary…
60
 97. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol 
therapy for severe congestive heart failure: The Flolan International Randomized Survival 
Trial (FIRST). Am Heart J. 1997;134:44–54.
 98. Montani D, Lau EM, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 
2016;47:1518–34.
 99. Sadushi-Kolici R, Jansa P, Kopec G, et  al. Subcutaneous treprostinil for the treatment of 
severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double- 
blind, phase 3, randomised controlled trial. Lancet Respir Med. 2019;7(3):239–48. https://
doi.org/10.1016/S2213-2600(18)30367-9.
 100. Yang J, Li X, Al-Lamki RS, et al. Sildenafil potentiates bone morphogenetic protein signal-
ing in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. 
Arterioscler Thromb Vasc Biol. 2013;33:34–42.
 101. Ogo T, Chowdhury HM, Yang J, et al. Inhibition of overactive transforming growth factor-β 
signaling by prostacyclin analogs in pulmonary arterial hypertension. Am J Respir Cell Mol 
Biol. 2013;48:733–41.
 102. Chen Y, Yang S, Yao W, et al. Prostacyclin analogue beraprost inhibits cardiac fibroblast pro-
liferation depending on prostacyclin receptor activation through a TGF beta-Smad signal 
pathway. PLoS One. 2014;9:e98483.
 103. Olschewski A, Veale EL, Nagy BM, et al. TASK-1 (KCNK3) channels in the lung: from cell 
biology to clinical implications. Eur Respir J. 2017;50:700754.
 104. Bohnen MS, Roman-Campos D, Terrenoire C, et al. The impact of heterozygous KCNK3 
mutations associated with pulmonary arterial hypertension on channel function and pharma-
cological recovery. J Am Heart Assoc. 2017;6:e006465.
 105. Gurney AM, Osipenko ON, MacMillan D, et al. Two-pore domain K channel, TASK-1, in 
pulmonary artery smooth muscle cells. Circ Res. 2003;93:957–64.
 106. Olschewski A, Li Y, Tang B, et al. Impact of TASK-1 in human pulmonary artery smooth 
muscle cells. Circ Res. 2006;98:1072–80.
 107. Ma L, Roman-Campos D, Austin ED, et  al. A novel channelopathy in pulmonary arterial 
hypertension. N Engl J Med. 2013;369:351–61.
 108. Navas TP, Tenorio CJ, Palomino DJ, et  al. An homozygous mutation in KCNK3 is asso-
ciated with an aggressive form of hereditary pulmonary arterial hypertension. Clin Genet. 
2017;91:453–7.
 109. Antigny F, Hautefort A, Meloche J, et  al. Potassium channel subfamily K member 3 
(KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation. 
2016;133:1371–85.
 110. Li Y, Connolly M, Nagaraj C, et al. Peroxisome proliferator-activated receptor-beta/delta, the 
acute signaling factor in prostacyclin-induced pulmonary vasodilation. Am J Respir Cell Mol 
Biol. 2012;46:372–9.
 111. Mant A, Elliott D, Eyers PA, et al. Protein kinase A is central for forward transport of two- 
pore domain potassium channels K2P3.1 and K2P9.1. J Biol Chem. 2011;286:14110–9.
 112. Kilisch M, Lytovchenko O, Arakel EC, et  al. A dual phosphorylation switch controls 
14-3-3-dependent cell surface expression of TASK-1. J Cell Sci. 2016;129:831–42.
 113. Cunningham KP, Veale EL, Abu-Hanna J, et  al. The role of the K2P channels TASK-1, 
TREK-1 and TREK-2 in the use of treprostinil therapy in pulmonary arterial hypertension. 
FASEB J. 2018;32:567.6.
 114. Davie NJ, Schermuly RT, Weissmann N, et al. The science of endothelin-1 and endothelin 
receptor antagonists in the management of pulmonary arterial hypertension: current under-
standing and future studies. Eur J Clin Invest. 2009;39(Suppl 2):38–49.
 115. Tang B, Li Y, Nagaraj C, et al. Endothelin-1 inhibits background two-pore domain channel 
TASK-1  in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol 
Biol. 2009;41:476–83.
 116. Seyler C, Duthil-Straub E, Zitron E, et  al. TASK1 (K(2P)3.1) K(+) channel inhibition by 
endothelin-1 is mediated through Rho kinase-dependent phosphorylation. Br J Pharmacol. 
2012;165:1467–75.
L. H. Clapp et al.
61
 117. Patel JA, Hall SM, Abraham DJ, et al. Comparison of current therapies to inhibit endothelin- 
induced growth of pulmonary artery smooth muscle cells (PASMCs) derived from patients 
with pulmonary arterial hypertension. Eur Respir J. 2014;44:P2355.
 118. Schermuly RT, Yilmaz H, Ghofrani HA, et  al. Inhaled iloprost reverses vascular remod-
eling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med. 
2005;172:358–63.
 119. Akagi S, Nakamura K, Matsubara H, et  al. Intratracheal administration of prostacyclin 
analogue- incorporated nNanoparticles ameliorates the development of monocrotaline 
and sugen-hypoxia-induced pulmonary arterial hypertension. J Cardiovasc Pharmacol. 
2016;67:290–8.
 120. Bhat L, Hawkinson J, Cantillon M, et al. Evaluation of the effects of RP5063, a novel, mul-
timodal, serotonin receptor modulator, as single-agent therapy and co-administrated with 
sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hyper-
tension rat model. Eur J Pharmacol. 2018;827:159–66.
 121. Pak O, Janssen W, Ghofrani HA, et al. Animal models of pulmonary hypertension: Role in 
translational research. Drug Discov Today. 2010;7:89–97.
 122. Chaudhary KR, Deng Y, Suen CM, et  al. Efficacy of treprostinil in the SU5416-hypoxia 
model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated 
with improvements in arterial remodelling. Br J Pharmacol. 2018;175:3976–89.
 123. Holmboe S, Andersen A, Johnsen J, et al. Inotropic effects of prostacyclins on the right ven-
tricle are abolished in isolated rat hearts with right-ventricular hypertrophy and failure. J 
Cardiovasc Pharmacol. 2017;69:1–12.
 124. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et  al. Simvastatin causes endothelial 
cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol 
Physiol. 2006;291:L668–76.
 125. Kawut SM, Bagiella E, Lederer DJ, et al. Randomized clinical trial of aspirin and simvastatin 
for pulmonary arterial hypertension: ASA-STAT. Circulation. 2011;123:2985–93.
 126. Aronoff DM, Peres CM, Serezani CH, et  al. Synthetic prostacyclin analogs differentially 
regulate macrophage function via distinct analog-receptor binding specificities. J Immunol. 
2007;178:1628–34.
 127. Raychaudhuri B, Malur A, Bonfield TL, et al. The prostacyclin analogue treprostinil blocks 
NFκB nuclear translocation in human alveolar macrophages. J Biol Chem. 2002;277:33344–8.
 128. Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hyperten-
sion: The hope for etiologic discovery and pharmacologic cure. Am J Physiol Lung Cell Mol 
Physiol. 2009;297:L1013–32.
 129. Chida A, Shintani M, Yagi H, et al. Outcomes of childhood pulmonary arterial hypertension 
in BMPR2 and ALK1 mutation carriers. Am J Cardiol. 2012;110:586–93.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter's Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder.
5 Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary…
63© The Editor(s) (if applicable) and The Author(s) 2020
T. Nakanishi et al. (eds.), Molecular Mechanism of Congenital Heart Disease  
and Pulmonary Hypertension, https://doi.org/10.1007/978-981-15-1185-1_6
B. Ranchoux (*) · V. F. Tanguay 
Research Center of the Institut Universitaire de Cardiologie et de Pneumologie de Québec, 
Laval University, Quebec City, QC, Canada 
F. Perros 
INSERM UMR_S 999, Université Paris-Sud and Université Paris-Saclay,  
Le Plessis-Robinson, France
6Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension
Benoît Ranchoux, Virginie F. Tanguay, and Frédéric Perros
Abstract
Pulmonary arterial hypertension (PAH) is an incurable disease characterized by 
an intense thickening of the pulmonary arteries leading to their progressive oblit-
eration. This vascular remodeling is a direct consequence of an aberrant accumu-
lation of α-smooth muscle actin (α-SMA)-positive cells in the intravascular area. 
This process is multifactorial and complex. Recent studies have demonstrated 
that part of α-SMA-positive cells from intimal and plexiform lesions have an 
endothelial origin through a process called endothelial-to-mesenchymal transi-
tion (EndoMT). Interestingly most of molecular pathways implicated in PAH are 
known inducers of EndoMT. This review describes how EndoMT appears to play 
a crucial role in PAH progression.
Keywords
Pulmonary arterial hypertension · Endothelial-to-mesenchymal transition · 
Vascular remodeling · Endothelial dysfunction
6.1  Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is histologically characterized by an aber-
rant remodeling of the pulmonary arterial bed that includes adventitial, medial and 
intimal thickening as well as neo-muscularization of pre-capillary arterioles. These 
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modifications of the pulmonary vessels increase the vascular resistance and ulti-
mately lead to the progressive occlusion of the lung vasculature. PAH is multifac-
torial and the underlying mechanisms that lead to the pathological accumulation of 
α-smooth muscle actin (α-SMA)-positive cells implicated in the remodeling pro-
cess are yet under investigation. Among the possible explanations, it has been 
reported that the pathologic α-SMA cells were derived from circulating bone mar-
row–derived cells, pericytes or mesenchymal stem cells [1]. Growing evidence 
also suggest that part of α-SMA-positive cells may have an endothelial origin via a 
trans- differentiation mechanism called endothelial-to-mesenchymal transition 
(EndoMT).
6.2  Endothelial-to-Mesenchymal Transition
EndoMT is a key process in vascular development and tissue regeneration. In 
healthy vessels, the endothelial cells (ECs) are bound in a monolayer fashion by 
tight and adherens junctions that control EC polarity and barrier functions. During 
the EndoMT process, ECs lose their junctions and polarity to the endothelium and 
progressively switch from endothelial to mesenchymal markers. This phenotype 
switch is accompanied with invasive and proliferative properties that allow 
EndoMT cells to colonize the surrounding environment. The resultant mesenchy-
mal cells become pluripotent and give rise to various lineages. EndoMT is crucial 
during embryonic development, angiogenesis and tissue regeneration but is also 
implicated in pathological process like cancer development, atherosclerosis and 
fibrotic diseases [2].
EndoMT is regulated by key transcription factors Snail/Slug/ZEB/Twist [3]. 
When expressed, these transcription factors primarily repress endothelial junc-
tions. These junctions are composed of transmembrane proteins (such as 
VE-cadherin, CD31, Claudins and occludin) that are bound to the cytoskeleton 
and stabilized by cytoplasmic scaffold proteins (such as p120-cathenin, β-catenin 
or ZO-1) [4]. EndoMT-related transcription factors down-regulate the junction 
proteins, inducing the dissolution of the cell-cell junctions and the loss of EC 
polarity in the early stages of transition [3]. The disruption of the junctions also 
releases free scaffold proteins in the cytoplasm that, if not degraded, trigger sec-
ondary pathways promoting ECs proliferation and motility. For example, the inhi-
bition of Claudins and occludin induces the release of ZO-1 from tight junction 
which promotes cell proliferation via CD1 and PCNA up-regulation [5]. Similarly, 
the inhibition of VE-cadherin leads to accumulation of free p120-catenin that pro-
motes invasiveness by inhibiting RhoA activity, up-regulating mesenchymal cad-
herin and activating Rac1/MAPK and Ras/MAPK signaling pathways [6]. 
Therefore, the chronic activation of EndoMT pathways causes the loss of endo-
thelium integrity (which directly regulates vascular homeostasis, angiogenesis 
and inflammation) and the invasion of the sub-endothelial area by proliferative 
mesenchymal cells.
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6.3  EndoMT in PAH Pathogenesis
6.3.1  EndoMT in PAH Vascular Remodeling
Aberrant vascular remodeling with occlusive α-SMA-positive cell accumulation 
forming a neo-intima and endothelial dysfunction are hallmarks of PAH pathogen-
esis. Both features can be the results of an unresolved EndoMT process as suggested 
by Arciniegas and colleagues [7]. Our laboratory was the first to confirm the occur-
rence of EndoMT in situ in idiopathic PAH [8]. Using immunofluorescence, trans-
mission electron microscopy and correlative light and electron microscopy, we 
provided phenotypic and ultrastructural evidences of ongoing EndoMT in remod-
eled PAH arteries. We were able to observe ongoing EndoMT in intimal and plexi-
form lesions where α-SMA-positive cells’ accumulation contributed to vessel 
obliteration. These findings were associated with a loss of endothelial p120-catenin, 
which is essential for adherens junction and with an overexpression of Twist in PAH 
lungs. Similar results were observed in two established animal models of pulmo-
nary hypertension (PH) induced by monocrotaline and Sugen/hypoxia. EndoMT 
was also observed in systemic sclerosis-associated PAH where cells expressing both 
endothelial and mesenchymal markers were found in 4% of the remodeled vessels 
[9]. Since then various studies have confirmed the occurrence of an ongoing 
EndoMT process in PAH with the overexpression of transcription factors Twist/
Snail/Slug [10–12].
6.3.2  Molecular Pathways of EndoMT in PAH
The mechanisms that regulate EndoMT are complex and not fully understood but 
appear to be close of those involved in the epithelial-to-mesenchymal transition 
(EMT). Interestingly the main characteristics of PAH pathological environment are 
known inducers of EndoMT and EMT. Indeed, the ECs in PAH are locally exposed 
to chronic inflammation, hypoxia, mechanical stress and loss of endothelial junc-
tion. Inflammation is highly associated with EMT-associated tumor progression and 
EndoMT. Tumor necrosis factor (TNF)-α, interleukin (IL)-6, transforming growth 
factor (TGF)-β or IL-8 promote ZEB/Snail/Twist expression via NFκB and JAK/
STAT signaling. Cells undergoing mesenchymal transition also induce local inflam-
mation via increased secretion of cytokines such as IL-6, IL-8 and TNF-α [3, 9, 13]. 
Hypoxia is also a well-described inducer of EndoMT though hypoxia-inducible fac-
tor 2α (HIF-2α) activation. Tang et  al. demonstrated that PAH ECs display an 
increased expression of HIF-2α even under normoxic conditions, and this leads to 
the up-regulation of Snail/Slug and therefore aberrant EndoMT [12]. Of note, 
HIF-1α, that is found up-regulated in PAH smooth muscle cells, induces overex-
pression of Twist. The increased pressure and shear stress due to disturbed blood 
flow are known to trigger EndoMT to initiate adaptative muscularization of vessels 
but are also linked to neointimal hyperplasia in other vasculopathies like 
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atherosclerosis [14]. Finally, the shear stress resulting from increased vascular resis-
tances further damages the endothelial junctions. As presented above, it triggers 
EndoMT to overcome the mechanical stress by increasing vascular thickness. 
Nevertheless, as EndoMT reduces the overall endothelium integrity and increases 
the vascular remodeling, it may enter in a vicious circle of unresolved EndoMT. The 
pathological environment of chronic inflammation and increased pressure may then 
lead to an undesirable feedback loop leading to further endothelial dysfunction, 
inflammation and shear stress as the vascular remodeling progresses.
The main molecular pathways implicated in PAH development are also related to 
EndoMT molecular mechanisms. The TGF-β signaling pathways play a crucial role 
in PAH. TGF-β is found increased in serum and lungs from PAH patients and most 
of the genetic mutations related to PAH occur in genes encoding receptors of the 
TGF-β superfamily [1]. Interestingly TGF-β signaling is a key actor of EndoMT 
either via Smad-dependent or Smad-independent pathways. The activation of 
TGF-β receptors initiates Smad2/3/4 cascade which up-regulates Snail/Slug/Twist/
ZEB. TGF-β also promotes EndoMT through various Smad-independent pathways 
leading, for example, to the inactivation of GSK-3β, a repressor of Snail- and 
β-catenin-induced EndoMT or to the PI3K/AKT-mediated up-regulation of Twist/
Snail/Slug/ZEB expression through mTOR and NF-κB activation. Finally autocrine 
feedback loops appear in TGF-β-induced EndoMT since Twist overexpression in 
human pulmonary ECs also up-regulates TGF-β expression [11].
In addition, deficient signaling through bone morphogenetic protein receptor type 
2 (BMPR-II), a member of the TGF-β receptor superfamily, plays a critical role in 
PAH. Indeed, mutations in the BMPR2 gene are found in 70% of cases of familial 
PAH and in 10–40% of cases of idiopathic PAH.  Moreover, in the absence of a 
BMPR2 mutation, reduced expression of pulmonary vascular BMPR-II has also been 
observed in non-hereditary PAH. We created a rat strain with monoallelic mutations 
on BMPR2, which develops spontaneously PAH.  In this animal model, altered 
BMPR-II signaling was associated with increased pulmonary Twist expression and 
EndoMT [8]. This link between the main genetic risk factor for PAH and unregulated 
EndoMT was confirmed by Hopper and colleagues as they found that reduced 
BMPR-II also promotes Slug overexpression via HMGA1 up-regulation [10].
The TGF-β pathways are not fully characterized, have feedback loops, talk to 
each other and have interactions with others signaling such as Notch, Wnt and 
receptor tyrosine kinases (RTKs), all involved in PAH pathogenesis and EndoMT 
[3, 15–20]. Notch1 was reported to be increased in lung from idiopathic PAH patient 
and Sugen/hypoxia rats [20], and Notch1/3 were found up-regulated in hypoxia- 
and MCT-induced PH [21]. Notch signaling also interacts with PAH-associated 
pathways such as HIF-1α and IL-6 [3, 15–19]. Notch activation up-regulates Snail/
Slug expression [3]. In PAH, both canonical Wnt and non-canonical Wnt were 
found up-regulated [22, 23]. In the first one, activation of Wnt leads to GSK-3β 
inhibition and Snail- and β-catenin-induced EndoMT [3, 15, 16]. In the non- 
canonical one, Wnt activates GTPases Rac/Rho/cdc42, all involved in migration and 
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cytoskeleton rearrangement [24]. Several growth factor signaling that act through 
RTKs are found up-regulated in PAH, including epidermal growth factor, fibroblast 
growth factor, vascular endothelial growth factor and platelet-derived growth factor 
[1]. Their roles are incompletely understood due to feedback loop regulations 
among given growth factor signaling and because of contradictory effects on pul-
monary vasculature when used in vivo probably due to their numerous isoforms of 
receptor and ligand as well as the structural similarities and signaling versatility 
between different RTKs. Some RTK inhibitors like imatinib or sorafenib have been 
shown to exert beneficial effects in animal models of PH whereas others like dasat-
inib or Sugen are known inducers of PAH [25]. Interestingly the activation of most 
of those RTK signalings initiates the PI3K/AKT/NF-κB and Ras/MAPK pathways 
that ultimately up-regulate Twist/Snail/Slug/ZEB. RTKs signaling also cross talks 
with other EndoMT pathways like TGF-β-, β-catenin or Wnt-induced EndoMT via 
the common PI3K/AKT-dependant inhibition of GSK-3β [3]. Nevertheless despite 
improvements in haemodynamics and exercise capacity, the serious adverse events 
associated with RKT inhibitors in PAH therapies currently outweigh their beneficial 
role observed in animal models [1].
Other molecular actors of PAH pathogenesis might also contribute to 
EndoMT. For example, endothelin-1, which is overexpressed in PAH and contrib-
utes to vasoconstriction and vascular remodeling [1], has also been reported to 
induce EMT. It can trigger transdifferentiation either by activating both ETA/ETB 
receptors and subsequent PI3K/ILK/GSK-3β and AMPK pathways, or by repress-
ing miR-300, a negative regulator of Twist or by inducing TGF-β overexpression 
[26–28]. Another hallmark of PAH is an increased level of serotonin in the patients’ 
serum [25]. This neurotransmitter was reported to induce EMT in renal proximal 
tubular epithelial cells [29] and inhibition of its receptors 5-HT1B/5-HT1D down- 
regulates ZEB/Snail expression and undergoing EMT in human pancreatic cancer 
cells [30]. Finally, angiotensin-II which is increased in patients’ blood with 
increased signaling through its type 1 receptor in PAH ECs [31] has also been 
implicated in EMT and EndoMT in cancer and diabetes-related cardiovascular dis-
eases [32–34].
6.4  Conclusion
PAH has a multifactorial and complex pathobiology. Growing evidences support 
that an unresolved EndoMT process is actively implicated in the vascular remod-
eling and endothelial dysfunction involved in the disease progression. EndoMT 
can be the direct consequence of PAH pathological environment and dysregulated 
molecular pathways. As presented, EndoMT mechanisms are yet incompletely 
understood but their cross talk with most of PAH hallmarks leads us to believe that 
EndoMT might be a crucial actor in PAH progression and a promising therapeutic 
target.
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6.5  Future Direction and Clinical Implications
EndoMT is a crucial actor in embryonic development and tissue regeneration in 
adult tissues. Numerous studies have demonstrated that the same cellular mecha-
nisms of EndoMT are also implicated in the progression of cancers and cardiovas-
cular diseases. Growing evidences support that EndoMT might play a central role in 
PAH pathogeny. These findings open exciting opportunities in the study of the ini-
tial triggers and the vascular remodeling process of PAH. A better understanding of 
EndoMT in PAH could lead to the development of novel anti-remodeling strategies 
in the management of PAH with potentially limited side effects on healthy tissues.
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7Extracellular Vesicles, MicroRNAs, and Pulmonary Hypertension
Tianji Chen and J. Usha Raj
Abstract
Pulmonary hypertension (PH) is a devastating disease that results in a progres-
sive increase in pulmonary vascular resistance, right ventricular failure, and ulti-
mately death of patients. Recent advances in our understanding of pathogenesis 
of diseases, including PH, have led to the study of extracellular vesicles (EV) as 
mediators of disease. Subsets of EV are microvesicles (MV), exosomes (Exo), 
and apoptotic bodies, and they are released from a variety of cell types and carry 
cargo such as proteins and microRNAs (miR). MicroRNAs contained within 
these EV play an important role in disease including in the pathogenesis of PH 
as well as other lung diseases.
Keywords
Extracellular vesicles ·  Pulmonary hypertension ·  Endothelial cells ·  Smooth 
muscle cells ·  microRNAs
7.1  Extracellular Vesicles (EV)
Extracellular vesicles (EV) are nano-sized, membrane-bound vesicles released from 
cells that can mediate intercellular communication [1]. Different EV types, includ-
ing exosomes (Exo), microvesicles (MV), and apoptotic bodies, have been 
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characterized on the basis of their biogenesis or release pathways: Exosomes (Exo) 
are 50–100 nm membrane vesicles of endocytic origin. They are released into the 
extracellular space by fusion with the plasma membrane. Exosomes contain 
endosome- specific proteins such as Alix and TSG101, components of microdo-
mains in the plasma membrane such as cholesterol, ceramide, integrins, and tet-
raspanins, mRNAs, microRNA (miRNAs), and other non-coding RNAs. ExoCarta, 
an exosome database, provides a comprehensive list of exosomes identified (http://
exocarta.org/) [2, 3]. Microvesicles (MV), also referred to as microparticles (MP), 
especially in the cardiovascular field, are sized 20–1000  nm. They are formed 
through the outward budding and separation of the plasma membrane. During their 





































Fig. 7.1 Endothelial (EC) and smooth muscle (SMC) cells release extracellular vesicles (EV) and 
interact through transfer of EV. Increased circulating levels of endothelium-derived microvesicles 
(MV) have been documented in PH patients (a). Visovatti et  al. demonstrated increased CD39 
expression and function in circulating MV of idiopathic PAH patients, which may be associated 
with the increased ATPase/ADPase activity in MV (b). Tual-Chalot et al. showed that circulating 
MV from hypoxic rats can suppress endothelial-dependent vascular relaxation in rat aorta and 
pulmonary arteries by decreasing NO production (c). More recently, Aliotta et al. reported that 
healthy mice injected with circulating or lung EV isolated from MCT-treated mice show elevated 
right ventricular-to-body weight ratio and pulmonary arterial wall thickness-to-diameter ratio 
compared to that of mice injected with control EV (d). Deng et al. showed a high abundance of 
miR-143-3p in PASMC-derived exosomes and a paracrine pro-migratory and pro-angiogenic 
effect of these miR-143-3p-enriched PASMC-derived exosomes on PAEC (e). However, the cross 
talk between EC and SMC through EV transfer, especially from EC to SMC, and underlying 
molecular mechanisms remain unclear (f)
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cytosolic content (proteins, RNAs, microRNAs) [3, 4]. Apoptotic bodies are the 
largest vesicles of the EV with a size of 1–5 μm. They are formed through outward 
blebbing of the cell membrane during the late steps of apoptosis. Apoptotic bodies 
contain cellular organelles, proteins, DNAs, RNAs, and microRNAs [2, 3, 5].
7.2  EV in Pulmonary Hypertension (PH)
Pulmonary hypertension (PH) is a devastating disease that results in a progressive 
increase in pulmonary vascular resistance, right ventricular failure, and ultimately 
death of patients [6, 7]. Recent studies have shown that abnormal EV secretion is 
associated with the pathogenesis of PH, and increased circulating levels of 
endothelium- derived MV have been documented in various cardiovascular diseases 
including PH [4, 8]. In PH patients the levels of circulating endothelial CD31+ 
(PECAM+)/CD41-, CD144+(VE-cadherin+), and CD62e+ (E-selectin+) positive 
microvesicles are increased compared with control subjects. Moreover, PAH 
patients exhibit higher values of endothelial PECAM+ and VE-cadherin+-positive 
MV versus those with chronic pulmonary disease-related PH [8]. Higher levels of 
endothelium-derived MV bearing E-selectin are also noted in thromboembolic PH 
as compared with non-thromboembolic PH subjects [9], suggesting that the etiol-
ogy of the disease may influence MV levels [10].
MV are not only a biomarker of PH but rather actively contribute to develop-
ment of PH [11, 12]. Visovatti and colleagues demonstrated increased CD39 
expression and function in circulating MV of idiopathic PAH patients, which may 
be associated with the increased ATPase/ADPase activity in MV [13]. The 
endothelium- dependent relaxation of rat pulmonary arteries is suppressed after 
incubation with MV obtained from rats exposed to chronic hypoxia as compared to 
control arteries exposed to normoxia, accompanied by attenuated eNOS activity 
and increased ROS production [11]. In another study, Lee and colleagues demon-
strated that mesenchymal stromal cell-derived exosomes exert a pleiotropic protec-
tive effect on the lung and inhibit vascular remodeling and hypoxic PH with 
suppression of STAT3/miR-17 levels and induction of miR-204 levels in the lung 
[14]. Moreover, a recent study reported that healthy mice injected with EV isolated 
from MCT-treated mice show elevated right ventricular-to-body weight ratio and 
pulmonary arterial wall thickness-to-diameter ratio compared to that of mice 
injected with control EV, providing direct in vivo evidence that EV contribute to 
pulmonary vascular remodeling and PH [12].
7.3  MicroRNA Transfer Through EV in PH
MicroRNAs (miRNAs, miRs) are small single-stranded non-coding RNAs that medi-
ate post-transcriptional degradation or translation repression of target messenger 
RNAs (mRNAs) [15, 16]. Many miRNAs have been identified to play important 
roles in disease development, including PH [17–19]. In addition to the primary 
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intracellular locations, miRNAs can be exported extracellularly into the circulation 
system [20–23] through the transfer of EV.  A recent study by Aliotta et  al. has 
reported dysregulated miRNA profiling in the circulating exosomes of monocrota-
line (MCT)-induced PH in mice, as well in patients with idiopathic pulmonary 
artery hypertension (IPAH) [24], suggesting that exosome (and maybe also other 
EV)-mediated miRNA signaling may play a role in the pathogenesis of PH. This 
hypothesis is supported by their finding that healthy mice injected with EV isolated 
from MCT-treated mice show induced right ventricular hypertrophy and pulmonary 
vessel wall thickening [12].
In the pulmonary vasculature, endothelial and smooth muscle cells (EC and 
SMC) are the two key cell types that play a major role in the pathobiology of PH 
[25]. The miRNA cross talk between EC and SMC via EV in pulmonary vasculature 
is exemplified by a recent study by Deng et al. [26]. This study demonstrates that 
migration and angiogenesis of pulmonary arterial endothelial cells (PAEC) are 
induced not only by exosome-derived miR-143 but also by co-culture of PAEC with 
pulmonary arterial SMC (PASMC) under conditions where direct cell-cell contact 
is prevented. The miR-143-enriched exosomes derived from PASMC are internal-
ized by PAEC which lead to increased EC migration and angiogenesis. This study 
also shows that miR-143 is upregulated in the pulmonary vasculature of murine 
models of PH and in patients with PH. Genetic deletion of miR-143 or pharmaco-
logical inhibition of miR-143  in mice prevented the development of hypoxia- 
induced pulmonary hypertension. Hence, cross talk between EC and SMC via 
miR-143-enriched exosomes may be involved in the pathogenesis of PH under 
in vivo conditions.
Our knowledge about the cross talk between EC and SMC through EV transfer, 
especially the information transfer from EC to SMC, is still very limited and further 
studies are warranted.
7.4  Future Direction and Clinical Implications
The release of extracellular vesicles (EV) is a phenomenon shared by most cell types, 
including EC and SMC [1]. EV released into the extracellular space can enter body 
fluids and/or potentially reach neighboring and/or distal cells. The cargo of EV 
includes the proteins, lipids, nucleic acids, and membrane receptors of the cells from 
which they originate. Hence, EV can function as the “mail carrier” and transfer infor-
mation (microRNAs, proteins, etc.) to their target cells, thus representing an impor-
tant mechanism for intercellular communications [3, 4, 27–32]. The EV-mediated 
intercellular communications are evolutionarily conserved [33]. Therefore, EV are 
rich sources of biomarkers for diagnosis and/or prognosis of human diseases [34–41] 
and provide us potential therapeutic approaches [42, 43].
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The T-box family genes are evolutionarily conserved transcription factors. In particular, 
Tbx4 and Tbx5 are closely conserved and play crucial roles in development and organo-
genesis. Tbx4 is essential for hindlimb and allantoic vessel formation [1]. Our data show 
that it is also highly expressed in the lung mesenchyme (Fig. 8.1), initially expressed at 
embryonic day (E) 9.25 and later expressed throughout murine embryogenesis [2].
Lung mesenchyme is stromal tissue that surrounds the epithelium and consists of 
undifferentiated progenitor cells, which give rise to various cell types, such as 
smooth muscle, cartilage, fibroblasts, endothelium, pericytes, and mesothelium. 
Although the behavior of epithelial progenitors has been elucidated, much less is 
known about the identity and behavior of mesenchymal progenitors in the lungs. 
Mesenchymal cells are generally thought to have highly proliferative, migratory, 
and multipotent potential. Lung-specific mesenchymal Tbx4 and Tbx5 deficiency 
revealed that these transcription factors cooperatively regulated branching 
morphogenesis, likely through the activation of fibroblast growth factor (Fgf) 10 
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signaling during the lung development [2]. Tbx4 is detectable at earlier stages of 
lung development compared to other mesenchymal transcription factors [3], sug-
gesting that Tbx4 functions upstream from them. Cell lineage tracing using trans-
genic mice harboring the lung-specific mesenchyme enhancer (LME) from the 
mouse Tbx4 locus (Tbx4-LME)-specific Cre transgene showed that Tbx4-expressing 
cells give rise to all cell types of the lung mesenchyme [3]. Although it remains 
controversial whether they become pulmonary vascular endothelial cells or not, 
Tbx4 lung enhancer-driven Tet-On inducible Cre reporter mice showed that both of 
pulmonary endothelium and vascular smooth muscle were targeted from E11.5; it 
was also found that the expression level of Tbx4 decreased once the pulmonary 
vascular cells were differentiated [4].
From these reports, Tbx4 in undifferentiated mesenchymal progenitor cells may 
be involved in the formation of both airways and vessels in the lungs. The roles of 
Tbx4 in the lung mesenchyme may pave the way for novel mechanisms underlying 
pulmonary vascular development.
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a b
Fig. 8.1 Tbx4 is expressed in the lung mesenchyme. Section ISH with Tbx4 anti-sense riboprobe 
(a low magnification, b high magnification of the square area in a) shows Tbx4 is expressed 
throughout the lung mesenchyme at E14.5. Ht heart, Li liver, Lu lung, Mes mesenchyme, Sm 
somite
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Pulmonary vasculature in mice develops through two main mechanisms, namely 
angiogenesis and vasculogenesis. At embryonic day (E) 9.5, vascular endothelial 
marker Tie2-driven LacZ expression in whole-mount transgenic lungs showed con-
tinuity between the primitive lung vasculature and the aortic sac [1]. Scanning elec-
tron microscopic study of vascular casts and graphic reconstruction in the 32- and 
34-somite (E10) embryos demonstrated that the primordium of the pulmonary 
artery (PA) arose from the proximal portion of the sixth pharyngeal arch artery and 
ran straight in the caudal direction [2]. At E10.5, though the afferent vessels were 
not yet defined as vascular tubes, they resembled two plexiform networks that 
coalesce alongside the trachea. From these observations, “distal angiogenesis” was 
proposed as a model for the pulmonary vascular morphogenesis where PAs arise 
from the pharyngeal arch artery and elongate into the lung buds [1]. Another study 
provided evidence to support vasculogenesis as the mechanism of both proximal 
and distal vessel formation during the development of murine lungs [3]. Detailed 
84
analysis using Mercox vascular casts revealed that vasculogenesis occurred periph-
erally in the lungs to form isolated blood islands and that angiogenesis centrally 
forms the axial and lateral arteries and veins. The fusion and coalescence of these 
central and peripheral systems lead to the development of the pulmonary circuit [4]. 
The earliest connection between the peripheral and central spaces was identified 
between E13 and E14.
Muscularization is part of the gradual maturation process of airways and vessels 
in the lungs [1]. Cells positive for α-smooth muscle actin in the vascular wall of PA 
are evident at E11.5 [1, 5]. In terms of local development of vascular smooth mus-
cle, the PA wall is constructed radially, from the inside out, by two separate, but 
coordinated processes: one is the sequential induction and recruitment of successive 
cell layers from surrounding mesenchymal progenitor cells and the other is the con-
trolled invasion of the surrounding layer by inner layer cells. Later on in the process, 
inner layer cells initially divide and migrate extensively within the layer before radi-
ally reorienting to either migrate into the second layer or radially divide to send 
daughter cells into the next developing layer [6].
Through the recent analysis of a transgenic mouse line harboring the lacZ 
reporter gene in a certain targeted locus, we found that the lacZ marker was spe-
cifically expressed in PA smooth muscle cells using whole-mount staining during 
the lung development (Fig. 9.1). Our results suggest that PA smooth muscle may 
elongate gradually from the proximal pulmonary trunk to the peripheral pulmo-
nary arteries similar to the “distal angiogenesis” model during development [7].
heart
lung
Fig. 9.1 Visualization of 
pulmonary artery using a 
reporter transgenic mouse. 
Whole-mount 
β-galactosidase staining 
heart and lungs at 
embryonic day (E) 15.5. 
The β-galactosidase-
positive pulmonary arteries 
continuously elongate from 
the central pulmonary 
trunk to peripheral small 
arteries (arrows). Scale bar, 
1 mm
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There is growing evidence that resident progenitor cell populations exist in murine 
lung tissues and differentiate into a mesenchymal cell lineage [1, 2]. Stem cell anti-
gen- 1 (Sca-1) is a cell surface glycoprotein, initially found in murine bone marrow–
derived stem cell subtypes, such as hematopoietic stem cells. Some studies showed 
Sca-1 expression in the pulmonary vascular endothelium of adult murine lungs [3], 
while a subset of Sca-1-expressing cells formed vascular-like structures under spe-
cific conditions [1].
We previously performed DNA microarray analysis using murine lung cells pos-
itive for vascular endothelial marker, CD31, selected by fluorescence-activated cell 
sorting (FACS) at embryonic and postnatal stages. Sca-1 was found to be more 
robustly expressed in postnatal pups than in embryos (Uchida K, unpublished obser-
vation), suggesting that a subset of Sca-1-expressing cells may be related to the 
formation of the capillary network during later development.
First, we performed immunohistochemistry using eight-week-old murine lung 
sections where Sca-1 immunostaining was found in the vascular wall of pulmonary 
vessels and alveolar capillaries. Some of these Sca-1-positive cells showed overlap-
ping expression with vascular endothelial marker, vWF. Cell populations were then 
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isolated from whole-lung cells by FACS, using antibodies for Sca-1 and CD31, fol-
lowing the depletion of CD45-positive cells. We investigated the tube formation 
ability of these sorted cells cultured in endothelial growth media and found that 
Sca-1 (–) CD31 (+) cells were more robust in tube formation than Sca-1 (+) CD31 
(+) cells (Fig. 10.1).
These results suggest that though Sca-1 (+) CD31 (+) cells form vascular tube 
structures, they have lower tube formation activity than Sca-1 (–) CD31 (+) cells. 
Sca-1 may possibly repress angiogenesis activity in the endothelial cells and poten-
tially make progenitor cell populations stay resident in adult murine lungs. Further 
analysis would delineate the physiological function of Sca-1  in developing lungs 
through embryonic to adult stages.





Fig. 10.1. The tube formation assay. The tube formation (arrows) reflecting angiogenesis is more 
robustly observed in Sca-1 (–) CD31 (+) cells than in Sca-1 (+) CD31 (+) cells. Scale bars, 100 μm
J. Maeda et al.
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Bronchopulmonary dysplasia (BPD) is one of the most significant medical compli-
cations in preterm infants, and pulmonary microvascular injury is associated with 
the pathogenesis of BPD [1]. Furthermore, impairments of developing pulmonary 
vasculature may cause secondary pulmonary hypertension (PH), which contributes 
significantly to morbidity and mortality among preterm infants [2]. To characterize 
the mechanisms of pulmonary vascular disease resulting from BPD, we studied the 
ultrastructural changes affecting pulmonary microvasculature.
Newborn ICR mice were exposed to 85% hyperoxia or normoxia for 14 days, 
and then normal air replacement conditions for the following 7 days. At postnatal 
day (P)14 and P21, lungs were harvested for ultrastructural examination and assess-
ment of PH. To this end, we studied ultrastructural changes in pulmonary microvas-
culature, such as endothelial cells (ECs) and blood-air barriers (BABs), and 
examined the structure of pulmonary arteries associated with terminal and respira-
tory bronchioles as well as right ventricular hypertrophy (RVH).
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ECs presented a heterogeneously thick and irregular cytoplasm with well- 
developed basal infoldings (Fig. 11.1a). Moreover, red blood cells inside the alveo-
lar capillary seemed to be stuck in the capillary lumen, suggesting collapsed 
capillaries and altered pulmonary microcirculation. BABs from injured lungs, com-
prising EC, alveolar epithelial cells, and the basal lamina, were much thicker than 
those of air-exposed lungs, and most BABs were filled with abnormal mitochondria- 
rich EC layers. In contrast, BAB basal lamina layers in hyperoxia-exposed lungs 
were not significantly different from those in controls. Even in the lungs of animals 
exposed to normal air replacement conditions, ECs presented a heterogeneously 
thick cytoplasm rich in organelles, collapsed alveolar capillaries, and EC layers 
occupying most of the BABs. Structural changes were accompanied by increased 
pulmonary artery medial thickness and RVH (Fig. 11.1b). Results were confirmed 
by morphometric quantification.
Pulmonary capillaries in the injured newborn mouse lung presented thick BABs 
consisting of ECs with abnormal morphology, which persisted following subse-
quent exposure to normal air replacement conditions. These ultrastructural changes 
might cause abnormal pulmonary microcirculation and finally lead to secondary PH 
in BPD.
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Fig. 11.1 (a) Pulmonary capillaries and blood-air barriers in Air-14d, Air-21d, O2-14d, and nor-
mal air replacement conditions after hyperoxia (O2-Air-21d). Scale bar black, 1.0 μm; white, 
0.35 μm. Black arrowheads denote the parts of BABs magnified in the lower panels. (b) H&E- 
stained lung sections indicating the thickness of pulmonary arteries associated with terminal and 
respiratory bronchioles. Scale bar (black), 50 μm
H. Nakanishi et al.
93
References
 1. Abman SH.  Bronchopulmonary dysplasia: “a vascular hypothesis”. Am J Respir Crit Care 
Med. 2001;164:1755–6.
 2. Nakanishi H, Uchiyama A, Kusuda S. Impact of pulmonary hypertension on neurodevelopmen-
tal outcome in preterm infants with bronchopulmonary dysplasia: a cohort study. J Perinatol. 
2016;36:890–6.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter's Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder.
11 Morphological Characterization of Pulmonary Microvascular Disease…
95© The Editor(s) (if applicable) and The Author(s) 2020
T. Nakanishi et al. (eds.), Molecular Mechanism of Congenital Heart Disease  
and Pulmonary Hypertension, https://doi.org/10.1007/978-981-15-1185-1_12
T. Zhang · N. Kawaguchi · E. Hayama · Y. Furutani · T. Nakanishi (*) 
Department of Pediatric Cardiology, Tokyo Women’s Medical University, Tokyo, Japan
e-mail: nakanishi.toshio@twmu.ac.jp
12Involvement of CXCR4 and Stem Cells in a Rat Model of Pulmonary Arterial 
Hypertension
Tingting Zhang, Nanako Kawaguchi, Emiko Hayama, 
Yoshiyuki Furutani, and Toshio Nakanishi
Keywords
Pulmonary arterial hypertension · CXCR4 · Mesenchymal stem cells · Pulmonary 
vascular remodeling
Pulmonary arterial hypertension (PAH) is a severe and fatal clinical syndrome. 
C-X-C chemokine receptor type 4 (CXCR4) is known to be expressed in cancer and 
stem/progenitor cells. In the present study, PAH was induced in a rat model by 5 
weeks of 10% hypoxia and treatment with a single subcutaneous injection of mono-
crotaline (60 mg/kg) [1] to investigate the involvement of CXCR4 in PAH develop-
ment [2].
The successful establishment of the PAH model was confirmed by significant 
differences in the right ventricular systolic pressure, Fulton index, wall thickness, 
vascular occlusion score determined by immunohistochemical staining, and the 
expression of inflammatory markers measured by reverse transcription quantitative 
polymerase chain reaction (RT-qPCR) between the PAH and control groups We 
compared the expression of CXCR4 and other stem cell markers in the PAH and 
control groups. The results of RT-qPCR revealed that the expression of CXCR4, 
SCF, c-Kit, and CD29 was significantly higher in the PAH group. 
Immunohistochemical staining also showed that the numbers of CXCR4-, c-Kit-, 
and CD90-positive cells were significantly higher in the PAH group. We hypothe-
sized that these markers play important roles in chemotaxis, proliferation, and sur-
vival of smooth muscle cells or endothelial cells, leading to pulmonary vascular 
remodeling. Further studies to clarify the role of CXCR4 and stem cells in PAH 
development may provide additional treatment options, such as CXCR4 inhibitors.
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Inositol triphosphate receptor (IP3R) is an intracellular Ca2+ release channel located 
on the membrane of the sarco/endoplasmic reticulum (SR/ER), a major intracellular 
storage site for Ca2+. There are three subtypes of IP3R (IP3R1, 2, and 3), each of 
which is known to have versatile roles in the pathophysiology of many organs [1].
In the cardiovascular system, all subtypes of IP3Rs are expressed from embry-
onic to postnatal periods. We previously reported that IP3R1-IP3R2 or IP3R1-IP3R3 
double-knockout (DKO) mice died around embryonic day (E) 11.5 due to disorder 
of cardiovascular development (Fig. 13.1). IP3R1-IP3R2 DKO mice showed devel-
opmental defects of the myocardium and endocardial cushion, resulting from the 
disturbance of calcineurin/NFAT signaling [2]. IP3R1-IP3R3 DKO mice demon-
strated hypoplasia of the outflow tract and the right ventricle of embryonic heart 
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with reduced expression levels of molecular markers for the second heart field [3]. 
In addition, IP3R1-IP3R3 DKO embryos exhibited defects in the vasculature of the 
labyrinth layers of the placenta, allantois, and yolk sac. Therefore, this suggests the 
essential redundant roles of endothelial IP3R1 and 3 for angiogenesis during embry-
onic and extra-embryonic vascular development [4].
Recently, we found the specific expression of IP3R in the pulmonary artery 
smooth muscle cells (PASMCs) of murine lungs. Although there are some reports 
that implicated IP3R1 in vasoconstriction or remodeling in vascular smooth muscle 
cells [5], the precise role of IP3Rs in PASMCs remains unknown. Since intracellular 
Ca2+ signaling in PASMCs is a major regulator for pulmonary vasoconstriction and 
remodeling, its dysregulation leads to the progression of pulmonary arterial hyper-
tension (PAH). It was reported that store-operated Ca2+ (SOC) entry was upregu-
lated in PASMCs with PAH patients. Our results suggest that intracellular Ca2+ 
depletion through Ca2+ release by IP3R from the SR/ER may lead to the opening of 
SOC channels, a mechanism potentially involved in the pathophysiology of PAH 
(Fig. 13.1) [6].
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Progression of pulmonary arterial
hypertension
Fig. 13.1 The role of IP3Rs for cardiogenesis, extra-embryonic vascularization, and suppression 
of pulmonary arterial hypertension. RV right ventricle, OFT outflow tract, PA pulmonary artery
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Pulmonary blood flow increases gradually during fetal life, and dramatic changes in 
the pulmonary circulation occur from the fetus to newborn, including decrease in 
pulmonary arterial resistance, increase in pulmonary blood flow, and closure of duc-
tus arteriosus. Upon initiation of breathing after birth, pulmonary circulation is 
important for gas exchange between the alveoli and capillary vessels. Presence of 
congenital heart disease modifies development of the lung and pulmonary vessels, 
even before birth. For example, enlarged right atrium due to severe Ebstein’s anom-
aly compresses the fetal lung and compromises lung development. Decreases in 
pulmonary blood flow during fetal life and especially after birth, for example, due 
to pulmonary stenosis or outflow stenosis may compromise the development of pul-
monary arteries. In the research of morphogenesis of congenital heart disease, it is 
important to understand normal and abnormal lung and pulmonary vessel 
developments.
14.1  Idiopathic Pulmonary Arterial Hypertension (IPAH)
IPAH was discussed in this symposium because genetic background plays an impor-
tant role and, therefore, IPAH is sort of a congenital disease. In IPAH, pulmonary 
smooth muscle cells and endothelial cells proliferate and obstruct small pulmonary 
arteries. Gene mutations such as bone morphogenic protein receptor II (BMPR II) 
are found in some patients with IPAH but the mechanisms how these gene muta-
tions cause proliferation of pulmonary smooth muscle cells are still not clear. In 
addition to the genetic background, other factors such as inflammation may be 
involved because penetration rate of gene mutation is low.
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Before pulmonary vasodilators were developed, calcium antagonists were the 
only drugs to treat IPAH, and prognosis of IPAH, especially pediatric IPAH, was 
very poor [1] (Fig. 14.1). In 1986, nitric oxide was found as a vasodilator, and after 
that various pulmonary vasodilators have been developed and used in patients with 
IPAH (Table 14.1). Time of government approval for clinical use differed in each 
country (Fig. 14.2). For example, intravenous epoprostenol was approved for clini-
cal use in 1995 by FDA and in 1999 in Japan. It has not been approved in China at 
this moment in 2019. Prognosis of IPAH has improved depending on the time when 
a certain vasodilator could be used [2] (Fig. 14.3).
Use of pulmonary vasodilators improves prognosis of patients, but these drugs 
may not change the background pathophysiology of IPAH. Research to clarify the 
pathophysiology of IPAH is important to further improve prognosis of patients. 
Good animal models of IPAH are important to study the pathophysiology of IPAH 
and to develop a treatment strategy for IPAH. iPS cells have the potential to estab-
lish a good IPAH model in vitro.
To understand molecular mechanisms of IPAH, it may be important to clarify nor-
mal pathways governing morphogenesis of the lung and pulmonary vessels. If we can 
clarify how the lung and pulmonary vessels are formed, how each gene is involved, and 
how each signal transduction is involved, then we may be able know the precise mech-
anisms how pulmonary smooth muscle cells and endothelial cells start to proliferate 
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Fig. 14.1 Prognosis of pediatric IPAH. Red diamond: historical data before 1963. Open triangle: 
non-responders to acute prostanlandin I2 testing. Open sun: responders to acute prostanlandin I2 












































Fig. 14.2 Time of government approval for clinical use in USA (FDA) and in Japan. In 1986, 
nitric oxide was found as a vasodilator, and after that various pulmonary vasodilators have been 
developed and used in patients with IPAH
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14.2  Pulmonary Hypertension with Congenital Heart 
Disease
Fish has only one atrium and one ventricle. Frog and turtle have basically one ven-
tricle and truncus, and yet it looks like they do not develop pulmonary hypertension 
although their blood pressure is low. Mammals have two ventricles and two circula-
tions, systemic (left) and pulmonary (right) circulation, and if pulmonary blood 
flow is more than the systemic blood flow due to left to right shunt and if the pulmo-
nary artery is exposed to high pressure, pulmonary smooth muscle cells and endo-
thelial cells start to proliferate and obstruct vessels. We still do knot know the 
precise mechanisms for the proliferation of the pulmonary smooth muscle cells and 
endothelial cells in these conditions. The threshold of the “high pressure” is unclear 
but in human the pulmonary artery systolic pressure higher than 50  mmHg can 
induce irreversible pulmonary obstructive disease. Once this condition has been 
established with the shunt remaining open, a relatively stable clinical condition con-
tinues until patients die earlier than a normal lifespan.
In IPAH and pulmonary hypertension with congenital heart disease, the right 
ventricle should tolerate increased afterload. Management of right ventricular con-
tractile force is important in the treatment of patients with Eisenmenger syndrome 
and IPAH.
14.3  Pulmonary Circulation in Patients with Congenital 
Heart Disease
Fontan operation is performed if only one ventricle is functional in conditions such 
as tricuspid atresia, hypoplastic left heart syndrome, or single ventricle. Pulmonary 
circulation after Fontan operation is unique. In this operation, the right atrium is 












Group A  42.9+/-13.2%
Group B  69.3+/-13.2%
Group C  84.3+/-7.2%
Group D  96.4+/-3.5%
A vs D p<0.001
















Fig. 14.3 Prognosis of pediatric IPAH in Japan. Prognosis of IPAH has been improved depending 
on the time when certain vasodilator could be used
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connected to the pulmonary artery directly, or the superior vena cava and the infe-
rior vena cava are connected to the pulmonary artery (Fig. 14.4). There is no pulsa-
tile flow in the pulmonary artery after Fontan operation. After Fontan operation, 
pulmonary resistance can be slightly higher (3–5 Wood unit.m2) than normal (less 
than 3 Wood unit.m2). This slightly higher pulmonary resistance may compromise 
quality of life and lifespan of patients. The high pulmonary resistance may decrease 
pulmonary venous return, decrease cardiac output, increase central venous pressure, 
induce atrial ahhrythmia, increase liver congestion, induce liver cihhrosis, and/or 
induce protein losing enteropathy. Whether pulmonary vasodilators are effective in 
the management of Fontan patients is not yet clear. More importantly, molecular 
and cellular mechanisms of abnormal pulmonary circulation after Fontan operation 
have not been investigated and should be clarified in future.
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Fig. 14.4 Two types of Fontan operation. (a) Total cavo-pulmonary connection (TCPC). (b) Atrio 
pulmonary connection (APC). In TCPC, superior vena cava (SVC) is connected to the pulmonary 
artery (PA) and inferior vena cava (IVC) is connected with PA using conduit. In APC, right atrial 
appendage is connected with PA
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Abstract
There are several types of abnormalities in the integrated physiology of pulmo-
nary circulation in congenital heart disease. The main pathology of Eisenmenger 
syndrome involves a change in pulmonary resistance and is the most commonly 
observed pathophysiology in pulmonary hypertension. Other diseases also pres-
ent with the main pathophysiological characteristic of reduced pulmonary com-
pliance, such as tetralogy of Fallot and multiple peripheral pulmonary stenosis. 
In addition, the cavo-pulmonary connection has the unique feature of both pul-
monary circulation and regulation. According to the differences in the patho-
physiological features of pulmonary circulation, therapeutic approaches may 
considerably differ between diseases and conditions. Physiology-based clinical 
insights with regard to pulmonary circulation in congenital heart disease will be 
discussed in this chapter.
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This chapter discusses the pathophysiology of pulmonary circulation in congenital 
heart disease. This refers to the macrophysiology of cardiovascular hemodynamics, 
an understanding of which is essential for the treatment of patients with abnormal 
pulmonary circulation and congenital heart disease. We hope this chapter can pro-
vide some hints and insights for use in future research on pulmonary hypertension 
in congenital disease as well as in the fields of physiology and molecular and cel-
lular biology.
We will first discuss how we comprehensively assess integrated pulmonary cir-
culation in congenital heart disease in vivo. Subsequently, using methodology for 
comprehensive assessment, we will discuss the pathophysiological characteristics 
of pulmonary circulation in patients with various types of congenital heart disease.
15.2  Comprehensive Assessment of Integrated Pulmonary 
Circulation
15.2.1  Physiologic Components of Pulmonary Circulation
Pulmonary circulation consists of the following three major components: resistive, 
elastic, and reflective components. The resistive component is described as pulmo-
nary vascular resistance (PVR). PVR acts in opposition to mean or non-pulsatile 
steady flow and is analogous to electric resistance, which acts in opposition to direct 
current in an electronic circuit. Thus, PVR can be calculated as the ratio of mean 
pulmonary flow to mean pulmonary arterial pressure according to Ohm’s law for an 
electric circuit. In other words, PVR only determines mean pulmonary pressure 
according to the amount of pulmonary blood flow. An increase in PVR causes an 
increase in mean pulmonary arterial pressure without a marked change in pulse 
pressure (Fig. 15.1a).
The elastic component is vascular compliance or capacitance. The pulmonary 
artery is not a rigid tube but has elasticity to buffer intermittent pulsatile flow ejected 
by the right ventricle. Pulmonary arterial capacitance is a vascular property in this 
buffering system and is determined by both arterial wall elasticity and vascular size 
or volume. Pulmonary compliance/capacitance is analogous to a capacitor or con-
denser in an electric circuit. An alternating current but not a direct current goes in 
and out of the capacitor. Similarly, only pulsatile flow goes in and out of the pulmo-
nary vascular bed with capacitance and is associated with a change in pulse pres-
sure. When pulmonary capacitance is decreased, in other words, when the pulmonary 
arterial wall is stiff and/or pulmonary vascular bed is small, blood pressure increases 
through an increase in pulse pressure without a change in mean blood pressure 
(Fig. 15.1b).
There is yet another property of the elastic component of the pulmonary vascular 
bed. This is termed characteristic impedance and represents wall stiffness in the 
proximal artery. In an electric circuit, characteristic impedance is described as 
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resistance upstream of the resistor-capacitor parallel circuit. When characteristic 
impedance increases, in other words, when the proximal pulmonary arterial wall 
stiffens, blood pressure increases by an increase in pulse pressure above the dia-
stolic pressure as shown in Fig. 15.1c.
The last major component is a reflective component. The pulmonary vascular 
bed is not an infinite system but has an end at the left atrium. The pulmonary vascu-
lar bed also has many bifurcations with caliber changes. In this type of system, 
blood flow and pressure waves produce reflections at the site of a bifurcation or 
vessel caliber change [1, 2]. Therefore, the measured pressure or flow we observe is 
the sum of forward and reflected waves, and thus augmentation of reflected waves 
causes significant pressure elevation (Fig. 15.1d).
Therefore, abnormalities in each component contribute differently to pressure 
elevation in patients with pulmonary hypertension. Resistance change increases 
pulmonary arterial pressure (PAP) by increasing mean arterial pressure, changes in 
capacitance and characteristic impedance increase arterial pressure by increasing 
pulse pressure, and wave reflection increases PAP by adding reflected pressure. 
Therefore, to better understand the pathophysiology of pulmonary hypertension, it 
is very important to identify to what extent each of these components is abnormal 
and contributes to pressure elevation in pulmonary hypertension.
a b
c d
Fig. 15.1 Effects of changes in resistance (a), compliance (b), characteristic impedance (c), and 
wave reflection (d) on pulmonary artery pressure
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15.2.2  Impedance Analysis
Impedance analysis is an ideal method for this purpose by providing comprehen-
sive information regarding the vascular system, including vascular compliance 
and wave reflection as well as vascular resistance [3, 4]. To briefly explain 
(Fig. 15.2), instantaneously measured pressure and flow data are mathematically 
transformed as the sum of pressure and flow waves at each frequency of the inte-
ger multiple of a fundamental frequency. The fundamental frequency corre-
sponds to the heart rate. The ratio of pressure to flow at each frequency yields 
impedance spectra. Fig. 15.3 shows examples of impedance spectra. Impedance 
at 0 frequency, or zero oscillation, represents pulmonary resistance. Characteristic 
impedance is calculated as the average impedance at higher frequencies. 
Compliance is calculated from lower frequency impedance or the time constant 
of diastolic pressure decay. Wave reflection increases oscillation of the imped-
ance spectra at higher frequencies and is directly calculated using the formula 
described in Fig. 15.3. Thus, all other vascular components, including character-
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Fig. 15.2 Fourier transformation of pressure and flow data, yielding impedance spectra in the 
frequency domain
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15.3  Pathophysiological Characteristics of Pulmonary 
Circulation in Congenital Heart Disease
Using impedance analysis, let us discuss the pathophysiological characteristics of 
pulmonary circulation in patients with various types of congenital heart disease.
15.3.1  Abnormal Resistance Is the Main Pathophysiology
In the disease entity of abnormal pulmonary circulation, increased pulmonary resis-
tance is the main pathophysiology. Eisenmenger syndrome due to high pulmonary 
flow and idiopathic pulmonary arterial hypertension (PAH) are examples. Fig. 15.4 
shows an example of PAH due to patent ductus arteriosus in a 1-year-old patient 
with trisomy 21. PAP is 80/40 mmHg. Compared to a control patient with normal 
pulmonary arterial pressure, wave reflection (shown via the dashed lines) is aug-
mented in this patient. Impedance spectra exhibit an upward shift in this patient, 
particularly at 0 frequency or pulmonary resistance. There are also mild abnormali-
ties in characteristic impedance (Zc), compliance (C), and wave reflection. In this 
patient, oral administration of sildenafil markedly reduced PAP as shown by the 
yellow lines. This is mainly the result of reduction of pulmonary vascular resistance, 
with some degree of improvement in vascular compliance and wave reflection.
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Pulmonary vascular resistance (Rp)
impedance at 0 Hz (no oscillation)
Characteristic impedance (Zc)
average of impedance at higher Hz
Pulmonary arterial compliance (C)
lower Hz impedance
Wave reflection
Pb = (Pm – Zc Fm) / 2
Pm and Fm: measured pressure and flow
C
Impedance
Fig. 15.3 Example of impedance spectra, which provide comprehensive measurements of vascu-
lar properties, including pulmonary vascular resistance, characteristic impedance, pulmonary arte-
rial compliance, and wave reflection
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Fig. 15.4 Pressure (left) and impedance (right) data before and after oral administration of silde-
nafil. R, Zc, C, and RF represent resistance, characteristic impedance, compliance, and reflection 
factor
























Fig. 15.5 Impedance data before and after oral administration of sildenafil. R, Zc, C, and RF 
represent resistance, characteristic impedance, compliance, and reflection factor
Here is another example of PAH in a 9-year-old girl after repair of transposition 
of the great arteries. PAP is 125/68 mmHg. Impedance spectra in this patient are 
characterized by a further upward shift of the yellow line compared to those in con-
trols and the previous case of PAH, indicating a more advanced stage of PAH 
(Fig. 15.5). Interestingly, oral administration of sildenafil, as shown by the yellow 
line, did not have a marked effect on pulmonary vascular resistance but still reduced 
PAP by 20 mmHg. This was mainly owing to the change in characteristic imped-
ance, which caused the reduction of pulse pressure (Fig. 15.6). These data show that 
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pharmacologic effects and the mechanism of action of pulmonary dilators can be 
different according to the disease stage and condition and that impedance analysis 
enables detailed assessment about where the main lesions of pathologic change are 
and how the vascular bed responds to medications.
In addition to each parameter of impedance, combining resistance and compli-
ance as their product, RC, also provides useful information about the pulmonary 
circulation. RC represents the time required for diastolic pressure decay, and a lon-
ger RC indicates that the blood does not go through the pulmonary vascular bed 
smoothly [5].
Therefore, advanced PAH should be associated with higher RC values. In fact, 
although PVR alone could not clearly distinguish pulmonary hypertension patients 
with irreversible pulmonary vascular disease from those whose PAP normalized 
after ventricular septal defect closure, plots of RC against Qp/Qs clearly distin-
guished the two groups [5].
15.3.2  Right Ventricular Function and Coupling to PA Load
In addition to the precise assessment and understanding of pathophysiological 
changes in the pulmonary vascular bed as shown thus far, an accurate assessment of 
intrinsic right ventricular (RV) contractility and its relation to the pulmonary artery 
(PA) load is essential for refining risk stratification and optimizing treatment in 
pulmonary hypertension because prognosis in PAH is now known to be strongly 
related to RV compensation rather than to the degree of the vascular injury itself as 
reported by many investigators [6–8]. Therefore, we will briefly introduce the 
method of assessing RV-PA interaction or RV-PA coupling.
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Fig. 15.6 Pressure (left) and impedance (right) data before and after oral administration of silde-
nafil. R, Zc, C, and RF represent resistance, characteristic impedance, compliance, and reflection 
factor
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The ventricular pressure-volume relationship is the best way to demonstrate 
this [9–11]. An instantaneous plot of ventricular pressure and volume change 
yields a pressure-volume loop [12]. We can further construct successive ventricu-
lar pressure- volume loops during transient preload reduction with inferior vena 
cava occlusion [11, 13, 14]. The slope of the end-systolic pressure-volume rela-
tionship, called end- systolic elastance (Ees), represents ventricular contractility, 
whereas arterial elastance (Ea) represents ventricular afterload and provides 
information on PA impedance [14, 15]. Therefore, the simple ratio of Ees/Ea rep-
resents ventricular- arterial (V-A) coupling status [16]. Figure 15.7a shows the PV 
relationship in the normal left ventricle (LV). Compared to that for the LV, the 
normal RV pressure-volume relationship has, as shown in Fig. 15.7b, a triangular 
shape with a low ventricular contractility corresponding to the low PA impedance 
or low ventricular afterload. With progression of pulmonary hypertension, the RV 
generally adapts to increased afterload by increasing contractility, preserving V-A 
coupling status and, thereby, cardiac output (Fig. 15.8a, b). However, once the RV 
contractile adaptation begins to fail, the RV needs to increase its volume to pre-
serve cardiac output, leading to a course of progressive failure and poor outcome 
as shown in the yellow lines. The PV relationship is also useful to predict treat-
ment response. Because Ees represents ventricular systolic stiffness, it predicts 


































Fig. 15.7 Examples of pressure-volume relationships in normal left ventricle (a) and right ven-
tricle (b)
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Fig. 15.8 Changes in pressure-volume relationships with progression (a, b) of pulmonary hyper-
tension (PH). Afterload-mismatched right ventricle (RV) represented by red lines (c)
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15.3.3  Abnormalities of Compliance Is the Main Pathophysiology
Next, we will discuss another disease entity of abnormal pulmonary circulation in 
which change in arterial compliance is the predominant pathophysiology of pulmo-
nary hypertension. Tetralogy of Fallot (TOF) and multiple peripheral pulmonary ste-
nosis are representative of this group. We measured pulmonary vascular impedance 
in 29 pediatric patients with repaired TOF [19]. Impedance spectra of TOF shifted 
upward compared to those of control patients, and PA exhibited augmented pulse 
pressure with increased wave reflection [19]. As summarized in Fig. 15.9, the abnor-
mality of pulmonary vasculature in TOF is more evident in elastic components than 
in resistive components as shown by the increased characteristic impedance and 
decreased arterial compliance. Wave reflection is also augmented, contributing to the 
change in pulsatile nature of the pulmonary circulation in TOF. These data indicating 
enhanced pulmonary arterial stiffness are consistent with a previous histologic exam-
ination of the pulmonary artery in patients with TOF [20, 21]. Bedard et al. reported 
abnormal elastic tissue configuration and a high proportion of medionecrosis and 
elastic fragmentation [20]. These changes suggest decreased distensibility of the pul-
monary arteries. Importantly, we also found that decreased pulmonary compliance 
was associated with RV dilation independent of the severity of pulmonary regurgita-
tion [19]. Therefore, decreased pulmonary compliance in TOF serves as a pulsatile 
afterload to the RV and contributes to the progression of RV failure.
15.3.4  Non-pulsatile Pulmonary Flow Is the Main 
Pathophysiology
Lastly, cavo-pulmonary connection, as in Fontan or Glenn circulation, is another 
disease entity of abnormal pulmonary circulation in congenital heart disease. 






































Fig. 15.9 Comparison of characteristic impedance (Zc), pulmonary resistance (Rp), compliance 
(C), and wave reflection (Ref) between tetralogy of Fallot (TOF) and control patients (Cont)
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unique pulmonary hemodynamics are characterized by non-pulsatile flow due to 
lack of a pulmonary ventricle [22]. The pulsatile nature of pulmonary blood flow is 
important for shear stress-mediated release of endothelium-derived nitric oxide 
(NO) and lowering of PVR, thereby reducing NO-cGMP-mediated vasodilatory 
capacity [23–25]. In addition, low cardiac output and elevated central venous pres-
sure (CVP) in Fontan circulation can activate vasoconstrictive hormones, including 
endothelin and angiotensin II [22, 26, 27]. Therefore, PVR is generally slightly but 
significantly higher than normal even in good Fontan status. In fact, we can decrease 
PVR using exogenous NO in patients late after Fontan surgery. Redington’s group 
examined NO responsiveness in 15 Fontan patients with a median postoperative 
period of 9 years and demonstrated significant reduction of PVR with inhaled NO. 
[28] Interestingly, the effect was even more evident in patients with total cavo- 
pulmonary connection (TCPC) than in those with atrio-pulmonary connection 
(APC) and some degree of pulmonary flow pulsatility, suggesting the importance of 
pulsatility [28]. Our own data also indicated significant reduction of PAP using 
sildenafil or tadalafil in 26 patients with Glenn circulation (Fig. 15.10).
There are many studies indicating activation of endothelin-1 or the renin- 
angiotensin system in Fontan circulation [29–31]. A significant correlation between 
endothelin-1 and PVR after the Fontan operation was also reported [31]. In addi-
tion, an endothelin receptor antagonist effectively reduced PVR in Fontan patients 
and improved exercise tolerance and quality of life [32]. Therefore, even in good 
Fontan status, pulmonary dilators targeting NO and endothelin pathways may have 
some role in improving Fontan pulmonary circulation and thereby improving the 
long-term outcome.
Let us briefly think about the role of pulmonary compliance or capacitance in the 
Fontan circulation. Theoretically, as we explained earlier, only pulsatile flow goes 
into capacitance, and thus, in the Fontan pulmonary circulation where pulmonary 





















Fig. 15.10 Changes in 
pulmonary artery pressure 
(PAP) before and after oral 
administration of sildenafil 
in Glenn patients
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Nonetheless, pulmonary vascular capacitance still possesses important pathophysi-
ological roles in the Fontan circulation. First, because of the direct connection of 
systemic and pulmonary circulation, pulmonary vascular capacitance serves as part 
of the total vascular impedance from the aorta to the pulmonary vascular bed [22]. 
Total vascular impedance is afterload to the Fontan single ventricle. As shown here, 
total vascular impedance, or ventricular afterload, increases with an increase in pul-
monary vascular capacitance [22]. Second, perhaps more importantly, our computer 
simulation clearly indicated that smaller pulmonary vascular capacitance is related 
to a more marked increase in CVP in response to changes in pulmonary blood vol-
ume, which can occur with exercise and excessive water intake [33, 34]. Therefore, 
CVP variation during daily life should be pronounced in Fontan patients with 
decreased pulmonary capacitance. As in the original “10 Commandments” or indi-
cations for Fontan surgery [35], pulmonary arterial size, which is related to pulmo-
nary capacitance, is important, independent of PVR, for the establishment of stable 
Fontan hemodynamics.
Similar to the effects of pulmonary artery capacitance, systemic venous capaci-
tance is important and is an even more important hemodynamic parameter to estab-
lish lower levels of CVP in the Fontan circulation [34, 36].
Figure 15.11 shows the effects of changes in each vascular parameter in Fontan 
hemodynamics [33]. Each parameter was changed by 50% from the baseline values 
and their effects on CVP were examined by computer simulation. As shown, venous 
capacitance has the strongest influence on the change in CVP, followed by pulmo-
nary capacitance and pulmonary resistance [33]. The importance of venous capaci-
tance is realized by our “super-Fontan” strategy, which is an aggressive venodilation 
therapy with nitrates and angiotensin-converting enzyme (ACE) inhibitors, and pul-
monary dilators if necessary, to achieve supernormal, extremely good Fontan circu-
lation [37]. In fact, this strategy significantly increases venous capacitance as 
measured by the dye-dilution technique [37–39]. As shown in Fig. 15.11, eight con-













Fig. 15.11 The effects of 
changes in each vascular 
parameter in Fontan.  
Cs systemic venous 
compliance, Rs systemic 
resistance, Rp pulmonary 
resistance, Cp pulmonary 
compliance
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significantly lower CVP values than patients without super-Fontan strategy at car-
diac catheterization 1 year after Fontan surgery; however, the cardiac index (CI) was 
comparable in both groups. Six patients who received super-Fontan therapy had 
CVP values of <10 mmHg.
In addition, we newly applied this strategy to 20 patients at an average 7 years 
postoperatively. The venous capacitance measured by the dye-dilution technique 
significantly increased after 6 months of this therapy. Importantly, with this change 
in venous capacitance, CVP again significantly and consistently decreased after the 
therapy without changes in heart rate and cardiac index.
We will close this chapter by presenting a case of protein-losing enteropathy 
(PLE) in which super-Fontan strategy was very effective. The patient was a 
16-year- old boy with asplenia syndrome, major atrio-pulmonary collateral arter-
ies, and atrioventricular valve regurgitation who underwent TCPC at the age of 7 
but developed PLE after the TCPC.  Every possible medication had been pre-
scribed. He was referred to our hospital and underwent the super-Fontan strategy, 
which effectively reduced CVP from 21 to 15  mmHg and, more importantly, 
resolved the PLE.
In summary, comprehensive assessment of changes in the pulmonary vascular 
bed and their coupling to RV function is important. Impedance analysis and deter-
mination of pressure-volume relationships are ideal methods for this purpose. There 
are several disease entities with abnormal pulmonary circulation in congenital heart 
disease characterized by abnormalities of resistance, compliance, and flow pulsatil-
ity. Venous capacitance as well as pulmonary resistance can be an important thera-
peutic target to improve Fontan prognosis.
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Pulmonary hypertension is a lethal disease in which inflammation and oxidative 
stress are deeply involved in the disease state. We have recently screened novel 
pathogenic molecules and have performed drug discovery targeting those mole-
cules. To confirm its clinical significance, we used patient-derived blood samples 
to evaluate the potential as a biomarker for diagnosis and prognosis. Finally, we 
conducted a high-throughput screening and found inhibitors for the pathogenic 
proteins. In this chapter, we would like to introduce the recent progress on the 
basic and clinical research focusing on the screening of pathogenic proteins in 
pulmonary hypertension.
Keywords
Pulmonary hypertension · Transnational research · Drug discovery · Biomarker  
Diagnosis
16.1  Introduction
Pulmonary arterial hypertension (PAH) is characterized by intimal/medial thicken-
ing and perivascular inflammation and fibrotic change. In addition to genetic back-
grounds, many environmental factors as well as volume overload due to heart 
disease and inflammation due to collagen disease are involved in the development 
of PAH. The identification of pathogenic genes, which induce the abnormal charac-
teristics of pulmonary artery smooth muscle cells (PASMCs), should be useful for 
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the development of novel therapies for PAH.  The characteristics of PASMCs of 
patients with PAH (PAH-PASMCs) are different from those of healthy controls. In 
this chapter, we would like to summarize our recent progress on the basic and clini-
cal research focusing on the screening of pathogenic proteins in PAH.
16.2  Endothelial Function in the Development of PAH
Endothelial dysfunction triggers a variety of vascular disorders such as PAH. We 
have reported a protective role of the endogenous erythropoietin (Epo)/Epo receptor 
(EpoR) system against the development of PH [12]. This system also plays a crucial 
role in the functional recovery of ischemic heart [20] and ischemic lower limb [6], 
demonstrating the importance of endothelial function [4, 10]. Additionally, we 
found that pravastatin and metformin protect pulmonary endothelial function and 
ameliorate hypoxia-induced PH in animals [8, 11]. AMP-activated protein kinase 
(AMPK) is a serine/threonine kinase that functions as an important energy sensor. 
AMPK has an anti-apoptotic effect in endothelial cells and a pro-apoptotic effect in 
vascular smooth muscle cells (VSMCs). Both endothelial nitric oxide (NO) produc-
tion and NO-mediated signaling in VSMCs are targets of the AMPK. In endothelial 
cells, AMPK positively regulates NO production. In VSMCs, AMPK reduces secre-
tion of growth factors that promote VSMC proliferation and vascular remodeling. 
Indeed, we have demonstrated that endothelial AMPK plays an important role in 
microvascular homeostasis in mice in vivo [2]. Additionally, AMPK activators (e.g., 
statins, metformin, and apelin) are protective against the development of PAH. We 
also demonstrated that endothelial AMPK plays protective roles against hypoxia- 
induced PH in mice [8, 11]. Circulating inflammatory cytokines downregulate 
AMPK and induce endothelial dysfunction in pulmonary circulation [9, 17]. Thus, 
endothelial AMPK as well as circulating inflammatory cytokines may be therapeu-
tic targets for the treatment of PAH. Thus, AMPK is a key molecule at the crossroad 
of inflammation and pulmonary artery endothelial dysfunction in the pathogenesis 
of PAH.
16.3  PASMCs in the Development of PAH
Pulmonary vascular inflammation plays a crucial role for the development of 
hypoxia-induced PH [11, 12], for which Rho-kinase plays a crucial role [1, 3, 16]. 
Excessive and continuous activation of Rho-kinase promotes secretion of cyclophilin 
A (CyPA) from VSMCs and extracellular CyPA stimulates VSMC proliferation 
[13]. Additionally, extracellular CyPA induces endothelial cell adhesion molecule 
expression and endothelial apoptosis [7]. Basigin (Bsg) is an extracellular CyPA 
receptor. Bsg is also known as an essential receptor for Malaria, which disrupts NO 
metabolism and causes harmful endothelial activation, including the Rho/Rho- 
kinase activation. Based on these backgrounds, we have demonstrated that CyPA 
and Bsg promote hypoxia-induced PH [15]. More importantly, plasma CyPA was 
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significantly increased in patients with PAH and well correlated with the disease 
severity and long-term survival. Thus, extracellular CyPA and its signaling through 
Bsg are novel therapeutic targets for PAH. We have previously reported that statins 
and Rho-kinase inhibitors reduce CyPA secretion from VSMCs [14, 19]. Thus, inhi-
bition of CyPA secretion by Rho-kinase inhibitors may have therapeutic efficacy in 
PAH. In addition, Bsg is strongly expressed in the pulmonary arteries of patients 
with PAH [15]. Thus, pharmacological agents that prevent the interaction of extra-
cellular CyPA and vascular Bsg could be useful for the treatment of PAH. Indeed, 
our drug discovery research demonstrated that celastrol significantly inhibits CyPA 
and Bsg, inhibiting proliferation of PAH-PASMCs [18]. Here, we used PASMCs 
and high-throughput screening to identify novel agents to inhibit both CyPA and 
Bsg. PASMCs in the remodeled pulmonary arteries have special characteristics with 
pro-proliferative features. Importantly, celastrol suppressed CyPA and Bsg expres-
sions in the heart and lung and ameliorated both heart failure (HF) and post- capillary 
PH. Taken together, inhibiting both CyPA and Bsg may represent a novel therapeu-
tic strategy for the treatment of HF patients with post-capillary PH [18]. As patients 
with HF and coexisting post-capillary PH show poor clinical outcomes, targeting 
both cardiac dysfunction and pulmonary vascular remodeling could be a novel con-
cept for the treatment of HF.
16.4  Selenoprotein P in the Development of PAH
Since conventional pulmonary vasodilators have limited efficacy for the treatment 
of severe PAH, we have performed a series of screens and tried to find a novel thera-
peutic target. To identify a novel pathogenic protein, we performed microarray 
analyses using PAH-PASMCs and found 32-fold upregulation of selenoprotein P 
(SeP) as compared with control PASMCs [5]. Indeed, SeP is highly upregulated in 
the distal pulmonary arteries of PAH patients. SeP is a secreted protein mainly pro-
duced by hepatocytes, which contains 10 selenocysteine residues and transports 
selenium to maintain cellular metabolism. SeP is upregulated in the liver of patients 
with type 2 diabetes and downregulates the metabolic switch, AMPK. Additionally, 
single-nucleotide polymorphisms in the SEPP1 gene have been reported to be asso-
ciated with abdominal aortic aneurysm formation. Based on these backgrounds, we 
further demonstrated that SeP in PASMCs promotes cell proliferation through 
increased oxidative stress and mitochondrial dysfunction in an autocrine/paracrine 
manner [5]. Moreover, we demonstrated a pathogenic role of SeP in the develop-
ment of hypoxia-induced PH in vivo. Since there is a limited efficacy in the treat-
ment of patients with severe PAH, we performed a series of screening to find a novel 
therapeutic target. Finally, we identified that sanguinarine, an orally active small 
molecule, reduces SeP expression and PASMC proliferation and ameliorates PH in 
mice and rats. When we consider the pro-proliferative role of SeP in PAH-PASMCs, 
the anti-proliferative effect of sanguinarine in several kinds of cancer in vivo could 
be attributed to the suppression of SeP. Actually, sanguinarine administration to the 
animal models of PH revealed therapeutic effects on PH and RV failure without any 
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adverse effects [5]. Moreover, serum levels of SeP were significantly elevated in 
PAH patients in whom higher serum levels of SeP predicted a poor outcome. Based 
on these results, serum levels of SeP can be used as a novel biomarker for PAH and 
are useful to evaluate the therapeutic effect of SeP inhibitors (companion diagnos-
tics). Using a combination of SeP inhibitors and serum levels of SeP, we may find 
good candidates among PAH patients that can be used to demonstrate the effective-
ness of this strategy.
16.5  Conclusion
In this chapter, we introduced our recent findings on Epo, AMPK, Rho-kinase, 
CyPA, Bsg, and SeP, all of which are substantially involved in the pathogenesis of 
PAH. Additionally, we have also mentioned as to the screening of inhibitors for 
those pathogenic proteins. By using the novel biomarkers and therapeutic agents, 
we will continue translational research for the early diagnosis and the development 
of fundamental therapy in PAH patients.
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Pulmonary arterial hypertension (PAH) is characterized by endothelial cell (EC) 
dysfunction, loss of peripheral pulmonary arterial (PA) microvessels, and prolif-
eration of vascular cells in proximal PAs, leading to occlusion of the lumen. Loss 
of function mutations in bone morphogenetic protein receptor (BMPR)2 occur in 
over 70% of heritable form of PAH (HPAH) patients. Intriguingly, only 20% of 
the mutation carriers develop clinical symptoms, suggesting that genetic varia-
tion may provide modifiers that alleviate the disease. Induced pluripotent stem 
cell (iPSC)-derived vascular cells provide a new opportunity to further under-
stand the disease mechanisms in a personalized manner. In our study, we demon-
strated that iPSC-derived endothelial cell (iPSC-EC) recapitulates the functional 
and gene expression abnormalities in native PAEC from the same PAH patients 
compared with healthy controls. Interestingly, PAH PAEC and iPSC-EC also 
respond similarly to potential PAH therapies elafin and FK506  in terms of 
improved angiogenesis. We then used iPSC-ECs to further understand the 
reduced penetrance of the BMPR2 mutation. iPSC-EC was generated from three 
families with unaffected mutation carriers (UMC), HPAH patients, and gender- 
matched controls. We identified patient-specific features of preserved function in 
UMC iPSC-EC attributed to the regulators of BMPR2 signaling or to cell sur-
vival gene revealed by RNA-Seq analyses. Our findings therefore highlight 
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protective modifiers for HPAH that could help inform development of future 
treatment strategies. Despite the site of disease in the lung and the particular 
vulnerability of the PA vasculature, iPSC-EC is a good surrogate for PAH model-
ing and drug testing.
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Pulmonary arterial hypertension
17.1  Introduction
PAH is a progressive disease in which small peripheral arteries are lost or obliter-
ated and more proximal vessels narrow and stiffen, progressively increasing resis-
tance to flow and eventually leading to right heart failure [1, 2]. While the cause of 
PAH remains poorly understood, the last two decades have shed light on genetic and 
cellular abnormalities responsible for predisposition to vascular remodeling in 
PAH. In particular, it has been shown that the endothelial cells (ECs) in PAH are 
dysfunctional, as evidenced by susceptibility to apoptosis associated with loss of 
peripheral arteries [3], reduced adhesion related to impaired regeneration [4], 
decreased migration [5] and tube formation in angiogenesis assays [3] as well as 
heightened glycolysis, and emergence of apoptosis-resistant cells [6].
One of the major genetic mechanisms driving the endothelial dysfunctions is the 
loss of function mutations in bone-morphogenetic-protein receptor 2 (BMPR2), 
which is seen in 70% of patients with the heritable form of PAH (HPAH) and in 
20% of sporadic cases of idiopathic PAH (IPAH). Intriguingly, in HPAH families, 
only 20% of the BMPR2 mutation carriers develop clinical symptoms. Various fac-
tors have been linked to the low penetrance: a TGF-β1 polymorphism [7], lower 
BMPR2 expression from the wild-type allele [8], and reduced expression of the 
estrogen metabolizing gene CYP1B1 [9]. However, due to lack of a reliable source 
of tissues or cells from affected and unaffected BMPR2 mutation carriers to per-
form in depth genetic and functional studies, our understanding of the protective 
modifiers or risk factors for BMPR2 mutation carriers remains incomplete.
Induced pluripotent stem cells (iPSC) reprogrammed from somatic cells provide 
a new resource to understand both personal and common genetic underpinnings as 
well as cellular dysfunction related to the pathogenesis of IPAH/HPAH. iPSC can 
be propagated indefinitely, differentiated into EC [10] and smooth muscle cells 
(SMC) [11], and used for vascular disease modeling [12] and drug testing [13] 
(Fig. 17.1). In our studies, we applied an iPSCs-based model to systematically study 
the EC abnormalities in PAH and to further understand the reduced penetrance of 
the BMPR2 mutation in causing the disease phenotype. By correcting the BMPR2 
mutation using CRISPR/Cas9 technology, we demonstrated that in the absence of 
protective modifiers, the BMPR2 mutation is sufficient for EC dysfunction associ-
ated with PAH. Our studies pave the way for using iPSC-derived vascular cells, 
integrative “omics,” and genome editing to better understand patient-specific dis-
ease mechanisms for developing precision medicine.
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17.2  Patient-Specific iPSC-Derived Endothelial Cells 
to Model PAH
The mechanism underlying PAH vary in individuals, perhaps because of genetic fac-
tors and environmental exposures. IPSC-EC that preserves the gene variants from the 
patient could be a good surrogate for native PAEC to understand the genotype-
phenotype correlation, and to increase the opportunity to individualized therapy.
17.2.1  iPSC-EC Recapitulates Native Pulmonary Arterial 
Endothelial Cell (PAEC)
To investigate the use of iPSC-EC as a surrogate for native EC to better understand 
and treat PAH, we compared PAH PAEC, harvested and cultured from lungs 
removed at the time of transplantation, with PAH EC differentiated from iPSC 
(iPSC-EC) that had been reprogrammed from skin fibroblasts obtained from a small 
biopsy taken at the incision site of the same patients. Control fibroblasts and PAEC 












Fig. 17.1 Disease modeling and drug screening using patient-specific iPSC in PAH. At the time 
of lung transplantation, both skin fibroblasts and primary PAEC were isolated from the same 
patient. Skin fibroblasts were then reprogramed to iPSC using Sendai virus overexpressing four 
Yamanaka factors. To model PAH phenotype “in a dish,” patient-specific iPSCs were further dif-
ferentiated into EC and SMC. By comparing primary PAEC and iPSC-EC, we identified disease 
phenotypes, gene expression abnormalities, and screened for compounds that could reverse EC 
and SMC dysfunctions associated with PAH. IPSC also has the potential to give rise to hepatocyte, 
which can be used to test drug toxicity in a personalized manner. PAEC pulmonary artery endothe-
lial cells. EC endothelial cell, SMC smooth muscle cell
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We found that there was marked similarity between iPSC-EC and native PAEC 
judged by the typical EC cobblestone morphology, acetylated low-density lipopro-
tein uptake, and expression of endothelial cell surface marker VE-cadherin (CD144) 
(Fig. 17.2). Interestingly, compared with HUVEC, iPSC-ECs from both control and 
PAH patients expressed increased arterial EC gene ephrin-B2 (EFNB2) and reduced 
venous EC gene ephrin type-B receptor 4 (EPHB4) and nuclear receptor subfamily 
2 (NR2F2), possibly due to the high dose of VEGF added during the EC differentia-
tion from iPSCs.
Additionally, PAH PAEC and iPSC-EC compared with those from control lungs 
showed reduced adhesion to laminin, decreased migration detected by wound clo-
sure scratch assay, increased vulnerability to apoptosis with serum withdrawal ana-
lyzed by caspase3/7 activity asssay, and impaired angiogenesis judged by the inability 
to form capillary-like tubes when seeded onto growth factor reduced Matrigel. These 
functional abnormalities could attribute to the impaired pSmad-ID1 pathway in both 
PAH PAEC and iPSC-EC compared with respective control cells. However, two 
abnormalities in PAH PAEC could not be recapitulated by iPSC-EC: an increase in 
unrepaired DNA damage judged by the “comet tails” of nuclear DNA following 
alkali digestion and higher mitochondrial membrane potential measured by the JC-1 
assay after serum starvation in PAH PAEC compared with control subjects. This 
indicates that DNA damage and increased mitochondrial membrane potential in PAH 
EC might be related to the environment exposure in the lung, and once the cells are 
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c
Fig. 17.2 Characterization of iPSC-EC from healthy control. (a) iPSC-EC differentiated from 
skin fibroblast-derived iPSC express the endothelial surface marker CD144 (green) and CD31 
(red). Nuclear staining using DAPI is in blue. (b) iPSC-ECs incorporate acetylated low-density 
lipoprotein (Ac-LDL, red; DAPI, Blue). (c) Angiogenesis assays: representative images of tube 
formation 6, 12, and 24 h after seeding cells in growth factor reduced Matrigel. iPSC-ECs start 
forming tubes at 6 h and will regress after 24 h
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17.2.2  Patient-Specific Drug Response in IPSC-EC and PAEC
Recent advances in iPSC technology also provide a new paradigm for drug screen-
ing by permitting the use of human cells with the same genetic background as the 
patients without the typical quantity constraints associated with patient primary 
cells. Thus, we compared drug response in PAH PAEC and iPSC-EC from the same 
group of patients using new promising treatments for PAH, FK506, and elafin. 
FK506 is an immunosuppressant identified as an activator of BMPR2 signaling 
[14], and elafin is a neutrophil elastase inhibitor that enhances BMPR2 signaling in 
a caveolin-1-dependent manner and improves angiogenesis in PAH [3]. In three 
patients with IPAH/HPAH, elafin and FK506 improved angiogenesis as judged by 
capillary-like tubes formed on Matrigel in both PAEC and iPSC-EC whereas in the 
other three patients, there was no change in either cell type. Our data indicates that 
PAH iPSC-EC could recapitulate the drug response in native PAEC based on in vitro 
EC functional assays.
17.3  Modeling Reduced Penetrance  
of BMPR2 Mutation in PAH
Due to the limited access to native PAEC from HPAH patients and no access from 
unaffected BMPR2 mutation carriers (UMCs), iPSC-EC could provide a unique 
platform to model the propensity to HPAH “in-a-dish.” The compensatory mecha-
nisms in UMC shed light on the protective modifiers for HPAH that could help 
inform development of future therapeutic strategies.
17.3.1  Preserved EC Function in Unaffected BMPR2  
Mutation Carrier (UMC)
To determine if the lack of clinic manifestation of the disease can be recapitulated 
in UMC iPSC-EC, we recruited 11 individuals from three HPAH families, with 
HPAH patients, UMC, and gender-matched controls [15]. We observed that cell 
adhesion to a wide variety of extracellular matrix substrates and cell survival mea-
sured by caspase3/7 activity either after serum withdrawal or following reoxygen-
ation after hypoxia were preserved in UMC iPSC-EC in that values were similar to 
those in control cells, whereas these functions were significantly impaired in HPAH 
iPSC-EC. Cell migration and tube formation in Matrigel were similarly impaired in 
iPSC-ECs from both UMCs and HPAH patients compared with controls. However, 
when iPSC-EC was stimulated with BMPR2 ligand BMP4, cell migration and 
angiogenesis were significantly improved in UMC iPSC-EC with values similar to 
those in control iPSC-EC whereas these features remained impaired in iPSC-EC 
from HPAH patients. Our study revealed that UMC iPSC-EC showed preserved EC 
functions that were similar to control iPSC-EC and different from HPAH 
iPSC-EC.
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17.3.2  Preserved pP38 Signaling Pathway in Unaffected  
BMPR2 Mutation Carrier
To determine whether compensatory BMPR2 signaling was responsible for preser-
vation of normal UMC iPSC-EC functions, we tested both canonical and non- 
canonical BMP signaling pathways including pSMAD1/5-ID1, pErk, pAkt, and 
pP38. Interestingly, the only pathway that could distinguish UMC versus HPAH 
iPSC-EC is the pP38 pathway, which was consistently activated in response to 
BMP4 or under cell adhesion condition in iPSC-ECs from both controls and UMCs, 
but not in the HPAH iPSC-EC from all three families. Further studies showed that 
the compensatory pP38 signaling in UMC iPSC-EC was due to an increase in 
BMPR2 activators LRP1 and caveolin1 as well as a reduction in BMPR2 inhibitors 
gremlin1 and FKBP12, which could be assessed prospectively to determine whether 
they are biomarkers that reduce the risk of HPAH in UMC.
17.4  Gene Editing in PAH IPSCs
Genome editing in human iPSCs represents an opportunity to examine the contribu-
tion of pathogenic and disease-modifying mutations to molecular and cellular phe-
notypes [16]. Here, we summarized recent studies that utilized CRISPR/Cas9 gene 
editing in iPSCs to address the controversial question of whether BMPR2 mutation 
alone is necessary and/or sufficient for establishing the major cellular phenotypes 
associated with PAH.
17.4.1  Correction of the BMPR2 Mutation in PAH iPSCs
To determine the extent to which the BMPR2 mutation accounts for the iPSC-EC 
dysfunction in HPAH, we corrected the BMPR2 missense mutation in one of the 
HPAH iPSC lines we previously characterized using CRISPR/Cas9-mediated 
homology directed repair. Upon differentiation, the corrected HPAH iPSC-EC line 
showed control levels of cell adhesion and survival in response to either serum with-
drawal or after hypoxia and reoxygenation. The pP38 signaling pathway was also 
rescued in the edited iPSC-EC.  Tube formation and cell migration were still 
impaired under baseline following editing of the BMPR2 mutation; however, these 
were improved to control levels with BMP4 stimulation. This suggests that both 
protective modifiers and a corrected BMPR2 mutation are necessary to fully nor-
malize EC function in HPAH patients.
17.4.2  Generation of iPSC Line with BMPR2 Mutation
To assess the effect of a BMPR2 mutation without the confounding effects of 
genetic differences between cell lines, Kiskin et  al. generated two isogenic lines 
carrying either a known causal BMPR2 mutation (W9X; referred to as C2 W9X+/−) 
or a deletion of exon 1 (C2 ΔExon1) from a wild-type iPSC line [17]. Subsequently, 
M. Gu
137
these iPSCs were differentiated into SMC expressing smooth muscle actin, cal-
ponin, and myosin heavy chain 11 that had a contractile phenotype as well as iPSC-
 EC, which were enriched for arterial-specific EC markers. Under serum-free, 
chemically defined conditions, BMPR2 heterozygosity alone was sufficient to cause 
reduced apoptosis and increased proliferation in iPSC-SMCs, which has been 
shown in native PASMCs. Additionally, after serum exposure for 1 week for iPSC- 
ECs and serum + TNFα exposure for 1 week or serum-only for 2 weeks for iPSC- 
SMCs, these cells acquire inner mitochondrial membrane hyperpolarization. 
Although the generation of pulmonary SMC and EC from iPSC is yet to be achieved, 
the differentiation protocols used in this study produced cells that recapitulated key 
phenotypes found in diseased adult PASMCs and PAECs.
17.5  Future Directions and Clinical Implications
The studies summarized here demonstrate that iPSC-EC and PAEC from the same 
group of PAH patients showed similar functional impairment, reduced BMPR2 sig-
naling, and subgroup responsiveness to potential PAH therapy, suggesting that 
despite the site of disease in the lung and the particular vulnerability of the PA vas-
culature, iPSC-EC are good surrogates for native PAEC to study the fundamental 
pathobiology in PAH. The results of these studies also suggest the potential of using 
of iPSC-derived vascular cells to model other vascular diseases where the pheno-
type may be variable, e.g., Marfan, Williams, or Alagille syndromes.
Because patient-specific iPSC has the potential to give rise to unlimited number of 
all the cell types in the vasculature including EC, SMC and fibroblasts, it holds great 
promise for screening compounds that reverse the cellular phenotype associated with 
PAH in a high-throughput manner, which may ultimately change the current paradigm 
of treating PAH with “one size fits all” strategy to precision medicine.
Additionally, since PAH iPSC-EC does not recapitulate all the phenotypes in native 
EC from the lung such as increased DNA damage and higher mitochondrial membrane 
potential, the next step would be to generate tissue-specific, functionally distinct endo-
thelial cell subtypes from iPSCs. This will allow us to study fundamental questions 
about lineage specification during development and provide a scalable cell-specific 
source for tissue engineering, cell therapy, disease modeling, and drug discovery.
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Heritable pulmonary arterial hypertension belongs to a group of pulmonary vas-
cular diseases for which there is currently no cure other than a heart and lung 
transplantation. Increased endothelial and smooth muscle cell proliferation leads 
to vascular remodeling, resulting in increased blood pressure in the lungs which 
ultimately causes right heart failure. Understanding the molecular mechanisms 
implicated in the establishment and progression of pulmonary arterial hyperten-
sion is hampered due to a lack of disease models, including a limited availability 
of patient-derived cells and the low penetrance of BMPR2, the major disease- 
associated gene. Induced pluripotent stem cells provide a series of advantages for 
disease modeling that could potentially allow theses issues to be overcome. These 
include (1) a limitlessly self-renewing capacity that overcomes the restricted sup-
ply of cells from diseased patients, (2) an epigenome that has been wiped of 
pathogenic modifications which have accumulated during the disease process, (3) 
an amenability to gene editing which allows the introduction of specific patho-
genic mutations in an otherwise isogenic background to facilitate the dissection of 
the precise contribution of disease-associated genetic mutations, and (4) the gen-
eration of isogenic cell, tissue, and organ-specific disease models.
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18.1  Heritable Pulmonary Arterial Hypertension
Heritable pulmonary arterial hypertension (HPAH) is a debilitating, often fatal dis-
ease caused by increased proliferation and apoptotic resistance of smooth muscle 
and endothelial cells which drive the vascular remodeling of small pulmonary arte-
rioles and results in their narrowing and obliteration. This causes increased pulmo-
nary vascular resistance and hence increased blood pressure in the pulmonary 
vessels, eventually leading to right-heart failure [1]. Although currently available 
therapies have improved life expectancy, they do not prevent disease progression.
18.1.1  Insights into the Pathobiology of PAH
Major insights into PAH pathobiology followed the identification of causal hetero-
zygous germline mutations in the gene encoding the bone morphogenetic protein 
type II receptor (BMPR2) in over 80% of cases of families with PAH [2]. BMPR2 
is a receptor for bone morphogenetic proteins (BMPs), which are members of the 
transforming growth factor-β superfamily. Furthermore, around 20% of cases of 
sporadic or idiopathic PAH harbor mutations in BMPR2 [2]. The BMPR2 locus is 
marked by considerable allelic heterogeneity with over 660 germline variants iden-
tified to date. Approximately 70% of mutations lead to haploinsufficiency due to 
nonsense-mediated mRNA decay of the mutant transcript. Additional mutations 
include missense mutations that lead to substitutions in highly conserved amino 
acids in important functional domains of the receptor [2].
The central role of the BMPR2 pathway in PAH is supported by the identification 
of causal mutations in other members of this pathway including ACVRL1, ENG, 
GDF2 (BMP9), and SMAD9 [3]. In addition, loss of BMPR2 signaling appears to 
play a critical role in non-genetic forms of PAH in humans and in preclinical rodent 
models. Furthermore, treatment with the selective BMPR2/ALK1 ligand BMP9 has 
been shown to increase lung endothelial BMPR2 expression and reverse PAH in 
rodent models [4]
18.1.2  Reduced Penetrance of BMPR2 in PAH
An important observation in heritable PAH is that BMPR2 mutations exhibit low 
penetrance (approximately 20–30% in families), suggesting a requirement for addi-
tional environmental or genetic triggers necessary for disease initiation and progres-
sion [5]. Interestingly, identical twins carrying mutations in BMPR2, where only 
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one sibling presents with PAH, have been identified [6]. Together, these argue that 
environmental factors must have a critical role in disease establishment, and in 
some contexts, these may be more important than the presence of particular genetic 
modifiers of BMPR2.
Insights into potential environmental factors that interact with BMPR2 to cause 
PAH have come from animal models free of genetic mutations in BMPR2, including 
lipopoly-saccharide-, monocrotaline-, Sugen-5416/hypoxia-, and chronic hypoxia–
induced mouse and rat models, as well as from mice with lung-specific overexpres-
sion of tumor necrosis factor (TNFα) [7]. However, a common and important feature 
of these non-genetic models of PAH is the general reduction in BMPR2 at the pro-
tein level, which further supports a central role of BMPR2 in the establishment of 
PAH.  In recent work from our labs, we have dissected the mechanism of how 
inflammatory signaling in the form of TNFα can cause a reduction in BMPR2 sig-
naling [8]. This is achieved by via the shedding of BMPR2 extracellular domain at 
the cell surface, which reduces intact receptor expression, as well as by the tran-
scriptional repression of BMPR2, which reduces the total overall expression of 
BMPR2 in cells. Taken together, these changes ultimately lead to hyper- proliferation 
of pulmonary artery smooth muscle cells.
18.2  Modeling Pulmonary Arterial Hypertension 
with Induced Pluripotent Stem Cells
The limited availability of human tissue from PAH patients with end-stage disease 
and only at the time of transplantation has hampered progress in understanding the 
initiation and progression of PAH. In addition, mouse knockout or transgenic mod-
els of BMPR2 deficiency fail to fully recapitulate the pathology observed in humans 
[7]. Hence, there is a pressing need for alternative human models of PAH to acceler-
ate the development of new treatments for this devastating disease.
Induced pluripotent stem cells (iPSCs) provide major opportunities for disease 
modeling because they can be derived from specific patients, possess a limitless 
ability to self-renew, differentiate into all somatic cell lineages, and are amenable to 
targeted genetic engineering [9]. Their epigenetic memory is also reset during the 
reprogramming process, wiping epigenetic remodeling marks accumulated during 
the disease process and therefore potentially providing a naïve non-diseased system 
which can be used to induce a disease state and thus elucidate hitherto unknown 
mechanisms of disease progression.
However, an important consideration is whether iPSC-derived cells resemble the 
relevant adult cell types closely enough. In the case of PAH, the goal is to mimic 
pulmonary arterial endothelial and distal smooth muscle cells. For example, funda-
mental differences in responses to hypoxia exist between the pulmonary vasculature 
and the systemic vasculature and also between the BMP responsiveness of proximal 
and peripheral (distal) portions of the pulmonary vascular branch.
While systemic arteries relax in response to tissue hypoxia in order to improve 
blood flow and oxygen supply in hypoxic tissues, pulmonary arteries respond by 
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contracting, thereby diverting blood flow from poorly ventilated regions toward the 
more oxygenated areas of the lungs [10]. Furthermore, previous work has demon-
strated that in contrast to proximal cells, peripheral PASMCs are not growth- 
suppressed and exhibit reduced apoptosis when treated with BMP4 [11].
18.2.1  Embryological Origins of the Pulmonary Vasculature
In order to differentiate iPSCs toward pulmonary vascular lineages we must con-
sider the embryological origins of the pulmonary vascular cells and the develop-
mental pathways that have directed them toward their specific fate. For example, the 
differences in responsiveness to hypoxia and BMP signaling might be due to cells 
of the pulmonary vasculature having different embryological origins. Lineage trac-
ing has shown that four major embryonic lineages contribute to the pulmonary vas-
culature: (1) Wnt1+ neural crest, which contributes to the SMCs at the root of the 
pulmonary artery, (2) cardiopulmonary progenitors (CPPs), which contribute ECs 
and SMCs to the proximal pulmonary artery and vein, (3) WT1+ mesothelium, 
which surrounds the lung and contributes widely to both ECs and SMCs throughout 
the vasculature, and (4) lateral plate mesoderm, which contributes to the PASMCs 
in peripheral pulmonary arteries [12]. The ability to recapitulate specific lineages 
and their vascular derivatives is likely to be critical for generating a high-fidelity 
model of PAH.
18.2.2  Current iPSC Models of PAH
Our group was the first to publish work on reprogramming patient-derived cells car-
rying BMPR2 mutations [13]. Since then, other reports have used iPSC-derived 
cells to gain insights into PAH.
West et  al. [14] used patient-derived iPSCs carrying mutations in BMPR2 to 
generate mesenchymal and endothelial-like cells. The authors noted an increase in 
Wnt signaling in these cells and found this was also the case in adult BMPR2 mutant 
fibroblasts and in human tissue. However, although the mesenchymal cells expressed 
some SMC markers, these cells were unable to model the characteristic hyper- 
proliferative phenotype observed in PASMCs. This highlights the important consid-
eration that iPSC-derived cells must approximate closely enough the relevant adult 
cell types.
Sa et al. [15] performed RNA-seq on iPSC-derived endothelial cells (iPSC-ECs) 
and pulmonary artery endothelial cells (PAECs) with and without BMPR2 muta-
tions and observed that cell adhesion and migration were decreased in cells carrying 
BMPR2 mutations compared to controls. This work also showed that KISS1 was 
upregulated in BMPR2 mutant cells compared to wild-type cells.
Gu et al. [16] reiterated the cell adhesion and cell migration defect in iPSC-
ECs but went on to look at why not all BMPR2 mutation carriers develop 
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PAH. Their approach was to take three different families, in which all individuals 
carried mutations in BMPR2, and then compare the phenotype and transcriptomes 
of iPSC- ECs of individuals within each family to see if there was a difference 
between those family members that present with PAH (FPAH) and those that did 
not (unaffected mutation carriers or UMC). Through this they found that apopto-
sis was higher in FPAH compared with UMC, while cell adhesion was reduced 
in both FPAH and UMC. This suggested that genetic modifiers might give UMCs 
a cell survival advantage. Through transcriptomic analysis, BIRC3, a gene impli-
cated in cell survival, was found to be reduced in FPAH compared to UMC. Taken 
together, the authors concluded that genetic background can influence whether 
or not an individual will develop PAH. However, as discussed earlier, regardless 
of the initial instigator (genetic or non-genetic) of PAH, all patients ultimately 
show a reduction in BMPR2 expression and signaling. Thus, the question of what 
BMPR2 is doing in disease is fundamental and remained unanswered.
We recently addressed this issue using iPSCs to model arterial ECs and distal 
PASMCs where we were able to transition cells from a naïve state lacking disease- 
associated cellular phenotypes to a diseased state, showing that a BMPR2 mutation 
per se is necessary and sufficient for the establishment of some but not all PAH-
associated cellular phenotypes in iPSC-ECs and iPSC-SMCs [21]. Omics analysis 
of the changes associated with this transition will reveal potentially novel and/or 
druggable pathways to prevent or reverse PAH disease progression.
18.3  Future Direction and Clinical Implications
Primary future uses of iPSCs include drug screening and the generation of human 3D 
multi-tissue constructs of the pulmonary system for disease modeling. Protocols to 
generate endothelial cells (ECs), smooth muscle cells, and pericytes from iPSCs have 
been established [17, 18], and advanced protocols to generate cells more akin to pul-
monary vascular cells are underway. Based on these protocols, functional evaluations 
in each cell type between normal and disease-carrying subjects can be performed to 
provide a powerful platform for cell type-specific drug discovery. Considering the 
importance of cell-cell communication during disease progression, modeling diseases 
will require using more than one cell type. Although it is possible to co-culture iPSC-
derived ECs and perivascular cells [19], the highly specialized and complex nature of 
the pulmonary vascular bed poses challenges for constructing a 3D pulmonary-spe-
cific vasculature. In addition, investigating merely vascular cells might lead us to mis-
interpret pulmonary vascular disease mechanisms. Although animal models have 
been widely used to model diseases, they are expensive, time-consuming, and often 
do not fully recapitulate human pathology. iPSC- derived organ-like tissue, termed 
‘organoids’, might eventually replace animal models [20]. Whilst liver and kidney 
organoids develop with vasculatures, current lung organoids lack vascular populations 
[20]. Developing better lung organoids or pulmonary artery-on-a-chip technologies 
would provide an advanced platform to model pulmonary vascular diseases.
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Impairment of the pulmonary endothelial communications contributes to the 
development and progression of pulmonary arterial hypertension (PAH). 
Investigations currently under way are likely to produce novel therapeutic strate-
gies that target pulmonary endothelial dysfunction linked to PAH. This chapter 
outlines the complex role of the dysfunctional pulmonary endothelium in PAH 
and its potential value as a target for innovative therapies.
Keywords
Pulmonary hypertension · Pathogenesis · Endothelial dysfunction · Cell-cell 
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19.1  Introduction
Pulmonary arterial hypertension (PAH) is a severe and progressive cardiopulmonary 
disorder characterized by non-specific symptoms (i.e., breathlessness, fatigue, weak-
ness, angina, and syncope) that take years before appearing, usually after the disease 
is in an advanced stage. In Europe, PAH prevalence and incidence are in the range of 
15–60 subjects per million population and 5–10 cases per million per year, respec-
tively. Despite recent progress in the treatment of PAH, most patients still die from 
the disease or fail to respond adequately to medical therapy with a 5-year survival of 
59%. Current treatments can relieve some PAH symptoms and slow the progress of 
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the disease in some patients, but they have limited impact on the progressive pulmo-
nary vascular remodeling that eventually culminates in right heart failure [1].
Pulmonary endothelial dysfunction is a critical contributor that could be detri-
mental for the onset and progression of this severe cardiopulmonary disorder [2–4]. 
Therefore, early diagnosis and better understanding of the mechanisms underlying 
the altered pulmonary endothelial cell (EC) phenotype and endothelial communica-
tions with both resident vascular cells (smooth muscle cells, fibroblasts, myofibro-
blasts, and pericytes) and inflammatory cells are needed to propose and develop 
new, more adapted and more powerful therapeutic tools.
19.2  Pulmonary Endothelial Dysfunction 
and the Pathobiology of PAH
At the interface between bloodstream and lung tissue, the pulmonary ECs play criti-
cal roles not only in optimizing gas exchanges but also in the local adaptations of 
vascular tone, in the maintenance of a thrombosis-free surface, in the control of 
inflammatory cell adhesion and trafficking, as well as in the maintenance of the vas-
cular wall integrity and for normal angiogenesis. Importantly, they are dynamic and 
adapt their roles and phenotypes according to the nature of the local milieu (Fig. 19.1). 
Indeed, the pulmonary ECs are highly metabolically active, sensing and responding 
to signals from extracellular environments by secreting the correct substance(s) by 
which it may maintain the vasomotor balance and vascular-tissue homeostasis [4].
As a vital part of the pulmonary vascular wall, alterations of the pulmonary endo-
thelium are now well established to be central role in the pathogenesis of PAH. The 
main characteristics of pulmonary endothelial alterations or dysfunction in PAH 
includes, among others, a reduction in the secretion of vasodilator molecules such as 
prostacyclin (PGI2) and nitric oxide (NO), and an increase in the potent vasoconstrictor 
endothelin (ET)-1 [5]. In addition, our group has highlighted that pulmonary ECs from 
PAH patients exhibit a pro-inflammatory phenotype characterized by an increased 
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Fig. 19.1 The pulmonary vascular endothelium is a multifunctional organ and is critically 
involved in modulating vascular tone and structure. Through their capacity to spatially segregate 
and temporally integrate a diverse range of extracellular signals (in gray), pulmonary ECs adapt 
their roles and phenotype (in blue) according to the nature of the local milieu
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expression of key adhesion molecules (E-selectin, ICAM- 1, and VCAM-1) together 
with an excessive secretion of different inflammatory mediators (such as interleukin 
(IL)-1α, IL-6, IL-8, IL-12, macrophage migration inhibitory factor (MIF), and CCL2) 
[6]. Pulmonary ECs from PAH patients also exhibit metabolic alterations including 
heightened glycolysis [7]. Finally, decreased capacities to form vascular tube in vitro 
[8] and acquisition of some mesenchymal markers have also been reported [9]. Finally, 
a pro-proliferative and apoptosis- resistant phenotype has been described [10–12]. 
Various stimuli such as high glucose, insulin resistance, disturbed blood flow, and oxi-
dative stress can lead to endothelial dysfunction. Therefore, further research is needed 
to elucidate their specific contribution to the altered pulmonary EC phenotype in PAH.
Importantly, this excessive local secretion of key factors by the dysfunctional 
pulmonary endothelium in PAH has also been demonstrated to play a critical role in 
modulating the behavior and functions of adjacent vascular cells (smooth muscle 
cells, fibroblasts myofibroblasts, and pericytes) and several immune cells that infil-
trate the remodeled pulmonary vessels, thereby contributing to the vascular remod-
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Fig. 19.2 Importance of endothelial miscommunication in PAH.  In PAH, the dynamic and 
unadapted pulmonary vascular remodeling is partly driven by several genetic and environmental 
factors and also by the presence of different intrinsic abnormalities within the pulmonary ECs that 
include, among others, a loss and/or dysfunctions of the BMPR-2 signaling, decreased PPAR-γ 
and FoxO signaling, and constitutive activations of NF-κB and/or PHD2/HIF axes. Consequently, 
the altered pulmonary ECs create a permissive pericellular/extracellular environment for the pro-
gression of the pulmonary vascular remodeling, mainly because they miscommunicate with both 
resident vascular cells (smooth muscle cells, fibroblasts, myofibroblasts, and pericytes) and inflam-
matory cells mainly through the secretion of different key molecules
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triggers, the mechanisms, and the consequences of dysfunctional pulmonary endo-
thelium in PAH are still not completely understood. A better knowledge of these key 
aspects would help finding new PAH biomarkers and/or novel therapeutic targets to 
reverse or even stop the progression of this irreversible vascular remodeling.
19.3  Current Promising Strategies for Restoring Pulmonary 
Endothelial Dysfunction and Cell-Cell Communications
Below, a few of the most promising therapeutic strategies that target the dysfunc-
tional pulmonary endothelium are underlined.
19.3.1  Restoring the Balance of Vasodilation and Vasoconstriction
In PAH, the discovery of abnormalities affecting the endothelial production and secre-
tion of the three main mediators (NO, PGI2 and ET-1) or defects in their signaling 
pathways involved in the regulation of pulmonary vasoreactivity has led to the develop-
ment of currently approved PAH therapies which have drastically improved the quality 
of life and clinical outcomes in PAH patients. Major therapeutic advances are also 
leading to the development of new molecules in these three pathways characterized by 
better pharmaceutical properties, such as longer half- life, increased receptor affinity, 
prolonged receptor binding, and routes of administration easier to manage. Nevertheless, 
other vasoreactive mediators are known to be involved and can represent new therapeu-
tic targets, such as RhoA/ROCK inhibitors, anti-serotoninergic drugs, apelin agonists, 
and inhibitors or blockers of the ACE (angiotensin-converting enzyme)-1/angiotensin 
(Ang)-II/AT1 receptor, agents that stimulate the ACE2-Ang-(1–7)-Mas pathway [13].
Beyond vasoconstrictors and vasodilators, the recent identification of familial cases 
of PAH related to heterozygous missense variants in the KCNK3 gene (encoding 
TWIK-related acid-sensitive potassium channel (TASK)-1) has revived interest in the 
concept of channelopathy in PAH [14]. The main challenge is this area is to identify 
specific small molecules to restore the activity of these ion channels in the dysfunc-
tional pulmonary endothelium in PAH. Undoubtedly, this strategy will have significant 
impact for future investigations in the field and in other cardiovascular disorders.
19.3.2  Restitution of the Defective BMPR-2 Signaling System
Several notions support that enhancement of the BMPR-2 axis pulmonary vascular cells 
could offer a novel approach for the treatment of PAH [15, 16]. Consistent with this 
observation, preliminary data suggested that low-dose of tacrolimus (FK506) is well 
tolerated and increases BMPR-2 in subsets of PAH patients [17]. Based on these find-
ings, a phase II randomized control trial in PAH has been initiated in stable PAH patients 
(NCT01647945). Interestingly, promising findings have also been obtained with exog-
enous BMP9 and ataluren, a drug that induces ribosomal read through of nonsense 
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mutations, and thus may offer the possibility of future therapies [18, 19]. Nevertheless, 
further studies are needed to validate these hypotheses [20]. Indeed, the low penetrance 
of the disease among BMPR2 mutation carriers suggests that additional genetic or envi-
ronmental factors are required for the development of PAH [15]. In addition, it has been 
recently shown that the selective BMP9 loss or inhibition does not predispose, but par-
tially prevent or protect against experimental pulmonary hypertension. Therefore, the 
apparent ambivalent role of the BMP9/BMPR-2 signaling pathway should stimulate 
work to better understand this feature and the underlying mechanisms.
19.3.3  Targeting Cell Proliferation and Cell accumulation
In PAH, several transcription factors [such as peroxisome proliferator-activated receptor 
(PPAR-γ), signal transducer and activator of transcription (STAT)-3, HIPPO, FoxO1, and 
hypoxia-inducible factor (HIF)] and growth factors are known to be overexpressed or 
overactive in the dysfunctional endothelium [5, 13]. Platelet- derived growth factor 
(PDGF), fibroblast growth factor (FGF)-2, epidermal growth factor (EGF), vascular 
endothelial growth factor (VEGF), and nerve growth factor (NGF) are key players in this 
regard. Furthermore, other factors and signaling may serve as potential target candidates 
for anti-proliferative strategies in PAH, such as the RhoA/Rho-kinase signaling system, 
the mammalian target of rapamycin (mTOR) and insulin-like growth factor signaling 
systems, connective tissue growth factor (CTGF), hepatocyte growth factor (HGF), and 
placental growth factor (PIGF). However, further studies on their pathogenic roles are 
important. Although targeting growth factors remains a relevant therapeutic strategy in 
PAH, a better understanding of tyrosine kinase inhibitor (TKI) properties and character-
istics, particularly for lung and heart homeostases, will help designing new drugs that 
specifically block PAH pathways without severe side effects.
Our group has underlined that the dysfunctional pulmonary endothelium in PAH 
partly contributes to the excessive pericytic envelope, notably through the overabun-
dance of the endothelial-derived FGF-2 and IL-6 [21]. We also demonstrated that 
this increase in pulmonary pericyte coverage in PAH could represent a local source 
of smooth muscle–like cells and actively contributes to the pulmonary vascular 
remodeling. Pericytes are central regulators of vascular development, stabilization, 
maturation, and remodeling, modulating EC proliferation, vascular tone and auto-
immunity. Although pulmonary pericytes could likely represent a source of promis-
ing therapeutic targets in PAH, little is known about the intrinsic characteristics of 
lung pericytes in PAH and their exact roles in the progression of this irreversible 
remodeling linked to PAH. Therefore, additional studies are needed.
19.3.4  Restitution of an Adapted Extracellular  
Matrix (ECM) Remodeling
In PAH, the dynamic and unadapted remodeling of the ECM not only leads to quali-
tative and quantitative changes that are important to modulate vessel stiffness, but 
also forms a permissive milieu that profoundly influences cell motility, proliferation, 
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apoptosis, and differentiation. In addition, the excessive release of growth factors and 
other molecules that are encrypted in the ECM together with the exposure of func-
tionally cryptic sites (i.e., within collagens, fibronectin, laminins, elastin) and the 
release of ECM fragments also have critical roles in modulating cell behavior and 
vascular remodeling. Beneficial effects of different strategies that restitute these 
ECM alterations in PAH have been reported [3].
19.3.5  Targeting Metabolic Changes
Several evidences suggest that a shift in energy production from mitochondrial 
oxidative phosphorylation to glycolysis is present in pulmonary ECs and contrib-
utes to PAH development and progression. In lines with this notion, a recent clini-
cal trial demonstrates that inhibition of pyruvate dehydrogenase kinase (PDK), an 
inhibitor of the mitochondrial enzyme pyruvate dehydrogenase (PDH, the gate-
keeping enzyme of glucose oxidation) improves PAH in the absence of functional 
variants of SIRT3 and UCP2 [22]. Other metabolic pathways and related factors 
also represent interesting targets for PAH therapy, including modulators of 
hypoxia-inducible factor (HIF) and the phosphoinositide 3-kinase/protein kinase 
B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway, mitochondrial 
phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1), and the 
HIPPO and p53 signaling pathways. However, a more complete understanding of 
the overall risk–benefit ratio of these different strategies with long-term follow-up 
has to be evaluated.
19.3.6  Targeting the Vicious Cycle Between Endothelial 
Dysfunction and Immune Dysregulation
The interplay between endothelial dysfunction and immune dysregulation war-
rants future clinical studies of newer biologic agents that can target specific inflam-
matory pathways [23]. Through the expression of adhesion molecules (ICAM-1, 
VCAM-1, and E-selectins) and the secretion of various key cytokines and che-
mokines, the dysfunctional pulmonary endothelium facilitates the infiltration of 
inflammatory cells in the perivascular area [6, 24]. Remarkably, we demonstrated 
that the dysfunctional pulmonary endothelium in PAH through its overproduc-
tion of leptin inhibits Treg cell function [25]. Consistent with this observation, 
our group has shown that PAH patients display normal Treg cell count but with 
an altered function. Interestingly, it is also known that the pulmonary vasculature 
is sensitive to inflammation and can respond to inflammatory stimuli by abnor-
mal proliferation and/or migration and apoptotic-resistant phenotype. In line with 
these notions, we recently identified ectopic upregulation of membrane-bound 
IL-6 receptor (IL6R) on PA-SMCs in PAH patients and in rodent models of pul-
monary hypertension and demonstrated its key role for PA-SMC accumulation 
in vitro and in vivo [26].
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19.4  Future Directions and Clinical Implications
In summary, substantial work remains to be done to discover and/or develop a new, 
better tolerated, and more powerful curative treatment for PAH that combines pro-
motion of vasorelaxation and restoration of endothelial communications. However, 
important discoveries in the molecular mechanisms contributing to the pulmonary 
endothelial dysfunction in PAH have been obtained and our knowledge continues to 
accelerate. Thus, our improved understanding of additional pathways in this condi-
tion will presumably lead to the development of novel therapeutic strategies that 
could specifically target endothelial dysfunction in the near future. A comprehen-
sive estimation and evaluation of risks and benefits, potential ways to circumvent 
the risk of adverse effects on the adaptative myocardial hypertrophy, and a targeted 
delivery of these new drugs in a safe and effective manner are still major challenges 
facing clinical researchers.
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Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine elevated in 
the serum of pulmonary arterial hypertension (PAH) patients and can predict the 
survival of idiopathic (I)PAH patients. Previous animal experiments and clinical 
human studies indicate that IL-6 is important in the pathogenesis of PAH; how-
ever, the molecular mechanisms of IL-6-mediated pathogenesis of PAH have 
been elusive. We recently identified IL-21 as a novel downstream cytokine of 
IL-6-signaling in PAH. First, we found that IL-6 blockade by the monoclonal 
anti-IL-6 receptor antibody, MR16–1, ameliorated hypoxia-induced pulmonary 
hypertension (HPH) and prevented the hypoxia-induced accumulation of Th17 
cells and M2 macrophages in the lungs. Furthermore, the hypoxia-induced 
upregulation of IL-17 and IL-21, which are primarily produced by Th17 cells, 
was also ameliorated by IL-6 blockade in mice. Whereas IL-17 blockade with an 
anti-IL-17 neutralizing antibody had no effect on HPH, IL-21 receptor-deficient 
mice were resistant to HPH and exhibited no significant accumulation of M2 
macrophages in the lungs. Consistently, IL-21 indeed promoted the polarization 
of primary alveolar macrophages toward the M2 phenotype. Moreover, signifi-
cantly enhanced expressions of IL-21 and M2 macrophage markers were detected 
in the lungs of IPAH patients who underwent lung transplantation. Together, the 
above data suggest that IL-21 promotes PAH through M2 macrophage polariza-
tion, downstream of IL-6-signaling. IL-6/Th17/IL-21-signaling axis might be a 
novel potential target for treating PAH.
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20.1  Background
Pulmonary arterial hypertension (PAH) is a serious disease characterized by arteri-
opathy in the small- to medium-sized distal pulmonary arteries, which is associated 
with arterial muscularization, concentric intimal thickening, and the formation of 
plexiform lesions [1, 2]. Inflammation and autoimmunity are currently thought of as 
critical factors to the pathogenesis of PAH [3, 4]. Inflammatory cells such as T cells, 
B cells, and macrophages infiltrate the plexiform lesions in patients with advanced 
PAH. Thus, proinflammatory cytokines produced by these cells may be responsible 
for the hyperproliferation of pulmonary artery endothelial cells and pulmonary 
artery smooth muscle cells (PASMCs) [5, 6].
Interleukin (IL)-6 is a multifunctional proinflammatory cytokine linked to 
numerous autoimmune diseases [7, 8]. Patients with idiopathic (I)PAH exhibit 
increased IL-6 serum levels, which correlate with their prognoses [3, 9, 10]. 
Consistent with these findings, lung-specific IL-6 transgenic mice display spontane-
ous PH in normoxia and develop greatly exaggerated hypoxia-induced PH (HPH) 
[11], whereas IL-6-deficient mice show resistance to HPH [12]. These findings sug-
gest that IL-6 has a significant role in the pathogenesis of PH; however, the down-
stream target(s) of IL-6 in HPH have been elusive when we started the following 
study on the pathogenesis of PH. We recently reported that the IL-6/interleukin- 
21(IL-21)-signaling axis played critical roles for the development of HPH in asso-
ciation with M2 macrophage polarization [13]. In this manuscript, we elaborate on 
the role of IL-6/IL-21-signaing axis in the pathogenesis of PAH.
20.2  IL-6 in the Pathogenesis of HPH
We examined the effect of hypoxia (10% oxygen) on the expression of Il-6 mRNA 
in the lungs of C57BL/6 mice using quantitative (q)RT-PCR. The Il-6 mRNA levels 
peaked on day 2 and returned to basal levels by day 7 after hypoxia exposure. Next, 
we investigated the effect of IL-6 blockade on HPH development by measuring the 
right ventricular systolic pressure (RVSP), Fulton’s Index (right/[left  +  septum] 
ventricular weight), and the medial wall thickness index, which is estimated by 
elastic Van Gieson staining of the pulmonary arterioles. In control antibody-treated 
mice, hypoxia exposure for 4  weeks induced significant increases in the RVSP, 
Fulton’s Index, and medial wall thickness index compared to the values observed 
under normoxic conditions. On the other hand, the hypoxia-induced elevation of 
these parameters was significantly inhibited by treatment with MR16–1. Similarly, 
thickened medial vascular walls were detected in the lung sections of control 
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antibody-treated mice but not in those of MR16–1-treated mice. These data indicate 
that IL-6 blockade by MR16–1 effectively prevents HPH.
20.3  IL-21 in the Pathogenesis of HPH
IL-21 is an IL-2 family cytokine produced by activated T cells, including Th17 
cells, that regulates immune responses [14]. We found that the Il-21 mRNA level 
peaked on day 2, remained elevated until day 14, and returned to the basal levels on 
day 28 after hypoxia exposure. In addition, hypoxia induced significantly increased 
numbers of Th17 cells, which produce both IL-17 and IL-21, in the lungs of mice 
treated with control antibody but not in those treated with MR16–1. These data sug-
gest that IL-6 promotes the accumulation of IL-21-producing Th17 cells in the 
lungs after hypoxia exposure.
Next, we evaluated the effect of hypoxia on IL-21 receptor (IL-21R) knockout 
(IL-21RKO) mice [15]. Wild-type (WT) mice exposed to hypoxia for 4 weeks. 
exhibited significantly increased RVSP, Fulton’s Index, and medial wall thickness 
compared with mice exposed to normoxia. In contrast, the hypoxia-induced eleva-
tion of these parameters was significantly inhibited in IL-21RKO mice. Similarly, 
remodeling of the medial vascular walls following hypoxia exposure in WT mice 
was also significantly inhibited in the lungs of IL-21RKO mice. These data suggest 
that IL-21R-deficient mice are resistant to HPH.
Alveolar macrophages have been reported to undergo M2 macrophage polariza-
tion in response to hypoxia [16]. We hypothesized that IL-21, which has been 
reported to be majorly secreted from Th17 cells in mice, might play a role in the 
hypoxia-induced generation of M2 macrophages in the lung. IL-21 treatment of 
BALF-isolated alveolar macrophages significantly upregulated the mRNA levels of 
M2 signature genes, such as Fizz1, Arg1, and Cxcl12, but had no effect on the 
mRNA levels of M1 signature genes, including Nos2, Il-12β, and Tnf-α, indicating 
that IL-21 specifically induces the M2 polarization of alveolar macrophages.
We next examined the effect of IL-21R deletion on the hypoxia-induced upregu-
lation of M2 signature genes, including Fizz1, Arg1, and Cxcl12, in the alveolar 
macrophages isolated from the BALF after exposure to hypoxia for 4 days. All of 
these genes were significantly upregulated in the alveolar macrophages isolated 
from WT mice but not in those from IL-21RKO mice. Similarly, Fizz1 protein 
expression was increased in the lungs of WT mice but not in those of IL-21RKO 
mice after exposure to hypoxia for 1 week. In contrast, M1 signature gene expres-
sion was comparable in the WT and IL-21RKO mice after exposure to hypoxia. 
Consistent with these findings, the hypoxia-induced generation of M2 macrophages 
in the lung was significantly inhibited by treatment with an anti-IL-21-neutralizing 
antibody but not a control antibody. Collectively, these findings suggest that IL-21 
is essential for hypoxia-induced M2 macrophage polarization in the lung.
We next examined the effect of IL-21 blockade on the in vivo hypoxia-induced 
proliferation of PASMCs. Hypoxia exposure significantly increased the number of 
anti-Ki67 antibody-positive PASMCs in the lungs of WT mice but not in those of 
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IL-21RKO mice. Consistent with this finding, hypoxia exposure significantly 
increased the number of anti-phospho-Histone H3 antibody-positive PASMCs in 
the lungs of mice treated with control antibody but not in those treated with the anti- 
IL- 21 neutralizing antibody. Together, these data suggest that IL-21 plays a critical 
role in the hypoxia-induced proliferation of PASMCs in association with M2 mac-
rophage skewing (Fig. 20.1).
20.4  Increased Expression of IL-21 and M2 Macrophage 
Markers in the Lungs of IPAH Patients
Immunohistochemical analyses of the lung tissues from IPAH patients undergoing 
lung transplantation showed an excessive infiltration of IL-21-positive cells in the 
adventitia, obliterative intimal proliferative lesions, and plexiform lesions of the 
remodeled pulmonary arteries. In contrast, IL-21-positive cell infiltration was barely 
detected in the lungs of the control patient. We also observed both Arg1-positive and 
MRC-1-positive cells in all layers of the remodeled pulmonary arteries and alveolar 
areas examined in the lungs from IPAH patients but not in the tissue from control 
patients. Taken together, these findings strongly suggest that IL-6/IL-21-signaling 
axis is essential for the pathogenesis of human PAH in association with M2 macro-
phage polarization (Fig. 20.1).
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Fig. 20.1 Schematic illustration of the pathogenesis of PAH. IL-6/IL-21-signalling has a central 
role for the pathogenesis of PAH
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Abstract
The aim of this study was to determine the clinical outcomes of gene mutations in 
Chinese pediatric patients with idiopathic and heritable pulmonary arterial hyperten-
sion. We screened gene mutations in 62 pediatric patients who visited Beijing Anzhen 
Hospital from 2008 September to 2017 August with targeted exome kits containing 
22 pulmonary arterial hypertension-related genes. The clinical and hemodynamic 
characteristics and outcomes of these patients were retrospectively analyzed. In a 
cohort of 62 patients, a total of 27 gene mutations were identified with 20 mutations 
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in BMPR2, two mutations in ACVRL1, two mutations in KCNK3 and three muta-
tions in NOTCH3. The average age at diagnosis was 77.5 ± 53.8 months. 28 patients 
(14 mutation carriers) underwent cardiac catherization examinations, with the acute 
vasodilator testing. Mutation carriers had higher right atrial pressure and tended to 
have higher pulmonary arterial pressure and pulmonary vascular resistance index 
than mutation non- carriers. Eight patients responded to acute vasodilator testing and 
all were mutation non-carriers (p = 0.002). The median survival for mutation carriers 
was 24.0 months. Although similar treatments were employed, mutation carriers had 
higher mortality rates than mutation non-carriers (p = 0.036). The 1-, 2-, 3- year sur-
vival rate of mutation non-carriers were 93.6%, 90.0%, and 66.9%, respectively, 
while for mutation carriers, the proportion were 79.8%, 49.9%, and 33.3%. In con-
clusion, early gene screening for pediatric patients with idiopathic pulmonary arterial 
hypertension and heritable pulmonary arterial hypertension is recommended, and 
more aggressive treatment for mutation carriers is advisable.
Keywords
Mutation · hemodynamics · mortality
21.1  Introduction
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vessel disease, 
which can ultimately lead to progressive right-sided heart failure and premature 
death [1]. Idiopathic pulmonary arterial hypertension (IPAH) is a sporadic form of 
PAH, which occurs without family aggregation or known etiology [2], while heri-
table pulmonary arterial hypertension (HPAH) occurs in a familial aggregate. 
Without adequate treatment, these patients’ condition deteriorates rapidly with a 
median survival time of 2.8 years in adults and 10 months in children [3, 4]. Despite 
recent advances in management and improvement of prognosis, the pathophysiol-
ogy of IPAH is not yet explained in detail.
Genetic studies showed that gene mutations in some members of the transform-
ing growth factor-β (TGF-β) pathway were associated with heritable PAH, includ-
ing bone morphogenetic protein receptor type II (BMPR2), activin receptor-like 
kinase 1 (ALK1), endoglin (ENG) and SMAD family [5–8]. Mutations in ALK1 
and ENG are thought to be linked to hereditary hemorrhagic telangiectasia (HHT), 
an autosomal dominant genetic disorder typically characterized by small arteriove-
nous malformations [9, 10]. With the development of gene detection technology, 
more additional gene mutations were found out to be the disease-causing genes, 
including KNCK3 (potassium two pore domain channel subfamily K member 3), 
CAV1 (Caveolin 1), NOTCH3, BMPR1B (bone morphogenetic protein receptor, 
type 1B), EDN1 (endothelin 1), TBX4 (T-box 4), TRPC6 (transient receptor poten-
tial cation channel, subfamily C, member 6), TOPBP1 (topoisomerase (DNA) II 
binding protein 1), and SERPINE1 (serpin family E member 1) [7, 8, 11]. IPAH and 
HPAH were seen more commonly in pediatric patients [12, 13], indicating more 
genetic factors participate in the pathogenesis of pediatric PAH.
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In addition to the effect on the pathogenicity of PAH, gene mutations have previ-
ously been linked to worse clinical outcomes in adult patients [14, 15]. An international 
multi-center research revealed that patients with childhood IPAH or HPAH with 
BMPR2 or ACVRL1 mutation have poorer clinical outcomes than mutation non-carri-
ers [16]. However, the study sample was relatively small, and data addressing the rela-
tionship of gene mutations with clinical outcomes of pediatric patients is scarce till now.
In this study, we applied a targeted capture exome sequence to investigate the 
genetic etiology of Chinese pediatric patients with IPAH and HPAH. We aimed to 
assess the prevalence of gene mutations in this group of patients and to assess the 
relationship between genotypes and phenotypes.
21.2  Methods
21.3  Selection of Patients
Sixty-two pediatric patients with IPAH and HPAH who visited Beijing Anzhen 
Hospital from 2008 September to 2017 August were included in the study. PAH was 
defined as a mean pulmonary arterial pressure (MPAP) ≥25 mmHg with a pulmo-
nary artery wedge pressure ≤15 mmHg and pulmonary vascular resistance >3 Wood 
units by cardiac catheterization [1]. Acute vasodilator testing was performed during 
cardiac catheterization and a positive response was defined according to current 
guidelines as a decrease in MPAP of at least 10 to <40 mmHg with a stable cardiac 
output [17]. Clinical, functional, and hemodynamic characteristics of patients were 
collected at the time of diagnosis and during the follow-up period. The study proce-
dures were approved by the Research Ethics Committee of Beijing Anzhen Hospital. 
All patients gave informed consent in accordance with local ethical guidelines.
21.4  Genetic Studies
Genomic DNA was isolated using QIAamp Blood Midi kit (Qiagen). Libraries were 
prepared according to the Illumina standard protocol. Exon and exon–intron junc-
tion sequences of 22 candidate genes (ACVRL1, AGTR2, ANGPT1, BMPR2, 
BMPR1A, BMPR1B, ENG, NOS3, HTR2B, KCNA5, KCNQ1, SLC6A4, SMAD1, 
SMAD2, SMAD3, SMAD4, SMAD5, SMAD6, SMAD7, TGFB1, TRPC6, THBS1) 
were enriched using a GenCap custom enrichment kit (My-Genostics). The enriched 
libraries were sequenced on an Illumina Hi Seq 2000 sequencer for paired reads of 
100 bp in length.
21.5  Statistical Analysis
Qualitative variables were expressed as frequency and percentage and mean ± stan-
dard deviation and median [interquartile range] for quantitative variables. We 
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compared clinical and hemodynamic characteristics between mutation carriers and 
non-carriers by one-way analysis of variance or the median test for continuous mea-
sures and the chi-square test for categorical measures. The Kaplan-Meier survival 
curve and the Log-rank test were used to assess the difference in survival rates 
between two groups. A p-value less than 0.05 was considered to indicate statistical 
significance. All analyses were performed with the Statistical Package for Social 
Sciences for Windows (SPSS, Chicago, IL) version 19.0.
21.6  Results
21.6.1  Clinical Characteristics
Sixty-two unrelated childhood IPAH or HPAH probands, 26 (41.9%) female, were 
included in this study. The average age at diagnosis was 77.5 ± 53.8 months. The 
median interval from onset of symptoms to diagnosis was 4 months (1~48 months). 
Twenty-eight (45.2%) patients were presented with markedly decreased cardiac 
function (NYHA class III–IV). The average plasma BNP concentration was 
1198.8  ±  2239.9  pg/mL.  Of 62 children evaluated, 20 (32.3%) carried BMPR2 
mutations, and 2 (3.2%) carried ALK1 mutations; 2 (3.2%) carried KCNK3 muta-
tions and 3 (4.8%) carried NOTCH3 mutation. Patients were divided into two 
groups based on the presence or absence of gene mutations, and clinical and hemo-
dynamic characteristics were compared (details in Table  21.1). Twenty-eight 
patients, half of them mutation carriers, underwent cardiac catherization examina-
tions, with acute vasodilator testing (details in Table 21.2). Mutation non-carriers 
had lower right atrial pressure than mutation carriers (p = 0.016). Mutation carriers 
tended to have higher pulmonary arterial pressure and higher pulmonary vascular 
resistance index than mutation non-carriers although the differences were not statis-
tically significant. Eight patients responded to acute vasodilator challenge testing; 
all were mutation non-carriers (p = 0.002).
Table 21.1 Clinical characteristics of patients at diagnosis
Variables Mutation carriers (n = 27) Mutation non-carriers (n = 35) p-value
Female (%) 8 (29.6) 18 (51.4) 0.120
Age at diagnosis, months 80.7 ± 49.8 77.5 ± 53.6 0.992
NYHA function class 0.921
I–II 15 19
III–IV 12 16
BNP, pg/mL 953.0 ± 1874.7 1358 ± 2487.8 0.502
TBIL, μmol/L 13.3 ± 5.7 16.0 ± 9.4 0.220
DBIL, μmol/L 3.3 ± 1.5 4.0 ± 2.5 0.214
UA, μmol/L 421.2 ± 173.0 424.7 ± 159.3 0.940
NYHA New  York Heart Association, BNP brain natriuretic peptide, TBIL total bilirubin, DBIL 
direct bilirubin, UA uric acid
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21.6.2  Targeted Drug Therapy
Fifty-six patients received PAH-targeted treatment. The utilization of targeted drugs 
is listed in Table 21.3. Endothelin-receptor antagonists were the medications most 
commonly used. The percentage of patients who received monotherapy, dual ther-
apy, and triple therapy were 41.7%, 45.8%, and 12.5% in mutation carriers and 
59.4%, 37.5%, and 3.1% in mutation non-carriers, respectively. No differences 
were found between mutation carriers and mutation non-carriers.
Table 21.2 Hemodynamic characteristics of patients at diagnosis
Variables Mutation carriers, n = 14 Mutation non-carriers, n = 14 p-value
PASP, mmHg 100.1 ± 22.9 83.8 ± 33.4 0.144
PADP, mmHg 59.8 ± 14.0 45.7 ± 22.0 0.054
MPAP, mmHg 74.5 ± 16.2 59.1 ± 23.3 0.052
RAP, mmHg 10.5 ± 4.1 7.2 ± 2.0 0.016
PVRI, WU·m2 20.3 ± 11.1 14.1 ± 9.5 0.130
CI, l/min/m2 3.3 ± 1.3 3.9 ± 1.1 0.669
SvO2, % 59.3 ± 11.3 67.2 ± 6.6 0.564
AVT (%) 0 (0) 8 (57.1) 0.002
PASP pulmonary artery systolic pressure, PADP pulmonary artery diastolic pressure, MPAP mean 
pulmonary arterial pressure, RAP right atrial pressure, PVRI pulmonary vascular resistance index, 
WU Wood units, CI cardiac index, SvO2 mixed venous oxygen saturation, AVT acute pulmonary 
vasodilatation test




Monotherapy (%) 29 (51.8) 10 (41.7) 19 (59.4)
Bosentan 21 8 13
Sildenafil 2 0 2
Tadalafil 4 0 4
Beraprost sodium 2 0 2
Dual therapy (%) 23 (41.1) 11 (45.8) 12 (37.5)
Bosentan and sildenafil 5 3 2
Bosentan and tadalafil 10 2 8
Bosentan and beraprost sodium 3 3 0
Ambrisentan and sildenafil 1 1 0
Ambrisentan and tadalafil 1 1 0
Macitentan and sildenafil 1 1 0
Sildenafil and beraprost sodium 1 0 1
Vardenafil and beraprost sodium 1 0 1
Triple therapy (%) 4 (7.1) 3 (12.5) 1 (3.1)
Bosentan, sildenafil, and iloprost 2 2 0
Bosentan, tadalafil, and beraprost sodium 1 0 1
Bosentan, beraprost sodium, and treprostinil 1 1 0
21 Genotypes and Phenotypes of Chinese Pediatric Patients with Idiopathic…
168
21.6.3  Outcome of Patients
The median duration of follow-up was 20.5 months (0–108 months). One patient under-
went lung transplantation at the age of 16, after 4 years of targeted drug therapy. Eleven 
out of 20 BMPR2 mutation carriers, both of the 2 ALK1 mutation carriers, 1 of 2 
KCNK3 mutation carriers, and 9 of 39 mutation non-carriers died during the follow-up 
period. The median survival for mutation carriers was 24.0 months. The 1-, 2-, 3-year 
survival of mutation non-carriers were 93.6%, 80.0%, and 66.9%, respectively, while 
for mutation non-carriers, the proportions were 79.8%, 49.9%, and 33.3% (see Fig. 21.1), 
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Fig. 21.1 Survival rate of mutation carriers and non-carriers with IPAH/HPAH
Table 21.4 Characteristics of dead and surviving patients
Variables Deaths, n = 23 Survivors, n = 34 p-value
Female (%) 7 (30.4) 18 (52.9)
Age, months 69.9 ± 57.6 87.9 ± 50.0 0.227
NYHA function class 0.849
I-II 15 23
III-IV 8 11
Gene mutation, (%) 14 (60.9) 11 (32.4) 0.033
BNP, pg/ml 1763.9 ± 3179.5 920.1 ± 1367.5 0.195
PASP, mmHg 97.2 ± 13.4 89.1 ± 37.2 0.496
PADP, mmHg 58.2 ± 10.0 50.0 ± 23.6 0.292
MPAP, mmHg 75.4 ± 10.3 63.3 ± 26.3 0.277
RAP, mmHg 11.9 ± 3.8 6.9 ± 2.1 0.000
PVRI, WU·m2 22.8 ± 11.5 14.0 ± 9.5 0.044
CI, L/min/m2 2.9 ± 1.2 4.0 ± 1.1 0.032
SvO2, % 64.5 ± 12.5 70.8 ± 6.2 0.098
NYHA New York Heart Association, BNP brain natriuretic peptide, PASP pulmonary artery sys-
tolic pressure, PADP pulmonary artery diastolic pressure, MPAP mean pulmonary arterial pres-
sure, RAP right atrial pressure, PVRI pulmonary vascular resistance index, CI cardiac index, SvO2 
mixed venous oxygen saturation
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were compared (for details, see Table 21.4). The results showed that dead patients had 
higher RAP, PVRI, and lower cardiac index than the survival group. The mutation of 
PAH-related genes is the main risk factor of death (OR = 6.418, 95% CI 1.393, 27.123).
21.7  Discussion
In this study, we retrospectively analyzed the clinical outcomes of gene mutations 
in Chinese pediatric patients with idiopathic and heritable pulmonary arterial hyper-
tension. Gene mutations are important causes of PAH. The BMPR2 gene encodes a 
transmembrane serine/threonine kinase receptor of the bone morphogenetic protein 
(BMP) pathway, which is involved in the regulation of growth and apoptosis of 
pulmonary smooth muscle cells and pulmonary endothelial cells [18]. Hundreds of 
BMPR2 mutations have been identified in 70% of familial PAH patients and up to 
40% of IPAH cases [12, 19]. In our study, BMPR2 was also the most often muta-
tion—accounting for 32.3% of all the patients.
Mutations in ALK1 are identified as the major cause of HHT [15]. Neither of the 
two patients with ALK1 mutations in our study met the diagnostic criteria for 
HHT. As clinical manifestations of HHT develop with increasing age, the majority 
of ALK1 mutation carriers might not have clinical evidence of HHT during child-
hood [15]. Both of the two patients carrying ALK1 mutations died during the fol-
low- up period, suggesting it a rapidly progressing type. A larger sample size is 
needed for the assessment of ALK1 on phenotype of these patients.
The KCNK3 gene encodes for an outward K+ channel and is a member of two- 
pore- domain K+ channels (K2P) [20]. KCNK3 inhibition participates extensively 
in the whole spectrum of PAH pathomechanism from vasoconstriction and vascular 
cell proliferation to PAH-associated chronic inflammation [21]. NOTCH3 is a trans-
membrane receptor protein that participates in the modulation of cell proliferation, 
differentiation, apoptosis, and migration [22]. Compared with that of BMPR2 and 
ALK1, the research on KCNK3 and NOTCH3 is relatively less. The relationship 
between these gene mutations and clinical phenotypes needs further verification.
Previous studies on adult patients have suggested that mutation carriers present 
PAH approximately 10 years earlier than noncarriers, with more compromised hemo-
dynamic status and worse prognosis [14]. Similar results were also obtained from 
studies on pediatric patients with IPAH and HPAH [16, 23]. In our study, two groups 
of patients were similar in gender and age, while mutation carriers tended to have 
higher pulmonary arterial pressure and pulmonary arterial resistance index than muta-
tion non-carriers although the difference was not statistically significant. Moreover, 
mutation carriers had higher right atrial pressure compared with mutation non-carri-
ers, indicating right heart burden of mutation carriers higher than mutation non-carri-
ers. Similar with the results of previous research, our study showed that pediatric 
patients with PAH-related gene mutations responded poorly to acute vasodilator test-
ing. No differences were found between two groups in WHO function class and blood 
biochemical index. As the clinical symptoms of IPAH were atypical, the majority of 
patients came to our center until obvious symptoms of right heart failure occurred and, 
thus, blood biochemical index and heart function indexes at baseline could not be used 
to assess the whole progression of the disease.
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Targeted drugs have benefited the patients with pulmonary hypertension [24, 
25]. Targeted drugs were approved in China from 2000s: bosentan in 2005, fol-
lowed by iloprost, inhaled, in 2007, ambrisentan in 2012, treprostinil in 2014, and 
tadalafil in 2015. Endothelin receptor antagonists were the most commonly used 
targeted drugs in our patients, followed by phosphodiesterase inhibitors. More than 
90% of our patients accepted monotherapy or dual therapy in spite of the relatively 
serious condition. Treatment options were usually made according to the status of 
the patients, as well as their financial situation. As the only available intravenous 
prostanoid, the application of treprostinil was limited due to the price and side 
effects of subcutaneous catheterization.
Our results indicated that the prognosis of pediatric patients with IPAH and 
HPAH was poor in China. The 3-year survival rate of patients with gene mutations 
was only 33.3%, with a median survival time of 24 months, even in the modern 
targeted drugs era. More effort is needed to explore the pathophysiological mecha-
nisms of IPAH and HPAH as well as more effective treatments.
In conclusion, pediatric patients with IPAH and HPAH had worse outcomes when 
gene mutations exist. Early gene screening for pediatric patients with IPAH and HPAH 
is recommended, and more aggressive treatment for mutation carriers is advisable.
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In Japan, we have a unique experience with pulmonary arterial hypertension 
(PAH): mandatory electrocardiography (ECG) screening in apparently healthy 
school children and lung biopsy study in infants with congenital heart disease 
and atypical PAH. Our recent nationwide survey demonstrated that the school 
ECG screening in Japan detects a substantial pediatric IPAH population that is 
associated with already established PH but without apparent right heart failure; 
early treatment in PAH patients was associated with better outcomes. Our lung 
biopsy study in small infants with atypical CHD-PAH in a single institute showed 
that microscopic respiratory disease was associated with the development of 
severe PH, which is unexplained by CHD but is reversible in acute vasodilator 
testing. We presented some experimental data supporting the benefit in initiating 
early treatment in PAH and targeting at-risk population from the perinatal period.
Keywords
Pulmonary hypertension · Electrocardiogram · Lung biopsy · Lifelong cardiol-
ogy · Congenital heart disease
Pulmonary arterial hypertension (PAH) is a progressive and fatal disorder character-
ized by occlusive vascular disease (PVD), including intimal hyperplasia and plexi-
form lesions in small pulmonary arteries. Since PAH still remains an incurable 
disease, it is required to explore the pathobiological mechanisms, which may confer 
new therapeutic targets and strategies. In Japan, we have a unique experience with 
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PAH: mandatory electrocardiography (ECG) screening in apparently healthy school 
children and lung biopsy study in infants with congenital heart disease and atypical 
PAH. In this presentation, recent clinical and experimental data are presented on the 
basis of lessons from PAH in Japan.
22.1  Early Detection and Early Treatment of PAH: 
Mechanistic Insights
For the early detection of cardiovascular diseases, a school ECG screening has been 
executed for all the first graders in elementary, middle and high schools in Japan. 
Our recent nationwide survey demonstrated that the school ECG screening in Japan 
detects a substantial pediatric IPAH population that is associated with already estab-
lished PH but without apparent right heart failure; early treatment in PAH patients 
was associated with better outcomes. In exploring the pathobiological basis of these 
findings, experimental studies using a human PAH-like rat model produced by 
Sugen/hypoxia (SuHx) treatment were performed. Animal studies showed that early 
but not late treatment reversed occlusive PVD, which was associated with increased 
apoptosis and suppressed anti-apoptotic molecule survin expression inα-SMA cells 
in the intima. Further studies using SuHx models and human samples showedα- 
SMA cells in the intima were immature SMC-like cells although the origin of such 
cells remains to be explored; microarray analysis indicated distinct gene expression 
profiles in the early treatment.
22.2  Pathological Basis of Atypical CHD-PAH: Clinical 
and Mechanistic Implications
Some patients with Eisenmenger syndrome experience no obvious heart failure due 
to systemic pulmonary shunting in infancy, which is unexplained. Although a com-
plex interplay of epithelial-endothelial cells is required for lung morphogenesis, its 
clinical relevance is unclear. Our lung biopsy study in small infants with atypical 
CHD-PAH showed that microscopic respiratory disease was associated with the 
development of severe PH, which is unexplained by CHD but is reversible in acute 
vasodilator testing. Such lung disease could be related to high functional PVR in 
infancy and late irreversible PAH unless CHD is timely repaired.
Y. Mitani and H. Sawada
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23Risk Stratification in Paediatric Pulmonary Arterial Hypertension
Shahin Moledina
Abstract
Risk stratification can be defined as clinical assessment and investigation with 
the purpose of determining a person’s risk of suffering a particular outcome and 
thereby guiding the need for preventative intervention (McGraw-Hill Concise 
Dictionary of Modern Medicine 2002). The need for risk stratification comes 
from the realisation that although the presence of pulmonary arterial hyperten-
sion significantly impairs survival, the degree of impairment can vary across the 
population of patients by as much as an order of magnitude.
Furthermore the understanding that therapies aimed at palliating symptoms 
and prolonging life has negative consequences both for the patients by way of 
side effects and society by way of costs and should therefore be targeted at those 
for whom potential benefit outweighs harm.
Keywords
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23.1  Why Risk Stratify?
Current drug therapies for pulmonary hypertension are licensed based on randomised 
control trials primarily demonstrating improvement in exercise intolerance. Currently 
there are five main therapy classes which may be used in combination, resulting in poten-
tially numerous permutations of therapy. However, with polypharmacy comes a potential 
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for increased disease burden and side effects. Data from our own centre (unpublished) 
shows that the number of therapies a patient is receiving negatively impacts health-related 
quality of life scores even when adjusting for other measures of disease severity. Tools to 
identify those patients at highest risk of adverse outcome in whom to offer more aggres-
sive therapy are therefore increasingly important. The same is true for interventional pro-
cedures used to treat pulmonary hypertension such as balloon atrial septostomy or reverse 
Potts procedure. Each has a significant procedural mortality between 5 and 15% which 
must be balanced against the potential for significant palliation. They therefore should be 
targeted at those patients who are most likely to benefit.
Finally, cadaveric lung transplantation is a special case where risk stratification 
is exceedingly important. Lung transplantation especially for younger patients in 
whom the potential donor pool is restricted, by size and therefore availability, 
requires anticipation of prognosis. At the time of listing, for a young child in the 
United Kingdom, for example, might expect to wait a median of 12 months before 
a suitable matched graft is available. Therefore, if one enters the transplant waiting 
list too late there is a chance that the patient will succumb to their disease prior to 
transplantation [1]. Conversely, transplantation itself carries both immediate and 
longer-term morbidity. The procedure risk is between 5 and 10%, and the median 
survival is approximately 10 years. Therefore, listing a patient too early in the dis-
ease course will serve to impair the outcome and will result in harm.
23.2  Multidimensional Risk Stratification
Risk stratification is borne from the observation of discernible differences between 
patients who experience an early adverse outcome and those who enjoy better 
longer- term results. These differences span a number of domains and are not always 
congruous. For example, a patient with very severe vascular disease may have mild 
symptoms or a patient with mildly increased vascular resistance at assessment may 
have a particularly aggressive form of disease with rapid progression in vascular 
disease. Therefore, we proposed a multidimensional assessment of patients to guide 
risk stratification but also to allow a full understanding of the patient for more holis-
tic treatment and to further understanding of the disease.
23.3  Factors to Consider in Multidimensional Risk 
Stratification of children with Pulmonary Arterial 
Hypertension
The paradigm of pulmonary arterial hypertension is of vascular remodelling result-
ing in progressive vascular obstruction and therefore the haemodynamic sequelae of 
the disease. These processes are thought to result from a combination of inherent 
susceptibility combined with vascular injury. It is therefore natural to consider the 
cause of pulmonary hypertension in a particular patient to inform the likely progres-
sion of the vascular disease. Since the core of the disease is vascular remodelling, 
S. Moledina
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measures of vascular structure and function are also considered important in gaug-
ing disease severity and risk. Data however indicate that whilst vascular disease is 
the source of the problem in pulmonary hypertension, outcome is largely mediated 
by its impact on cardiac function. Finally, as with any chronic disease, the body 
employs different compensatory mechanisms and therefore a downstream indicator 
of severity and risk would be the impact of the disease on the patient as a whole.
23.4  Cause of Pulmonary Hypertension
It is well known that different aetiologies of pulmonary arterial hypertension have 
different survival rates [2]. Patients with Eisenmenger syndrome have better sur-
vival in most registries than those with idiopathic or postoperative disease. It is 
likely that patients who develop pulmonary vascular disease despite minimal vascu-
lar injury may have more aggressive disease progression compared to those where 
vascular disease develops only after considerable insult to the vasculature. A prime 
example of this is the BMPR2 mutation. It has now been demonstrated that patients 
harbouring a BMPR2 mutation have poorer survival than those with idiopathic pul-
monary arterial hypertension without this mutation [3].
23.5  Vascular Burden
Since vascular remodelling is central to the disease, measures of remodelling may 
aid risk stratification. Vascular disease at the microscopic level is difficult to study 
in patients due to access to tissue, and histology is not routinely performed. 
Functional cellular assays acting as biomarkers of vascular disease burden have not 
been well validated and are not in routine clinical use; however, they do represent 
exciting potential for further research. The classical way of assessing burden of 
disease in the vasculature in totality is to measure its impact on haemodynamics 
and, in particular, on pulmonary vascular resistance. As a vessel lumen obstructs the 
resistance will increase resulting in an aggregate assessment of vascular disease. 
The ability of pulmonary vascular resistance to predict outcome understandably has 
been assessed in numerous studies with varying results. A meta-analysis of these 
data demonstrates a significant association between pulmonary vascular resistance 
index (PVRI) and outcome with a 32% increased risk of adverse event for every 
10 WU.m2 increase in PVRI [4]. Since the pulmonary vasculature experiences pul-
satile blood flow the degree of vascular remodelling cannot be described solely in 
terms of resistance. The other components of vascular load are total arterial compli-
ance and wave reflection. Wave reflection has not been studied; however, arterial 
compliance has been investigated to some extent and does predict mortality with the 
total arterial compliance falling with increased vascular disease. In a number of 
small studies, pulmonary arterial compliance is seen to be as good as, or better, at 
predicting outcome than pulmonary vascular resistance. The reason for this is 
unclear. Finally assessing the acute response of the vascular bed to vasodilators is 
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important. In this procedure, patients undergo acute testing of the pulmonary vaso-
dilator, typically inhaled nitric oxide to assess the degree to which the vascular bed 
will respond by dilating. It is estimated that patients who respond to acute vasodila-
tor testing have about a quarter to a third the risk of patients who do not respond to 
acute vasodilator testing [4].
As well as assessment of haemodynamics, one can image the vasculature itself 
with three-dimensional imaging techniques such as computed tomography. In one 
study CT angiograms from patients with varying degrees of pulmonary hyperten-
sion were segmented to look at the complexity of the overall branching structure as 
a measure of vascular remodelling. In the pilot study, vascular branching complex-
ity correlated both with functional class and pulmonary vascular resistance index 
but most importantly predicted survival [5].
23.6  Ventricular Function
Many of the effects of vascular disease are mediated via its impact on right ventricu-
lar function resulting in the observation that patients with very advanced disease, 
but preserved ventricular function often has a lower symptom burden and better 
outcome than those with more modest vascular disease but more severe ventricular 
dysfunction. Ventricular function can be assessed in aggregate during haemody-
namic testing by considering total cardiac index which informs prognosis (hazard 
ratio of 0.66 per 1 L/min/m2 increase). Pump failure may also be assessed by mea-
suring right atrial pressure RAP, and this is a robust prognostic indicator with hazard 
ratio of 1.12 per 1 mmHg increase in RAP. NT-proBNP has been used in various 
forms of heart failure as a circulating biomarker of ventricular wall stress and dys-
function. Tested in a number of small paediatric studies, this measure also informs 
prognosis and can be used for risk stratification. One advantage to this measure is 
that it can be performed in a serial fashion.
Finally the gold standard for measuring cardiac function is cardiac MRI. This 
can now be performed even for the youngest of children. One study of 100 children 
undergoing cardiac MRI found a number of measures which are prognostic. These 
include measures of right ventricular dilatation, severity of tricuspid regurgitation 
and right ventricular mass; however, the most robust measure in predicting outcome 
was right ventricular ejection fraction [6].
23.7  Impact on the Patient
The most common symptom experienced by patients with pulmonary hypertension 
is exertional dyspnoea and exercise limitation with nearly 80% of patients experi-
encing this [7]. Exercise limitation may be measured by 6-min walking distance; 
however, numerous studies have failed to demonstrate this as a useful prognostic 
indicator. A more objective measure of exercise tolerance can be obtained by car-
diopulmonary exercise testing, and in an unpublished study from our centre both 
peak oxygen consumption peak O2 and ventilatory efficiency slope (VE/VCO2) 
S. Moledina
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were highly prognostic. Perhaps the best way of determining the impact on a 
patient’s ability to function as a result of that disease is to ask them in a structured 
fashion. This can be scored as in the WHO functional class assessing severity of 
symptoms. Despite its crude appearance as a subjective score, functional class has 
been demonstrated consistently to inform prognosis and is a very robust measure. 
Other ways of assessing impact on patient is to use a structured quality of life ques-
tionnaire to score measures of quality of life in different domains. A study from our 
centre using the PedQL questionnaire has demonstrated good correlation between 
physical domain of the questionnaire and prognosis.
Finally, children are in the unique position of growing and developing. Chronic 
diseases impact on this growth and development and therefore measures of growth may 
be considered as an aggregate measure of the impact on the disease on the patient’s 
biology as a whole. Children with pulmonary hypertension have been shown to have 
growth failure, and their severity of the growth failure also predicts outcome [7].
23.8  Summary
Whilst there is no cure for paediatric pulmonary arterial hypertension at present, 
treatments have advanced and with more treatment options comes complexity in 
decision making leading to a need to stratify risk. Numerous markers of adverse 
outcome have been described across the breadths of domains; however, we believe 
a multidimensional assessment considering causation, vascular disease burden, car-
diac function and overall impact on patient will lead to more accurate risk stratifica-
tion, promote holistic care of patients and provide deeper insight into disease 
mechanisms which can later be exploited to therapeutic advantage. Such assess-
ments should be a dynamic process.
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Pulmonary hypertension (PH) is a rare disease with significant mortality despite 
targeted therapies. Among patients with PH, both survival and functional class 
are more closely correlated with right ventricular (RV) function than with the 
degree of pulmonary artery pressure elevation or pulmonary vascular resistance. 
Unfortunately, the RV is usually exquisitely sensitive to increases in afterload 
associated with PH, and progressive RV failure is the typical clinical course 
among most patients over time. However, in the subset of PH patients with con-
genital heart disease and Eisenmenger syndrome, survival is prolonged and RV 
function is preserved compared to patients with primary PH.  This functional 
superiority may be due to a persistent RV fetal phenotype as patients continue to 
have a biventricular hypertrophy pattern which mimics fetal cardiac morphology. 
We have utilized an ovine model of congenital heart disease to demonstrate supe-
rior RV function following acute afterload stimulus—a unique RV Anrep effect. 
Further, we have shown shared gene expression patterns in the fetal and CHD 
model RV. In the future, understanding the underlying mechanisms of RV adap-
tation in CHD and PH may yield novel therapeutic strategies for all patients with 
pulmonary hypertension.
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24.1  Introduction
Pulmonary arterial hypertension (PAH) is a rare but devastating disease that carries a 
significant burden of morbidity and mortality. Most investigations have focused on 
mechanisms that underlie abnormal pulmonary vascular reactivity and remodeling, 
which have led to the development of new therapies and improved survival. Similarly, 
much of the clinical evaluation of patients with PAH is based upon assessments of 
pulmonary arterial pressure and pulmonary vascular resistance. However, mortality 
is due to right ventricular (RV) failure, and there is growing recognition that indices 
of RV function in patients with PAH—including right atrial pressure and cardiac 
index—are correlated most closely with not only survival but also functional class [1, 
2]. Interestingly, patients with PAH associated with CHD have better functional 
capacity and survival than patients with other forms of PAH despite equivalent pul-
monary artery pressures and advanced pulmonary arteriopathy [3]. However, the 
mechanisms that might account for this difference are unknown and have been the 
subject of limited investigation. Among patients with primary PH, there is consider-
able variability in indices of RV function (cardiac output and right atrial pressure) 
relative to pulmonary artery pressure elevation. There is a subpopulation of patients 
who retain an adaptive phenotype with concentric hypertrophy and preserved 
mechanical efficiency; accordingly, these patients have improved survival compared 
to patients with a “maladaptive” RV phenotype [4]. A better understanding of pre-
served RV function in these patients might lead to novel therapeutic targets.
24.2  Improved Survival in Eisenmenger Syndrome
For decades, there has been a consistently observed survival advantage among 
patients with Eisenmenger syndrome compared to those with idiopathic PH or PH 
secondary to other causes [5]. Despite equivalent elevations in PA pressure and 
pulmonary vascular resistance compared with patients with IPAH, these patients 
have lower right atrial pressures and higher cardiac output. Moreover, at a similar 
level of PAP elevation, patients with ES have superior echocardiographic features of 
RV function [6]. Two major mechanisms for this observed survival benefit have 
been theorized. The presence of a communication at either the atrial or ventricular 
level (or both) allows right-to-left shunting of blood—a “pop-off”—preserving left- 
sided output during right ventricular failure. Another intriguing potential factor is 
persistence of a fetal RV phenotype due to the presence at birth of an unrestrictive 
post-tricuspid valve left-to-right shunt that applies systemic-level afterload to the 
RV.  In this situation, the RV does not undergo the deconditioning that normally 
occurs as pulmonary vascular resistance decreases after birth and, thereby, may be 
better suited to function against an increasing afterload as pulmonary hemodynam-
ics worsen [5, 7]. Interestingly, a recent multicenter study of predictive factors of 
survival in patients with ES found that those with pre-tricuspid lesions had worse 
survival [8]. These data support the hypothesis that RV remodeling in the setting of 
high afterload associated with post-tricuspid CHD lesions confers additional benefit 
beyond right-to-left unloading through an intracardiac shunt.
R. J. Kameny et al.
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24.3  Preserved Fetal Morphology in Eisenmenger Syndrome
During fetal life, the right ventricle is the dominant ventricle, responsible for approxi-
mately two-thirds of combined cardiac output [9]. Commensurate with this function, the 
right and left ventricles are equally hypertrophied in fetal life; in normal physiology, RV 
hypertrophy regresses postnatally as the RV remodels into a highly efficient, compliant 
chamber which pumps a full cardiac output to the low resistance pulmonary vascular bed 
with approximately 1/5 the energy expenditure of the left ventricle. In patients with post-
tricuspid lesions, the RV is continually exposed to high afterload and regression from 
fetal characteristics is attenuated or absent. Hopkins and Waggoner compared morpho-
logic characteristics of 50 patients with Eisenmenger syndrome, infants with unrestrictive 
VSDs, and fetuses with normal anatomy; they found a consistent linear relationship 
between LV and RV wall thickness among these groups (Fig. 24.1) [10]. Furthermore, 
among patients with Eisenmenger syndrome, those with post-tricuspid (as opposed to 
a
Fig. 24.1 Preserved fetal biventricular hypertrophy in patients with Eisenmenger syndrome (ES). 
Adapted from Hopkins and Waggoner. Severe pulmonary hypertension without right ventricular 
failure: the unique hearts of patients with Eisenmenger syndrome. AJC 2002. Reproduced with 
permission. (a) Cardiac imaging top left, normal 20-week fetal echo; top right, echo of 26-year 
old with truncus arteriosus and ES; bottom left, magnetic resonance imaging of 41-year old with 
patent ductus arteriosus and ES, 77-year old with perimembranous ventricular septal defect and 
ES. (b) Wall thickness. Linear Regression of LV and RV wall thickness in structurally normal 
fetal hearts, infants with unrestrictive ventricular septal defects, and adolescents and adults with 
unrestrictive post-tricuspid lesions and ES
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pre-tricuspid) lesions have better RV function and survival [11]. These findings suggest 
that post- tricuspid CHD lesions allow for continued postnatal exposure of the RV to 
systemic- level afterload, prevent the typical regression of RV hypertrophy postnatally, 
and condition the RV to respond to later increases in afterload associated with PH.
24.4  Fetal Phenotype in Ovine CHD Model
Our laboratory has a well-established, clinical relevant model of CHD utilizing a large, 
fetally implanted aortopulmonary shunt, which continually exposes the RV to systemic 
level afterload during the perinatal transition and beyond (Fig. 24.2a) [12]. As a conse-
quence of this hemodynamic stimulus, the RV in the juvenile shunt lamb is signifi-
cantly hypertrophied compared to the control (Fig. 24.2b) [13]. In this CHD model, the 
RV of shunt lambs has many gene expression similarities with the RV of fetal lambs, 
including in α- and β-myosin heavy chain expression [13] and nitric oxide synthase 
expression and activity [14]. Further, we have utilized RNA sequencing to compare RV 
gene expression among fetal and juvenile shunt and control lambs. Eighty-two percent 
of genes that were differentially expressed in fetal RV tissue (compared to control) 
were also upregulated in shunt RV tissue (unpublished data). When subjected to gene 
ontology analysis, these 142 shared differentially expressed genes enrich a total of 25 
biological pathways, including those associated with ECM remodeling, negative regu-
lation of cellular proliferation, and cardiovascular system development—all pathways 
which might contribute to the observed adaptive RV phenotype.
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24.5  The Adaptive RV Response to Acute Afterload—RV 
Anrep Effect
In our model of CHD with chronic left-to-right shunting, we demonstrated that 
the RV of shunt lambs has an adaptive response compared to control RV when 
challenged with an acute afterload increase (imposed by pulmonary artery band-
ing) with increased contractility and preservation of mechanical efficiency and 
ventricular- vascular coupling (Fig.  24.3). Our observation of a sustained 
increase in contractility in the shunt RV following afterload challenge is evi-
dence of a novel Anrep effect, the second slow increase in contractility in 
response to myocyte stretch. Previously, this critical physiologic mechanism 
had only been observed in the left ventricle (LV) as the normal RV is exquisitely 
sensitive to increased afterload. Furthermore, after pulmonary artery banding, 
the RV in shunted animals had preserved ventricular-vascular coupling and ven-
tricular efficiency relative to controls [13]. These adaptive physiologic responses 
to acutely increased afterload in shunted lambs may correlate with the response 
in patients with CHD and PH.
24.6  Potential Mechanisms of RV Anrep Effect
Having established this novel Anrep effect, we next sought to understand 
potential underlying mechanisms. We first examined nitric oxide signaling as 
increased cardiac NO signaling has a variety of paracrine and autocrine effects 
which ultimately maximize cardiac function including improved excitation-
contraction coupling, which is crucial for the Anrep effect [15]. We found a 
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Fig. 24.3 Superior RV performance in ovine CHD model with acute RV afterload stimulus. 
Following 4 h of acute pulmonary artery banding to 50% of systemic pressure, (a) shunt lambs 
demonstrated continued superior cardiac index compared to controls and (b) shunt lambs increased 
RV contractility (Ees) by 2.5-fold baseline
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distinct shunt RV phenotype with consistently increased NOS expression, 
activity, and association of important cofactors for NOS activation; this dis-
tinct pattern was consistent in the RV of fetal and shunt but not control lambs 
(Fig. 24.4).
We next examined non-coding microRNA expression patterns as potential mod-
ulators of multiple pathways of gene expression [16]. We found important differ-
ences in miRNA expression in our adaptive RVH model compared human and 
animal maladaptive RVH with significant overlap in the fetus. Next, we investigated 
downstream effects of miR-199b and miR-29a expression as they relate to NFAT- 
calcineurin mediated cardiac hypertrophy and fibrosis. Alterations in miR-199b and 
miR-29a and downstream effects are shown in Fig. 24.5 [17]. These changes yield 
valuable insight into one of the potential mechanisms behind adaptive RV hypertro-
phy seen in our model of ovine CHD.
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Fig. 24.4 RV nitric oxide signaling in ovine CHD model. (a) Increased expression of all nitric 
oxide synthase isoforms (eNOS, nNOS, and iNOS) in shunt and fetal RV. (b) Increased NOS activ-
ity in shunt and fetal RV, and (c) increased post-translational nitrosylation of ryanodine receptor 2 
(RyR2) in shunt and fetal RV. Nitrosylation of RyR2 predisposes the open confirmation with resul-
tant increased intracellular calcium and increased contractility
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24.7  Future Directions and Clinical Implications
Preserved RV function among patients with Eisenmenger Syndrome remains a clin-
ical observation without a clearly identified pathophysiologic mechanism. Although 
a preserved RV fetal phenotype in these ES patients seems a logical conclusion 
based on both cardiovascular development and preliminary animal data, this hypoth-
esis remains unproven. As the mechanisms for preserved RV function in these cir-
cumstances is better defined, the next step will be targeting of these pathways in all 
patients with preserved RV function in the hopes of improving the survival and 
functional status of these patients.
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Fig. 24.5 miR 29 and 199b effects. Cartoon of downstream effects of observed changes in miR 
expression in shunt and fetal RV tissue. Increased miR-29 leads to decreased collagen 1 and 3 
expression and decreased fibrosis. Decreased miR199b expression leads to increased Dyrk1a 
expression, which promotes NFAT phosphorylation and inhibits NFAT translocation to nucleus 
and transcription of NFAT/calcineurin-dependent heart failure gene program
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Pulmonary hypertension (PH) causes cardiac hypertrophy in the right ventricle 
(RV) and eventually leads to RV failure due to persistently elevated afterload. 
Considerable clinical and experimental animal studies have shown that abnormali-
ties of endothelial function represent a hallmark of heart failure. However, the rela-
tionships between right coronary endothelial dysfunction and the development of 
heart failure remain to be fully established especially in the right heart. Synchrotron 
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radiation (SR) microangiography has provided the temporal and spatial resolution 
required to visualize microvessels of various organs in vivo [1]. Therefore, in this 
study, we aimed to validate a new approach for the in vivo assessment of endothelial 
coronary function of the rat right heart using SR microangiography.
Imaging of the right coronary circulation was performed under pentobarbital 
anesthesia with monochromatic SR at 33.2 keV for producing maximal absorption 
contrast of the iodine contrast agent in the vascular lumen (Fig. 25.1a). ImageJ (ver. 
1.41, NIH, Bethesda, MD) was used to identify coronary vessels and determine 
their caliber. Vessels were labeled and classified according to branching orders from 
first-order main segment (Fig. 25.1b). The visible vessel internal diameter (ID) of 
each vessel was determined from a single field of view for all cine sequences. The 
ID of each vessel was averaged over at least ten consecutive frames [2].
The figure shows a typical imaging pattern of right coronary arteries from the 
aortic root to the third or fourth branching. It was possible to observe an arteriole 


































Fig. 25.1 SR microangiography for assessing vascular function in a rat. Schematic of SR micro-
angiography for the rat right coronary artery using SPring-8 facilities (a). Typical SR angiogram 
image of the right coronary vasculature (b). Schematic of right coronary arteries in lateral view 
depicting the coronary branching nomenclature used in this study (c). Range of vessel size at each 
of the branching generations of right coronary circulation in the normal rat (d). Asterisks indicate 
~50 μm vessels not included in (d)
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branches were 312.7  ±  15.4, 159.3  ±  12.4, and 113.1  ±  7.5  μm, respectively 
(Fig. 25.1d). The present investigation demonstrates the ability to clearly visualize 
the right coronary circulation of the closed-chest anesthetized rat using SR micro-
angiography. The use of SR microangiography provides a powerful tool for assess-
ing coronary hemodynamics in unprecedented detail in PH models. Ultimately, 
future studies using SR microangiography will provide important new insights into 
the pathophysiology of right heart failure.
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Hereditary hemorrhagic telangiectasia (HHT) is a hereditary disorder that causes 
refractory nasal bleeding, arteriovenous malformations in the lung (pulmonary arte-
riovenous fistula: PAVF), central nervous system (CNS-AVF), and liver (hepatic 
AVF). HHT is caused by genetic abnormalities in endoglin (ENG), ACVRL1 
(ALK1), and other rare genes (e.g., SMAD4). The relationship between these gene 
mutations and the affected organs remains unclear.
We performed genetic analysis from whole blood of 464 suspected HHT patients 
or HHT carriers from April 2005 to November 2015 in 35 hospitals and found 264 
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patients positive for mutation in ENG, ALK1, and SMAD4 genes. Of these 264 posi-
tive results, we excluded 68 patients who were sporadic, non-familial cases and 
performed proband gene analysis. We also excluded 107 non-symptomatic mutation 
carriers and leaving a total of 89 patients with AVFs.
To clarify the relationship between gene mutations and the affected organs, we 
assessed the mutations and clinical presentation of these 89 patients. We found 25 
mutations in the ENG gene from 68 patients and 8 mutations in the ALK1 gene from 
21 patients. We then grouped patient AVF presentation (PAVF, CNS-AVF and 
hepatic AVF) according to the genetic mutation (Table 26.1).
Among patients with mutations in ENG, 19/25 (79%) mutations and 46/68 (69%) 
of patients presented with the same affected organ pattern. PAVFs were tending to 
Table 26.1 Gene mutation and affected organs
Gene Mutation N Type PAVF CNS-AVF HAVF
ENG Met368Thr 4 Missense All(+) ALL(−) NA
ENG Cly331Ser 6 Missense All(+) NA NA
ENG IVS3 ds G-C +1 3 Splicing All(+) ALL(−) NA
ENG Leu162Pro 2 Missense All(+) NA NA
ENG Skipping of ex.2 2 Splicing All(+) NA NA
ENG Ala229Profs 2 Frame shift All(+) ALL(−) NA
ENG Gln505Ter 2 Nonsense All(+) ALL(−) NA
ENG Leu107Cysfs 2 Frame shift All(+) NA NA
ENG Gln145Ter 3 Nonsense All(+) NA NA
ENG Leu194Pro198del5 2 Missense All(+) NA NA
ENG Glu276IlefsX57 2 Frame shift All(+) All(+) NA
ENG (Novel1) 2 Frame shift All(+) ALL(−) NA
ENG (Novel2) 2 Missense All(+) ALL(−) NA
ENG (Novel3) 2 Splicing All(+) NA NA
ENG Arg93Ter 2 Nonsense All(+) NA NA
ENG Arg339GlyfsX22 2 Frame shift All(+) ALL(−) NA
ENG Glu563Lysfs 2 Frame shift All(+) NA NA
ENG Leu506Pro 2 Missense All(+) NA NA
ENG IVS7−1G>A 2 Splicing All(+) ALL(−) NA
ENG IVS3+1G>A 2 Splicing Hetero Hetero NA
ENG IVS6 ds T-A +2 4 Splicing All(+) Hetero NA
ENG Ex.3-8 del 4 Exon del. All(+) Hetero NA
ENG Cys412Thr 3 Missense Hetero All(+) NA
ENG IVS8 ds G-A −1 7 Splicing Hetero Hetero Hetero
ENG (Novel4) 2 Splicing Hetero Hetero NA
ALK1 Arg479Ter 5 Nonsense All(+) ALL(−) All(+)
ALK1 IVS6ds insAA+4_5 3 Splicing All(+) NA NA
ALK1 Pro424Leu 2 Missense ALL(−) NA All(+)
ALK1 Arg200Gly 2 Missense All(+) ALL(−) All(+)
ALK1 Gln118Ter 2 Nonsense NA ALL(−) All(+)
ALK1 IVS5-3C>G 2 Splicing All(+) NA NA
ALK1 Arg484Gln 3 Missense NA ALL(−) Hetero
ALK1 Asp437Gly 2 Missense ALL(−) ALL(−) Hetero
PAVF pulmonary arterio-venous fistula, CNS-AVF central nervous system arterio-venous fistula, 
HAVF hepatic arterio-venous fistula, NA not assessed
Novel1-Novel4 gene: novel gene mutations
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be the same. Hepatic AVFs were rarely described in patient profiles so we were 
unable to evaluate hepatic AVF presentation patterns in mutated ENG patients.
In patients with mutations in ALK1, 8/10 (80%) mutations, 16/21 (76%) patients 
presented with the same affected organ pattern. For example, all five patients with 
the Arg479X mutation presented with the same affected organ pattern.
Previous reports have suggested that patients with mutations in ENG frequently 
have PAVFs. In contrast, patients with mutations in ALK1 frequently have hepatic 
AVFs and gastrointestinal telangiectasias but rarely have CNS-AVFs [1–3]. 
However, previous reports have not discussed similarity and combination of AVF 
patterns for each mutation.
In our analysis, approximately 70–80% of HHT patients with a previously 
detected genetic mutation presented with the same AVF pattern. Our result empha-
sizes the importance of genetic testing in HHT even if the patient had already been 
diagnosed according to other clinical findings.
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Pulmonary arterial hypertension (PAH) is a lethal disease [1]. Although mutations 
in BMPR2 and other genes have been reported, the genetic causes in large numbers 
of patients, especially with sporadic PAH, remain unknown. In 2013, Kerstjens- 
Frederikse et al. first reported TBX4 mutations in patients with PAH [2]. TBX4 is an 
essential transcription factor for the development of the hindlimbs and lungs [3]. In 
European countries, the frequency of TBX4 mutation was reported as 2.4–4.1% in 
adult-onset PAH [2, 4] and as 7.5–30% in child-onset PAH [2, 5] (Fig.  27.1). 
However, its frequency in Asian patients with PAH has yet to be studied.
In our genetic analysis for patients with PAH, at least nine sequence variants in 
exons and six sequence variants in flanking introns of TBX4 were found. The allele 
frequencies of variants in the Japanese population are under investigation. The 
detected variants will be validated using the following web databases: UCSC 
genome browser (https://genome-asia.ucsc.edu), Ensembl (http://www.ensembl.
org), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2), SIFT (http://sift.jcvi.org), 
Human Splicing Finder (http://umd.be/HSF3), and Protein Data Bank Japan (https://
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pdbj.org) for their functional significance. We are further attempting to establish the 
experimental system of functional analysis for the identified variants of TBX4 using 
cell culture with luciferase, immunoprecipitation, and immunohistochemistry 
assays in order to elucidate the molecular mechanism underlying PAH resulting 
from TBX4 mutations.
This study suggests that TBX4 may be a prevalent genetic cause of PAH not only 
in Caucasians but also within Japanese/Asian populations. Our ongoing studies 
would soon reveal the functional relevance and genotype–phenotype correlations in 
patients with PAH associated with TBX4 mutations.
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Fig. 27.1 Summary of the position of the previously reported variants in TBX4. Upper labels 
indicate variants with child-onset PAH; lower labels indicate variants with adult-onset PAH. NLS 
nuclear localization signal
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As neonatal right ventricular (RV) function undergoes transition from fetal to neo-
natal circulation, evaluation of the neonatal right ventricle is important. We ana-
lyzed the RV function of three infants with persistent pulmonary hypertension of the 
newborn (PPHN) using three-dimensional transthoracic echocardiography (3D 
echo) and herein report the results.
Patient 1 was a boy born at 40 weeks (weight, 3284 g; Apgar score (Ap), 7/8) 
with neonatal asphyxia, meconium aspiration syndrome, and PPHN. His oxygen 
saturation increased with inhaled nitric oxide (iNO) therapy; 3D echo was per-
formed 6 and 12 h after iNO therapy.
Patient 2 was a girl born at 41 weeks (weight, 3010 g; Ap, 1/6) with neonatal 
asphyxia, neonatal pneumonia, and PPHN.  She underwent iNO therapy and 
improved; 3D echo was performed before and after iNO therapy.
Patient 3 was a boy with congenital cystic adenomatoid malformation and 
hydrops fetalis. He was born by cesarean section at 35 weeks with uncontrollable 
pleural fluid and ascites. His pulmonary hypertension (PH) and respiratory condi-
tion did not improve even after thoracentesis, lobectomy, and sildenafil. He died 
27 h after birth. Echocardiography was performed after lobectomy.
In each case, we performed 3D echo with an EPIQ system and X7-2 transducer 
(Philips Healthcare, Amsterdam, Netherlands) and analyzed the images with a 
TomTec system (TomTec Imaging Systems, Unterschleißheim, Germany) 
(Fig. 28.1). 3D data were acquired in a full-volume data set from the four-chamber 
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apical view. The frame rate was 50  Hz. In Patient 1, the right ventricular end- 
diastolic volume (RVEDV) was the same (5.7 ml) at 6 and 12 h after starting iNO 
therapy; however, the right ventricular stroke volume (RVSV) and right ventricular 
ejection fraction (RVEF) increased from 1.6 to 2.3 ml and from 28% to 40%, respec-
tively. In Patient 2, the RVEDV slightly decreased from 5.1 to 4.9 ml before and 
after iNO therapy. The RVSV and RVEF increased from 1.4 to 1.9 ml and from 28% 
to 39%, respectively. In Patient 3, the RVEDV was 4.7 ml, RVSV was 3.5 ml, and 
RVEF was 27% (Fig. 28.2).
The RVEF increased in Patients 1 and 2 following the improvement of PH and 
remained low in Patient 3. This may suggest that RVEF is significantly correlated 
Fig. 28.1 3D RV image 












































Fig. 28.2 Data of RVEDV, RVSV, RVEF in Cases 1–3
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with PH. Murata et al. [1] reported that RVEF measured by 3D echo could help to 
noninvasively predict the clinical outcomes of PH. Thus, 3D echo data might be 
useful for evaluating patients’ cardiac condition and choosing treatment.
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Pulmonary hypertension (PH) is a frequent complication in patients with congenital 
heart disease (CHD), before or after cardiac surgery. According to the recent clinical 
classification, PH associated with CHD is categorized into subclasses depending on 
the pathogenesis: (1) Eisenmenger syndrome, (2) left-to-right shunts, (3) PH with 
coincidental CHD, and (4) postoperative PH [1]. Postoperative PH means that CHD 
was repaired, but PH either persists immediately after surgery or recurs/develops 
months or years after surgery, in the absence of significant postoperative hemody-
namic lesions. The anatomical features are varied and the clinical phenotype is often 
aggressive [2–4].
We encountered many patients with PH associated with postoperative tetralogy 
of Fallot (TOF), especially those with major aortopulmonary collateral arteries 
(MAPCAs). The etiology of PH associated with TOF with or without MAPCAs is 
uncertain. During cardiovascular development, MAPCAs are formed to supply 
blood flow to the lungs through remnants of inter-segmental arteries (ISAs) as a 
result of abnormal regression of the sixth pharyngeal arch arteries (PAA) in the 
embryonic stages (Fig.  29.1). Maldevelopment of the sixth PAA also leads to 
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hypoplasia or aplasia of the ductus arteriosus and peripheral pulmonary artery 
(PPA). The postoperative TOF, especially with MAPCAs, was implicated in hypo-
plasia of the lungs and pulmonary vasculature, thrombosis, and/or previously large 
systemic- to- pulmonary shunts. MAPCAs are connected to hypoplastic or segmen-
tally unequal pulmonary vascular beds and branches, resulting in arborization 
abnormalities as observed in the pulmonary angiography (Fig. 29.1) [5]. We, there-
fore, speculate that inadequate pulmonary vascular beds due to segmentally unequal 
pulmonary blood flow, vascular spasm in the area of alveolar hypoventilation, and/
or residual peripheral pulmonary stenosis (PPS) may result in high pulmonary blood 
pressure in postoperative TOF with MAPCAs. The hemodynamic and clinical pre-
sentations of patients with PH associated with postoperative TOF and MAPCAs are 
sometimes similar to those in Eisenmenger syndrome.
To better recognize the PH associated with TOF, especially with MAPCAs, the 
updated subclass as “segmental PH associated with CHD” should be important. Our 
clinical experience suggests that PH-targeted therapy may be effective for some of 
such patients, especially combined with percutaneous pulmonary angioplasty for 














ISAs lead to MAPCAs
Bilateral PAs are MAPCA dependent
No confluent central PA
(~10% of TOF with Pat.)
Bilateral PAs are MAPCA dependent
Hypoplastic central PA is present
(~20% of TOF with Pat.)
Fig. 29.1 Development of the aortic and pulmonary artery system, and the genesis of major aorto-
pulmonary collateral arteries (MAPCAs). MAPCAs are formed to supply blood flow to the lungs 
through remnants of inter-segmental arteries (ISAs). Types of pulmonary blood supply in tetralogy of 
Fallot (TOF) with pulmonary atresia (Pat.) are illustrated with approximate frequencies. Pulmonary 
angiography of the patient is also shown. Ao aorta, PA pulmonary artery, PAA pharyngeal arch artery, 
PPA peripheral pulmonary artery, PT pulmonary trunk
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Links between impaired lung development/growth and pulmonary hypertension 
(PH) have been demonstrated in infants with bronchopulmonary dysplasia or con-
genital diaphragmatic hernia. Experimental studies also suggest that a complex 
interplay of epithelial-endothelial cells is required for normal pre/postnatal lung 
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morphogenesis [1]. In this chapter, we focus on the role of lung development/growth 
abnormality in the development of pulmonary vascular disease (PVD) associated 
with congenital heart defect (CHD).
Children with large systemic-to-pulmonary shunt typically exhibit symptoms of 
heart failure in early infancy (tachypnea, failure to thrive), have PH with increased pul-
monary blood flow and do not develop irreversible PVD if closure of defect is performed 
before 9 months to 2 years of age [2]. In general, the patient’s age and type of lesion 
contribute to the risk of developing irreversible PVD. Conditions with pressure overload 
and high flow, such as large ventricular septal defect or patent ductus arteriosus, are 
likely to cause PVD earlier than low-pressure, high-flow lesions (pre-tricuspid shunt 
such as atrial septal defect). However, we sometimes encounter children with “atypical” 
PH which is associated with CHD but unexplained by the type or magnitude of coexist-
ing CHD (e.g., pre-tricuspid shunt or small post-tricuspid shunt with severe PH and 
elevated pulmonary vascular resistance [PVR]; large post-tricuspid shunt lacking symp-
tom of heart failure due to high PVR sustained from neonatal period.
Our recent observation suggests that microscopic airway abnormality caused by 
genetic or pre/postnatal conditions may be associated with PVD in infants with 
“atypical” PH.
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Abstract
Respiratory syncytial virus (RSV) is a major causative agent of respiratory infec-
tion in infants because of its affinity for bronchial and alveolar epithelial cells. 
Serious and sometimes fatal RSV infection may develop in premature infants as 
well as infants with chronic lung disease and congenital heart disease (CHD). In 
infants with CHD, the addition of RSV infection to the underlying respiratory 
pathology resulting from increase or decrease in pulmonary blood flow may 
cause significant problems such as serious symptoms, increases in hospitaliza-
tion rate, postponement of elective heart surgery, or death. Strict infection con-
trol measures with administration of anti-RSV antibody are essential in the 
management of infants with heart and lung diseases.
31.1  Clinical Characteristics of RSV Infection
Respiratory syncytial virus (RSV) accounts for more than 30% of hospitalizations 
of children under 3 years of age due to respiratory infection [1]. RSV infection typi-
cally develops acute upper respiratory tract inflammation associated with watery 
nasal discharge, cough, and fever. Although RSV infection causes only mild or 
moderate upper respiratory tract inflammation in most adults and older children, 
serious RSV infection may develop in babies and young infants who often experi-
ence acute bronchiolitis and pneumonia associated with expiratory wheezing and 
tachypnea. Serious and sometimes fatal RSV infection may develop in infants with 
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underlying conditions such as a history of premature birth, chronic lung disease 
(CLD), and congenital heart disease (CHD).
31.2  Impact of RSV Infection on CHD
RSV infection in infants with CHD is of particular significance in the following 
respects:
 1. Severe RSV infection may develop in infants with CHD [2, 3].
 (a) The rate of hospitalization due to RSV infection is higher in infants with 
CHD than in those without CHD.
 (b) The use of ICU care and ventilation for the treatment of RSV infection is 
more common in infants with CHD than in those without CHD.
 (c) Mortality due to RSV infection is higher in infants with CHD than in those 
without CHD.
 2. The prognosis of surgical treatment for CHD (open heart surgery) is poor when 
surgery is performed before complete recovery from RSV infection [4].
31.3  Respiratory Pathophysiology and Severe RSV Infection 
in Infants with CHD
CHD is classified into two main classes: left-to-right shunt lesion associated with 
congestive heart failure and right-to-left shunt lesion associated with cyanosis. In 
both types of CHD, infants typically have the respiratory pathophysiological 
changes which may predispose to severe RSV infection [5].
Normal respiratory function in normal infants features sufficient tidal volume, 
pulmonary compliance, and airway resistance. It is known that RSV infection 
decreases alveolar liquid clearance and pulmonary compliance by injuring alveolar 
epithelial cells and inducing inflammatory edema of tissues surrounding the periph-
eral pulmonary arteries. Bronchiolitis due to RSV infection causes airway obstruc-
tion with increase in airway resistance as well. These changes result in decrease in 
tidal volume and increase in imbalance of ventilation and blood flow (V/Q mis-
match), which promote hypoxemia and hypercapnia.
In cases of CHD with a left-to-right shunt such as ventricular septal defect and 
patent ductus arteriosus, increases in pulmonary capillary wedge pressure and left 
atrial pressure due to the increase in pulmonary blood flow are observed, and pul-
monary hypertension may occur in some cases. Due to the presence of extravasation 
of fluid resulting from increased blood flow and pressure in the pulmonary vessels, 
the excessive fluid leaking into interstitial tissues tends to flow into the alveoli. In 
cases of significant pulmonary congestion, decrease in pulmonary compliance and 
increase in airway resistance due to compression of the airways by surrounding 
dilated vessels may occur, resulting in increase in respiratory rate. When children 
with such underlying conditions contract RSV infection, alveolar liquid compliance 
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and lung compliance will be further decreased, and airway resistance will rapidly 
increase. As a result, lung tissue swelling and pulmonary edema may develop with 
decrease in functional residual capacity and rapid deterioration of V/Q mismatch, 
and severe respiratory signs/symptoms may occur. RSV infection may become par-
ticularly serious in children with pulmonary hypertension, who must thus be moni-
tored carefully.
On the other hand, in cases of CHD with right-to-left shunt and decrease in pul-
monary blood flow such as the tetralogy of Fallot, cyanosis and hypoxemia are 
constantly present. Due to the small lung volume and underdevelopment of airways 
resulting from low pulmonary blood flow, peripheral airway resistance is high and 
lung compliance is low in such patients. Although this type of CHD is not fre-
quently associated with pulmonary edema, unlike CHD with increased pulmonary 
blood flow, RSV infection accelerates the increase in airway resistance and decrease 
in pulmonary compliance with significant deterioration of cyanosis and hypoxemia 
and development of severe respiratory signs and symptoms.
In cases of complex heart disease such as complete transposition of the great 
arteries and hypoplastic left heart syndrome, which are characterized by increase in 
pulmonary blood flow and hypoxemia, mixtures of the above-described pathophysi-
ological conditions are present, and RSV infection induces clinical deterioration.
31.4  Prevention of RSV Infection in Infants with CHD
To date, no specific treatment for RSV infection has been established. Therefore, 
prevention of RSV infection is essential in the management of infants with CHD.
In our hospital, infants and young children ≤3 years of age are usually hospital-
ized in the infant ward (a large room) with full nursing service. In the infant ward, 
standard infection control procedures including hand washing when entering and 
leaving the ward, hand disinfection before and after examining each patient, wear-
ing a gown specific to each patient, and use of a stethoscope specific to each patient 
are strictly adhered to. Since many children hospitalized in the infant ward have 
CHD and/or CLD and are at high risk for severe RSV infection, all children to be 
hospitalized in the infant ward are subjected to a rapid RSV antigen test in the 
ambulatory setting on the day of hospitalization during RSV infection is prevalent. 
Children with a positive test for RSV antigen are not allowed to enter the infant 
ward and are hospitalized in a private room or referred to other hospitals. The first 
step to preventing RSV infection in infants with CHD is preventing sources of 
infection from entering the infant ward.
When signs/symptoms of respiratory infection develop in patients hospitalized 
in the infant ward especially during the period of prevalent RSV infection, they are 
subjected to a rapid RSV antigen test to detect RSV infection as early as possible. 
Children with mild RSV infection (a positive RSV antigen test) who do not require 
ventilation or intensive care are transferred to private rooms with prior consent 
while children with severe RSV infection requiring ventilation and/or intensive 
care, who are difficult to care for in private rooms, enter the infant ICU with the 
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following measures taken to avoid transmission of RSV infection. Each infected 
child’s bed is surrounded by portable partitions with metal frames and transparent 
plastic panels to separate the child from others and avoid droplet infection in the 
crowded infant ward, which features small distances between beds. In addition, a 
hand washer and a specific door to the infant ward are used only by healthcare pro-
fessionals and visitors who care for children with RSV infection to ensure separa-
tion of them in the infant ward. Children with RSV infection are attended only by 
designated nurses who do not attend other children.
Education of staff members is essential to ensuring appropriate infection control 
measures. In the CDC’s guidelines, education of hospital staff is rated as Category 
IA [6]. In our hospital, an infection control section regularly provides “pediatric 
infection control seminars” by pediatric infection specialists in order to increase 
awareness of infection control.
31.5  The Use of Palivizumab in Infants with CHD
A humanized monoclonal antibody specific to RSV (palivizumab, Synagis®) was 
developed and released. Palivizumab is an antibody specific to the antigenic region 
of the F protein of RSV, neutralizes the infectivity of RSV, inhibits amplification 
and growth of RSV, and thereby prevents the onset of severe lower respiratory tract 
disease.
From 1998 to 2002, a multicenter clinical study of palivizumab in CHD patients 
was conducted in Europe and the United States. A total of 1, 287 children were 
randomized and allocated to a palivizumab group (639 children) or placebo group 
(648 children). The rate of hospitalization due to RSV infection was decreased by 
45% in the palivizumab group (9.7% in the placebo group vs. 5.3% in the palivi-
zumab group; p  =  0.03) [7]. Palivizumab was administered intramuscularly at a 
dose of 15 mg/kg body weight every month throughout the RSV season.
In October 2005, palivizumab was approved for infants with CHD by the 
National Health Insurance in Japan, and Japanese guidelines for the use of palivi-
zumab in infants with CHD was prepared [8]. Since palivizumab does not affect the 
efficacy of vaccinations, treatment with it can be continued without changing vac-
cination schedules. Even if RSV infection develops during treatment with palivi-
zumab, palivizumab should continue to be administered thereafter during the RSV 
season since reinfection with RSV causing serious disease may occur during the 
same season.
31.6  Conclusions and Future Perspectives
Cox et  al. noted that “conventional infection control measures failed to prevent 
spread of RSV infection, and palivizumab could prevent occurrence of nosocomial 
RSV infections” [9]. We believe that performance of standard infection control 
measures considering the mode of transmission of RSV and education of hospital 
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staff are important steps in preventing RSV infection in children with CHD. Efforts 
to detect sources of infection as early as possible and use of preventive treatment 
with palivizumab are also essential.
It has been generally accepted that palivizumab should be administered from 
September–October to March–April in Japan. However, a child with a positive RSV 
antigen test is recently often observed in May, July, and August. Duration of palivi-
zumab treatment should thus be modified based on the prevalence of RSV infection 
in the relevant geographical area and trends in the incidence of RSV infection in 
each year. It is preferable that serum palivizumab concentration be high enough to 
ensure prevention of RSV infection. Physicians should also consider whether to 
perform additional administration of palivizumab after surgery using cardiopulmo-
nary bypass, which is known to decrease serum palivizumab concentration. 
Although no serious adverse events related to treatment with palivizumab have been 
reported, monitoring should be continued to ensure the safety of palivizumab treat-
ment in each year.
References
 1. Kaneko M, Watanabe J, Kuwahara M, et al. Impact of respiratory syncytial virus infection as 
a cause of lower respiratory tract infection in children younger than 3 years of age in Japan. J 
Infect. 2002;44:240–3.
 2. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial 
virus infection among children in Medicaid. J Pediatr. 2000;137:865–70.
 3. Navas L, Wang E, de Carvalho V, Robinson J. Pediatric Investigators Collaborative Network on 
Infections in Canada; Improved outcome of respiratory syncytial virus infection in a high-risk 
hospitalized population of Canadian children. J Pediatr. 1992;121:348–54.
 4. Khongphatthanayothin A, Wong PC, Samara Y, et  al. Impact of respiratory syncytial virus 
infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care 
Med. 1999;27:1974–81.
 5. MacDonald NE, et  al. Respiratory syncytial viral infection in infants with congenital heart 
disease. N Engl J Med. 1982;307:397–400.
 6. Greenough A. Respiratory syncytial virus infection; clinical features, management, and pro-
phylaxis. Curr Opin Pulm Med. 2002;8:214–7.
 7. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization 
due to respiratory syncytial virus in young children with hemodynamically significant congeni-
tal heart disease. J Pediatr. 2003;143:532–40.
 8. Nakazawa M, Saji T, Ichida F, et al. Guideline for the use of palivizumab in infants and young 
children with congenital heart disease. Pediatr Int. 2006;48:190–3.
 9. Cox RA, Rao P, Brandon-Cox C, et al. The use of palivizumab monoclonal antibody to control 
an outbreak of nosocomial respiratory syncytial virus infection in a special care baby unit. J 
Hosp Infect. 2001;48:186–92.
31 Respiratory Syncytial Virus Infection in Infants with Heart and Lung Diseases
220
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter's Creative Commons license and your intended use is not permitted by 





Bridge Over Troubled Vessels
223© The Editor(s) (if applicable) and The Author(s) 2020
T. Nakanishi et al. (eds.), Molecular Mechanism of Congenital Heart Disease  
and Pulmonary Hypertension, https://doi.org/10.1007/978-981-15-1185-1_32
T. Nakanishi (*) 




The ductus arteriosus (DA) is open before birth and normally closes after birth. The 
unique anatomy and normal and abnormal behavior of the DA are discussed by 
Gittenberger, Shelton, and Sterren in this chapter.
The DA sometimes closes before birth or does not close after birth; both situations 
cause problems. Normally only 10–20% of right ventricular output goes to the lung 
and the rest goes to the aorta though DA during fetal life. If the DA closes before birth, 
right ventricular afterload increases because the right ventricle has to eject blood to 
the lung, which has high pulmonary arterial resistance. Early closure of the DA may 
result in right ventricular hypertrophy and somehow left ventricular dilatation [1].
If the DA does not close after birth, left (aorta) to right (pulmonary artery) shunt 
occurs, resulting in patent DA.  In congenital heart diseases with severe outflow 
stenosis or atresia to the pulmonary artery, pulmonary circulation is dependent on 
the DA from the aorta. In hypoplastic left heart syndrome, systemic circulation is 
dependent on the DA from the pulmonary artery. Thus, the DA is clinically an 
important bridge over troubled vessels.
The precise mechanisms for the DA closure after birth remain unclear. The trigger 
for the DA closure is most likely O2, but how O2 causes DA closure has not been clari-
fied. We [2] reported that ATP-sensitive K channel (KATP) might be an O2 sensor, which 
causes DA closure based on in vitro experiments. Momma et al. also report in this sym-
posium that inhibition of KATP results in closure of DA in in vivo experiments. The 
group of Archer, however, reported that voltage-dependent K channels (Kv) might be an 
O2 sensor [3, 4]. They suggest that Kv channels close in the DA, resulting in DA closure, 
and open in the pulmonary artery, resulting in pulmonary artery dilation, in response to 
O2 and reactive oxygen species produced in mitochondria.
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In addition to O2, prostaglandin E plays an important role in opening DA before 
birth and closure of DA after birth. Prostaglandin E concentration in the neonatal 
blood decreases after birth, facilitating DA closure. Furthermore, Yokoyama et al. 
[5, 6] have shown that prostaglandin E and its receptor EP4 promote neointimal 
formation during fetal life and inhibit elastic fiber formation, preparing DA closure 
after birth.
The DA is such an important and interesting vessel. Further investigation of the 
O2 sensor in the DA is necessary because the O2 sensor is biologically important not 
only in the DA but also in other vessels such as the pulmonary artery. Basic research 
regarding arterial elastogenesis could be expanded to the aorta in which the elastic 
fiber is disrupted in some patients with tetralogy of Fallot [7].
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The muscular ductus arteriosus (DA) has many unique characteristics setting it 
apart from the adjoining elastic arteries. Preparation for neonatal closure takes 
place in utero with the development of intimal thickening. Ductus-specific gene 
and protein expression patterns were demonstrated during this process. We pos-
tulated that the closing process, with increased expression of progerin, might 
reflect aspects of premature ageing. Persistent patency of the DA, can be con-
genitally or immaturity based. During embryonic development the sixth pharyn-
geal arch arteries are the last to develop. In avian embryos this arch is divided 
into a proximal (part of the future pulmonary artery) and a distal part (on the left 
side the origin of the DA). The consequence is that the pulmonary arteries have 
a double vascular contribution being a proximal sixth arch artery component and 
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a distal true pulmonary artery segment. We have conclusive evidence that this is 
not encountered in the human embryo. Both sixth arch arteries and the right and 
left pulmonary arteries connect separately and at distinct locations to the pulmo-
nary trunk side of the aortic sac. The insertion of the wall of the DA between the 
proximal and distal part of the left pulmonary artery, referred to as pulmonary 
coarctation, constitutes a congenital malformation and not a remnant of what is 
encountered during normal development. This configuration is found almost 
exclusively in combination with pulmonary atresia leading to neonatal interrup-
tion of the proximal left pulmonary artery with consequences for surgical or 
intervention repair.
Keywords
Vascular development · Patent ductus arteriosus · Persistent ductus arteriosus · 
Congenital heart disease · Pulmonary atresia · Pulmonary ductal coarctation · 
Juxtaductal pulmonary coarctation 
33.1 The Normal Closing Ductus Arteriosus
The DA is a functional shunt before birth, directing oxygen-rich blood to the sys-
temic circulation, bypassing the pulmonary circulation. Perinatally, the DA shows a 
physiological contraction followed by anatomical closure after birth. Eventually the 
closed DA is remodeled into a fibrous strand, the ligamentum arteriosum [1]. The 
characteristics of the muscular DA are reflected in its histological make-up, setting 
it apart from the elastic adjoining arteries [2]. Around 17 weeks of human gestation 
there is the start of formation of typical intimal thickenings (cushions). The first 
indication is the subendothelial appearance of hyaluronic acid and detachment of 
the endothelium [3]. The process of hyaluronic acid production continues during 
ductal maturation and even after birth [4]. In the second half of gestation the matu-
ration process progresses and marked intimal thickenings develop containing 
media-derived synthetic smooth muscle cells and fine elastin fibers [5]. 
Accompanying the first physiological contractions the DA develops degeneration of 
the inner media, showing apoptosis and extracellular matrix filled mucoid lakes [5]. 
A recent study shows that this process is accompanied by a different lamin A/C to 
progerin balance. Progerin, an indicator of vascular ageing, is increased in the 
mature DA [6]. This observation has lead us to postulate that a process akin to pre-
mature ageing might accompany postnatal ductal closure [6]. In Fig. 33.1, sche-
matic and correlating histological features of the DA are presented.
More advanced methodology has allowed to shift focus to the unique gene and 
protein profiles of the DA.  The data derive from DNA microarray profiling [7], 
transcriptional profiles [8] and gene profiling after single-cell microcapture isola-
tion [9]. These studies unravel pieces of the puzzle underlying DA closure and mat-
uration. Results show that the important relaxing factor, PGE2, inhibits elastogenesis, 
clarifying the muscular nature of the DA [10]. Furthermore the endothelin receptor 
EP4 promotes hyaluronic acid–induced intimal thickening [4].
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With increased information, showing the distinct characteristics of smooth mus-
cle and endothelial cells (Fig. 33.2) we gain insight into the pathological and delayed 
DA closure.
33.2 Persistent Patency Versus Delayed Closure of the DA
Several causes lead to a non-adequate to non-closure of the DA. The most common 
cause is delayed closure after premature birth because of immaturity of the ductal 
wall [5]. A different cause for ductal patency is a structural wall abnormality inhibit-
ing anatomical closing. We have described that a DA with an additional and marked 
subendothelial elastic lamina (Fig. 33.1) is not capable of permanent anatomical 
closure [2]. As this anomaly can only be detected by histology, it poses a problem 
to differentiate it clinically from delayed closure. Very little is known about the 
genetic or environmental background of persistent DA. A few genes have been dis-
covered like the TFAP2B gene mutation [11] that lead to persistent patency.
33.3  Normal Sixth Pharyngeal Arch Formation 
and Connections to the Surrounding Arteries
During development, pharyngeal arch arteries connect the aortic sac bilaterally to the 
dorsal aortae. The sixth arch, important for DA and pulmonary artery formation, has a 
separate status [12]. In various animal species it has been described that the putative left 
and right pulmonary arteries connect end to side to the sixth pharyngeal arch artery 
[13]. We have shown in quail embryos that this connection results from ingrowth of the 
pulmonary sprout into the sixth arch artery opposed to an outgrowth towards the lung 
mesenchyme [12]. This implies that the proximal part of the sixth arch artery forms the 
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Fig. 33.2 Relative gene expression levels of Rgs5 and Tfap2B after microarray and quantitative 
RT-PCR, showing the differences between endothelial cells (EC: red) and smooth muscle cells 
(SMC: green) in aorta (Ao) and ductus arteriosus (DA) (Modified after [9])
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characteristic DA structure. This necessitates a major remodeling process to achieve 
the mature situation in the human fetus and neonate in which the DA and left and right 
pulmonary arteries have a distinct connection site with the pulmonary trunk (Fig. 33.3). 
Investigation of human embryos, before 6 weeks of age, revealed that the ingrowth of 
the pulmonary arteries together with the proximal part of the sixth arch is incorporated 
into the pulmonary side of the aortic sac. Thus the distal part of the left-sided sixth 
pharyngeal artery develops into the left-sided DA. The distal right-sided sixth arch 
disappears together with the distal part of the right-sided dorsal aorta early in develop-
ment by selective apoptosis [14]. These observations in the human embryo are relevant 
for understanding some forms of congenital heart disease and related complications.
33.4  Pulmonary Coarctation (PC) and Proximal Left 
Pulmonary Artery Interruption
DA problems can exist in right heart congenital heart disease with narrowing to 
atresia of the right ventricular outflow tract and hypoplasia of the pulmonary trunk. 
The most extreme is complete absence of the DA with the question whether a sixth 






















Fig. 33.3 (a) Schematic configuration of end-to-side ingrowth of pulmonary sprout (ppa) between 
the proximal (p) and distal (d) part of the sixth arch artery (VI). (b) Situation as encountered in a 6 
week human embryo with right (RPA) and left (LPA) arteries connecting to the aortic sac (AS). (c) 
Normal neonatal situation with distinct connections of RPA, LPA and ductus arteriosus (DA) to the 
pulmonary trunk (PT). (d) Pulmonary coarctation (PC) in a case of pulmonary atresia. Ascending 
aorta (aAo), descending aorta (dAo), fourth arch artery (IV)
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mild pulmonary stenosis towards complete atresia the DA became hypoplastic to 
atretic. In the most severe cases major aorto-pulmonary collateral arteries (MAPCAs) 
developed [15]. We published data on a set of human neonatal specimens with vari-
ous degrees of pulmonary stenosis and atresia that had developed a PC [16]. We 
assumed that this anomaly mimicked the aortic coarctation in which DA tissue 
extends within the inner circumference of the aortic arch in which the roof of the 
coarctation always consisted of elastic aorta tissue (Fig. 33.2). More recent observa-
tions showed that PDC could lead to a complete obstruction of the proximal left 
pulmonary artery. DA tissue was, however, not only observed on the inside lining of 
the pulmonary artery but could completely encircle the lumen [17], being thus inter-
posed between the proximal and distal part of the left pulmonary artery. Progressive 
narrowing by DA tissue could result in left pulmonary artery interruption. We con-
cluded that a more left lateral insertion of the DA into the left pulmonary artery is 
not a normal position but a congenital anomaly. Reversed hemodynamics through 
the DA might play a secondary role as cause for PC.
33.5 Future Directions and Clinical Implications
 – Is PC exclusively linked to anomalies with pulmonary atresia or can it also be 
associated with less severe obstructions of the right ventricular outflow tract and 
pulmonary valve?
 – Is there a link to the 22q11 deletion syndrome and thus to mutations within the 
second heart field and its interaction with neural crest cells?
 – A clinical implication of the complete encircling of the DA tissue of the left 
pulmonary artery is that by surgical restoration of the left pulmonary artery it 
should be aimed to completely excise the DA tissue or completely stent the 
DA-infested region.
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34Molecular, Genetic, and Pharmacological Modulation of the Ductus Arteriosus: 
KATP Channels as Novel Drug Targets
Elaine L. Shelton and Jerod S. Denton
Abstract
Maintaining fetal patency and facilitating neonatal closure of the ductus arterio-
sus are complex processes that involve nuanced developmental programing and 
a precise balance of perinatal vasodilators and constrictors. Work over the past 
40 years has identified “master regulators” of ductus tone, namely oxygen, pros-
taglandins, and nitric oxide signaling. Yet, prolonged neonatal patency of the 
ductus remains a significant clinical problem with limited therapeutic options. 
Understanding the molecular and genetic underpinnings of normal ductus func-
tion and PDA pathophysiology will facilitate the development of new therapeutic 
strategies to regulate ductus tone.
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34.1  Introduction
The ductus arteriosus (DA) is an essential fetal vessel connecting the main pulmo-
nary artery and aorta. In utero, high pulmonary vascular resistance coupled with 
relatively low systemic resistance promotes right-to-left blood flow through the DA, 
allowing blood oxygenated by the placenta to bypass the developing lungs [1, 2]. 
Soon after birth, the DA must close in order to facilitate proper perfusion of the 
newly inflated lungs, a process normally complete by 12–48  h in full-term 
neonates.
In some cases, the DA fails to close after birth, a condition termed patent ductus 
arteriosus (PDA). PDA is a common congenital heart defect, occurring in up to 80% 
of premature infants weighing <1000 g [3]. Several comorbidities including neuro-
developmental impairment, intraventricular hemorrhage, pulmonary hemorrhage, 
respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocoli-
tis, and spontaneous intestinal perforation have been attributed to or associated with 
prolonged patency of the DA [4]. In contrast, keeping the DA open to preserve 
pulmonary or systemic circulation is essential in certain cardiovascular conditions 
where blood flow to the lungs or body is disrupted [5]. Unfortunately, there are 
surprisingly few therapies currently available to promote DA closure or maintain 
vessel patency. Pharmacology-based therapeutics are non-specific and relatively 
inefficient. While surgical ligation, catheter-based closure, and stent implantation 
are effective alternatives, these mechanical approaches come with their own risks 
and are sometimes limited by the anatomical size constraints of extremely prema-
ture newborns [6].
34.2  Molecular Regulation of the DA
The fetal DA has intrinsic tone and requires factors to maintain its patency in 
utero (summarized in Table 34.1) [2, 7, 8]. While nitric oxide (NO) and prosta-
glandin E2 (PGE2) are typically considered the primary mediators of DA dilation, 
other factors clearly play a role. Potassium (K+) channels are well-characterized 
Table 34.1 Molecular regulators of DA tone
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DA dilators. Voltage-gated K+ channels, large-conductance voltage-dependent 
and calcium- activated K+ (BKCa) channels, and ATP-gated K+ (KATP) channels are 
all specifically enriched in the DA compared to other vascular beds [9]. KATP chan-
nels are hetero- octameric complexes of pore-forming inward rectifier K+ channel 
subunits (Kir6.1 or Kir6.2) and regulatory sulfonylurea receptor subunits (SUR1, 
SUR2a, or SUR2b) [10]. Different combinations of these subunits are expressed 
in a tissue-specific manner and exhibit different pharmacological properties, 
thereby making them attractive targets for DA-specific therapies. This notion is 
supported by animal studies demonstrating that activating or inhibiting KATP chan-
nels directly modulates DA tone [11, 12].
While nitric oxide (NO) and prostaglandin E2 (PGE2) are typically considered 
the primary mediators of DA dilation, other factors clearly play a role. Potassium 
(K+) channels are well-characterized DA dilators. Voltage-gated K+ channels, large- 
conductance voltage-dependent and calcium-activated K+ (BKCa) channels, and 
ATP-gated K+ (KATP) channels are all specifically enriched in the DA compared to 
other vascular beds [9]. KATP channels are hetero-octameric complexes of pore- 
forming inward rectifier K+ channel subunits (Kir6.1 or Kir6.2) and regulatory sul-
fonylurea receptor subunits (SUR1, SUR2a, or SUR2b) [10]. Different combinations 
of these subunits are expressed in a tissue specific manner and exhibit different 
pharmacological properties, thereby making them attractive targets for DA-specific 
therapies. This notion is supported by animal studies demonstrating that activating 
or inhibiting KATP channels directly modulates DA tone [11, 12].
At birth, the DA constricts in response to a sharp increase in oxygen (O2) tension 
coupled with a loss of vasodilators. Several mechanisms have been proposed to 
explain the DA’s unique ability to sense and respond to O2. These include cyto-
chrome P450-mediated induction of endothelin 1 and production of “constrictor” 
isoprostanes (8-iso-PGF2α), and mitochondrial-mediated reactive oxygen species 
inhibition of Kv1.5 and Kv2.1 [8]. O2 can also inhibit KATP channels resulting in 
membrane depolarization, activation of voltage-dependent calcium (Ca2+) channels, 
and increased intracellular Ca2+ accumulation [12]. Other factors known to regulate 
DA contraction are listed in Table 34.1 [2, 6–8]. While it is clear that multiple mech-
anisms are involved, all pathways eventually converge on Ca2+-mediated phosphor-
ylation of myosin light chain, leading to actin/myosin interaction and ultimately DA 
smooth muscle cell contraction [2, 8].
34.3  Genetic Regulation of the DA
While occurring most often in the setting of prematurity, twin studies gave the first 
indication that PDA has a genetic component [6]. Several mouse models of PDA 
have been created and are summarized in Table 34.2 [6–8]. Not surprisingly, many 
of these models result from disruption of genes involved in smooth muscle function 
or prostaglandin signaling.
Syndromes featuring PDA (Table 34.2) can also be informative regarding genetic 
regulation of DA development and function [6, 13]. For instance, clinically 
34 Molecular, Genetic, and Pharmacological Modulation of the Ductus Arteriosus…
238
significant PDA occurs in 50% of patients with Cantu syndrome, a condition caused 
by gain-of-function mutations in KATP channel genes, KCNJ8 and ABCC9, which 
encode the vascular-specific KATP channel subtype Kir6.1/SUR2B. In these cases, 
PDA is resistant to indomethacin therapy and often requires surgical ligation to 
achieve closure [14].
While only 10% of PDA cases are associated with chromosomal abnormalities 
[7], identifying single-nucleotide polymorphisms (SNPs) associated with non- 
syndromic PDA may be more informative regarding the more common sporadic 
cases of PDA (Table 34.2). Variants in TFAP2β, TRAF1 (TNF receptor-associated 
factor 1), and AGTR1 (Angiotensin II type 1 receptor) were associated with an 
increased risk of PDA while SNPs in PTGIS (prostaglandin I2 synthase), ESR1 
(estrogen receptor-α), and IFN-γ (interferon-γ) were found to be protective [6]. 
Unfortunately, replicating many of these findings in other cohorts has proved diffi-
cult to this point [15].
34.4  Pharmacological Regulation of the DA
Only three drugs are currently available to treat PDA (indomethacin, ibuprofen, and 
acetaminophen). All are non-selective cyclooxygenase inhibitors that suppress 
prostaglandin signaling. Alternately, infusion of prostaglandin E1 (PGE1) is the only 
pharmacologic option used to maintain DA patency in cases of ductus-dependent 
congenital heart defects. None of these therapies specifically target the DA, leading 
to off-target effects on other vascular beds. Furthermore, indomethacin and ibupro-
fen have been associated with spontaneous intestinal perforation and necrotizing 
Table 34.2 Genetic regulators of DA tone







































E. L. Shelton and J. S. Denton
239
enterocolitis while PGE1 has been associated with apnea, fever, and other physio-
logic disturbances [16, 17].
The fetal DA can also be affected by drugs administered to pregnant women 
(summarized in Table 34.3). Use of tocolytics, ACE inhibitors, antihistamines, anti-
convulsants, amphetamines, and alcohol during pregnancy have all been associated 
with PDA [18]. In contrast, maternal use of NSAID pain-relievers and antidepres-
sants can cause fetal DA constriction [18, 19].
Furthermore, drugs commonly administered to neonates often have vasoactive 
properties and may inadvertently affect postnatal DA closure [18]. Several drugs 
have been shown to specifically dilate the DA or cause resistance to indomethacin 
therapy (Table 34.3). Of note, DA reopening has been reported after exposure to 
diazoxide, a KATP channel activator used to treat neonatal hyperinsulinism [20].
34.5  Clinical Implications and Future Directions
PDA remains a significant problem that is inefficiently managed with currently 
available therapies. Therefore, a greater emphasis must be placed on identifying 
other factors that can be targeted to regulate DA tone.
The identification of drug targets outside of the prostaglandin pathway is 
informed by the molecular findings, mouse models of PDA, and human genetic 
studies mentioned above. While these provide several pathways that could be tar-
geted therapeutically, one with a high likelihood of success is KATP channels. The 
vascular form of KATP channels (i.e., Kir6.1/SUR2B) is enriched in smooth muscle 
cells of the DA [9, 21] making it a promising target for developing DA-preferring 
dilators and constrictors. Advances in molecular target-based high-throughput 
screening of large compound libraries have enabled the ability to discover small 
molecules that target specific KATP channel subtypes [22]. We recently performed a 
thallium flux-based high-throughput screen of compounds for modulators of Kir6.1/
SUR2 and identified several novel-scaffold inhibitors of this channel (Denton, 
Table 34.3 Pharmacological regulators of DA tone
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unpublished data). The most potent inhibitor, termed VU278, exhibited preferential 
activity toward the vascular form of KATP channels (Kir6.1/SUR2) over the pancre-
atic beta/neuronal cell form (i.e. Kir6.2/SUR1). Using isolated vessel pressure 
myography assays, we evaluated the specificity and vasoactive potential of these 
drugs (Fig. 34.1). Fetal mouse DAs were exposed to increasing concentrations of 
glibenclamide (non-specific sulfonylurea receptor inhibitor), VU063 (pancreatic/
neuronal Kir6.2/SUR1 activator) [22], or VU278 (vascular Kir6.1/SUR2 inhibitor). 
As expected, glibenclamide constricted the DA in a dose-dependent manner. 
Importantly, VU063 had no effect on the DA while VU278 induced constriction.
In conclusion, an emerging body of genetic, physiological, and pharmacological 
evidence paints a bright future for the treatment of PDA. Developing a comprehen-
sive understanding of the molecular mechanisms and signaling pathways that regu-
late DA patency, coupled with focused efforts to develop specific pharmacological 
modulators of these new targets, is creating unprecedented opportunities for improv-
ing PDA outcomes. Among several potential drug targets emerging from these stud-
ies, vascular-specific Kir6.1/SUR2 channels hold significant promise due to their 
enriched expression in the DA and unique pharmacological properties. Ongoing 
efforts by our laboratories will explore the therapeutic potential of Kir6.1/SUR2B 
channels in regulating DA patency.
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35New Mediators in the Biology of the Ductus Arteriosus: Lessons 
from the Chicken Embryo
Saskia van der Sterren, Riazudin Mohammed, 
and Eduardo Villamor
Abstract
The chicken embryo is an ideal model for the study of new hypotheses on the 
developmental biology of ductus arteriosus (DA). A unique characteristic of 
chicken DA is that it is the result of the fusion of two vessels with different 
embryological origins, morphologies, and functionalities. The pulmonary side 
(PulmDA) consists almost exclusively of neural crest-derived cells, shows the 
structure of a muscular artery, and responds to O2 with contraction whereas the 
aortic part is of mesodermal origin, shows the morphology of an elastic artery 
and relaxes in response to O2. In addition the two parts of the DA show marked 
differences in responsiveness to other contractile and relaxant agents.
In mammals, the most accepted model of O2-induced DA constriction involves 
a rise in O2 modulating the function of the mitochondrial electron transport chain 
(the sensor), leading to an increased production of H2O2 (the mediator) that 
causes the inhibition of KV channels (the effector) with Rho kinase acting as 
another downstream effector of the O2-sensing system in the DA. In the chicken 
embryo, we verified the very same pathway, proving a conserved mechanism for 
O2 sensing/signaling in mammalian and nonmammalian DA. Moreover, we dem-
onstrated a developmentally regulated response to O2, which is restricted to the 
mature PulmDA and involves parallel maturation of the three components: sen-
sor, mediator, and effectors. Besides O2, we used the chicken embryo model to 
investigate the possible ductal effects of vasoactive mediators such as ceramide, 
H2S, isoprostanes, or platelet-derived vasoactive mediators.
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35.1  The Chicken Embryo as a Model for Ductus Arteriosus’ 
Developmental Biology
Several mammalian models have helped to unravel the biology and pathobiology of the 
ductus arteriosus (DA) and to understand the factors responsible for its closure or 
patency after birth. However, these models are technically complex and experimental 
manipulations affect both the mother and the fetus [1, 2]. Therefore, there is a need for 
additional models, addressing these limitations. In the last years, the chicken embryo 
has emerged as a suitable model for the study of DA vascular biology [3–15].
A unique characteristic of chicken DA is that it is the result of the fusion of two 
vessels with different embryological origins, morphologies, and functionalities [1, 
3, 6, 7]. The pulmonary side (PulmDA) consists almost exclusively of neural crest- 
derived cells, shows the structure of a muscular artery, and responds to O2 with 
contraction whereas the aortic part (AoDA) is of mesodermal origin, shows the 
morphology of an elastic artery and relaxes in response to O2 [1, 3, 6, 7]. The two 
parts of the DA show marked differences in responsiveness not only to O2 but to 
other contractile and relaxant agents as well [4, 5]. These differences are summa-
rized in Table 35.1. Another advantage of the chicken DA model is that we have an 
exhaustive developmental calendar. The developmental changes in PulmDA respon-
siveness to contractile and relaxant agents are summarized in Table 35.2.
Table 35.1 Effect of vasoactive mediators in the pulmonary (PulmDA) and the aortic (AoDA) 
side of chicken DA
Vasoactive agent Nature or mechanism of action
Effect in 
PulmDA Effect in AoDA Ref.
Oxygen Gaseous mediator Contraction ≠ Relaxation [3]
KCl Depolarizing agent Contraction < Contraction [3]
PGE2 Prostaglandin Contractiona > Contraction [4]
Norepinephrine Adrenoceptor agonist Contraction > Contraction [3]
U46619 TP receptor agonist Contraction > Contraction [3]
Isoproterenol β-Adrenoceptor agonist Relaxation > Relaxation [4]
Forskolin Adenylyl cyclase activator Relaxation > Relaxation [4]
Milrinone Phosphodiesterase-3 inhibitor Relaxation > Relaxation [4]
Acetylcholine Muscarinic agonist Relaxationb < Relaxation [5]
SNP NO-donor Relaxation < Relaxation [5]
BAY 41-2272 sGC stimulator Relaxation < Relaxation [5]
CO2 Gaseous mediator Relaxation = Relaxation [8]
15-E2t-IsoP Isoprostane Contraction > Contraction [14]
15-F2t-IsoP Isoprostane Contraction > Contraction [14]
H2O2 Reactive oxygen species Contraction ≠ Relaxation [6]
Hydroxyfasudil Rho-kinase inhibitor Relaxation = Relaxation [6]
Y27632 Rho-kinase inhibitor Relaxation = Relaxation [6]
CO Gaseous mediator Relaxation = Relaxation [13]
H2S Gaseous mediator Relaxation = Relaxation [13]
17α-estradiol Estrogen hormone Relaxation = Relaxation [15]
17β-estradiol Estrogen hormone Relaxation = Relaxation [15]
Ceramide Membrane sphingolipid Contraction ≠ Relaxation [9]
Serotonin Amine Contraction > Contraction [16]
Thrombin Protease Contraction > Contraction [18]
aIn the presence of TP receptor blockade, PGE2 evokes relaxation
bConcentrations >3 μM of acetylcholine evoke contraction
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35.2  Oxygen Sensing and Signaling in the Chicken DA
In mammals, the most accepted model of O2-induced DA constriction involves a 
rise in O2 modulating the function of the mitochondrial electron transport chain (the 
sensor), leading to an increased production of H2O2 (the mediator) that causes the 
inhibition of KV channels (the effector) with Rho kinase acting as another down-
stream effector of the O2-sensing system in the DA. In the chicken embryo the very 
same pathway has been verified, proving a conserved mechanism for O2 sensing/
signaling in mammalian and nonmammalian DA [1, 6, 7]. Moreover, we demon-
strated a developmentally regulated response to O2, which is restricted to the mature 
PulmDA and involves parallel maturation of the three components: sensor, media-
tor, and effectors [6].




of action 15-day DA 19-day DA 21-day DA Ref.
Oxygen Gaseous mediator No response ≠ Contraction < Contraction [3]
KCl Depolarizing agent Contraction < Contraction < Contraction [3]
4-AP KV-channel blocker Contraction < Contraction < Contraction [3]
Norepinephrine Adrenoceptor agonist No response ≠ Contraction < Contraction [3]
Phenylephrine α-Adrenoceptor 
agonist
No response ≠ Contraction < Contraction [3]
U46619 TP receptor agonist Contraction < Contraction = Contraction [3]
Endothelin-1 Polypeptide Contraction < Contraction > Contraction [3]
ACh (≥3 μM) Muscarinic agonist Contraction < Contraction > Contraction [10]
PGE2 Prostaglandin Relaxation ≠ Contraction ≠ No response [4]
PGE2 
(+TP-blockade)
Prostaglandin Relaxation > Relaxation > Relaxation [4]
Acetylcholine 
(<3 μM)
Muscarinic agonist Relaxation > Relaxation > Relaxation [5]
SNP NO-donor Relaxation = Relaxation > Relaxation [5]
Isoproterenol β-Adrenoceptor 
agonist
Relaxation = Relaxation > Relaxation [4]
BAY 41-2272 sGC stimulator Relaxation = Relaxation = Relaxation [5]
8-Br cGMP cGMP analog Relaxation = Relaxation = Relaxation [5]
Forskolin Adenylyl cyclase 
activator
Relaxation = Relaxation = Relaxation [4]
Milrinone Phosphodiesterase-3 
inhibitor
Relaxation < Relaxation = Relaxation [4]
H2O2 ROS No response ≠ Contraction [6]
BAY K8644 Calcium-channel 
activator
No response ≠ Contraction [6]
Nifedipine Calcium-channel 
blocker
Relaxation < Relaxation [6]
Hydroxyfasudil Rho-kinase inhibitor Relaxation < Relaxation [6]
Y27632 Rho-kinase inhibitor Relaxation < Relaxation [6]
H2S Gaseous mediator Relaxation = Relaxation [13]
CO Gaseous mediator Relaxation = Relaxation [13]
15-E2t-IsoP Isoprostane Contraction < Contraction [14]
15-F2t-IsoP Isoprostane Contraction < Contraction [14]
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35.3  New Mediators in the Biology of the DA
35.3.1  Role of Ceramide in DA Oxygen Sensing and Signaling
Ceramide is synthesized from membrane sphingomyelin by sphingomyelinases 
(SMases) which are activated by multiple membrane receptors and non-receptor stim-
uli. Using the chicken model, we observed that inhibition of the ceramide- generating 
enzyme neutral SMase reduced the hypoxic vasoconstriction in the pulmonary artery 
(PA) and the normoxic contraction of the DA [9]. Moreover, ceramide content and 
H2O2 production were increased by hypoxia in PAs and by normoxia in the 
DA. Accordingly, ceramide mimicked the contractile responses of hypoxia in PAs and 
those of normoxia in the DA. In addition, ceramide inhibited Kv currents in PA and DA 
smooth muscle cells. Finally, the role of nSMase in acute oxygen sensing was con-
firmed in human PA and DA [12]. However, the mechanisms matching the putative O2 
sensor(s) (i.e., mitochondria and/or NADPH oxidase) and ceramide remain unknown.
35.3.2  Vasoactivity of H2S in the Chicken DA
Oxygen is not the only gaseous mediator with a relevant role in DA reactivity. CO2 
and non-respiratory gases, such as NO and CO, are also ductal vasoactive mediators 
[1, 16]. In the last years H2S has been identified as an endogenous gaseous transmit-
ter, playing multiple physiological roles in animal systems [13]. Furthermore, H2S 
has been proposed as a vascular O2 sensor. We have investigated the vasoactivity of 
H2S and CO in the chicken DA. We observed that either H2S or CO induces relax-
ation of chicken DA. However, this relaxation is not vessel-specific since PulmDA, 
AoDA, and chicken embryo pulmonary and femoral arteries were similarly relaxed 
by H2S and CO [13]. Moreover, the presence of precursors/inhibitors of H2S and CO 
synthesis did not significantly affect the response of the chicken DA to normoxia/
hypoxia and did not affect endothelium-dependent or -independent relaxation [13]. 
Therefore, our results indicate that the gasotransmitters H2S and CO are vasoactive 
in the chicken DA but they do not suggest an important role for endogenous H2S or 
CO in the control of chicken ductal reactivity.
35.3.3  Response of Chicken DA to Isoprostanes
Isoprostanes (IsoPs) are a unique series of prostaglandin-like compounds formed 
in vivo from the free radical-catalyzed peroxidation of arachidonic acid indepen-
dent of the cyclooxygenase enzymes [17]. Initially, IsoPs were recognized as valu-
able markers of oxidative stress and numerous pathological conditions have been 
shown to be associated with increases in urinary, plasma, and tissue levels of IsoPs. 
Later it became apparent that IsoPs exhibit significant bioactivity and could contrib-
ute to the functional consequences of oxidative stress and participate in oxygen 
signaling, particularly during the transition to extra-uterine life [17]. Surprisingly, 
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until our study, the possible vascular effects of IsoPs in the DA had not been inves-
tigated. We observed that 15-E2t-IsoP evoked a potent and efficacious, TP receptor- 
mediated, contraction in the chicken DA [18]. On the other hand, 15-F2t-IsoP is 
probably acting as a partial agonist at TP receptors. The contractile response of the 
PulmDA to IsoPs increased with development and both 15-E2t-IsoP and 15-F2t-IsoP 
were particularly efficacious in contracting the PulmDA in comparison with the 
AoDA and the femoral or the pulmonary arteries [14]. Altogether, our data suggest 
that IsoPs, acting through TP receptors, may play a role in the control of chicken DA 
tone and could participate in its closure.
35.3.4  Role of Platelet-Derived Vasoactive Mediators in DA 
Biology
Several cohort studies have shown an association between low platelet counts in the 
first day(s) of life and patent DA (PDA) in preterm infants [19]. Activated platelets 
release different substances with vasoactive properties, like serotonin, thromboxane 
A2 (TXA2), platelet activating factor, or thrombin. The two former agonists are vaso-
active in the chicken DA [10, 16]. In addition, we investigated the possible vasoactive 
effects of thrombin in the DA. Cellular effects of thrombin are mediated by protease-
activated receptors (PARs), members of the G-protein-coupled receptors that carry 
their own ligand, which remains cryptic until unmasked by proteolytic cleavage. 
PAR-1 and PAR-2 have been shown to be involved in regulating vascular tone. Our 
preliminary results indicate that thrombin, acting through PAR- 1, is a selective vaso-
constrictor in the DA of the chicken, providing the first functional evidence for a role 
of PARs in DA biology [18]. Currently, we are analyzing the expression of PARs in 
the DA of several species (human, lamb, rat, mouse, and chicken).
35.4  Future Direction and Clinical Implications
The hope for future targeted therapies and for the prevention of patent DA (PDA) 
requires knowledge of the fundamental mechanisms controlling its development 
and pathogenesis [20]. In addition, new drugs or even those that are commonly used 
in the neonatal intensive care unit may have unexpected effects on the ability of the 
DA to spontaneously close, resulting in increased risks for PDA [20]. The chicken 
DA is a feasible model to test the possible ductal effects of drugs or therapeutic 
strategies to which the infants are exposed in utero or after birth.
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36Constriction of the Ductus Arteriosus with KATP Channel Inhibitors
Kazuo Momma, Katsuaki Toyoshima, Emiko Hayama, 
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Abstract
The cause of fetal death by sulfonylureas (SUs), used for diabetes in pregnancy 
in the early 1960s, remained unsolved for decades. In 1993, Nakanishi discov-
ered constriction of ductus arteriosus (DA) strips in rabbit fetuses with gliben-
clamide, a SU and inhibitor of the KATP channel. Later, Momma showed 
dose-dependent fetal DA constriction by glibenclamide injected directly into the 
fetus in rats. Every first-generation SU constricted the fetal DA by oral adminis-
tration to the pregnant rat. DA constriction with the clinical dose of these SUs 
was mild, whereas a 100 times larger dose was needed to close the DA com-
pletely. Coadministration of SUs and cylooxygenase inhibitors caused additive 
severe constriction and complete closure of the fetal DA. These data suggested 
that the aforementioned high fetal death rate (63% in 1962) with chlorpropamide 
was due to the coadministration of this SU and aspirin-like drugs.
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36.1  Transplacental Fetal Death by Sulfonylureas
Sulfonylureas (SUs) were used for diabetes treatment in the early 1950s. In 1962, it 
was reported from South Africa that chlorpropamide, a first-generation SU (an 
inhibitor of the KATP channel) administered to diabetic pregnant women caused 63% 
fetal death rate during the latter half of gestation [1]. Fetal autopsies revealed no 
malformations and the mechanism of death remained uncertain. In 1964, a survey 
of diabetic pregnant patients in the United Kingdom confirmed the association of 
chlorpropamide and tolbutamide with fetal death. Although the mechanism of fetal 
death was unknown, the use of these SUs became contraindicated during pregnancy 
from then onward.
36.2  Closure of Fetal Ductus Arteriosus with Non-Steroidal 
Anti-Inflammatory Drugs
Aspirin was discovered in 1901. Cardiac catheterization and angiography was the 
major cardiovascular diagnostic methods in the 1960s. In 1969, the first case of trans-
placental premature fetal DA closure was reported by Arcilla [2]. In this case, a full-
term mother had severe arthritis and she took massive doses of salicylates for 11 days. 
The neonate was severely cyanotic, and cardiac catheterization and angiography at 4 h 
postpartum revealed pulmonary hypertension, atrial right-to-left shunting, and a closed 
DA at the aortic end. Since 1978, we studied fetal rat DA with a rapid whole-body 
freezing method, and we showed transplacental constriction of the fetal DA with all 50 
non-steroidal anti-inflammatory drugs (NSAIDs) [3–5] (Fig.  36.1). Experimentally, 
























Fig. 36.1 Fetal DA 
diameters following 
orogastric administration 
of non-steroidal anti- 
inflammatory drugs to the 
near-term rat. Time course 
of fetal DA constriction by 
14 mg/kg Acetoaminophen 
(black squares) and 14 mg/
kg Aspirin (white squares), 
0.7 mg/kg Indomethacin 
(black circles), and 6 mg/
kg Ibuprofen (white 
circles) to d21 pregnant 
rats (mean ± SEM)
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36.3  Constriction of Ductus Arteriosus with Glibenclamide
In 1993, Nakanishi discovered constriction of DA strips in rabbit fetuses with glib-
enclamide, a second-generation SU and inhibitor of the KATP channel. Glibenclamide 
passed into the placenta slowly [7]. Since 2012, we studied direct intraperitoneal 
injection of glibenclamide into the rat fetus and demonstrated dose-dependent DA 
constriction in the preterm and term fetus [8]. The DA constriction with the clinical 
doses was mild, and the DA inner diameter decreased to 70% in 30 min. The DA 
closed completely with a 100 times larger dose compared to the clinical dose 
(Figs. 36.2 and 36.3).
36.4  Constriction of Fetal DA with Other Sulfonylureas
Since 2010, we demonstrated transplacental constriction of the fetal DA with 
first- generation sulfonylureas in the rat model (Table 36.1). Every SU constricted 
the fetal DA mildly in 4 h after orogastric administration of the drug to the near-
term rats. The fetal DA constriction was severe, or the DA closed completely with 
100 times larger doses (Table 36.1). Rat fetuses survived with clinical doses of 
SUs with associated mild DA constriction, whereas fetal death increased with 
closure of the DA. Severe DA constriction with 100 times larger doses of SUs 
persisted up to 24 h later.
a b
Fig. 36.2 Frontal sections of the frozen rat fetus through aortic arch (Ao), ductus arteriosus (DA), 
and right and left pulmonary artery (RPA, LPA). The inner diameter of the Ao, DA, and main 
pulmonary artery (PA) were 0.8 mm, respectively. The DA/PA ratio was 1.0 in the control (a). A 
large dose (100  mg/kg, injected into the fetal abdomen) of glibenclamide constricted the DA 
severely in 30 min, the DA inner diameter diminished to 0.1 mm, and the DA/PA ratio was 0.1 (b)
36 Constriction of the Ductus Arteriosus with KATP Channel Inhibitors
254
36.5  Fetal DA Closure with Combined Administration 
of Cyclooxygenase Inhibitors and SUs
We studied the combined effects of indomethacin and glibenclamide in the fetal 
DA model (Fig. 36.4). Indomethacin (0.1, 1, and 10 mg/kg) was administered 
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a b
Fig. 36.3 Time courses of fetal DA constriction with maternal orogastric administration of chlor-
propamide (a), and those with fetal intraperitoneal injection of glibenclamide (b) in rats. Time 
course of fetal DA constriction in rats exposed to chlorpromide, 1 mg/kg (black squares), 10 mg/
kg (white squares), 100 mg/kg (black circles), and 1000 mg (white circles) (mean ± SEM)







mg/kg Route Fetal rat DA constriction
Tolbutamide 10–40 A:10
B:1000
OG Experimentally with orogastric administration to 
the mother rat, clinical doses (A) induced mild 
DA constriction and DA/PA decreased from 1.0 to 
0.9–0.7 in 3 h. Large doses (B) induced severe DA 















IP IP of clinical doses (A) induced mild DA 






First-generation SUs were administered orogastrically (OG) to the near-term pregnant rats. 
Second-generation SUs were injected intraperitoneally (IP) to the fetal rats
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administered to the fetus at 3 h, and the fetal DA was studied at 4 h. As shown 
in Fig.  36.4, indomethacin and glibenclamide constricted the DA additively. 
These data suggest that the aforementioned high fetal death rate with chlorprop-
amide was due to the additional intake of cyclooxygenase inhibitors (COX-I), 
used as analgesics and antipyretics, combined with the SU effects of KATP chan-
nel inhibition.
36.6  Early Fetal Exposure to COX-I
Fetal DA contractility in the presence of oxygen is the basic mechanism of neo-
natal DA closure. In 1986, we discovered in rat experiments the following para-
doxical phenomenon: early exposure to COX-Is impaired fetal DA contractility 
to late administration of COX-Is or oxygen, respectively [9]. The same phenom-
enon was reported in clinical patent DA in premature infants [10]. The molecu-
lar mechanism of this paradox was only clarified recently [11, 12]. We created a 
rat model with this paradox [13]: the fetal rats with exposure to large doses of 
indomethacin during the latter 30% of the total fetal gestational period showed 
much reduced DA contractility. Moreover, they showed eight times slower DA 
closure in the postpartum period. In this fetus model, DA constriction with glib-





















































Fig. 36.4 Fetal rat DA constriction in 4 h with three doses, 0.1 mg/kg (white circles), 1 mg/kg 
(white diamonds), and 10 mg/kg (white squares)、of indomethacin with orogastric administration 
to preterm rats on the 19th day (a) and to near-term rats on 21st day (b). Glibenclamide (1 mg/kg) 
was injected to the fetus intraperitoneally at 3 h after administration of indomethacin
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36.7  Effects of Massive Doses of Glibenclamide in Newborn Rat
As is shown in Fig. 36.3, glibenclamide constricted the fetal DA only mildly with 
clinical doses, and closed the DA completely with massive doses. The effects of 
massive doses of glibenclamide were studied with orogastric administration in one- 
day- old newborn rats under maternal nursing. Large doses of glibenclamide (100 mg 
and 1000 mg/kg) were well tolerated, and more than 90% of these rats survived with 
normal weight gain up to 3 weeks. Severe hypoglycemia, as low as 30 mg/dL of 
plasma glucose, developed and persisted for up to 3 days. The hypoglycemia was 
treated with large doses of orogastric glucose. Laboratory tests at 1 day after gliben-
clamide administration revealed hypoglycemia, but other parameters were normal.
36.8  Future Direction and Clinical Implications
Recent studies of cord bloods at birth in neonates of diabetic mothers with gliben-
clamide treatment revealed the presence of the drug in concentrations at about 50% 
of the maternal levels [14]. This suggests mild DA constriction and increased risk of 
premature DA closure in the fetus of mothers treated with glibenclamide. The clini-
cal application of glibenclamide to close patent DA in premature infants is difficult 
because of the associated prolonged hypoglycemia when used in large doses, and a 
decreased constrictive effect in DA with early exposure to COX-Is.
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Abstract
The ductus arteriosus (DA) must be closed after birth for the establishment of 
adult circulation. Extremely preterm infants, however, frequently have patent 
ductus arteriosus (PDA), which associates with significant morbidity and mortal-
ity. At birth, the separation of the fetus from its maternal environment constitutes 
a dramatic change for the infant. Initiation of respiration changes serum compo-
sition and oxygen tension resulting in the closure of the DA. We found that serum 
osmolality was significantly decreased early after birth in rats, and that the hypo- 
osmolality sensor transient receptor potential melastatin (TRPM) 3 had increased 
expression in the rat DA compared to the aorta. Our data suggest that a decrease 
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in serum osmolality promotes DA closure via TRPM3 and that an increase in 
osmolality dilates the DA. For extremely preterm infants, recent recommenda-
tions include immediate amino acid supplementation. We examined plasma 
amino acid composition and found an association between low glutamate con-
centration and PDA. Our data suggest that glutamate induces DA contraction 
through the AMPA receptor GluR-mediated noradrenaline production. Based on 
these data, maintaining proper levels of serum osmolality and amino acid com-
position may improve the therapeutic outcome of PDA in extremely preterm 
infants.
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37.1  Introduction
In the fetus, the ductus arteriosus (DA) diverts ventricular output away from the 
high-resistance pulmonary vascular bed into the systemic circulation. Although its 
patency is essential for fetal circulation, once pulmonary circulation is established, 
the DA must be closed.
Despite considerable progress in medical management for preterm infants, 25% 
of PDA in extremely preterm infants is still resistant to pharmacological therapies, 
i.e., cyclooxygenase inhibitors, which have been the only pharmacological thera-
peutic strategy since the mid-1970s [1–3]. Therefore, novel strategies for PDA in 
extremely preterm infants are required.
At birth, dynamic changes occur in serum components. A previous study demon-
strated that serum osmolality decreased transiently after birth, but recovered over 
the next few days in full-term human neonates [4]. However, the significance of this 
transient decrease in osmolality has never been addressed. Amino acid composition 
is also changed after birth. Amino acid administration beginning immediately after 
birth has recently been suggested [5]. However, the role of amino acids on DA regu-
lation has not been reported. Therefore, we investigated the roles of serum osmolal-
ity and amino acid composition in DA closure.
37.2  Novel Mechanisms Regulating DA Closure
37.2.1  Decreased Serum Osmolality Promotes DA Contraction
Under physiological conditions, body-fluid osmolality is tightly regulated to near 
300 mOsm/kg through the intake or excretion of water and salt [6]. Hypotonicity is 
sensed, partly, by the transient receptor potential (TRP) channels, such as TRP 
vanilloid 4 (TRPV4) [7] or TRP melastatin 3 (TRPM3) [8, 9], which acts as a Ca2+ 
channel. Because changes in intracellular Ca2+ are associated with DA contraction 
[10–12], we focused on TRP channels.
U. Yokoyama et al.
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We found that rats exhibited a similar transient hypo-osmolality after birth as in 
humans. Hypotonic stimulation induced constriction of DA rings and increased 
Ca2+ transient in DA smooth muscle cells. TRPM3 was highly expressed in the rat 
DA, and TRPM3-targeted siRNA abolished the Ca2+ response to hypo-osmolality. 
The TRPM3 stimulator, pregnenolone sulfate, induced rat DA constriction ex vivo 
and in vivo. Contrary to these findings, intra-peritoneal hypertonic fluid administra-
tion impaired rat DA closure.
In humans, neonatal serum hypo-osmolality was observed in relatively mature 
preterm infants (≥28 weeks). In extremely preterm infants (<28 weeks), however, 
this hypo-osmolality was not observed. Instead, a rapid increase in osmolality 
occurred after birth in extremely preterm infants. The degree of osmolar increase 
was greater in patients with PDA.
These data suggest that a transient decrease in serum osmolality may promote 
DA closure during the first few days of life (Fig. 37.1) [13].
37.2.2  Glutamic Acid Contributes to DA Closure
First, we analyzed amino acid composition in human neonates. Aminogram 
results in human neonates at day 2 revealed that the plasma glutamate concentra-
tion was significantly lower in extremely preterm infants (<28 weeks gestation) 
with PDA than in those without PDA and relatively mature preterm infants (28–
29 weeks gestation).
It has been shown that glutamate stimulates noradrenaline release [14, 15]. Many 
adrenergic nerve terminals were shown in the muscular walls of the human DA, and 
fluorometric results revealed the presence of noradrenaline in the human DA [16]. 
A previous report demonstrated that noradrenaline induced significant constriction 
of the DA even in the 20-week human fetus [16]. Moreover, a recent study demon-
strated that glutamate induces noradrenaline release through glutamate inotropic 
receptor alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) type 
subunit 1 (GluR1) [17]. As a result, we investigated the role of glutamate in DA 
closure.
In the rat, GluR1 mRNA was highly expressed in the DA compared to the aorta 
on gestational day 19 (preterm) and gestational day 21 (term). GluR1 proteins were 
co-localized with tyrosine hydroxylase-positive autonomic nerve terminals in the 









Fig. 37.1 Proposed diagram for the role of serum osmolality after birth. Transient decrease in 
serum osmolality induces DA contraction via TRPM3. [Ca]i: intracellular Ca2+
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noradrenaline production in the rat DA. Glutamate administration induced DA con-
traction in both preterm (gestational day 20) and term rat fetuses in vivo. Glutamate-
induced DA contraction was attenuated by the Ca2+-sensitive GluR receptor 
antagonist NASPM or the adrenergic receptor α1 blocker, prazosin.
These data suggest that glutamate induces DA contraction through GluR- 
mediated noradrenaline production (Fig. 37.2) [18].
37.3  Future Direction and Clinical Implications
PDA often causes serious problems in very premature infants, depending on the 
degree of left-to-right shunting. It has been reported that more than 50% of infants 
with birth weights <1000 g receive pharmacological therapy consisting of cyclo-
oxygenase (COX) inhibitors or surgical ligation of the DA.  Because the current 
pharmacological and surgical therapies for treating PDA are not always ideal, it is 
highly desirable to find a relatively simple and noninvasive strategy that would pre-
vent PDA from occurring.
Our study demonstrated that serum osmolality is transiently decreased after 
birth, and this decrease may be a physiological mechanism to facilitate DA contrac-
tion. The significance of this transient decrease in serum osmolality has been largely 
overlooked. It may be time to reconsider the importance of serum osmolality. 
Keeping their serum osmolality at the proper, but not elevated, level may be impor-
tant among preterm infants at risk for PDA.
Our data also suggest that glutamate promoted DA contraction in preterm infants. 
The composition of amino acid mixtures varies between commercially available 
solutions. Of note, glutamate concentration is markedly different compared to the 
other components among commercially available amino acid solutions (0.8–
10.0 g/L). Supplementation of glutamate might help to prevent PDA in extremely 
preterm infants, and the importance of amino acid composition, i.e., glutamate, may 
need to be considered in postnatal circulatory adaptation.
Acknowledgments The authors are grateful to Yuka Sawada for technical assistance. This study 
was funded by MEXT/JSPS KAKENHI (U.Y., JP17K19403, JP16H05358, JP15H05761; S.I., 
JP17K16276; J.S., JP16H07107; Y.I., JPH1605300), and the Yokohama Foundation for the 
Advancement of Medical Science (J.S.), the Japan Agency for Medical Research and Development 
(AMED) (Y.I., 66890007, 56689113), and the Kitsuen Research Foundation (Y.I., 71890005).
Glutamate




Fig. 37.2 Proposed diagram for the role of glutamate in the DA. Glutamate stimulates autonomic 
nerve terminals of the DA, resulting in noradrenaline release. This noradrenaline promotes DA 
contraction via α1 adrenergic receptor (α1 AR)
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Antenatal betamethasone (BTM) is a standard therapy to reduce respiratory distress 
syndrome [1], and some reports indicate that BTM decreases prevalence of patent 
ductus arteriosus in preterm infants [2]. Closure of the ductus arteriosus (DA) 
requires morphological remodeling, i.e., intimal thickening (IT) formation [3]. 
However, the role of BTM in IT formation of the preterm DA has not been reported.
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First, we analyzed the expression of glucocorticoid receptor (GR) in preterm and 
term DA tissues. Quantitative RT-PCR of rat DA tissues (day 19 and day 21 of ges-
tation) and immunohistochemistry of the human DA tissue (day 7, coarctation of the 
aorta) showed that GR was highly expressed in the human and rat DAs. We then 
performed DNA microarray analysis using smooth muscle cells of preterm rat DA 
(DASMCs) on day 20 of gestation stimulated with or without BTM. Among all of 
the genes detected in preterm DASMCs, the gene X was markedly increased by 
BTM stimulation, which was confirmed by quantitative RT-PCR in rat preterm 
DASMCs, but not in preterm rat aortic smooth muscle cells. A scratch assay dem-
onstrated that BTM promoted preterm DASMC migration, which was attenuated by 
the gene X-targeted siRNA.
Furthermore, we examined whether BTM increased IT formation in  vivo. 
Maternal rats were administered intravenously with BTM or normal saline (control) 
on day 18 and 19 of gestation, and fetal rat DA tissues were obtained on day 20 of 
gestation. The ratio of IT to tunica media was significantly higher in BTM treatment 
group (n = 5, p < 0.05).
In conclusion, these data suggest that antenatal BTM administration promotes IT 
of the DA through the gene X-mediated DASMC migration.
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The normal closure of the ductus arteriosus (DA) consists of two steps: vasocon-
striction and intimal thickening (IT). We have revealed that prostaglandin E2 
(PGE2)-EP4 signaling plays a critical role in IT formation via smooth muscle cell 
(SMC) migration through hyaluronic acid [1]. In this study, we found that fibulin-1 
was the most significantly up-regulated gene by EP4 stimulation in DA smooth 
muscle cells (SMCs).
It has been reported that fibulin-1 has binding domains for ADAMTS-1 (a disin-
tegrin and metalloprotease with thrombospondin motif type 1) and versican [2, 3], 
which participates in cell migration, and this fibulin-1-binding protease ADAMTS-1 
promotes versican fragmentation [4, 5]. Furthermore, coupling of fragmented versi-
can and hyaluronic acid promotes cell migration [6]. We speculated that fibulin-1 
promotes DASMC migration and induces IT of the DA with ADAMTS-1 and versi-
can. We aimed to examine the role of PGE2-EP4-signaling-mediated fibulin-1in IT 
of the DA.
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Based on the microarray analysis showing that fibulin-1 was the most increased 
gene by EP4 stimulation in DASMCs, we performed RT-PCR and confirmed similar 
findings. EP4 stimulation did not increase fibulin-1 in aortic SMCs. Protein expres-
sion of fibulin-1 was markedly increased by EP4 stimulation in DASMCs. 
Immunohistochemistry of rat DA tissues showed that fibulin-1, ADAMTS-1, and 
fragmented versican were co-localized in the area of IT. VersicanV1 mRNA expres-
sion was significantly higher in endothelial cells than in DASMCs, and ADAMTS-1 
was expressed in both endothelial cells and DASMCs. EP4 stimulation significantly 
increased binding of hyaluronic acid to fragmented versicanV1 protein in DASMCs. 
A Scratch assay showed that EP4 promoted DASMC migration, which was attenu-
ated by fibulin-1-targeted siRNA and ADAMTS-1-targeted siRNA.
In conclusion, PGE2-EP4-mediated fibulin-1 integrates extracellular matrices such as 
ADAMTS-1, versican V1, and hyaluronic acid to promote SMC migration of the DA.
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The ductus arteriosus (DA) of oviparous animals differs from mammals’ in the 
embryonic gas exchange system and its anatomy. We performed transcriptional 
analysis of chicken DA, attempting to elucidate the similarity and diversity in the 
mechanism of DA closure among species.
Chicken DA proximal to the pulmonary arteries (proximal DA) closes after 
hatching while the DA proximal to the aorta (distal DA) remains open even after 
hatching [1]. Histological analysis revealed that the ductal wall of the proximal DA 
became thicker with fragmented elastic fibers from embryonic day (ED) 19. 
Therefore, we performed microarray analysis with proximal DA, distal DA, and 
aorta from chicken embryo at ED19. Clustering analysis found that the expression 
pattern of distal DA was similar to that of proximal DA than that of aorta although 
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distal DA has a similar structure to aorta. Subsequent pathway analysis with DAVID 
[2] revealed that proximal DA had enhanced expression of the melanogenetic genes 
compared with distal DA and aorta (Table  40.1). This result appears reasonable 
because proximal DA shares its developmental origin, neural crest, with melano-
cytes. Although several known genes such as transcription factor AP-2 beta (tfap2b) 
[3] were highly expressed in proximal and distal DA, we newly found proximal- 
DA- dominant genes. Further investigation would be required to understand the role 
of these genes in DA closure not only for the chick but also for mammals.







Proximal DA dominant pathways
Melanogenesis/tyrosine metabolism
DCT Dopachrome tautomerase (dopachrome 
delta-isomerase, tyrosine-related protein 2)
1.44∗ 1.06
EDNRB2 Endothelin receptor B subtype 2 1.31∗ 1.07 (1)
TYR Tyrosinase (oculocutaneous albinism IA) 1.54∗ 0.94 (1)
TYRP1 Tyrosinase-related protein 1 1.48∗ 1.03




CYP2C45 Cytochrome P-450 2C45 1.44∗ 1.02
HPGDS Hematopoietic prostaglandin D synthase 1.56∗ 1.02
PTGS2 Prostaglandin-endoperoxide synthase 2 





FIGF c-fos-Induced growth factor (vascular endothelial 
growth factor D)
1.50∗ 1.29∗ (2)
KDR Kinase insert domain receptor (a type III receptor 
tyrosine kinase)
1.34∗ 1.32∗ (2)
LAMA4 Laminin subunit alpha 4 1.33∗ 1.24
LAMB1 Laminin, beta 1 1.36∗ 1.27∗
TNC Tenascin C 2.15∗ 1.82∗
VWF von Willebrand factor 1.39∗ 1.31∗
CHAD Chondroadherin 1.24 1.22∗
ITGA1 Integrin, alpha 1 1.28 1.21∗
VEGF signaling pathway
HSPB1 Heat shock 27kDa protein 1 1.34∗ 1.21∗
KDR Kinase insert domain receptor (a type III receptor 
tyrosine kinase)
1.34∗ 1.32∗
PTGS2 Prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase)
1.31∗ 1.21∗
PLCG2 Phospholipase C, gamma 2 
(phosphatidylinositol-specific)
1.17 1.20∗
The asterisk indicates that the component genes appeared in the result of DAVID analysis
(1) Only appeared in “melanogenesis,”
(2) Only appeared in “focal adhesion”
S. Shinjo et al.
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Ductus arteriosus (DA) is an essential fetal artery that connects the main pulmonary 
artery and the descending aorta. Mammalian DA closes right after birth through 
vasoconstriction via a decrease in circulating prostaglandin E2 (PGE2) [1]. Avian 
DA also closes after birth although avians have no placenta that is a source of PGE2 
in mammals. Previous studies have demonstrated that the PGE2 signal pathway is 
not involved in the constriction of isolated chicken DA [2]. However, the in vivo 
effect of PGE2 in avian DA has been little investigated.
We first measured blood concentration of PGE2 in chicken at embryonic day 19 
(just before hatching) by enzyme immunoassay to confirm whether PGE2 circulated 
in the chicken blood during a perinatal period. Plasma PGE2 was significantly high 
in chicken compared to rat. PGE2 was strongly produced in chicken DA compared 
to chicken aorta and rat DA. Next, we determined the expression of prostaglandin E 
receptors (EP1, EP2, EP3 and EP4) in chicken DA. EP2 and EP3 receptors in fetal 
chicken DA were significantly higher than that of fetal chicken aorta. Especially, the 
EP2 receptor was significantly up-regulated before hatching and down-regulated 
after hatching. Finally, we performed a rapid whole-body freezing method to evalu-
ate DA closure in vivo. We measured the internal diameter of DA two hours after in 
ovo injection of indomethacin, which is a non-selective cyclooxygenase inhibitor. 
Indomethacin constricted chicken DA at embryonic day 19 but did not constrict 
chicken aorta. These data suggest that, similar to mammals, PGE2 acts as a vasodila-
tive factor on DA closure in avians.
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We demonstrated that factors of the PGE2 signal were detected in chicken DA 
and inhibition of cyclooxygenase contracted chicken DA. We concluded that the 
PGE2 signal may play an important role in acute vasodilatation of chicken DA 
closure.
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Patent ductus arteriosus (PDA) often occurs in premature infants [1]. At present, the 
cyclooxygenase inhibitor indomethacin is used to treat patients with PDA by inhib-
iting prostaglandin E2 synthesis. However, its efficiency is frequently limited [2] 
and adverse effects are problematic [3]. We have demonstrated that the prostaglan-
din E2 receptor EP4 specifically expresses in the rat ductus arteriosus (DA) [4]. 
Therefore, we hypothesized that EP4 inhibition promoted closure of the DA with 
fewer side effects.
We first examined the effect of the EP4 antagonist RQ-15986 (CJ-042794) on 
isometric tension of the ex  vivo DA at embryonic day 19 (e19) and 21 (e21). 
RQ-15986 at a dose of 10−4 M significantly increased the isometric tension of the 
DA up to 57 ± 14% and 78 ± 11% of 120mM KCl contraction at e19 and e21, 
respectively. The constrictive effect of RQ-15986 was greater on the DA than on the 
aorta. Second, we tested the effect of RQ-15986 on in vivo DA. RQ-15986 was 
intraperitoneally injected into fetuses at e19 and e21. We measured the inner diam-
eter of the vessels by a rapid whole-body freezing method. RQ-15986 constricted 
the DA but not the aorta in a dose-dependent manner. The contraction percentage 
was greater at e21 than at e19. Finally, RQ-15986 did not constrict the marginal 
artery of the colon.
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We demonstrated that RQ-15986 constricted the DA with fewer side effects. We 
concluded that EP4 inhibition would be a promising alternative strategy to treat a 
patient with PDA.
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43.1  Background
We previously reported that ATP-sensitive potassium (KATP) channels regulate ductal 
constriction in response to oxygen [1]. Diazoxide is a KATP channel opener while the 
usefulness of diazoxide for hyperinsulinemic hypoglycemia is well established. 
Yoshida et al. reported DA reopening in very low-birth-weight infants [2]. The objec-
tives of this study were to elucidate the effect of KATP channel openers on the DA in 
neonatal rats as well as the different effects in preterm and full-term fetal rats [3].
43.2  Methods
Near-term rat pups delivered via a cesarean section were housed at 33 °C. After 
rapid whole-body freezing, the ductus arteriosus (DA) diameter was measured using 
a microscope and a micrometer. Full-term pregnant rats (gestational day 21) were 
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intraperitoneally injected with diazoxide (10 and 100 mg/kg) 4 h before delivery, 
and the neonatal DA diameter was measured at 0, 30, or 60 min after birth. The 
newborn rats were also intraperitoneally injected with diazoxide (10 and 100 mg/
kg) at birth or 60 min after birth. DA was measured at 0, 30, or 60 min after injec-
tion. In the fetal study, constricted by COX and NOS inhibition the dilating effects 
of diazoxide was studied by simultaneous administration of indomethacin (10 mg/
kg) and l-nitroarginine methyl ester (100 mg/kg) in gestational day 21 and 19.
43.3  Results
DA closure was delayed in rats exposed to prenatal diazoxide. Both doses of trans-
placentally administered diazoxide induced significant and dose-dependent inhibi-
tory effect in postnatal DA constriction. Intraperitoneal injection of diazoxide at 
60 min after birth induced DA reopening in a dose-dependent manner.
Diazoxide (10 mg/kg) dilatated the fetal DA in both near-term and preterm fetal 
rats. The effect of diazoxide in dilating the DA at preterm was the same as at full- 
term fetal rats.
43.4  Conclusion
KATP channel openers attenuate postnatal DA constriction and dilatate a closing DA 
in neonatal rats. If the DA is affected in a similar manner in human neonates, then 
PDA could be warranted for use with KATP channel openers to treat infants with 
hyperinsulinemic hypoglycemia, especially preterm infants.
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Abstract
The morphological and histopathological effects of PGE1 infusion for ductus arte-
riosus were clarified through novel modality XPCT and immunohistochemical 
analyses, EP4, and LOX expression. Recognition of microstructural changes of 
ductal tissue induced by extended administration of PGE1 is profound to establish 
the safety usage of PGE1 for HLHS patients with staged Norwood repair.
Keywords




Prostaglandin E1 (PGE1) is essential to maintain the ductus arteriosus (DA) in 
ductal- dependent congenital heart diseases. Recently, relatively long-term adminis-
tration of PGE1 has become common, especially in patients with hypoplastic left 
heart syndrome (HLHS). Staged Norwood approach which consists of PGE1 infu-
sion, bilateral pulmonary artery banding and Norwood procedure provided excel-
lent survival benefit. However, microstructural changes in DA after long-term PGE1 
administration remain unknown. Therefore, we sought to investigate the features of 
DA after long-term PGE1 infusion using synchrotron-based X-ray phase contrast 
tomography (XPCT), a novel modality to inspect biological soft tissue and patho-
logical scrutiny including DA-specific immunostaining.
44.2  Methods
Seventeen DA tissues from HLHS patients were obtained during the Norwood pro-
cedure. The median duration of PGE1 was 48 days (range 3–123). Radiographic 
microstructural analysis of DA was performed using XPCT at SPring-8 (Hyogo, 
Japan). Histological changes focused on elastic fiber and smooth muscle formation 
were evaluated by Elastica van Gieson staining. Expressions of prostaglandin E2 
receptor (EP4) and LOX, a cross-linking enzyme that forms insoluble mature elastic 
fibers, were evaluated by immunohistochemical analyses.
44.3  Results
The XPCT study showed sclerotic changes in ductal media. There was a significant 
correlation between the duration of PGE1 infusion and the mass density of ductal 
media (R: 0.723, p = 0.001). The histological study showed that the duration of 
PGE1 infusion was positively correlated with the elastic fiber formation (R: 0.795, 
P = 0.002) and negatively correlated with smooth muscle formation in a disorga-
nized manner (R: –0.83, P < 0.001). EP4 was disappeared in DAs that were admin-
istered PGE1 over 20 days. LOX expression was observed in all DAs, especially 
LOX strongly emerged in specimens where elastic fiber formation was immature.
44.4  Conclusion
Long-term administration of PGE1 induced disorganized elastogenesis and density 
growth of the ductal media. In addition, downregulation of EP4 and LOX expres-
sion might emphasize this hypothesis. These results suggested that the dosage of 
PGE1 could be decreased after a definite period of administration.
R. Iwaki et al.
283
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter's Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder.
44 The Effect of Long-term Administration of Prostaglandin E1 on Morphological…
285© The Editor(s) (if applicable) and The Author(s) 2020
T. Nakanishi et al. (eds.), Molecular Mechanism of Congenital Heart Disease  
and Pulmonary Hypertension, https://doi.org/10.1007/978-981-15-1185-1_45
O. Nakagawa (*) · Y. Watanabe · T. Tanaka 




Department of Molecular Physiology, National Cerebral and Cardiovascular Center Research 
Institute, Osaka, Japan 
Laboratory of Stem Cell and Regenerative Medicine, Department of Biomedical Sciences, 
College of Life Sciences, Ritsumeikan University, Shiga, Japan 
T. Kawamura 
Laboratory of Stem Cell and Regenerative Medicine, Department of Biomedical Sciences, 
College of Life Sciences, Ritsumeikan University, Shiga, Japan
45Significance of SGK1 as a Protein Kinase Transcriptionally Regulated by ALK1 
Signaling in Vascular Endothelial Cells
Osamu Nakagawa, Yusuke Watanabe, Yukihiro Harada, 
Toru Tanaka, and Teruhisa Kawamura
Keywords
Serum/glucocorticoid-regulated kinase 1 · AGC family kinases · ALK1 signaling · 
Endothelial transcription · Vascular development
Bone morphogenetic protein 9 (BMP9)/BMP10-ALK1 receptor signaling is essential 
for endothelial differentiation and vascular morphogenesis and is implicated in hered-
itary hemorrhagic telangiectasia and pulmonary arterial hypertension [1]. The ALK1 
signal induces SMAD1/5/9-dependent transcription of its own signaling components, 
transcription factors and membrane ligands/receptors. In addition, we recently identi-
fied Serum/glucocorticoid-regulated kinase 1 (SGK1) to be transcriptionally regu-
lated by ALK1 signaling in vascular endothelial cells [2] (Fig.  45.1a). The ALK1 
signal is known to evoke post-translational activation of protein kinases such as TAK1 
and ERK as a non-canonical pathway, but SGK1 is the first example of protein kinases 
whose expression is controlled by the SMAD-dependent pathway (Fig. 45.1b).
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SGK1 belongs to the AGC (named after PKA, PKG and PKC) superfamily of 
protein kinases often involved in cardiovascular development and disease [3]. The 
microarray screen using BMP9-stimulated endothelial cells demonstrates that only 
SGK1 shows significant increase in mRNA expression among the AGC kinases 
(Fig. 45.1a). SGK1 plays pivotal roles in renal sodium reabsorption and T cell dif-
ferentiation as well as cardiovascular diseases such as hypertension and cardiac 
arrhythmia [3]. Furthermore, Sgk1 null mice with a particular genetic background 
exhibit severe abnormalities of vascular development and embryonic lethality [4], 
suggesting its role in the mechanisms of angiogenesis defects due to ALK1 
a b
c
Fig. 45.1 (a) Specific induction of SGK1 mRNA expression by ALK1 signaling. Microarray 
results of the AGC family kinases using human umbilical artery endothelial cells at 2 hours after 
BMP9 stimulation (10 ng/mL) are shown. (b) A schematic of the SMAD-dependent and -indepen-
dent pathways of ALK1 signaling and representative downstream targets. (c) Endothelial expres-
sion of Sgk1 mRNA during embryonic development. The in situ hybridization result of a mouse 
embryo (embryonic day 9.0) is shown
O. Nakagawa et al.
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signaling deficiency. While Sgk1 mRNA is clearly enriched in vascular endothelial 
cells of mouse embryos (Fig.  45.1c), nothing was known as to how its specific 
expression was achieved in  vivo. It is important to identify an Sgk1 endothelial 
enhancer and examine whether SMAD cooperates with endothelial transcription 
factors to control the Sgk1 expression. Moreover, the expression and kinase activity 
of SGK1 are regulated not only by its transcription but also by mRNA turnover, 
protein degradation and phosphorylation. It will be of significance to clarify how 
SGK1 function is optimized in developing vasculature.
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Structural heart disease is the most common congenital anomaly, affecting almost 
1% of live births [1]. Approximately 25% of newborns with congenital heart disease 
(CHD) require surgical or trans-catheter intervention in the first year of life [2]. 
Artificial materials such as polytetrafluoroethylene are used for the surgical repair 
of CHD, but these materials lack growth potential and lead to stenosis according to 
patient’s growth. Therefore, biological tissue-engineered blood vessels are desired 
for pediatric patients. Recently, we fabricated implantable “scaffold-free” grafts 
consisting of rat vascular smooth muscle cells by periodic hydrostatic pressure 
(PHP) [3]. Here we aimed to fabricate implantable human grafts and examine the 
molecular response to PHP.
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We seeded human umbilical arterial smooth muscle cells (hUASMCs) on a cul-
ture disk to make the first cell layer. Twenty-four hours after seeding, cells were 
exposed to PHP for 24 h, and then cells for the next layer were seeded on the top of 
the first layer, followed by repeating the same procedure to construct ten layered 
cell sheets. The multi-layered construct exhibited high elasticity (Fig. 46.1) and was 
successfully implanted at the aorta of nude rat. Echocardiography confirmed 
patency, and histological analysis demonstrated complete endothelialization.
We previously demonstrated that PHP promoted actin polymerization and fibro-
nectin fibrillogenesis [3]. We further investigated the molecular response to PHP. 
hUASMCs were exposed to PHP and subjected to a microarray analysis. A microar-
ray analysis revealed PHP-response genes, which are related to angiogenesis and 
stabilization of fibronectin. These genes were increased in a pressure-dependent 
manner, and co-localized with focal adhesion. These mechanoresponse molecules 
may contribute to construct the multi-layered cell sheets.
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Kawasaki disease is the most common acute systemic vasculitis of unknown etiol-
ogy in children [1] and can cause inflammation of the coronary arteries leading to 
aneurysms. Candida albicans extract is one of the materials commonly used to 
induce coronary arteritis in a mouse model of Kawasaki disease [2, 3]. Here we 
report an optimized method for preparing C. albicans cell wall extra (CAWE).
 1. 80% of the mice administered CAWE that had been alkalinized at 87 °C showed 
massive inflammation around the origin of the coronary arteries. By contrast, the 
mice administered CAWE that had been alkalinized at 97  °C showed no 
inflammation.
 2. 60% of the mice administered CAWE adjusted to 640 μg protein/mouse died 
within 2 days whereas 100% of the mice administered CAWE adjusted to 320 μg 
protein/mouse exhibited inflammation but survived.
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In conclusion, high heat processing causes poor pathogenicity and high protein 
content causes excessive pathogenicity. Therefore, CAWE that has been heat pro-
cessed at 87  °C and adjusted to 320 μg protein/mouse is optimal for the mouse 
model of Kawasaki disease.
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The advances that have been made in understanding the developmental processes 
and molecular pathways that control cardiac development have been enormous in 
the last several decades. It was the original goal of the first Takao Symposia in 1978 
to promote the scientific understanding of cardiac morphogenesis to form a founda-
tion for investigating the mechanisms of congenital heart disease. However, even 
the ambitious investigators who attended that first meeting would not have antici-
pated the rapid progress that has occurred in this field. Furthermore, few would 
have predicted that there would be serious discussion about exploiting developmen-
tal paradigms to promote cardiac stem cell differentiation as an approach to attain 
cardiac regeneration. In this section we get a glimpse of some exciting new develop-
ments in these areas that have been the direct result of insights presented at and 
encouraged by the Takao Symposia.
One of the major advances in understanding the early stages of cardiac develop-
ment has been the discovery that the entire heart does not arise from a single devel-
opmental field but rather the right ventricle, outflow track, and portions of the atria 
were derived from a second population of cells, now known as the second heart field 
(SHF), and the left ventricle appears to be primarily derived from anterior or the first 
heart field (FHF) derivatives. In this volume, Narematsu and Nakajima (Chap. 59) 
show that these distinct heart fields demonstrate differential response to the mutagen 
retinoic acid as early exposure of the FHF result in Transposition of the Great Vessels 
(TGA) and the double outlet right ventricle while exposure of the SHF at the same 
age results in persistence of the truncus arteriosus (PTA). Robert Kelley, one of the 
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initial investigators to identify and delineate the SHF, and colleagues (Chap. 49) 
utilized an intricate combination of immunohistochemistry, Cre lineage tracing, tran-
scriptome analysis, and novel in vivo morphological analysis to identify the heterog-
enous nature of the SHF cell populations. They specifically detailed the epithelial 
like characterization of cell populations important in defining the transitional cell 
populations at both the arterial and venous poles of the SHF that are critical for nor-
mal morphogenesis. Kodo et al. (Chap. 58) added to the characterization of this het-
erogenous SHF population by demonstrating that expression of the neurovascular 
molecule, semaphorin 3c, within the arterial pole of the SHF is essential for correct 
navigation of the cardiac neural crest cell (cNCC) populations essential for OFT 
development. Watanabe and Nakagawa (Chap. 60) expand the studies on novel fac-
tors regulating SHF and NCC interaction by showing that, Hey1, a downstream tar-
get of Notch 1 and Alk1 signaling is critical in aortic arch formation as null animals 
display an increased incidence or right sided aortic arch, interrupted aortic arch, 
aberrant origin of the right sub-clavian artery. Further adding to the complexity of 
understanding the heterogeneity of SHF progenitor cell components, Kokubo et al. 
(Chap. 50) used a new lineage tracing model based on expression of secreted friz-
zled-related protein 5 (Sfrp5) to identify a novel progenitor cell population that con-
tributes to the OFT, sinus venosus, left atria, and also to the left ventricle, which was 
previously thought to be primary, if not exclusively, derived from FHF progenitors. 
These studies raise the intriguing possibility of a single progenitor cell population that 
contributes to both the SHF and FHF. Regional heterogeneity of cardiac gene expres-
sion in distinct regions of the heart may not only be important for developmental regu-
lation but may also play an important role in pathology of the mature organism. In a 
fascinating study, Steimle et al. (Chap. 51) used transcriptional profiling to examine 
genetic differences that may actually regulate early post-natal cardiac function as well 
as cardiac function in the adult. They were able to identify discrete differences in gene 
expression between the left atrial appendage and the peri-pulmonary vein region of 
the left atria which is believed to be the nidus for many forms of atrial fibrillation.
With the development of induced pluripotent stem (iPS) cell technology, scien-
tific interest in factors that regulate cardiac stem cell differentiation into functional 
components of the mature heart has expanded well beyond the focus on early events 
of cardiac ontogeny as these cells could provide a foundation for future cell based 
regenerative therapies. New methods to identify differentiated progenitor cells in 
vitro will be required for clinical utilization of iPS cells. Kawaguchi et al. (Chap. 
61) showed that c-kit, a stem cell factor receptor often used for identifying cardiac 
progenitor cell populations, demonstrated robust expression in iPS cells grown on 
feeder cells but was subsequently downregulated following mesodermal and myo-
cardial differentiation. They suggested that this factor might affect the early stages 
of cardiomyocyte differentiation. In an elegant study, Morita and Takeuchi (Chap. 
57) developed transgenic iPSCs that could be induced to differentiation in func-
tional cardiomyocytes, without the addition of extrinsic growth factors, by induc-
tion of two critical factors that they identified in a single cell screening of early 
cardiac progenitors. While iPS cells can be differentiated into cells that express 
myocardial markers, a major limitation has been achieving myocyte maturation that 
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would achieve clinical utility. As such Brockmeier and co-workers (Chap. 55) pres-
ent a novel in vitro model to quantify myocardial contractility of both embryonic 
stem cell (ESC) and iPS derived cardiomyocytes by assessing the ability of these 
cells to integrate, in situ, with both normal and damaged myocardial tissue slices 
instrumented for measurement of isometric force transduction. This system allows 
for precise pharmacologic manipulation and they found that ESCs and IPS cells 
showed quantifiable increases in force/contractility as measured in the system and 
few differences were noted between the two cell types. However, neither generates 
contractile forces comparable to native heart tissue and their work points to devel-
opment of the sarcoplasmic reticulum as a limiting feature of ESC and iPSC dif-
ferentiation strategies. In a “tour de force”, Keller and colleagues (Chap. 54) go 
beyond an isolated single cell iPSC strategy in favor of the use of multiple cell lin-
eages in 3D matrix formulations to form implantable engineered cardiac tissues 
(ECTs) from several sources including human iPS cells. They showed that these 
ECT tissues had improved maturation, could be optically paced, and were capable 
of improving the myocardial function after infarction. They describe several recent 
modifications that enhance the potential use in human tissue engineering strategies. 
To further expand the utility of iPSCs, Hayama et al. (Chap. 62) were able to deter-
mine that iPSCs could be derived from immortalized B cell lines and successfully 
differentiated into cardiomyocytes. This dramatically expands the potential of the 
iPS methodology to evaluate human diseases as these cell lines have been utilized 
to identify genetic mutations associated with an array of CHDs and thus now pro-
vide a new source for in vitro disease modeling. The utility of iPSCs in modeling 
human diseases is further illustrated by the work of Furutani et al. (Chap. 63) who 
developed an in vitro model to study Long QT Syndrome 3 by generating iPSCs 
from patient derived immortalized B-cell lines.
While significant attention has been paid to the early stages of cardiac morpho-
genesis including organization of the first and second heart fields as discussed 
above, heart tube looping, septation, and valve formation during latter stages of 
cardiac morphogenesis have been inaccessible to laboratory investigation because 
of the early embryonic demise of many genetic mutants. However, newer Cre medi-
ated deletion strategies allowing temporal and tissue specific deletion of genes have 
been increasingly utilized to interrogate gene regulation in later gestational events. 
Qu and Baldwin (Chap. 52) offer novel insights into the important dynamic process 
of ventricular trabeculation. Using Cre mediated endocardial specific deletion of the 
receptor tyrosine kinase Tie2, they showed that signaling via this RTK is required 
for endocardial proliferation and development of the endocardial “sprouts” that 
define the trabeculae. Perhaps equally important, they showed that endothelial Tie2 
mediated paracrine signaling suppresses myocardial proliferation, thus regulating 
the proper number of myocytes in the developing ventricle. Ishida et al. (Chap. 56) 
showed that following trabeculation, Glial cell line-derived neurotrophic factor 
receptor alpha (Gfra) is required in subsequent stages of ventricular compaction 
as Gfra1&2 compound mutants developed a no-compaction cardiomyopathy. 
Furthermore, this phenotype was the result of perturbation in non-canonical Notch 
signaling. Nogimori et al. (Chap. 64) turned to human genetic studies to document 
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the clinical variability in the process of left ventricular non-compaction by compar-
ing one case of Gata4 mutation which was only mildly symptomatic with a patient 
harboring a TBX20 mutation who showed severe pulmonary hypertension and dia-
stolic dysfunction. In a fascinating study, Steimle et al. (Chap. 51) used transcrip-
tional profiling to examine genetic differences that may actually regulate post-natal 
cardiac function after birth and in the adult. They were able to identify discrete 
differences in gene expression between the left atrial appendage and the peri- 
pulmonary vein region of the left atria which is believed to be the nidus for many 
forms of atrial fibrillation.
The advances that have occurred since the first Takao Symposia have truly been 
impressive. Yet as Nakagama and Inuzuka remind us (Chap. 65) there are still sig-
nificant challenges that remain in elucidating the pathogenesis of CHD and particu-
larly challenging is developing vertebrate models that recapitulate human CHD to 
distinguish truly causal genetic variants from benign mutants. In addition, Dr. Bittel 
(Chap. 53) elegantly describes a potential role of non-coding RNAs in the etiology 
of Tetralogy of Falot further complicating the possible genetic mechanisms leading 
to CHD. It is clear that the mechanisms of normal and abnormal cardiac develop-
ment are much more complicated than ever imagined. But based on the progress 
seen since the first Takao Symposia, we can be optimistic that the mechanisms and 
treatments for CHD will ultimately be unraveled.
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Abstract
The deployment of progenitor cells from the second heart field (SHF) to the 
poles of the cardiac tube drives heart tube elongation during looping morphogen-
esis. Defects in this process underlie a spectrum of common forms of congenital 
heart defects (CHDs) affecting the cardiac poles, including conotruncal and 
atrioventricular septal defects. In this chapter recent findings will be reviewed 
concerning sequential steps in SHF development: the early emergence of the 
SHF lineage, the epithelial properties of SHF cells during heart tube elongation, 
and the importance of the transition zone as progenitor cells differentiate at the 
cardiac poles. Together these studies define critical regulatory nodes at succes-
sive stages of SHF deployment, providing new insights into mechanisms of heart 
development and the origins of CHD.
Keywords
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49.1  Introduction
The second heart field (SHF) contributes cardiac progenitor cells to the poles of 
the vertebrate heart as it elongates during looping morphogenesis [1]. This pro-
cess occurs between E8 and E10.5 of mouse gestation or between weeks 3–5 of 
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human development. The embryonic heart thus grows by a process of progenitor 
cell recruitment, separating proliferation of multipotent cardiac progenitor cells 
in the SHF from differentiated cells of the first heart field (FHF) in the early 
heart tube. Correct SHF deployment is essential to maximally elongate the heart 
tube and for subsequent alignment and septation of the future cardiac chambers 
[2]. Failure of SHF addition at the arterial pole results in conotruncal CHD, 
including ventricular septal defects, overriding aorta and tetralogy of Fallot, 
while defects of SHF addition at the venous pole result in primum type atrial 
and atrioventricular septal defects. Dissecting the mechanisms regulating SHF 
deployment is therefore a critical step towards understanding the origins of 
common forms of CHD.
In this chapter we will briefly summarize recent advances in SHF biology, 
focusing on three successive steps of progenitor cell deployment: (1) emergence 
of SHF lineages in the early mouse embryo, (2) evidence that the epithelial prop-
erties of SHF cells play an important role in controlling the progenitor cell niche 
during heart tube elongation, and (3) new insights into events at the cardiac poles 
as SHF cells transit through a transition zone to acquire a differentiated 
phenotype.
49.2  Emergence of SHF Lineages in the Early Embryo
Clonal analyses have shown that FHF and SHF cells segregate extremely early in 
the developing embryo, at or before the time of gastrulation, and prior to the acti-
vation of Mesp1, one of the earliest transcription factors expressed in the cardiac 
lineage [3, 4]. Single cell RNA sequencing data of nascent precardiac mesoderm 
in the Mesp1 lineage has recently revealed early segregation of anterior and pos-
terior SHF populations, ultimately contributing to the arterial and venous poles of 
the heart, respectively. This study demonstrated that different cardiac progenitor 
cells emerge from a population of multipotent heterogeneous precardiac meso-
derm, through which pseudotime trajectories to distinct emergent fates can be 
mapped (Fig. 49.1a) [5]. Moreover these data provide evidence of transcriptional 
priming of anterior and posterior SHF sub-populations, consistent with clonal 
analysis and vital dye labeling experiments indicating that these cells emerge 
from common progenitor cells in the early embryo. Progressive segregation of 
arterial and venous pole progenitor cells has been shown to depend on the tran-
scription factor Tbx1, encoded by the major gene for 22q11.2 deletion syndrome 
(22q11.2DS, also known as Takao or DiGeorge Syndrome) [6]. CHDs affecting 
both conotruncal development and atrioventricular septation are observed in Tbx1 
null embryos and 22q11.2DS patients, consistent with a requirement for Tbx1 in 
both anterior and posterior SHF sub-populations. Moreover, the SHF itself lies 
within a larger population of evolutionarily conserved cardiopharyngeal meso-
derm giving rise to skeletal muscles of the head and neck as well as myocardium; 
segregation of the heart and head muscle fate within cardiopharyngeal mesoderm 
occurs after the segregation of FHF and SHF lineages [7].
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49.3  Epithelial Properties of the SHF Cell Regulate 
the Progenitor Cell Niche
Inducible Cre recombinase alleles allowing genetic tracing of early differentiat-
ing cardiomyocytes (Smooth muscle actin) or progenitor cells (Six2) reveal the 
progressive contribution of SHF cells to the early heart tube [8, 9]. Whereas 
FHF cells differentiate in epithelial splanchnic mesoderm in the anterior lateral 
region of the embryo, SHF cells are situated in medial splanchnic mesoderm 
forming the dorsal pericardial wall (DPW). SHF cells also have an epithelial 
phenotype with a smooth apical surface with adherence and tight junctions fac-
ing the pericardial cavity [10]. In contrast to typical epithelia, the basolateral 
side of DPW cells is characterized by a mesenchymal-like convoluted cell mem-
brane with actin-enriched filopodial structures (Fig. 49.1b). Confocal time-lapse 
Fig. 49.1 Advances in the second heart field. (a) Early segregation of SHF cells in nascent cardiac 
mesoderm visualized by single cell gene expression analysis (adapted from [5]). (b) Actin enriched 
basal filopodia (arrows) in epithelial SHF cells visualized using Utrophin-GFP (adapted from [10]). 
(c) Segmentation of the apical surface of cells in the dorsal pericardial wall showing an increased 
cell size (red) and elongation in the posterior region (adapted from [15]). (d) Cartoon showing the 
transition zones (arrows) between proliferating progenitor cells (green) and differentiated cardio-
myocytes (red) at the arterial and venous poles. (e, f) Failure of dorsal mesenchymal protrusion 
(DMP) development results in atrioventricular septal defects (asterisk) in Tbx1 null hearts (adapted 
from [6]). aSHF anterior second heart field, pSHF posterior second heart field, FHF first heart field, 
End endocardium, AP arterial pole, VP venous pole, PAS primary atrial septum, RA right atrium, LA 
left atrium, RV right ventricle, LA left ventricle. Scale bars: b, 10 μm; e, f: 200 μm
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imaging of living SHF cells in thick slice culture has revealed that these filopo-
dia are highly dynamic and contact the underlying endodermal and mesenchy-
mal cells [10]. Phospho-Tyrosine accumulates in the basal filopodia of SHF 
cells, consistent with activation of intercellular signaling receptors and a poten-
tial signaling role in maintaining the progenitor cell niche. Filopodia formation 
is impaired in mouse embryos lacking Tbx1, associated with elevated levels of 
the apical determinant atypical PKCz and abnormal SHF deployment. Exposure 
of embryos to a physiological activator of aPKCz phenocopies the filopodial 
phenotype of Tbx1 null embryos, reducing proliferation and enhancing differen-
tiation in the SHF [10].
N-cadherin is also required in the SHF to maintain the progenitor cell niche. 
Conditional loss of N-cadherin results in elevated differentiation and reduced 
proliferation associated with decreased Wnt β-catenin signaling [11]. Non-
canonical Wnt signaling also plays important roles in SHF development. In par-
ticular, loss of Wnt5a, expressed in splanchnic mesoderm in the posterior SHF, 
results in arterial pole defects similar to those observed in Tbx1 null embryos 
[12]. Furthermore, Wnt5a has been shown to be a direct target gene of Tbx1 in 
the SHF [13]. The regional expression of Wnt5a has been proposed to drive mes-
enchymal cell intercalation in the DPW, creating a pushing force promoting SHF 
deployment to the arterial pole [14]. Increased cell adhesion in the anterior SHF 
may reinforce this process by creating a pulling force, supported by missexpres-
sion experiments in transgenic mice [14] and evidence that E-cadherin accumu-
lates in the apical membrane of cells in the anterior but not posterior SHF [10].
Ventral views of the dorsal pericardial wall epithelium have shown that cells in 
the posterior region are under greater epithelial tension than cells close to the arte-
rial pole. This is observed as an increase in the cell size, cell elongation oriented 
towards the arterial pole and accumulation of active actomyosin complexes along 
the long membrane of elongated cells (Fig. 49.1c) [15]. Moreover this is associ-
ated with elevated proliferation in the posterior SHF, oriented distribution of 
daughter cells after cell division, and clonal growth patterns directed towards the 
arterial pole of the heart, likely promoting heart tube elongation. A biomechanical 
feedback loop between SHF deployment and tension in the DPW, driven by the 
process of heart tube elongation itself, may accelerate terminal stages of SHF 
deployment [15]. Cells in the DPW are initially attached to the heart tube along 
its entire length by the dorsal mesocardium. Rupture of this transient mesentery 
isolates the SHF from the looping heart tube with the exception of the cardiac 
poles. Elevated epithelial tension in the posterior SHF is observed only after addi-
tion of SHF cells is restricted to the cardiac poles and tension is dependent on 
heart tube elongation [15]. Interestingly, elevated nuclear accumulation of the 
transcriptional co-factor YAP in the posterior region of the SHF may provide a 
link between epithelial tension and proliferation [15]. Ongoing work aims to 
refine this working model by characterizing the sources of tension and the path-
ways by which this impacts on proliferation in the SHF.
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49.4  SHF Cells at the Cardiac Poles Pass Through  
a Transition Zone
As SHF cells contribute to the cardiac poles they pass through a transition zone 
(TZ), or zone of commitment (Fig. 49.1d). The TZ is characterized by a cardio-
myoblast phenotype, altered cell shape and actin cytoskeleton remodeling asso-
ciated with sarcomere assembly and the onset of differentiation [16–18]. Cells 
in the TZ are distinguished by reduced FlnA and Hopx expression, the latter 
associated with modulating intercellular signals controlling the switch from 
proliferation to differentiation [17, 18]. Downregulation of the SHF transcrip-
tional program is mediated by the cardiac transcription factor Nkx2-5 that com-
petes with the SHF activator Isl1 to repress transcription at the Fgf10 locus [19]. 
Similarly, binding of Nkx2-5 to sites in the Popdc2 gene initially bound by 
Meis1 is associated with spatiotemporal progression of cells through the TZ 
[20]. Defects in TZ development result in failure to fully extend the outflow 
tract and subsequent ventriculoarterial alignment defects. For example, the pla-
nar cell polarity gene Vangl2 controls the epithelial properties of cells in the TZ, 
and outflow tract alignment defects including double outlet right ventricle are 
observed in conditional mutant embryos [16]. At the venous pole, SHF cells 
give rise to the dorsal mesenchymal protrusion (DMP) contributing to the mus-
cular base of the primary atrial septum [21]. Multiple transcription factors, 
including Tbx5, Osr1, Gata, and Fox factors, as well as several intercellular 
signaling pathways, have been implicated in DMP development [21, 22]. Defects 
in the development of the DMP underlie atrial primum type CHD, a class of 
atrioventricular septal defect. Such defects, in addition to failure of sub- 
pulmonary myocardium development at the arterial pole, are observed in Tbx1 
null hearts and constitute part of the CHD spectrum in TBX1 haploinsufficent 
22q11.2DS patients (Fig. 49.1e, f) [6, 23].
49.5  Future Directions and Clinical Implications
The studies discussed above identify critical regulatory nodes at successive stages of 
SHF deployment, providing new insights into the mechanisms of heart morphogene-
sis. Further analysis using dynamic approaches, single cell transcriptomic and epigen-
etic studies and lineage analysis will refine our understanding of these steps and 
generate a more complete blueprint of SHF deployment with which to dissect the 
origins of CHD and develop future preventive and, potentially, therapeutic approaches.
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Abstract
Mammalian heart is first recognized as the cardiac crescent at the egg cylinder 
stage, which had been thought to form all components of the heart. Recently, 
several lineage-tracing experiments using dye-labeling and mouse genetic tech-
nique have demonstrated that another cardiac progenitor population, called the 
second heart field, contributes to the outflow tract, the right ventricle, and a part 
of the atria. This finding has provided a great impetus for the understanding of 
cardiac morphogenesis, but it has also raised additional questions such as the 
potential existence of unique cardiac progenitors that give rise to the left ventri-
cle and the conduction system. Here, we show that a novel cardiac progenitor 
population is identified by expression and lineage tracing analysis of the Sfrp5 
gene. We found that Sfrp5 gene expression was constantly seen in the venous 
pole of the forming heart, which is later differentiated into the myocardium of 
the sinus venosus, a precursor of the sinoatrial node. Descendants of Sfrp5- 
expressing cells were found to contribute not only to the sinus venosus, but also 
to the left ventricle, atria, and the outflow tract by lineage-tracing analysis using 
Sfrp5-Cre and -Ert2Cre mice. These results indicate that Sfrp5-expressing cells 
could include progenitors for the sinus venosus, atria, the left ventricle, and the 
outflow tract, but not in the right ventricle, implying that the origin of the right 
ventricle essential for pulmonary circulation could be unique from progenitors 
for other components in mammalian cardiac development. In this session, we 
would like to discuss a new understanding of cardiac progenitor distribution.
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Mammalian cardiac development starts with the cardiac crescent, which forms the 
primary heart tube and then the four-chambered heart along with the progressive 
differentiation of progenitors into cardiomyocytes [1–3]. In this process, two 
independent pulmonary and systemic circulatory systems are established. For the 
establishment of these systems, remodeling of the ancestral heart into these two 
separate systems might occur with the production and rearrangement of progeni-
tor cells. Recent findings pertaining to another cardiac lineage called the second-
ary heart field (SHF) modified the classical view of cardiac development that the 
myocardium was derived from a single source. The SHF emerges in the splanch-
nic mesoderm to supply cells at both the arterial and venous poles of the heart 
tube, including the right ventricle (RV), most of the atria and outflow tract (OFT). 
However, the progenitor population that forms the first heart field (FHF), which 
gives rise to the left ventricle (LV) and the rest of the atria and the sinus venosus 
(SV) are still ambiguous. Since Wnt signalling is one of the most important regu-
latory pathways in vertebrate cardiogenesis [4–8], we focused on the Secreted 
frizzled-related protein (Sfrp) sub-family, known to encode secreted decoy recep-
tors for Wnt signalling, and analyze its expression and lineage during cardiac 
development [9].
We first observed expression of Sfrp5. At E7.5, Sfrp5 was detected in the lateral 
and caudal region of the Mlc2a and Nkx2-5 expressing region in the cardiac cres-
cent. This region was distinct from the Isl1 and Hcn4-expressing region, but mostly 
overlapped with the region marked by Tbx5. These observations suggest that Sfrp5 
expression seems to be restricted in undifferentiated FHF progenitors existing in the 
lateral sides of the cardiac crescent. During the heart tube looping stage (E8.0–
E8.5), Sfrp5 was continuously expressed in the venous pole of the heart. This Sfrp5- 
expressing area was distinct from the expression area of Mlc2a and Nkx2-5, 
indicating that Sfrp5 is exclusively expressed in the undifferentiated cardiomyo-
cytes. At E9.5, Sfrp5 expression was restricted to the Tbx18 and WT1 expressing 
the ventral venous pole, suggesting that Sfrp5 is expressed in progenitors of such 
SV and epicardium.
Since Sfrp5 expression was found in progenitors of the FHF at E7.5, and also 
detected continuously in the progenitors of the SV and the epicardium, we hypoth-
esize that Sfrp5-expressing cells include progenitors for the LV, the atrium, the SV 
and the epicardium. To test this possibility, we performed lineage analysis of 
Sfrp5- expressing cells by crossing the Sfrp5-Cre line with Rosa26R or CAG-
floxed-CAT- eGFP reporter mice [10]. We found that β-galactosidase (LacZ) 
labeled cells were detected in the OFT, LV, atria, and venous pole, but not in the RV 
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at E9.5. Labeled cells overlapped with TnT in the OFT, LV, and atria, suggesting 
that descendants of Sfrp5-expressing cells differentiated into the chamber myocar-
dium in addition to the SV. At E13.5, LacZ-stained cells were mostly found in the 
LV and also in the WT1-expressing pericardium and the CD31-expressing endo-
cardium. Labelled cells were found in part of the interventricular septum but rarely 
in the RV. These observations suggest that Sfrp5 is expressed in progenitors of the 
SV, pericardium, epicardium, endocardium, and the OFT, as well as in all chamber 
myocardium except for the RV.
Since Sfrp5 expression is restricted in the venous pole of the heart at E8.5, which 
does not include the chamber myocardium, we speculated that cells expressing 
Sfrp5 prior to E8.5 might include progenitors of the FHF. To evaluate the fate of 
Sfrp5-expressing cells at specific developmental stages, we crossed a tamoxifen 
inducible Sfrp5- ERT2 Cre mouse line with reporter mice and found that LacZ 
staining revealed that cells labelled at E7.5 were found in the OFT, LV, atria, SV, and 
venous pole but not in the RV. Moreover, labelled cells at E8.5 and E9.5 were still 
found in the atria, indicating that Sfrp5-expressing cells at the venous pole may sup-
ply cardiomyocytes for the inflow tract. These data suggest that Sfrp5-expressing 
cells at E7.5 include common progenitors for the SV, OFT, and all chamber myocar-
dium except for the RV.
Although the expression pattern of Sfrp5 was distinct from that of Isl1, an SHF 
marker at E7.5, descendants of Sfrp5-expressing cells were found in the OFT, which 
was thought to be derived from the SHF. This observation gave rise to a hypothesis 
that the expression of Sfrp5 precedes that of Isl1 in the splanchnic mesoderm. To 
test this possibility, we performed lineage-tracing analysis using Isl1-Cre and CAG- 
floxed- CAT-mRFP reporter/Sfrp5-venusYFP mice and found that the YFP signal in 
the ventral venous pole rarely overlapped with derivatives of Isl1-expressing cells. 
Instead, in Sfrp5-Cre/CAG-floxed-CAT-eGFP-reporter mice, GFP-labelled cells 
expressed Isl1 in the dorsal splanchnic mesoderm and part of the OFT. These find-
ings indicate that part of the SHF lineage is derived from Sfrp5-expressing cells to 
contribute to the OFT and atria.
Based on our findings, we propose a model for the contribution of Sfrp5- 
expressing cardiac precursors to heart development (Fig. 50.1). We found that 
Sfrp5-expressing cells at E7.5 contributed to the OFT, the LV, the atria, and the 
SV, but not to the RV, by fate mapping experiments using Sfrp5-Cre and -ERT2Cre 
mice. This observation indicates the possibility that the FHF lineage and the SV 
might share a common origin. Given that Isl1 lineages contribute to all myocar-
dium except for the LV [11, 12], the fate of Isl1 lineages to the RV or Sfrp5 lin-
eages to the LV may be exclusively determined during the earliest stages of 
cardiogenesis.
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Fig. 50.1 A new model for heart development: Crescent shaped heart primordium is divided into 
two layers along the mediolateral axis. The medial side of heart crescent, expressing Islet1, forms 
splanchnic mesoderm and its decedents contribute to all cardiac components except the LV. On the 
other hand, the lateral side of heart crescent, expressing Sfrp5, localizes in the mesenchymal cells in 
the inflow tract to form the SV, and its decedents contribute to all cardiac components except the RV
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Atrial fibrillation, characterized by irregular atrial depolarization leading to an 
uncoordinated contraction of the atrial muscle, is the most common cardiac 
arrhythmia. The T-box transcription factor TBX5 regulates atrial rhythm and has 
been genetically associated with human atrial fibrillation by both familial and 
genome-wide association studies. Over the last 30 years, the pulmonary veins 
and peri-pulmonary region of the left atrium have been implicated as a physical 
locus that frequently initiates atrial fibrillation. Regional gene expression differ-
ences within the atria have been reported that may reflect distinct ontogeny of 
these regions and impact arrhythmia mechanisms. In this study, we investigated 
transcriptional differences between regions of the adult left atrium in the mouse. 
We performed and compared transcriptional profiling of the left atrial append-
age and peri-pulmonary vein atrium of the adult mouse. We identified novel 
markers and transcriptional differences between the two regions, including of 
multiple known AF genes. Furthermore, we compared Tbx5-dependent genes 
between each region and identified Hcn4 as a novel dysregulated gene in the 
peri- pulmonary vein atrium. Regional and Tbx5-dependent gene expression 
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differences between the left atrial appendage and peri-pulmonary vein atrium 
are considered in the context of the genetic basis of atrial fibrillation.
Keywords
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51.1  Introduction
51.1.1  Atrial Fibrillation and the Pulmonary Vein
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting 
more than 7 million Americans and 33 million people worldwide [1]. AF is charac-
terized by an irregular pattern of atrial depolarization, resulting in rapid and disor-
ganized atrial conduction and lack of effective atrial chamber contraction. The 
rhythm abnormality in AF manifests with circulatory deficits and systemic throm-
boembolism that greatly increase morbidity and mortality. Patients with AF have an 
increased risk of developing major complications including heart failure and stroke. 
In addition, the prevalence of AF is expected to rise significantly as the population 
ages. AF has become a major clinical and economic burden, owing to the limitations 
and side effects associated with current AF therapies. Although AF most often man-
ifests in the context of pre-existing cardiac pathologies, idiopathic or lone AF forms 
indicated a heritable component [2]. Over the last decade, genome-wide association 
studies (GWAS) have identified over one hundred AF-associated loci [3, 4]. These 
advances in understanding the genetic basis of AF portend an understanding of the 
complex molecular pathways provoking AF.
The current paradigm of AF requires two arrhythmogenic components: (1) ecto-
pic (triggered) atrial myocardial activity such as early or delayed afterdepolarizations 
and (2) a fibrillogenic substrate that propagates these triggers throughout the atrial 
chambers [5]. The most common source of triggered activity is the pulmonary veins, 
which connect the lungs to the left atria [6, 7]. It has been shown that the pulmonary 
vein (PV) and peri-pulmonary vein (PPV) myocardium can demonstrate automatic-
ity which can trigger atrial depolarization [8]. A pacemaker current has been observed 
in the PV-left atrial junction in atrial fibrillation, and gene expression contributing to 
myocardial automaticity, such as the HCN4 channel protein, is observed in the pul-
monary veins [9]. A common treatment for AF is to isolate the PV myocytes from the 
atrial myocardium by catheter ablation, severing the electrical connectivity between 
these two populations and preventing inappropriate PV depolarizations from initiat-
ing global atrial depolarization and atrial arrhythmias [6, 7].
An important advance in the understanding of the pathophysiology of AF has 
been the demonstration that the pulmonary vein plays an important role in the initia-
tion of AF [6, 10]. Other initiating foci include the superior vena cava and the left 
atrium; however, the pulmonary vein remains the most common source of focal 
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activity. This observation has stimulated consideration of the distinctions between 
the myocardium of the pulmonary/peri-pulmonary vein region and other regions of 
the atrium. However, the gene expression profile promoting focal activity around 
the PVs in humans has been difficult to elucidate, owing to the limitations of tissue 
samples from patients. The molecular identity of the PV myocardium, including 
specific ion channels and transcription factors expressed in this tissue, has only 
recently been described. Analysis of a whole-lung transcriptome data set uncovered 
a set of 24 transcripts, including sarcomeric structural proteins, genes regulating 
sarcomere assembly, ion transport proteins and hormone signaling in the pulmonary 
cardiomyocyte gene network [11]. Some of these genes have been linked to AF in 
humans, suggesting that perturbation of this transcriptional network might lead to 
altered calcium handling, altered myocardium contractile force and electrophysio-
logical properties which may contribute to the initiation of atrial arrhythmias.
51.1.2  TBX5 and Pulmonary Vein Development
Holt-Oram syndrome is an autosomal dominant disorder caused by mutations in the 
T-box family transcription factor TBX5 [12–14], occurring in approximately 1  in 
100,000 live births [15, 16]. The clinical diagnosis of Holt-Oram syndrome includes 
completely penetrant upper-limb malformations and variable congenital heart 
defects, most commonly septal and cardiac conduction defects [17]. Specifically, 
the conduction defects can manifest as long PR interval, AV and bundle branch 
block, bradycardia, sick sinus syndrome and atrial fibrillation with or without overt 
structural defects [18, 19]. The observation that conduction abnormalities can occur 
in the absence of structural heart defects was an early indication that TBX5 may 
play a direct role in controlling gene expression essential for normal cardiac con-
duction. Recently, GWAS have implicated TBX5 in altered cardiac conduction 
speed (PR and QRS intervals) and AF in structurally normal hearts. Although strict 
clinical diagnosis of Holt-Oram Syndrome does not involve defects of the pulmo-
nary veins [14, 17], pulmonary vein abnormalities are often associated with Holt- 
Oram syndrome and TBX5 mutations [20–22]. Furthermore, homozygous mutation 
of Tbx5 in the mouse germline [23] results in complete morphological failure of the 
cardiopulmonary progenitors, which would normally generate portions of the atria, 
the atrial septum, pulmonary vein myocardium and smooth muscle cells and air-
ways smooth muscle cells [24, 25]. These observations suggested that TBX5 may 
drive gene expression important for the development of the pulmonary vasculature 
in the embryo and for the suppression of atrial arrhythmias in the pulmonary veins 
or peri-pulmonary vein atrial myocardium in the adult.
Here, we describe regional differences between the transcriptome of the left 
atrial appendage and the peri-pulmonary vein of the left atrium from adult mice. 
RNA sequencing revealed previously known and novel regional differences, includ-
ing several genes implicated in atrial fibrillation. We further compared Tbx5- 
depedent transcripts between the left atrial appendage and the peri-pulmonary vein 
of the left atrium from adult mice. Important distinctions were observed between 
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the two regions including Hcn4, which demonstrated differential Tbx5-dependence. 
Our data suggests that underlying regional differences in the transcriptome of the 
atrial myocardium may enlighten susceptibility to atrial fibrillation.
51.2  Results
51.2.1  Comparison of Peri-Pulmonary Vein and Atrial Appendage 
Transcriptomes
We investigated transcriptional differences between regions of the left atrium in 
7-week-old mice. The left atrium was microdissected into two parts: the left atrial 
appendage (LAA) and the peri-pulmonary vein (PPV) (Fig. 51.1a). Transcriptional 
profiling was performed by RNA sequencing (RNA-seq; n = 4 in each group) as 
previously described [26]. Principal component analysis (PCA) demonstrated that 
atrial region was responsible for the first principal component, accounting for 32% 
of the variation between samples (Fig.  51.1b). Differential expression testing 
between the PPV and LAA samples identified 747 significantly different genes 
(|log2FC| > 1; FDR < 0.01) with 582 expressed more strongly in the PPV samples 
and 165 expressed more strongly in the LAA samples (Fig. 51.1c, full table avail-
able at GEO accession GSE128870). Gene ontology (GO) terms and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways were examined using 
metascape (http://metascape.org) for both the LAA and PPV genes [27]. GO terms 
associated with the PPV indicated a preponderance of genes associated with immune 
cells. We observed GO terms that were unambiguously related to the immune sys-
tem and only containing genes associated with the PPV, including phagocytosis 
(GO:0006909), inflammatory response (GO:0006954), humoral immune response 
(GO:0006959), lymphocyte differentiation (GO:0030098) and cytokine-cytokine 
receptor interaction (mmu04060). Although these 141 genes are of potential inter-
est, they were separated from the remaining 441 PPV genes to focus on those genes 
previously verified as myocardially expressed or those with unknown roles or 
expression domains (Fig. 51.1c).
Because of the relationship between the left atria, pulmonary vein and AF, we 
examined region-specific gene expression against a list of 235 AF associated genes 
[3, 28–30]. Of the 606 genes that demonstrated regionalized expression in our 
RNA-seq, 19 have been associated with AF (Fig. 51.1d). Specifically, Adrb1, Nkx2- 
5, Tmem182, Nppa, Nppb, Gja5 and Kcnh7 are more strongly expressed in the LAA 
while Ntrk2, Tubb4a, Cacna1d, Tbx3, Scn3b, Shox2, Kcne4, Hcn4, Adra1a, Adrb3, 
Tubb3 and Cacna2d2 have higher expression in the PPV.
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Fig. 51.1 Transcriptional comparison of the left atrial appendage and peri-pulmonary vein 
atrium. (a) The left atrial appendage (LAA, blue) and the peri-pulmonary vein region of the left 
atrium (PPV, red) were microdissected from 7-week-old adult mice. (b) Principal component 
analysis comparing the LAA (blue) and PPV (red) transcriptomes. (c) Volcano plot showing 
log2(fold- change PPV/LAA). One hundred and sixty five were associated with LAA and 582 
were associated with the PPV (|log2FC|>1 and FDR < 0.01). Of the PPV genes, 141 genes were 
associated with GO terms related to the immune system (red) and removed from downstream 
analysis. (d) Overlap of genes associated with atrial fibrillation and either the LAA (7 genes) or 
PPV (12 genes). P-values derived from Fisher’s exact test
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51.2.2  Tbx5-Dependent Transcriptome of Peri-Pulmonary Vein 
Atrium Identifies Genes Involved with Cardiac Conduction
We hypothesized that Tbx5-dependent gene expression may vary between different 
regions in the left atria. Previous work has demonstrated that Tbx5 regulates a gene 
regulatory network for atrial identity and its removal from the adult mouse results 
in atrial fibrillation [26]. Tbx5 is robustly expressed in both the LAA and PPV tis-
sues with an average TPM of 79.7 ± 9.9 SEM and 97.1 ± 18.4 SEM, respectively 
putting Tbx5 within the top 8% of all genes expressed in either area of the left 
atrium (TPM > 1). To investigate differential Tbx5-dependent regional gene expres-
sion in the left atrium of the adult mouse, we performed Tbx5-dependent transcrip-
tional profiling of the PPV tissue and compared it to previously described 
Tbx5-dependent transcriptional profiling of the left atrial appendage [26]. We per-
formed RNA-seq on the PPV of an adult-specific conditional knockout of Tbx5 
[26]. Control (R26creERT2/creERT2; Tbx5+/+) and conditional mutant (R26creERT2/creERT2; 
Tbx5flox/flox) animals were treated with tamoxifen at 6-weeks old and tissue was har-
vested one week later prior to the onset or atrial arrhythmias (Fig. 51.1a) [26]. PCA 
analysis demonstrated clustering along PC1 and PC2 of samples (cumulative varia-
tion > 50%). PC1 demonstrated clustering associated with genotype (control versus 
conditional Tbx5 mutant), and PC2 demonstrated clustering associated with LA 
region (LAA versus PPV), indicating that genotype differences drove the majority 
of variance followed by regional atrial differences (Fig. 51.2a).
We identified 338 significantly dysregulated genes (|log2FC| > 1; FDR < 0.01) 
comparing the PPV between Tbx5 conditional mutant and controls (Fig.  51.2b, 
GEO accession GSE128870). Of these, 149 were up-regulated and 189 were down- 
regulated in the Tbx5 mutants (Fig. 51.2b). Utilizing metascape [27], we identified 
seven representative GO terms associated with the up-regulated genes and two 
representative GO terms associated with the down-regulated genes (Fig. 51.2c). 
Fig. 51.2 Tbx5 conditional knockout from the peri-pulmonary vein reveals Tbx5-dependence of 
multiple unique features. (a) Principal component analysis comparing the left atrial appendage 
(LAA, blue) and peri-pulmonary vein (PPV, red) transcriptomes from control (R26creERT2/creERT2; 
Tbx5+/+, “Tbx5Ctrl”, circles) and Tbx5 conditional knockout (R26creERT2/creERT2; Tbx5flox/flox, 
“Tbx5CKO”, squares) adult mice. (b) Volcano plot comparing the PPV Tbx5 CKO and control 
samples. One hundred and forty nine genes were significantly up-regulated and 189 were signifi-
cantly down-regulated (|log2FC|>1 and FDR< 0.01). (c) Summary GO terms representing all GO 
terms associated with up- and down-regulated genes (red and blue, respectively) with greater than 
five associated genes and −log10(P-value) greater than 5. (d) Full GO term list represented by 
“multicellular organismal signaling” with percent of genes identified (bar) and corresponding −
log10(P-value) (dot). (e) Correlation of fold changes between the LAA and PPV samples. Colors 
and shapes represent whether the genes residuals were in the outermost one-thousandth quantiles 
(purple square, red circle, blue triangle, dark grey circle) or not (light grey circle). Furthermore, 
colors and shapes represent whether those outliers were significantly different in both datasets 
(purple square), the PPV only (red circle), the LAA only (blue triangle) or neither (dark grey 
circle)
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The down-regulated GO terms are reminiscent of the LAA previously reported 
[26]. In particular, examining the full set of GO terms under “multicellular organ-
ismal signaling,” we identified multiple GO terms associated with the regulation of 
cardiac conduction, including ion channels, action potential and transmembrane 
signaling (Fig. 51.2d).
We identified 1492 significantly dysregulated genes in the LAA conditional 
mutant and control, with 770 up-regulated and 722 down-regulated, similar to our 
prior analysis of this dataset [26]. Although the numbers of significantly dysregu-
lated genes were different between the PPV and LAA, the dysregulation between 
the LAA and PPV experiments were significantly correlated (p-value < 2.2E-16, 
Fig. 51.2e), suggesting that the removal of Tbx5 had broadly similar effects in the 
LAA and PPV regions. In order to identify genes demonstrating distinct Tbx5- 
dependent effects between the atrial sub-regions, we correlated the Tbx5-dependent 
changes between the LAA and PPV samples. We identified the 28 genes with resid-
uals in the outermost one-thousandth quantiles (Table 51.1). Amongst those genes, 
we identified 11 genes that were significantly different in both experiments with 
10/11 demonstrating changes in the same direction, 4 genes that were significantly 
increased in only the LAA samples (Cemip, Col9a2, Itgb7, Lars2), 7 genes that 
were significantly different in only the PPV samples (increased: Gm42417, Lrtm1; 
decreased: Alox8, Cntn2, Hcn4, Scarna10, Vsnl1) and 6 genes that were not signifi-
cantly different in either sample. Interestingly, among the genes that were in the 
outermost one-thousandth quantiles, we identified Hcn4, which encodes the potas-
sium channel essential for the depolarizing “funny current” of the sinoatrial node. 
Hcn4 was significantly down-regulated only in the PPV and was also significantly 
more expressed in the PPV samples than the LAA (Fig. 51.1d).
51.3  Discussion
51.3.1  The Genetics of Atrial Fibrillation Implicates 
Developmental Transcription Factors
Most genetic loci implicated in AF encode ion channels that affect arrhythmia trig-
ger or substrate. Initial transcriptional studies of AF have focused on a restricted set 
of candidates, associating remodeling with changes in ion channels and components 
of cellular signaling cascades [31, 32]. Early transcriptomic or proteomic investiga-
tion of AF has been limited to animal models and/or chronic AF [33–36]. For exam-
ple, animal models based on disruption of specific ion channels do not exhibit 
spontaneous AF in the absence of concomitant cardiac pathophysiology [37]. 
However, a recent transcriptomic study using the left atrial appendage of patients 
with AF revealed that AF susceptibility was associated with decreased expression of 
transcription factors involved in inflammation, oxidation and the cellular stress 
response [38]. This study further suggested that remodeling of ion channel expres-
sion occurs later in the onset of the disease. Accumulating evidence suggests that 
transcription factors are important contributors to the pathogenesis of AF [39].
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Acta1 Increased Increased Skeletal muscle alpha-actin associated with 
myopathies [65]
Bub1 Increased Increased Spindle assembly checkpoint and 
centromeric cohesion [66]
Kifc1 Increased Increased Mitotic kinesin protein involved in 
centromsome duplication [67]
Kntc1 Increased Increased Kinetochore-binding mitotic checkpoint 
gene [68]
Myl3 Increased Increased Ventricular and slow skeletal muscle myosin 
light chain [69]
Parpbp Increased Increased Inhibits inappropriate homologous 
recombination in mitosis [70]
Scgb1c1 Increased Increased Secretoglobin protein associated with 
anti-inflammatory function [71]
Aldh3b3 Decreased Decreased Removes lipid-derived aldehydes generated 
by oxidative stress [72]
Cpne5 Decreased Decreased Calcium-dependent, phospholipid-binding 
proteins [73]
Sbk3 Decreased Decreased Uncharacterized cardiac expressed, SH3 
domain binding kinase [74]
Gm30003 Increased Decreased Lung-expressed predicted gene [75]
Cemip Increased NS Depolymerizes hyaluronic acid [76]
Col9a2 Increased NS Type IX collagen found with type II fibrillar 
collagen [77]
Itgb7 Increased NS Leukocyte associated integrin beta  
subunit [78]
Lars2 Increased NS Mitochondrial leucyl-tRNA synthetase [79]
Gm42417 NS Increased Predicted gene [80]
Lrtm1 NS Increased Transmembrane protein with homology to 
Slit3 [81]
Alox8 NS Decreased Peroxidizes polyunsaturated fatty acids [82]
Cntn2 NS Decreased Membrane junction protein associated with 
axons [83]
Hcn4 NS Decreased Hyperpolarization-activated current/“funny” 
current [84]
Scarna10 NS Decreased Small Cajal body-specific RNA 10 ( [85])
Vsnl1 NS Decreased Neuronal calcium sensor [86]
Gm13938 NS NS Antisense lncRNA [80]
Gm33051 NS NS Kidney-expressed antisense lncRNA [75]
Igf2 NS NS Fetal growth hormone signaling and tissue 
differentiation [87]
Rab3c NS NS Calcium-triggered vesicle transport [88]
Slc27a2 NS NS Fatty acid transport [89]
Snhg3 NS NS Competing endogenous RNA to miR-
182-5p [90]
The 28 genes identified as outliers in the outermost one-thousandth quartiles when comparing the 
Tbx5-dependent gene changes in the LAA and the PPV. The genes are listed with whether they 
were significantly increased (red), decreased (blue) or not significant (NS) in each of the two com-
parisons. Furthermore, a short description of each gene is provided
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GWAS of AF have identified numerous transcription factor loci that play funda-
mental roles during cardiac development, including TBX5, NKX2-5, GATA4 and 
PITX2. The implication of transcription factor genes essential for cardiac develop-
ment in in AF raises the fundamental question of whether AF is a function or a result 
of a developmental defect, for example, of the pulmonary veins, or a later manifes-
tation of altered transcriptional control of cardiac rhythm genes in the adult. The 
first GWAS of AF identified a susceptibility locus on chromosome 4q25 adjacent to 
PITX2 [40]. There is evidence that Pitx2c affects adult gene expression in the 
atrium. PITX2 is expressed both in the left atrium and the pulmonary myocardial 
sleeve and that its levels are decreased in patients with AF [41, 42]. Atrial-specific 
deletion of Pitx2c leads to hallmarks of AF, which is also observed in Pitx2c hetero-
zygous mice or adult-specific deletion of this gene [41, 43, 44]. Furthermore, micro-
array analysis of Pitx2c heterozygous mice revealed impaired gap and tight junction 
gene expression, consistent with the hypothesis that structural genes are remodeled 
later in the onset of AF [44].
We previously demonstrated that adult-specific deletion of Tbx5 causes sponta-
neous and sustained AF with atrial gene regulatory network dysfunction [26]. TBX5 
drives the atrial expression of Pitx2, and TBX5 and PITX2 co-modulate the expres-
sion of cardiac rhythm effector genes, including Ryr2 and Atp2a2. These findings 
indicated that interactions between TBX5 and PITX2 provide tight control of an 
atrial rhythm gene regulatory network and that perturbation of this network trig-
gered AF susceptibility. This example suggested that cardiac TFs implicated in AF 
by genetic association may co-regulate a gene regulatory network for atrial rhythm 
homeostasis in the adult atrium.
51.3.2  Transcription Factors and AF: A Pulmonary Vein 
Developmental Relationship?
The requirement of developmental TFs in the adult for normal cardiac rhythm con-
trol does not rule out the possibility that developmental defects caused by their 
deficiency in the embryo also contributes to AF susceptibility. During embryonic 
development, the cardiopulmonary progenitors give rise to parts of the atria, pulmo-
nary vein and lungs [25]. Distinct functional characteristics between the PPV and 
LAA regions may reflect distinct developmental ontogeny. The myocardium of the 
pulmonary veins has a distinct developmental origin from that of the atrial free 
walls [45]. Subsequently, the myocardium surrounding the pulmonary veins is dis-
tinct from that of other regions in the atrium [46]. These developmental distinctions 
may set the stage for regional gene expression differences within the mature atrium 
of the adult that normally maintains atrial rhythm but which make the PPV region 
susceptible to trigger formation when faced with environmental or genetic insult.
Mutations in NKX2-5, PITX2C and TBX5 increase susceptibility to AF, and all of 
these transcription factors (TF) play critical roles during cardiovascular develop-
ment [26, 47–50]. Each of these TFs are expressed in the pulmonary veins, suggest-
ing that perturbations of the transcription program in the PV myocardium may 
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underlie the pathogenesis of AF. The caudal myocardium, including the developing 
pulmonary vein myocardium, expresses Tbx5, Pitx2c, Nkx2-5 and Gja5 (Cx40) at 
high levels [51, 52] consistent with a fast-conducting atrial myocardial phenotype. 
In a Nkx2-5 haploinsufficient mouse model, Gja5 levels are decreased whereas 
Hcn4 levels are increased in the pulmonary vein myocardium. Nkx2-5 and Pitx2c 
are both required for the development and maintain identity of the pulmonary myo-
cardium [45, 53]. The changes in gene expression observed in Nkx2-5 haploinsuf-
ficient mice could be reflective of a loss of fast conduction and acquisition of 
pacemaking conduction phenotype. This type of transition provided a conceivable 
model for how genetic changes could result in automaticity in the PPV region that 
resulted in arrhythmia initiation.
Absence of the lungs and pulmonary vasculature in Tbx5 knockout mice sug-
gests that it may play an essential developmental role specifically within the pulmo-
nary veins as well [24]. We observed that a decrement in Tbx5 in the PPV region 
decreased Hcn4 expression, which is not overtly consistent with this transformation 
model. On the other hand, we observed that many genes with important roles in 
myocardial automaticity, including Tbx3, Shox2, Cacna1d, Cacna2d2 and Hcn4 
were more highly expressed in the PPV than the LAA region, and remained more 
highly expressed in the context of adult-specific Tbx5 conditional deletion. 
Furthermore, other Tbx5-dependent genes in the PPV region are classical fast con-
duction genes, including Scn5a, Gja5 and Kcnk3. Reduction in the expression of 
these fast conduction genes in the context of retained high expression of automatic-
ity genes such as Hcn4 could diminish fast conduction physiology and allow the 
emergence of myocardial automaticity, providing a nidus for the initiation of atrial 
arrhythmias including AF.
51.4  Methods
51.4.1  Animal Experiments and Ethics Statement
All murine experiments were performed under University of Chicago Institutional 
Animal Care and Use Committee (IACUC) protocol number 71737. Mice harboring 
the ROSA26 tamoxifen-inducible cre recombinase transgene, Gt(ROSA)26Sortm1(cre/
ERT2)Tyj (R26creERT2), were bred with mice harboring the Tbx5tm1Jse allele (Tbx5flox) to 
generate Tbx5 conditional mutants, R26creERT2/creERT2; Tbx5flox/flox, and controls, 
R26creERT2/creERT2; Tbx5+/+ [23, 54]. Tamoxifen was administered by intraperitoneal 
injection for three consecutive days at 6 weeks of age and tissue samples were har-
vested 1 week after treatment as previously reported [26].
51.4.2  Transcriptional Profiling and Analysis
Transcriptional profiling was performed on the peri-pulmonary vein region of the 
left atrium (Fig.  51.1a). Total RNA was extracted from four controls and six 
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conditional mutants. Following rRNA removal (Ribo-Zero rRNA Removal Kit, 
Illumina), libraries were prepared using the TruSeq RNA Sample prep kit v2 
(Illumina). Samples were pooled in equimolar ratios and sequenced on the Illumina 
HiSeq4000 platform. Library preparation and sequencing were performed by the 
Genomics Core Facility at the University of Chicago.
The peri-pulmonary vein samples were compared with the previously published 
corresponding left atrial appendage samples [26]. Both the peri-pulmonary vein and 
left atrial appendage samples were analyzed in parallel as described below.
Between 20 and 22 million reads were generated for each replicate (14–19 mil-
lion reads for left atrial appendage) and aligned to the GRCm38/mm10 build of the 
Mus musculus genome (retrieved from UCSC May 23, 2012) using TopHat v2.1.1 
[55, 56]. Reads were filtered to remove poorly aligned (MAPQ<10), duplicated and 
unmapped reads using BamTools v2.4.1 [57]. Post-alignment, post-filtered reads 
were assigned to transcripts using StringTie v1.3.3 [58, 59].
Downstream analysis was performed using R v3.4.0 [60]. Differential expres-
sion testing was performed using edgeR v3.18.1 [61] and limma v3.32.10 [62]. Low 
level genes were removed within each condition using median log-transformed 
counts per gene per million mapped reads (cpm) cutoff of 1. A generalized linear 
model (GLM) framework was used to test for differential expressed genes between 
Tbx5fl/fl;R26cre-ERT2 conditional mutants and Tbx5+/+;R26cre-ERT2 controls for each tis-
sue and between controls of the left atrial appendage and peri-pulmonary vein tis-
sues. Data was plotted using the ggplot2 v2.3.0 [63] and scales v0.5.0 [64] packages. 
GO term analysis was performed using metascape (http://metascape.org) [27]. The 
raw and processed data as well as the full outputs were deposited in GEO at acces-
sion number GSE128870.
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52The Endocardium as a Master Regulator of Ventricular Trabeculation
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Abstract
Ventricular chamber morphogenesis, characterized by trabeculae formation, is cru-
cial for cardiac function and embryonic viability and depends on cellular interac-
tions between the endocardium and myocardium. The ang1-Tie2 pathway is 
required for normal heart chamber development, but its molecular effectors are not 
well defined. Here we show that loss of Tie2 in endocardial cells (EC) results in 
mid-gestation lethality due to heart defects including hyperplastic myocardium tra-
beculation (fewer but thicker trabeculae), thinner compact myocardium and simpli-
fied endocardial network. The thicker trabeculae phenotype results from enhanced 
proliferation of trabecular cardiomyocytes. Meanwhile, endocardial loss of Tie2 
reduces proliferation and production of ECs and impairs endocardial sprouting, 
which provides necessary support for trabecular assembly and extension, thus 
resulting in a dramatically simplified trabecular meshwork. These findings reveal 
two seemingly apposing functions of Tie2 in myocardium trabeculation: ensuring 
normal trabeculation by supporting EC proliferation and sprouting while preventing 
hypertrabeculation by inhibiting trabecular cardiomyocyte proliferation.
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52.1  Introduction
Congenital heart diseases are some of the most common human birth defects. In 
many congenital heart diseases, genetic defects lead to impaired embryonic heart 
development or growth. A key development process in cardiac ontogeny is ventricu-
lar chamber formation. One of the first signs of chamber development is the forma-
tion of trabeculae [1]. Lack of trabeculation frequently causes embryonic lethality 
in mice and excess trabeculation causes cardiomyopathy and heart failure in humans 
[2]. A number of signaling molecules from myocardium, endocardium and cardiac 
extracellular matrix (ECM) have been implicated in trabeculation and an intimate 
communication between endocardium and myocardium promotes cardiomyocyte 
(CM) proliferation and differentiation leading to trabeculae formation [2]. The 
Notch signaling pathway has been the most intensely investigated in this process 
with Bmp10, Nrg1 and EphrinB2 identified as downstream targets of Notch signal-
ing during trabeculation [3]. However, the molecular and cellular mechanisms con-
trolling trabeculation are still poorly understood.
The Tie (tyrosine kinase with immunoglobulin-like and EGF homology) recep-
tors, Tie1 and Tek/Tie2, are type 1 transmembrane protein receptor tyrosine kinases 
(RTKs) [4]. Along with the vascular endothelial growth factor (VEGF) receptors, 
these are the only known endothelial cell (EC)-specific RTKs. Although deficiency 
in Tie1 results in cardiovascular demise in utero [5–7], Tie1 is dispensable for car-
diac trabeculation. Mutations in Tie2 have been described to cause ventricular sep-
tal defects and cutaneomucosal venous malformations in humans [8, 9]. Previous 
reports have suggested a role for Tie2 signaling in trabeculation because Tie2-null 
embryos have no trabeculae [5, 10] and deficiency of Ang1; the primary agonist for 
Tie2 results in a marked reduction in cardiac trabeculation [11, 12]. However, the 
molecular basis for these phenotypes has remained elusive. In addition, Tie2- 
deficient mouse embryos with abnormal trabeculation also had lethal vascular 
defects raising the question of whether the cardiac defects observed were primary or 
secondary to more global vascular compromise. Here, we show that loss of endocar-
dial Tie2 results in embryonic heart failure that is characterized by impaired endo-
cardial growth and hyperplastic trabeculation.
52.2  Mouse Models for Endocardial Specific Gene Deletion
In order to allow temporal and tissue-specific gene inactivation, we have developed 
a conditional allele of the mouse Tie2 gene by introducing Cre recombinase recog-
nition sites (loxP) into the Tie2 locus. This strategy involved introducing a loxP site 
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within the first intron, and another loxP site just upstream of the minimal promoter 
region. To specifically determine the role of Tie2 in cardiac trabeculation, we uti-
lized this floxed Tie2 allele and an endocardial specific Cre transgenic line previ-
ously generated in our lab (Nfatc1Cre) [13]. We first analyzed Cre activity by X-gal 
staining of R26fslz;Nfatc1Cre heart sections showing that Cre expression was restricted 
to the endocardium from E9.0 but not in the ECs of the peripheral vasculature 
(Fig. 52.1).
52.3  Tie2 Is Essential for Ventricular Chamber Development
Mice with a floxed Tie2 allele were crossed with the Nfatc1Cre line. We refer to 
Nfatc1Cre/+;Tie2f/f mice as Tie2 conditional knockout (Tie2-cko). Similar to the global 
deletion of Tie2, no endocardial Tie2-cko animals survived to birth. Tie2-cko 
embryos were grossly indistinguishable from their littermates until E12.5 at which 
point most began to show dorsal edema that increased until demise at E13.0–E13.5. 
Histological analysis of their hearts confirmed abnormal trabeculation, thin com-
pact myocardium and ventricular septal defects compared with littermate controls 
(Tie2+/f and Tie2f/f). Dual-fluorescence staining of heart sections with antibodies for 
troponin T (myocardial marker) and endomucin (which identifies ECs) (Fig. 52.2) 
revealed fewer but thicker trabeculae in Tie2-cko hearts. In addition, the endomucin- 
positive endocardial network and sproutings were abnormal.
To determine if the thicker trabeculae in Tie2-cko hearts were due to enhanced 
proliferation rate in myocardium, we assessed MCs proliferation rate by BrdU pulse 
labeling. There is no significant difference in the percentage of BrdU-positive car-
diomyocytes in the compact zone between the control and Tie2-cko hearts at E11.5 
and E12.5. However, in the trabecular zone the percentage of BrdU-positive MCs in 
Fig. 52.1 Nfatc1Cre 
mediates loxP excision 
exclusively in the 
endocardium. X-gal 
staining of R26fslz;Nfatc1Cre 
heart sections at E12.5 
shows that Nfatc1Cre-
mediated recombination is 
restricted to the embryonic 
atrial and ventricular 
endocardium but not in the 
endothelial cells (ECs) of 
the peripheral vasculature. 
RA right atrium, RV right 
ventricle, LA left atrium, 
LV left ventricle, IVS, 
interventricular septum
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the Tie2-cko was significantly higher than that in the control, 36.6% vs. 24.6% at 
E11.5 and 32.4 vs. 11.8% at E12.5. Co-immunostaining for endomucin and Erg 
(EC-specific ETS transcription factor) revealed that the reduced endocardial sprout-
ings in Tie2-cko mice was accompanied by a decreased number of ECs; the total 
endocardial EC number was determined by counting cells positive for Erg 
(Fig. 52.3). BrdU analysis also revealed that EC proliferation in the Tie2-cko endo-
cardium was reduced by nearly 50% compared with control mice at E10.5 and 
E11.5. Thus, endocardial attenuation of Tie2 leads to impaired endocardial growth 
and hyperplastic trabeculation.
In summary, we propose a model of trabeculation regulation by Endocardial Tie2 
(Fig. 52.4). In wild-type mice, at E9.0, the first stage or initiation of trabeculation is 
characterized by endocardial sprout formation and touchdown coincident with 
Fig. 52.2 Endocardial specific deletion of Tie2 results in abnormal trabeculation. (a, b) Gross 
images of control (a) and Tie2-cko (b) embryos at E12.5 showing pericardial effusions (arrow) and 
edema (arrowhead) in the mutant embryos. (c, d) Control and Tie2-cko ventricular sections at 
E12.5 were stained with troponin T (myocardial marker, red) and endomucin (endocadial marker, 
green) antibodies. Compared to the control, the mutant heart had fewer but thicker trabeculae 
(arrows), thinner compact myocardium and simplified endocardial network
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myocardial delamination. Next endocardial sproutings progress laterally beneath 
the myocardial lamina resulting in isolated clusters of myocardial cells within a 
“bubble” of cardiac ECM, covered by endocardium. By E9.25 the endocardial 
sprouting- enveloped myocardial lamina assemble to isolated short trabecular clus-
ters (stage 2: assembly), which is followed by trabecular extension (stage 3) at E9.5, 
leading to finger-like long trabecular structures. In Tie2-cko mice, only limited 
Fig. 52.3 Endocardial attenuation of Tie2 results in decreased EC number and simplified endo-
cardial network. Dual immunostaining of control and Tie2-cko heart sections (left ventricle) for 
Erg (red) and endomucin (green) at E11.5 reveals a significant decrease in Erg-positive endocardial 
cell number in the mutant ventricles (b) compared to control ventricles (a) following endocardial 
loss of Tie2. DAPI, blue












Fig. 52.4 Proposed model of trabeculation regulation by endocardial Tie2. In wild-type mice, 
myocardial trabeculation develops as a three-step model: stage 1 at E9.0, initiation of trabecula-
tion, stage 2 at E9.25, trabecular assembly and stage 3 at E9.5, trabecular extension. In Tie2-cko 
mice, only limited endocardial sproutings reached the outer layer myocardium. Although the myo-
cardial wall in mutant ventricles was able to thicken to a multicellular layer and form sheet-like 
protrusions (myocardial lamina), assembly and extension of trabeculae were impaired, thus lead-
ing to thicker but reduced trabeculae. CJ cardiac jelly, CM cardiomyocytes, End, endocardium
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endocardial sproutings reached the outer myocardial layer. Although the myocar-
dial wall in mutant ventricles was able to thicken and form multicellular sheet-like 
protrusions (myocardial lamina), assembly and extension of trabeculae were 
impaired, thus leading to thicker but reduced trabeculae.
52.4  Future Directions and Clinical Implications
Despite the absolute requirement for functional Tie2 signaling in normal cardiovas-
cular development as well as its essential role in the progression of adult heart and 
vascular diseases, there is a paucity of information delineating the mechanism(s) of 
Tie2 activation or the subsequent signaling events that modulate heart ontogeny. 
This work reveals a critical role for the endocardium in the orchestration of ven-
tricular trabeculation which is dependent on endocardial RTK Tie2 signaling. Tie2 
not only plays a primary autocrine function in support of EC proliferation and 
angiogenic sprouting and touchdown but also is instrumental in the generation of 
paracrine signaling that results in inhibition of trabecular CM proliferation that pre-
vents hypertrabeculation. Further investigation on this project will focus on delin-
eating downstream targets of Tie2 activation in both endocardium (cell autonomous 
effect) and myocardium (paracrine effect) during ventricular trabeculation. These 
new insights will be important in further defining mechanisms of disease pathology 
related to ventricular chamber morphogenesis and function and will ultimately be 
critical in elucidating the etiology of congenital heart diseases.
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Abstract
Research in the last 10 years has led to improved understanding of the genetic 
regulation of vertebrate heart development, but despite this effort, approximately 
70% of all congenital heart defects (CHDs) still have an unknown etiology. 
Alternative splicing of mRNA has been documented to play roles in normal and 
abnormal development. Dysregulated splicing of mRNA has been shown to cause 
heart defects in mice, however a link between mRNA splicing and CHDs has not 
yet been shown in humans. We reported that more than 50% of genes associated 
with heart development were alternatively spliced in the right ventricle (RV) of 
infants with tetralogy of Fallot (TOF) relative to the RV of normally developing 
infants. Moreover, there was a significant decrease in the level of 12 scaRNAs 
340
(small cajal body associated RNAs) in the RV from infants with TOF. These small 
noncoding RNAs guide the biochemical modification of specific nucleotides in 
spliceosomal RNAs that are critical for spliceosomal function. We used primary 
cells derived from the RV of infants with TOF to show a direct link between 
scaRNA levels and alteration in mRNA splicing of several genes that regulate heart 
development. We modified the expression of sets of scaRNAs and consequentially 
documented distinctive mRNA splicing, accompanied by corresponding protein 
isoform changes suggesting a unique contribution by each scaRNA. Furthermore, 
we knocked down two homologous scaRNAs in zebrafish and saw a disruption of 
heart development with an accompanying alteration in splice isoforms of cardiac 
regulatory genes. These combined results provide compelling evidence that scaR-
NAs contribute to the regulation of cardiac development by fine-tuning the fidelity 
of the spliceosome that adjusts exon retention as cell differentiation occurs. 
Importantly, our findings are consistent with the concept that disruption of mRNA 
splicing patterns during early embryonic development disturbs normal signaling 
pathways, resulting in conotruncal misalignment and TOF.
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53.1  Introduction
Congenital heart defects (CHDs) are the most common birth defects and represent 
a substantial health care burden even in countries with advanced health care systems 
[1]. Approximately 70% of all CHD cases are idiopathic and a significant effort has 
been made in the last 10 years to identify the genetic basis of CHDs. However, there 
remains a significant gap in our understanding of the genetic heritability of CHDs. 
Splicing in the vertebrate heart has been shown to be dynamic and carefully regu-
lated [2–5]. However, no direct link between alternative splicing and CHDs has 
been established. In the developing embryo, precise spatial and temporal signaling 
is required between the first heart field from which the left ventricle is derived and 
the second heart field (SHF) from which the right ventricle and the conotruncal 
outflow tract are derived [3, 6–11]. The regulatory networks that control heart mor-
phogenesis are mediated by multiple master regulatory genes (e.g. NKX2.5, GATA4, 
MBNL1) that control key pathways, including the WNT and NOTCH pathways, all 
of which have alternatively spliced messages.
Nearly all protein-coding genes in eukaryotic genomes contain introns (94% in 
humans) which must be removed to produce a mature messenger RNA [12]. 
Additionally, recent estimates of alternative splicing suggest as many as 90% of 
human genes have alternative transcript isoforms [13, 14]. There is growing appre-
ciation for the role that alternative splicing plays in normal development and patho-
genesis [2, 15–19]. The spliceosome facilitates pre-mRNA processing (splicing) of 
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almost all primary transcripts in eukaryotic genomes. The primary spliceosome, 
termed the U2 spliceosome, is a multi-megadalton ribonucleoprotein complex com-
posed of numerous proteins and five small nuclear RNAs (snRNAs or spliceosomal 
RNAs, U1, U2, U4, U5 and U6). The conformation and composition of the spliceo-
some are highly dynamic and conserved between yeast and humans [20]. Elaborate 
RNA–RNA–protein interactions align the reactive subgroups and repeatedly rear-
range as each intron is identified, intron-exon boundaries are located, and catalysis 
proceeds to remove each intron in every pre-mRNA.
Some exons are constitutive, that is, they are present in every mature message; 
however, there are a surprising number of alternatively spliced transcripts that dra-
matically increase the complexity of the transcriptome and thus the proteome. The 
significance of alternative splicing for vertebrate evolution was highlighted by two 
companion papers in the December 21, 2012, issue of Science [21, 22]. Alternative 
splicing is temporally and spatially controlled resulting in unique splice variants in 
different tissues and at different time points in the same tissue. Recently, the transi-
tion from a fetal to postnatal pattern of a conserved set of alternatively spliced iso-
forms was shown to regulate mouse heart development [23]. Clearly, mRNA 
splicing plays a significant role in mammalian cardiac development, but the poten-
tial contribution to human heart pathology remains unknown.
Only about 2% of the human genome is translated into protein, but it is now evi-
dent that as much as 80% of the genome is transcribed [24]. The importance of non-
coding RNA (ncRNA) for heart development has recently been shown by the 
requirement for correct spatiotemporal expression of specific microRNAs to ensure 
proper heart development [25]. In addition, there are clear spatial and temporal tran-
script splicing transitions that are conserved in the vertebrate heart during fetal and 
postnatal development [23, 26]. It is likely that there are multiple checkpoints to 
ensure proper transcriptome content for correct heart development. If these check-
points fail, it is likely that cardiac development will also fail. It is possible that some 
of the checkpoints may be encoded in ncRNA families yet to be investigated.
A significant class of evolutionarily conserved ncRNA is the small nucleolar 
RNAs (snoRNAs) with homologs in all eukaryotes. The snoRNAs primarily guide 
biochemical modifications of specific nucleotides (e.g., methylation and pseudouri-
dylation) of ribosomal RNAs and small nuclear RNAs (snRNAs, also referred to as 
spliceosomal RNAs). Those snoRNAs that target spliceosomal RNAs are associated 
with Cajal bodies in the nucleus and are known as scaRNAs (small Cajal-body- 
specific RNAs). In most vertebrate species, snoRNAs reside in the introns of other 
genes and require splicing to initiate snoRNA maturation [27]. Interestingly, intron- 
encoded snoRNAs may have special promoters to drive transcription, suggesting 
tissue specificity [28]. While the biochemical targets of snoRNAs have been clearly 
elucidated over the last 20 years, there is a surprising paucity of information regard-
ing the developmental significance of this abundant class of ncRNA.
Our initial studies focused on analyzing the transcriptome of cardiac tissues dis-
carded after surgical correction of tetralogy of Fallot (TOF), a congenital heart dis-
ease which is phenotypically representative of disruption of normal conotruncal 
development. Our preliminary data demonstrated that scaRNAs and their target 
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spliceosomal RNAs are reduced in TOF myocardium [29]. It is therefore possible 
that reduced levels of scaRNAs may impact stability or fidelity of the spliceosome, 
causing alterations in mRNA maturation that contributes to TOF. The accumulation 
of moderate reductions in scaRNA level may cause alterations in spliceosomal 
function, thus contributing noise to the communication between the first and second 
heart fields, and resulting in conotruncal misalignment. We hypothesize that tissue- 
specific control of the pattern of scaRNA expression could provide temporal and 
spatial specificity to the spliceosome, thus providing a ubiquitous mechanism for 
regulating splicing in the developing embryo.
While the epigenetic role that scaRNAs play in maintaining spliceosomal integ-
rity and precision is currently unexplored in terms of human health, we have col-
lected substantial evidence that scaRNAs and splicing patterns are tissue-specific 
and indeed play a critical role in vertebrate cardiac development. We have examined 
the impact on spliceosome function made by dysregulated scaRNAs using human 
primary cells derived from the right ventricle of infants with TOF and from nor-
mally developing infant heart tissue. In addition, using the well-established zebraf-
ish model, we characterized the nature of scaRNA interaction and its impact on 
vertebrate heart development. These experiments allowed us to confirm that these 
epigenetic elements affect vertebrate heart development, which represents a para-
digm shift in our understanding of human heart development.
scaRNAs direct the posttranslational biochemical modification of spliceosomal 
RNAs. Without this modification the spliceosome will fail to function properly [30]. 
Recent studies show that without site-specific modification the RNA–RNA interac-
tions of the spliceosomal RNAs, U2 and U6 do not achieve the correct conformation 
[31]. We previously identified 12 scaRNAs that were moderately but significantly 
reduced in TOF myocardium [29], similar to fetal levels of expression of the scaR-
NAs (Fig. 53.1). Interestingly, the majority of these scaRNAs target nucleotides that 
20
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Fig. 53.1 ScaRNAs have 
reduced expression in fetal 
and TOF myocardium 
compared to normal 
myocardium
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are important for conformational integrity of the U2–U6 complex [31]. Reduced 
levels of scaRNAs in TOF myocardium suggest a failure of adequate regulation of 
the scaRNA level early in gestation resulting in inadequate spliceosomal function. 
In the proposed investigation, we will carefully characterize the synergy between 
scaRNAs and assess the impact on spliceosome function (i.e., splicing) and verte-
brate heart development. It is our contention that scaRNA function may serve as a 
checkpoint in transcriptional processing, regulating many aspects of development, 
including heart formation.
53.2  Subjects
Our subjects were children less than 1 year of age with CHDs: TOF; tranposi-
tion of the great arteries (TGA); or pulmonary atresia with intact ventricular 
septum (PA/IVS) requiring surgical reconstruction. Informed consent was 
obtained from a parent or legal guardian after reviewing the consent document 
and having their questions answered (IRB #11120627). Our original observa-
tions were based on analysis of tissue from 16 infants with idiopathic TOF 
(nonsyndromic, without 22q11.2 deletions, 11 males, 5 females), comparison 
tissues from eight normally developing infants (3 males, 5 females). In addition, 
we have now characterized scaRNA, spliceosomal RNAs and the splicing pat-
tern of 6 key transcription factors from an additional 21 infants with idiopathic 
TOF. Our acquisition and characterization of control human infant heart tissues 
and human fetal heart tissue have been previously described [29, 32]. The fetal 
hearts were dissected by Dr. James O’Brien, a pediatric cardiac surgeon and co-
investigator, who performed the reconstruction of the conotruncal defects to 
ensure the tissue analyzed was from a similar location as the tissues removed 
during surgery.
53.3  Results and Discussion
53.3.1  scaRNAs Target U2 and U6 snRNAs and Both snRNAs Are 
Significantly Reduced in TOF
We used the scaRNABase database (http://www-scarna.biotoul.fr/index.php) to 
identify the nucleotides targeted for modification by the 12 scaRNAs that are 
reduced in TOF.  Only two snRNAs were predicted to be targeted: U2 and U6 
snRNAs. Six of the scaRNAs targeted 10 nucleotides (of 23 nucleotides that are 
known to be modified by scaRNAs) in U2 and 6 scaRNAs targeted 5 nucleotides (of 
8 total modified nucleotides) in U6. Interestingly, U2 and U6 had significantly 
reduced expression in our 16 TOF samples compared to the 8 controls (U2 was 
reduced 1.8-fold in TOF RV, p = 0.04, and U6 was reduced 3.2-fold in TOF RV 
p < 0.0001). This is consistent with reduced stability of U2 and U6 as a consequence 
of inefficient scaRNA biochemical modification.
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53.3.2  Cardiac Regulatory Networks Are Enriched for Alternative 
Splice Isoforms in TOF
Coordinated control of alternative splicing modifies the transcriptome and hence 
the proteome, while participating in most developmental processes [33, 34]. 
Studies of animal models have shown the importance of appropriate splicing for 
proper heart development [3, 5, 23, 35]. Still, knowledge of the sequence of 
events leading to tissue-specific alternative splicing is limited. More impor-
tantly with respect to the current proposal, nothing is known about the signifi-
cance of scaRNA-guided nucleotide modification in spliceosomal RNAs and the 
potential impact on transcript splicing. Intriguingly, our analyses of splicing 
variants in TOF myocardium revealed a substantial increase of alternative tran-
script isoforms which were enriched in gene networks known to be critical for 
regulating heart development, including the WNT and NOTCH pathways. More 
importantly, ~50% of these alternative isoforms are present in normal fetal RV, 
suggesting regulation of splicing did not proceed properly during heart develop-
ment in the infants with TOF (Alternative splicing of mRNA is dynamic in 
human fetal heart development, in prep). Figure  53.2 shows representative 
examples of alternative splicing, DICER and DAAM1, which have a similar pat-
tern of splicing in fetal and TOF tissues (blue and green lines) compared to the 
control tissue (red line). Dicer was shown to be important in mouse heart devel-
opment playing a role in splicing regulation [3], and splice variants of Daam1, 
a member of the WNT pathway, were recently shown to impact angiogenesis 
and endothelial cell migration and tube formation [36].
Fig. 53.2 Alternative splicing (e.g., DICER and DAAM1) is similar in TOF and fetal 
myocardium
D. C. Bittel et al.
345
53.3.3  Reduced scaRNA Expression and Alternative  
Splicing Are Not a Consequence of Hypertrophy
Hypertrophy is known to reactivate the expression of some fetal genes. Thus we 
wanted to determine if the fetal expression patterns we observed could be a conse-
quence of hypertrophy. As a comparison to TOF, we analyzed right ventricular sam-
ples from infants with TGA and PA/IVS. The embryological origins of TOF and 
TGA likely share some common features involving miscommunication between the 
first and second heart fields. However, PA/IVS is distinct and probably less complex 
in terms of origin of the regulatory defect. Nevertheless, TOF, TGA and PA/IVS 
share a common attribute: right ventricular hypertrophy. We observed only ten snoR-
NAs with differential expression in PA/IVS right ventricular tissue compared to con-
trol tissue. The ten snoRNAs that were reduced in PA/IVS were in common with 
TOF, and all target the 28S rRNA. In addition, U2 and U6 levels were not reduced in 
PA/IVS relative to the control tissue, and splice isoforms were essentially unchanged 
relative to the controls. On the other hand, RV from children with TGA bore a strik-
ing resemblance to the TOF pattern of scaRNA, spliceosomal RNA expression and 
fetal type splice isoforms. Therefore, the fetal type pattern of scaRNA and spliceoso-
mal RNA expression, as well as fetal splice isoforms, does not appear to be simply a 
consequence of hypertrophy since they were not present in PA/IVS RV samples. 
These findings support our postulation that scaRNAs are of key importance in regu-
lating heart development and not simply a consequence of hypertrophy.
53.3.4  Primary Cell Lines Derived from TOF Myocardium Retain 
the Same Relative Expression Patterns as the Tissue
We have derived primary cell lines from right ventricular myocardium obtained 
from 15 infants with TOF (TOF primary cells—TOFpc). These cells are most 
likely fibroblasts. The cell type is somewhat inconsequential since what we wish to 
examine is spliceosome response to changing levels of scaRNAs. We compared 
scaRNA levels, U2 and U6 levels, and splice isoform patterns between TOFpcs and 
primary myocytes derived from normally developing infant heart tissue. TOFpcs 
retained the same fetal type pattern of scaRNA, spliceosomal RNA expression and 
splicing isoforms of index genes relative to cells derived from normally developing 
neonatal cardiac tissue (data not shown). Splicing patterns also retained a TOF pat-
tern in the TOFpcs relative to the normal cells. These changes were consistent 
through at least four passages of the cell lines.
53.3.5  Overexpression of ACA26 and SCARNA1 (ACA35)  
in TOF Primary Cells Was Associated with an Increase  
in U2 Levels and a Decrease in Fetal Splice Isoforms
The scaRNAs were cloned into an intron sequence between hemoglobin exons 
3 and 4 so that they would be correctly processed in vivo and expression was 
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driven with the CMV promoter [37]. When either plasmid was transfected alone, 
there was an increase in the scaRNA but no change in U2 level or in splicing 
(data not shown). However, when we simultaneously transfected plasmids 
pCGL-ACA26 and pCGL- SCARNA1 into TOF primary myocytes, there was 
modest (~50%) but significant upregulation in U2 level. This is consistent with 
the idea that the scaRNA-directed modification of snRNAs is necessary for 
snRNA stability. More importantly, there was a reduction in the level of the fetal 
type splice form (Fig. 53.3). These data were repeated in TOFpcs from three 
different infants (genotypes). This is an exciting discovery which squarely sup-
ports our hypothesis that the scaRNAs are playing a role in spliceosomal func-
tion. These novel new findings support the critical role that scaRNAs play in 
mammalian heart development. This connection has not been investigated 
previously.
53.3.6  Knockdown of scaRNAs (scaRNA1 Targeting U2, or 
snord94 Targeting U6) Causes Heart Defects in Zebrafish
Studies of snoRNA-directed modification of ncRNA in archaea and lower 
eukaryotes have shown that nucleotide modifications are crucial for ncRNA 
functions [38, 39]. However, similar studies in vertebrates have not been 







































Fig. 53.3 Levels of fetal splice isoforms are reduced after overexpression of scaRNAs. Data are 
fold change, averaged from three different TOF primary cell lines (genotypes). ∗Significantly dif-
ferent from levels in sham transfected TOF primary cells
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in zebrafish by Kenmochi and colleagues [40]. In summary, they suppressed the 
expression of several snoRNAs, including U26, in zebrafish (U26 was one of the 
snoRNAs that we identified as being down regulated in myocardium from infants 
with TOF). Using a unique highly sensitive mass spec analysis that they devel-
oped, they found that decreased U26 snoRNA expression reduced the snoRNA-
guided methylation of the target nucleotides. Impaired rRNA modification, even 
at a single site, led to severe morphological defects and embryonic lethality in 
zebrafish. Thus, nucleotide modifications in rRNA play an essential role in ver-
tebrate development. Additionally, as a preliminary study this past summer, in 
collaboration with Kenmochi and colleagues we have suppressed the expression 
of two scaRNAs, scarna1 and snord94 (both are homologous to scaRNAs identi-
fied by our screens of TOF myocardium) in zebrafish embryos. The knockdown 
of the scaRNAs resulted in developmental abnormalities, including heart malfor-
mations (Fig. 53.4) and altered splicing of genes that regulate heart development. 
This is an exciting finding and taken together with our observations that scaRNA 
levels impact splicing in TOF primary cardiomyocytes, suggesting that scaRNAs 
play a critical and, as yet, unrecognized role in vertebrate heart development. 
Furthermore, it appears that these particular scaRNAs primarily affect heart 




Fig. 53.4 Representative example of zebrafish morphant at 72  hpf (hours post fertilization, 
knockdown targeted at scarna1). Arrows indicate the heart, blue and grey outlines indicate enlarge-
ment of both the atria and ventricle, respectively. Eye and head size are slightly changed but other 
organs, brain, notochord, otic vesicles, and fins appear essentially normal at this stage
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53.3.7  Splice Isoforms Change During Development in Zebrafish 
and After Targeted Knockdown of scaRNAs
We downloaded RNA-Seq data from the Gene Expression Omnibus derived from 
developing zebrafish at 0.75 h, 6 h, 1 day, 2 days, 3 days and 5 days postfertilization 
(GEO#: GSE30603) and analyzed for alternative splicing. We found clear changes in 
ratios of splice isoforms of a large proportion of genes, including genes important for 
heart development (e.g., Gata4, Mbnl1, Notch1, Dicer, data not shown). We performed 
RNA-Seq on RNA extracted from 24hpf zebrafish embryos treated with antisense 
morpholinos directed at scaRNA1 or snord94 and WT untreated embryos and embryos 
treated with mismatch morpholinos. Paired-end sequencing runs were performed with 
101 base reads on the Illumina HiSeq 1500. RNA-Seq data were analyzed using the 
“Tuxedo suite.” There were no appreciable differences between mismatch morpholino 
and WT-type embryos. snord94 was reduced by 40%, and scaRNA1 was not detect-
able in their respective knockdown morphants compared to WT or mismatch treated 
embryos. We saw a clear shift in the predominant isoforms of our index genes after 
treatment with the antisense morpholino (Fig. 53.5 shows results of validation of the 
WNT pathway gene splicing variants in zebrafish morphants). These analyses clearly 














































Fig. 53.5 Splicing of WNT pathway genes is altered in zebrafish morphants. Treating zebrafish 
embryos with anti-scarna1 morpholino causes changes in exon retention of cardiac regulatory 
genes. Eleven of 39 members of the WNT family have changes in exon retention after treatment 
with antisense morpholino (assessed by RNA-Seq and qRT-PCR; values shown are from qRT-PCR 
data). The mismatch morpholino has no significant effect on splicing
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Furthermore, the knockdown experiments strongly support our hypothesis that scaR-
NAs are important for regulating splice variants and heart development. Furthermore, 
snord94 and scaRNA1 appear to be important for heart development.
53.4  Conclusions
We examined the noncoding transcriptome in myocardial tissue from children with 
tetralogy of Fallot (TOF) and observed changes in mRNA splice isoforms of genes 
that are critical for regulating heart development [29]. In parallel, we found a mod-
est but significant reduction in the levels of 12 small Cajal body-specific RNAs 
(scaRNAs are a subset of snoRNAs and direct the biochemical processing of spli-
ceosomal RNA) [29]. These patterns of scaRNA expression and splicing are similar 
to patterns we saw in the fetal myocardium. To explore the potential relevance of 
these findings, we manipulated the expression of two of these scaRNAs in cell cul-
tures and zebrafish. We saw clear changes in splicing patterns and, importantly, 
developmental deficiencies including heart defects in zebrafish. Our findings sup-
port a direct role for scaRNAs in fine tuning the fidelity of the spliceosome in a 
manner that is critical to support splicing transitions that are essential for correct 
heart development. Our observations open the door on a new paradigm in develop-
mental regulation and potentially may explain a substantial portion of the missing 
genetic heritability of CHDs. Importantly, by accurately characterizing the role of 
scaRNAs in disrupting genetic signaling, it is possible that this could lead to the 
identification of “targets” that may be amenable to change through intervention as 
is the case with microRNAs.
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Abstract
Despite improvements over the past 30 years, 10-year pediatric heart trans-
plantation survival rates remain low and mechanical support is both expen-
sive and relatively unavailable. In contrast to isolated cell therapies, 
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implantable engineered cardiac tissues (ECTs) recover myocardial mass and 
function, creating the opportunity for cardiac recovery rather than replace-
ment. Our ECT research has progressed from using embryonic avian and 
rodent cell compositions to human induced pluripotent stem cell (h-iPSC)-
derived, multiple cell lineage formulations with the goal of clinical transla-
tion. We generate ECTs from h-iPSC- derived cardiomyocytes (CM), 
endothelial cells (EC), and vascular mural cells (MC) in both linear 
(15 × 1 mm) and large format (LF, 20 × 20 mm) geometries using rodent-
derived and human-compatible reagents. H-iPSC ECTs undergo rapid gel 
compaction and begin intrinsic beating by day 3. CM fraction at ECT forma-
tion is approximately 60%. The ECT maximum capture rates increased dur-
ing in vitro culture up to 28 days and in response to optogenetic pacing (OP) 
using AAV-ChIEF from day 7 to 14. ECT relaxation times decreased, force- 
frequency relations became more neutral, and beat-to-beat hysteresis 
decreased with prolonged culture or OP.  H-iPSC-derived ECTs generated 
using human collagen I and human compatible MaxGel have comparable 
structural and functional features to rodent-derived ECTs. Linear and 
LF-ECTs implanted onto xenotolerant infarcted rat hearts survived, engrafted, 
improved ejection fraction, normalized regional echo strain, and reduced scar 
area at 4 weeks. Thus, these h-iPSC ECT compositions show promise as a 
strategy for pediatric myocardial recovery.
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54.1  Introduction
Despite dramatic progress in the surgical management and survival of infants 
with complex congenital heart defects, myocardial injury following cardiac sur-
gery and progressive cardiac dysfunction results in significant morbidity and 
mortality. There are currently many cardiac “cellular therapies” undergoing pre-
clinical and clinical trials in adults. There have been small, encouraging clinical 
trials using stem cells in infants with hypoplastic left heart syndrome in Japan 
[1–3] that have led to similar trials in the United States [4–6]. It is clear that 
injected or implanted cells do not survive and that functional improvement occurs 
via paracrine mechanisms that impact angiogenesis and/or remodeling. Rapid 
advances in tissue engineering over the past two decades have resulted in the 
generation of functional, multicellular, 3D cardiac tissues with the potential for 
translation to human cardiac repair and regeneration [7–14]. This chapter pro-
vides a concise overview of some of the key issues in the generation, maturation, 
and translation of these engineered cardiac tissues (ECTs) and related work in 
our laboratory.
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54.2  Continued Expansion of Engineered  
Cardiac Tissues (ECTs)
Following the initial description of 3D-reconstituted heart tissue using embryonic 
chick CM [7], CM species used to generate ECTs include chicken, mouse, and rat 
embryonic and post-natal CM, and a range of embryonic stem cells and induced 
pluripotent stem cells from rodents and human cell lines [8–16]. While initial for-
mulations used a combination of cells, matrix factors, and collagen, additional com-
positions have utilized fibrin rather than collagen to reduce the effect of matrix 
stimulated inflammation [17] and tunable matrix compositions [18]. ECTs became 
increasingly popular as in vitro platforms for drug toxicology models [19] as well 
as for in vitro models for cardiac genetic disease modeling and repair [20].
54.3  Human Induced Pluripotent Stem Cell  
(H-iPSC) Linear ECTs
While cells from multiple vertebrate species have been used to investigate ECT 
structural and functional maturation and to model cardiomyopathies, it is clear that 
human cells are required for clinical trials and future therapies. H-iPSCs can be dif-
ferentiated to cardiac lineages and produced in the quantities required for pre- 
clinical and future clinical trials. Multiple studies have validated the ability of 
h-iPSC-derived CM to mature and form implantable cell sheets [21]. To advance 
this paradigm, we developed and validated methods to generate linear (15  mm 
length × 1 mm diameter) ECTs from human iPSCs-derived CV lineages (h-iPSC- 
ECTs) [11]. We found that the coexistence of EC and MC vascular lineages with 
CMs within the 3D ECT compositions promoted tissue maturation (Fig.  54.1). 
Furthermore, we demonstrated the therapeutic potential of h-iPSC ECTs in an 
immune-tolerant rat myocardial infarction (MI) model showing the improvement of 
cardiac function with regenerated myocardium and enhanced angiogenesis [11].
54.4  Generation and Characterization  
of Large Format H-iPSC ECTs
Larger-format ECTs have been described using pre-vascularization, stacking cell 
sheets, scalable scaffolds, and bioprinting [12, 22]. Building on our success with 
linear h-iPSC ECTs and guided by initial works from the Bursac lab using polydimeth-
ylsiloxane (PDMS) molds, we fabricated a range of mold geometries from 0.5 mm 
thick PDMS sheets to generate a novel large-format hiPSC-ECT (LF-ECT, Fig. 54.2). 
As with our linear h-iPSC ECTs, these h-iPSC LF-ECTs undergo gel compaction, 
spontaneously and then synchronously beat, develop CM alignment along the inter-
nal bundle long axis, and survive in vivo implantation to recover myocardial function 
in an immune-tolerant rodent MI model [12]. Though unpublished, we have scaled 
this LF-ECT geometry to 30 × 30 mm, suitable for large animal pre-clinical studies.











































































Fig. 54.1 H-iPSC linear ECTs generate functional cardiac tissues that recover cardiac structure 
and function following injury. (A) Schematic diagrams for three ECT compositions (upper) con-
taining cardiomyocytes (CM), endothelial cells (EC), and/or mural cells (MC) and the proportions 
of each cell type used to generate ECTs (lower). (B) CM + EC + MC composition best preserved 
active force at increasing pacing rates. (C) Schematic timeline of rat MI surgery and ECT implan-
tation (upper panel), three hiPSC-ECTs bundled for implantation (middle panel), and representa-
tive M-mode images for sham-operated (left) and ECT-implanted (right) rats 4 weeks after surgery 
(lower panel). (D) (a–c) Left ventricular (LV) histology 4  weeks after implantation of h-iPSC 
ECTs with Masson’s trichrome staining (upper left panel, 500 μm scale bar), double immunostain-
ing for cTnT and HNA (human cell marker) with arrows indicating engrafted myocardium (upper 
right panel, 500 μm scale bar): (i) lower magnification with white arrows indicating capillary for-
mation around grafted tissue; orange arrows indicate penetrating vasculature and white dotted line 
indicates vasculature within the ECT graft (200 μm) with higher magnification in (ii) 50 μm scale 
bar and (iii) 20 μm scale bar. (Adapted from [11])
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54.5  Optogenetic Pacing of H-iPSC ECTs
One of the barriers to h-iPSC-derived ECT clinical translation is the relative electro-
physiologic and contractile immaturity of h-iPSC-derived CMs. Strategies to mature 
CM within tissue-engineered structures include cyclic mechanical loading and elec-
tric field stimulation. As a novel approach, we designed proof-of-principle experi-
ments to transfect h-iPSC-derived ECTs with a desensitization-resistant, chimeric 
channel rhodopsin, ChR (ChIEF) protein and then optically pace (OP) ECTs to 
accelerate maturation. We transfected h-iPSC ECTs using an AAV-packaged ChIEF 
and then verified OP by whole-cell patch clamp. ECTs were then chronically OP 
(C-OP) above their intrinsic beat rates in vitro from day 7 to 14. C-OP resulted in 



















































Fig. 54.2 H-iPSC large format LF-ECTs generate functional cardiac tissues that can recover car-
diac structure and function following injury. (a) Schematic diagrams for three ECT compositions 
of LF-ECTs: ME-ECT with 7 mm posts in a pattern to generate a mesh, ML-ECT with 16 mm 
posts to generate multiple linear bundles, and PS-ECT to generate a central cell sheet (upper) and 
representative images after 14 days in vitro. (b) Prolonging in vitro culture from 14 days (blue) to 
28 days (red) increased the rate of force generation and relaxation. Dashed lines highlight 90% 
contraction time (CT) and relaxation time (RT). (c) Representative Masson’s trichrome staining of 
SHAM and ME-ECT h-iPSC LF-ECT IMPLANT rat hearts 4 weeks post-implant. Red dotted line 
indicates engrafted area. Scale bar: 2 mm. (d) ME-ECT implantation reduced scar area (% of LV). 
(Adapted from [12])
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of some cardiac relevant genes though active force generation and histology were 
unchanged (Fig. 54.3). These results validate the feasibility of a novel C-OP para-
digm for non-invasive and scalable OP-induced ECT maturation strategies.
54.6  Incorporating Human Compatible Biomaterials into 
H-iPSC ECTs
An additional barrier to the clinical translation of h-iPSC-derived ECTs is the quali-
fication of all reagents for human use as required by the FDA. Therefore, we revised 
our h-iPSC ECT formulation to replace rodent-derived Matrigel with human- 
derived and clinically acceptable MaxGel and replaced rodent type with human type 
I collagen. These experiments required multiple variations in composition but ulti-
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Fig. 54.3 Optogenetic pacing (OP) of h-iPSC linear ECTs results in functional maturation. (a) 
Schematic for the generation of h-iPSC linear ECTs with CHiEF virus. (b) D14 chronic C-OP 
ECT showing 52% CM and 13% ChIEF-transfected cells. Nuclei (DAPI-blue), CM (cTnT-green), 
ChIEF-transfected cells with tdTomato (red). CM were predominantly located at the outer surface 
and the majority of transfected cells were CM. Inset in (b) shows higher magnification of double- 
positive cTnT and tdTomato cells. (c) Force measurement during intrinsic beating and during OP 
via 470 nm LED at 3.5 Hz. (d) Stress-frequency curves showed a less negative relationship after 
chronic (C-OP) or prolonged culture to D28 (unpublished data)
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and functional features equivalent or better than ECTs formulated with rodent-
derived matrix reagents (Fig. 54.4). While higher cost, these experiments provide 
additional insights for the formulations required for h-iPSC translation to humans.
54.7  Future Directions and Clinical Implications
Clearly, biological repair and replacement of lost myocardium using h-iPSCs that 
can form myocardium (versus skeletal muscle) are feasible, and clinical trials to 
determine safety and feasibility in adult heart failure patients should occur in the 
near future. It is important to note that many adult stem cell trials have shown sta-
tistically and clinically significant improvements in heart failure patients, and stud-
ies using stem cells have shown encouraging results for children with congenital 
heart disease [1–4]. The use of isolated cells, or the exosomes extracted from cells, 
may represent a much simpler therapeutic product to manufacture, verify, and dis-
tribute for future clinical therapy compared to the complexities of generating engi-
neered tissues (multi-layer cell sheets and ECTs). Translation of these more complex 
formulations will require the engagement of biotechnology and biopharma compa-
nies with expertise in semi-automated manufacturing techniques and complex bio-




















































Fig. 54.4 Comparison of rodent-derived and human component-derived h-iPSC linear ECTs. (a) 
Representative images of rodent-derived (Matrigel and rat collagen I) and human compatible com-
ponent (MaxGel and human collagen I) h-iPSC linear ECTs immediately after pouring on day 0 
and after 14 days of in vitro culture. (b) Comparison of active stress on day 14 between 3 ECT 
compositions: Matrigel and rat collagen I, MaxGel and rat collagen I, and MaxGel and human 
collagen I. Active stress was greatest in human component ECTs (unpublished data)
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innovation in CV care for infants and children has been shown to also be valuable 
for the treatment of the much larger adult market. Therefore, the opportunities to 
translate h-iPSC ECTs towards infants and children with significant myocardial 
injury and heart failure remain encouraging.
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55Quantification of Contractility in Stem Cell-Derived Cardiomyocytes
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Abstract
Murine embryonic stem cell derived cardiomyocytes (mESC-CMs) and murine 
induced pluripotent stem cell derived cardiomyocytes (miPS-CMs) were differ-
entiated and co-cultured with irreversibly injured myocardial tissue slices. When 
beating clusters had integrated morphologically into the damaged tissue, isomet-
ric force measurements were performed. Effects of Ca(2+), nifedipine, and beta- 
adrenergic modulation were studied during loaded contractions and compared 
with the contractile behavior of native murine myocardial slices. Both CM vari-
ants conferred force to the myocardial tissue. Contraction increased with higher 
concentrations of Ca(2+) and Isoproterenol, and decreased with nifedipine in all 
slice variants. Differences between mESC-CMs and miPS-CMs were non- 
significant, however, significantly different (P < 0.05), when compared to native 
myocardial slices.
Keywords
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55.1  Introduction
Therapy for heart failure is a challenge also in the setting of congenital heart disease. 
Up to now, there is no true solution of a repair of damaged myocytes. Stem cell-
derived cardiomyocytes are believed to offer possible solutions in the future. The 
possibility to potentially replace failing myocardium with stem cell-derived cardio-
myocytes will depend to a major part on the contractile properties of these cells.
In order to quantify the contractility of stem cell-derived cardiomyocytes, we 
present an in vitro model using slices of murine ventricles.
The aim of our work was to compare the contractile properties of (1) murine 
embryonic stem cell-derived cardiomyocytes (mESC-CMs), (2) murine induced plu-
ripotent stem cell-derived cardiomyocytes (miPS-CMs) and (3) contractile proper-
ties of native murine ventricular myocardium at a comparable age of differentiation.
As assumed in a prior work, it is almost impossible to assign myocardial contrac-
tile properties of transplanted cells in vivo; we therefore developed a tissue culture 
model mimicking the situation in vivo [1].
55.2  Materials and Methods
Experiments were carried out according to the Principles of Laboratory Animal care.
We prepared avital tissue slices from neonatal murine ventricles, which were 
used as a non-contractile matrix as described elsewhere [2]. In summary, neonatal 
murine ventricles were embedded in 4% low-melting agarose and cut into 
300-μm-thick slices along the short axis with a microtome (Leica Microsystems, 
Wetzlar, Germany), kept in cold (4 °C) Ca2+-free Tyrode’s solution, continuously 
aerated with pure oxygen and supplemented with CaCl2 if needed. Finally, the ven-
tricular tissue slices were exposed to irreversible myocardial injury by severe and 
long-standing deprivation of oxygen and glucose.
MESC-CMs and miPS-CMs were generated as described previously [3]. Beating 
clusters of miPS-CMs and mESC-CMs were microdissected 11 days after initiation of 
in vitro differentiation and co-cultured for 5–7 days on top of the oxygen- and glucose-
deprived ventricular slices, placing the non-vital slices into a funnel-shaped cavity and 
adding CM clusters in a very cautious way using a score to estimate attachment and 
“integration” under microscopic control. For the experiments of contractility measure-
ments, those two types of co-culture preparations and native embryonic heart slices 
were mounted onto two steel needles connected to an isometric force transducer in a 
customized dish within Tyrode’s solution. All three types of slices were conditioned 
stepwise by extending their length until maximal force resulted during continuous pac-
ing at 2–4 Hz. Signals from the force measurement transducer and electrical pacing 
were A/D converted, amplified and recorded on a digital medium using DASYLab 
software (National Instruments) with a sampling rate of 1 kHz, high and low pass fil-
tered (0.05–15 Hz) and signal averaged. Isometric force was measured in Tyrode’s 
solution after 5 min of spontaneous beating at constant resting conditions. The ampli-
tudes of 20 contractions before and after stimulation were normalized and analyzed.
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Effects of Ca2+ were analyzed in Ca2+-free Tyrode’s solution by increasing con-
centrations of Ca2+ (0.5, 2.5, 4.5, 6.5 and 8.5 mM, 10 min for each concentration). 
In addition, the effects of the Ca2+-blocker nifedipine (0.01–10 M) and ß-adrenergic 
isoproterenol (10.9–10.6 M) were analyzed.
Means and standard deviations, and ranges were calculated. Paired and unpaired 
t tests or one-way analysis of variance (ANOVA) was performed. P  <  0.05 was 
considered statistically significant.
55.3  Results
Native embryonic heart tissue as well as co-cultured preparations with mESC-CMs 
or miPS-CMs showed spontaneous contractions. During spontaneous contractions 
no difference between the beating frequency of preparations with mESC-CMs 
[2.9 ± 0.4(1.3–4.3) Hz, n = 11] and miPS-CMs [2.2 ± 0.2(1.5–4.0) Hz, n = 12] was 
found. There was significant slower contraction rate in native embryonic heart slices 
[0.8 ± 0.1(0.1–1.4) Hz, n = 8, P < 0.05]. In Ca2+-free Tyrode’s solution no contrac-
tion occurred. Contraction increased with increasing concentration of Ca2+ in 
mESC-CMs, miPS-CMs and native embryonic heart slices. Native embryonic heart 
slices showed significantly stronger contractility (P < 0.05 vs. both miPS-CMs and 
mESC-CMs). Comparison was achieved after data normalization using the force 
values at Ca2+ = 2.5 mM of individual experiments. 3/4 miPS-CMs preparations and 
2/4 mESC-CMs preparations showed decreasing contraction at a concentration of 
1 μmol and stopped contraction at concentrations of 10 μmol nifedipine. Native 
embryonic heart slices continued contractions also at high nifedipine doses. Dose- 
dependent negative inotropy of nifedipine was seen in all three groups (Fig. 55.1). 





















Fig. 55.1 The effect of nifedipin(NIF) is shown in the three preparations: native embryonic heart 
tissue, murine induced pluripotent cell derived cardiomyocytes (miPS-CMs) and murine embryo-
logic stem cell derived cardiomyocytes (mESC-CMs). Note the similar behavior of all three prepa-
rations. Important the different scales of amplitudes (micro Newton)—chosen for relative 
comparison
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A positive inotropic effect of isoproterenol was seen in all three groups. The inotro-
pic effect of isoproterenol was significantly stronger in native embryonic heart tis-
sue. Differences between mESC-CMs and miPS-CMs were non-significant.
55.4  Discussion
The results demonstrate that our ventricular slice model for analysis and compari-
son of contractility of co-cultured preparations with mESC-CMs, miPS-CMs and 
native embryonic heart tissue works sufficiently. The primary finding from this 
study is that stem cell-derived cardiomyocytes, both mESC-CMs and miPS-CMs 
attached to avital myocardial slices, showed quantifiable force/contractility after 
co-culture under defined conditions. There were only minor differences between 
such mESC-CM and miPS-CM preparations. However, significant differences in 
contraction behavior were found when compared to native embryonic heart slices of 
comparable age. Calcium dependency was demonstrated in all three preparations in 
a relative similar fashion, however, in a much lesser amplitude level seen in the 
pluripotent stem cell-derived cardiomyocyte preparations. MESC-CM and miPS-
 CM slice preparations exhibited contractile behavior of possibly immature sarco-
plasmic reticulum. The Ca2+-channel antagonist nifedipine induced a dose-dependent 
negative inotropy on the force of contraction of all three preparations underlining 
the importance of L-type calcium channels for contractility regulation. The stem 
cell-derived cardiomyocytes showed significantly diminished ß-adrenergic response 
compared to native embryonic heart slices.
So far there is no data that convincingly support the hypothesis that pluripotent 
stem cell-derived cardiomyocytes are capable of developing into a cardiomyocyte 
phenotype that is identical to mature ventricular cardiomyocytes in vitro [4]. The 
potential development of mature sarcoplasmatic reticulum in stem cell-derived car-
diomyocytes is still an issue, and the understanding of factors involved in differen-
tiation toward a functional and a mature cardiac phenotype is still incomplete [5].
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56A Neurotrophic Factor Receptor GFRA2, a Specific Surface Antigen for Cardiac 
Progenitor Cells, Regulates the Process 
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A surface marker specific for cardiac progenitors (CPs) allows the robust isola-
tion of CPs, effectively circumventing the necessity of genetic modification. 
Recently, we have reported that glial cell line–derived neurotrophic factor recep-
tor alpha 2 (Gfra2), which is anchored to the plasma membrane via 
Glycosylphosphatidylinositol, specifically marks CPs of both the first and sec-
ond heart fields within the early mouse embryo [1], identified by single-cell 
expression profiling on mouse embryonic CPs (Fig. 56.1) [2, 3].
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• GFRA2 facilitates the isolation of CPs by fluorescence-activated cell sorting 
from differentiating mouse and human pluripotent stem cells. If utilizing pan- 
mesoderm marker PDGFRA and hemangioblastic marker KDR in conjunction 
with GFRA2, multipotent CPs giving rise to cardiomyocytes, smooth muscle 
cells and endothelial cells are identified as GFRA2+/PDGFRA+/KDR+ whereas 
CPs already committed only to cardiomyocytes are identified as GFRA2+/
PDGFRA+/KDRneg.
Cell Reports 2016 16, 1026-1038 DOI: (10.1016/j.celrep.2016.06.050)
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Fig. 56.1 GFRA2 is a specific marker for CPs which governs myocardial compaction. Upper 
case: A signal transduction via GFRA1/2 is upstream of NOTCH signal that is indispensable for 
the myocardial compaction process. Lower case: GFRA2 is a specific surface antigen to identify 
CPs from differentiating pluripotent stem cells in mice and humans. This illustration is cited from 
Ishida, H et al. Cell Rep. 2016 Jul 26;16(4):1026–38, and is licensed under the Creative Commons 
Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 
94042, USA
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• In loss-of-function of Gfra2, the functional redundancy of GFRA1 compensated 
for the cardiac GFRA2 signal in the mutant mouse embryos. Compound mutant 
of Gfra1/2 showed non-compaction cardiomyopathy due to the down-regulation 
of NOTCH signal in the developing heart. Cardiac GFRA2 signal is distinct from 
the canonical pathway that depends on the RET tyrosine kinase and its estab-
lished ligands.
Collectively our findings establish a platform for investigating the biology of 
CPs as a foundation for the future development of CP transplantation therapies for 
treating heart failure.
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57Cardiac Cell Specification by Defined Factors
Yuika Morita and Jun Takeuchi
Our previous study has shown that Tbx5-Gata4-Baf60c-induced functional cardio-
myocytes via the ectopic expression of Nkx2-5/Islet1 in the mesodermal cells, but 
not in the endodermal/ectodermal cells [1, 2] (Fig. 57.1). Mesp1 is one of the major 
transcriptional regulators specifying the mesodermal lineage, but it also induces 
skeletal muscle, hematopoietic and vascular cells as well as cardiac cells [3–5]. 
Eomesodermin (Eomes), an upstream player of Mesp1, regulates mesodermal cell 
lineages, but it does not have a potential for specification of cardiac cell fate from 
cardiovascular lineages either [6]. Therefore, the study of cardiac cell fate specifica-
tion from the embryonic stem cells by the defined factors still remains at least two 
major questions.
 1. How the cardiac lineage is committed from the mesoderm via repressing skeletal 
muscle, hematopoietic and vascular cell fates?
 2. Are there any factors specifying the cardiac lineage directly from the undifferen-
tiated stem cells?
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To disclose these questions, we performed RNA sequencing from the anterior 
field at the early cardiac crescent stage, and we identified Sall1 gene as a suitable 
key regulator for the cardiac cell lineage [7]. Overexpression of Sall1 in mouse 
ES accelerated cardiogenesis and also promoted cardiac cell fate in human iPS 
cells with upregulation of several cardiac transcriptional genes (ISLET1/NKX2-5/
MEF2C) and sarcomeric genes (TNNT2/MYL7/MYH6/MYH7). Sall1 also acts as 
a modulator to recruit the histone-modification/the chromatin remodeling factors 
and the other transcriptional factors to commit the cardiac cell fate. Interestingly, 
permanent expression of Sall1 in differentiating human iPS cells increased the 
number of cardiac progenitor cells [7] (Fig. 57.2). These data suggest that Sall1 
acts as a key factor to promote and maintain the cardiac progenitor cell phase 
from undifferentiating stem cells, and down-regulation of Sall1 expression after 
induction of cardiac progenitor cells is necessary to shift the cell fate to cardio-
myocyte differentiation.
Our data just show that a novel gene, Sall1, programs cardiac cell fate and accel-
erates cardiogenesis, but this factor may act as a defined player for the cardiac cell 
fate with and the other transcriptional factors to define. Thus, the study for isolation 
of in vivo Sall1 partners and establishment of its regulation will give us the next 

















Fig. 57.1 The defined factors for cardiogenesis
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Fig. 57.2 The critical expression of Sall1 for promoting cardiogenesis
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58A Temporo-Spatial Regulation of Sema3c Is Essential for Interaction 
of Progenitor Cells during Cardiac 
Outflow Tract Development
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Cardiac neural crest cell · Second heart field · TBX1 · Congenital heart disease
The two cardiac progenitor cell lineages, cardiac neural crest cells (cNCCs) and 
the second heart field (SHF), play key roles in the development of the cardiac 
outflow tract (OFT). Both cardiac progenitor cells interact with each other and 
contribute to OFT formation cooperatively. The neurovascular guiding molecule, 
semaphorin 3c (Sema3c), is thought to serve as a key attractant for the migration 
of cNCCs. A previous study reported that Tbx1 null mice showed a significant 
reduction in Sema3c expression in the OFT region [1]. However, the regulatory 
effect of Tbx1 on Sema3c was unclear. Here, we show that Sema3c plays key 
roles in cNCCs-SHF interactions through the regulation by Tbx1 and other mol-
ecules during OFT development [2].
By generating reporter transgenic mice harboring Sema3c enhancer fragments 
and lacZ transgene, we found that Foxc1/c2 directly regulated Sema3c expression 
in the OFT via direct binding to the Fox-site on the 5′ flanking sequence of Sema3c 
where Tbx1 synergistically enhanced the Foxc1/c2 function. In comparison, 
Tbx1 in the SHF inhibited ectopic Sema3c expression in cNCCs within the pha-
ryngeal arch region via Fgf8-ERK signaling. Consistently, the ectopic expression 
of Sema3c in the cNCCs of Tbx1 hypomorphic mouse embryos caused abnormal 
migration and/or aggregation, and the overexpression of Sema3c in cultured 
cNCCs inhibited their migration, resulting in their aggregation. These results sug-
gest that Tbx1-Fgf8-ERK signaling negatively regulates Sema3c expression in 
cNCCs for the proper guidance of their migration from the dorsal pharyngeal 
region to the OFT.
In conclusion, a proper temporo-spatial expression of Sema3c, which is tightly 
regulated positively by Foxc1/c2 and negatively by the Tbx1-Fgf8 cascade, is essen-
tial for the correct navigation of cNCCs towards the OFT (Fig. 58.1). This report is 
the first evidence of a detailed signal transduction mechanism for the interaction 
between cNCCs and SHF progenitor cells through Sema3c, providing a new molec-
ular basis for a potential therapeutic strategy for congenital heart diseases involving 
OFT defects.
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Research (B) and Grant-in-Aid for Young Scientists (B), Keio University Academic 
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Fig. 58.1 Temporo-spatial regulation of Sema3c by Foxc1/c2 and Tbx1-Fgf8 cascade from the sec-
ond heart field for proper navigation of cardiac neural crest cells towards the developing outflow tract
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59Spatiotemporally Restricted Developmental Alterations 
in the Anterior and Secondary Heart 




During the early heart development, heart outflow tract elongates by the addition 
of cardiomyocytes from the anterior heart field (AHF)/secondary heart field 
(SHF). Dye-marking experiments in early chick embryos clarified that each 
AHF/SHF migrates to distinct conotruncal regions. Local administration of reti-
noic acid to the AHF/SHF causes distinct conotruncal heart defects in a region 
and stage dependent manner. For example, impaired development of AHF at HH 
stage 12 (corresponding to Carnegie stages 10–11  in human embryos) causes 
dextroposed aorta including transposition of the great arteries (TGA), while SHF 
at HH stage 12 persistent truncus arteriosus (PTA). Our results indicated that the 
abnormal development of certain AHF/SHF at certain stages causes specific 
spectrum of conotruncal heart defects.
Keywords
Second heart field · Heart outflow tract · Transposition of great arteries · 
Congenital heart defects · Retinoic acid
Developmental alterations of the heart outflow tract (OFT) cause conotruncal heart 
defects (CTHDs), which are often diagnosed in infants with congenital heart defects. 
During the early heart development, the OFT elongates by the addition of 
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cardiomyocytes from the second lineage of heart-forming regions, which reside in 
the first and second pharyngeal arches (anterior heart field [AHF]) as well as in the 
splanchnic mesoderm of the pericardial coelom in the posterior pharyngeal arches 
(secondary heart field [SHF]) [1]. As the arterial pole moves in the anterior-to-pos-
terior (cranial-to-caudal) direction, the AHF is first added to the OFT followed by 
the SHF. Therefore, abnormal development of certain parts of the AHF or SHF at 
certain stages may cause specific CTHDs.
Dye-marking experiments in chick embryos at the early looped-heart stage 
showed that the right and left AHFs migrate ipsilaterally to form the proximal OFT, 
whereas SHFs migrate rotationally to form the distal OFT beneath the semilunar 
valves [2]. The results indicated that each AHF/SHF migrates to generate distinct 
conotruncal regions.
Retinoic acid (RA) is a potent teratogen to induce CTHDs. Local administration 
of RA to the AHF in chick embryos at early looped-heart stage (stage 12) caused a 
truncated OFT, thereby resulting in transposition of the great arteries (TGA) and 
double outlet right ventricle (DORV) (Table 59.1) [3]. The left AHF was more sen-
sitive to RA in the development of TGA. Accordingly, the proximal OFT, especially 
the subpulmonic region, may play a role in conotruncal rotation to establish the left 
ventricle-to-aortic connection [4]. Persistent truncus arteriosus (PTA) occurred 
when RA was added to the SHF at stage 12 as well as to the AHF/SHF at stage 14 
(Table 59.1). Accordingly, normal development of the distal OFT is necessary for 
conotruncal septation involving the aortico-pulmonary septum, a derivative of the 
cardiac neural crest. In conclusion, AHF at the early looped-heart stage, correspond-
ing to Carnegie Stages 10–11  in human embryos, is the region responsible, and 
impediment of which causes a dextroposed aorta including TGA.
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Table 59.1 Conotruncal heart defects 
produced by local administration of RA 
to the AHF or SHF at early looped-heart 
stage in chick embryonic hearts
RA addition At stage 12a At stage 14b
To AHF TGA, DORV PTA
To SHF PTA PTA, DORV
aCorresponding to embryonic day (ED) 8.5  in 
mouse and Carnegie stage 10 in human
bED 9.0 in mouse and Carnegie stage 11 in human
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Congenital cardiovascular disease · Great arteries · Notch signaling
Members of the Hey transcriptional factor family are Notch target genes [1], and 
they have unique and redundant functions in cardiovascular development. Among 
them, we recently reported that Hey1 had an indispensable role for the great artery 
formation (Fig. 60.1) [2].
Dysfunction of several transcription factors is correlated with anomalies of the 
great arteries. Human TBX1 is the gene responsible for 22q11.2 deletion syndrome, 
and mutant mice for Tbx1 recapitulate the phenotypes such as interruption of aortic 
arch type B and right-sided aortic arch. These defects are originated from the 
impaired development of the fourth pharyngeal arch arteries (PAAs) at early embry-
onic stages, and migration, proliferation and survival of the neural crest cells are 
affected in Tbx1 mutant mice [3]. Similarly, the deficiency of upstream and down-
stream transcription factors of Tbx1, such as Foxc2, Gbx2 and Hes1, results in 
abnormal great arteries.
The malformation of great arteries in Hey1 knockout mice is also associated with 
the fourth PAA defect although the expression of Tbx1 and target genes as well as 
the behavior of neural crest cells are normal [2]. Interestingly, the tubular endothe-
lial structure is disturbed, and the expression of a Notch ligand, Jagged1, in endo-
thelial cells is markedly reduced in the defective fourth PAAs of Hey1 knockout 
embryos (Fig. 60.1) [2], suggesting that Hey1 is necessary for the endothelial orga-












































Fig. 60.1 Defects of great 
artery morphogenesis and 
pharyngeal arch artery 
development in Hey1 
knockout mice
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tissue specificity and direct target genes, and relationship with Tbx1 pathway will 
provide further understanding of the fourth PAA development and related human 
congenital cardiovascular diseases.
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c-kit is a stem cell factor (SCF) receptor and is known to be expressed in hemato-
poietic stem cells, prostate stem cells, mast cells, and melanocytes. Since c-kit was 
reportedly expressed in cardiac stem cells, which are believed to have the ability to 
become cardiac myocytes or to support cardiac myocyte survival [1, 2], this protein 
has been used as a marker for cardiac regeneration [3].
iPS cells have been established and used for cardiac regenerative medicine and 
for developing disease models [4]. However, c-kit expression during cardiomyocyte 
differentiation using human iPS cells has not yet been studied. Therefore, we char-
acterized the gene expression levels in cultured iPS cells and the change in expres-
sion levels during cardiomyocyte differentiation by reverse transcription quantitative 
polymerase chain reaction (RT-qPCR).
c-kit expression was positive, and its level was much higher in iPS cells cultured 
with feeder cells than in iPS cells cultured without feeder cells. The RNA from 
feeder cells was extremely low, and the primer for c-kit expression did not contain 
the murine-specific sequence, suggesting that c-kit expression in the iPS cells cul-
tured with feeder cells was from the iPS cells. c-kit expression was not detected or 
was detected at extremely low levels in the feeder-free iPS cells. In both cell condi-
tions (with or without feeder), c-kit expression was detected in the early phase of 
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cardiomyocyte differentiation (1–3 days after iPS cells were treated with differen-
tiation medium) before Brachyury was expressed. Brachyury is the transcription 
factor that is essential for mesoderm formation. c-kit was not expressed thereafter. 
We examined the SCF expression level in iPS cells cultured with or without feeder 
cells, but SCF was not detected in either condition.
These results suggest that SCF is independent of c-kit expression, and c-kit 
might affect the early stage of cardiac differentiation.
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62Establishment of Induced Pluripotent Stem Cells from Immortalized B Cell 
Lines and Their Differentiation into 
Cardiomyocytes
Emiko Hayama, Yoshiyuki Furutani, Nanako Kawaguchi, 
Eiko Oomichi, Mitsuyo Shimada, Kei Inai, 
and Toshio Nakanishi
Collection of peripheral blood from many patients over a long period of time has 
resulted in the establishment of a library composed of more than 4400 immortalized 
B cell lines, which have been used to identify mutated genes responsible for con-
genital heart defects (CHD). Because of the current progress in induced pluripotent 
stem cell (iPSC) technology and the ability of these iPSC lines to differentiate into 
cardiomyocytes, we started a project to establish an in vitro cardiac disease model 
using patient specific-iPSC-derived cardiomyocytes. As part of this project, we have 
established more than 20 iPSC lines from patients with CHD and from normal con-
trols. All generated iPSC lines expressing pluripotent stem cell marker genes and 
proteins were alkaline phosphatase-positive. After reprogramming, the mutated 
genes were not altered and normal karyotypes were observed; Epstein–Barr viral 
genes were also not expressed. Most iPSC lines were confirmed to be able to dif-
ferentiate into ectoderm, mesoderm and endoderm in vivo, indicating that we had 
successfully established iPSC lines. These iPSC lines were then induced to differ-
entiate into cardiomyocytes. Most of these iPSC lines were observed to differentiate 
into beating cardiomyocytes, with some diversity in cardiomyocyte differentiation 
among the cell lines. In this study, we examined the effect of serial dilutions of 
agents on early stages of cardiomyocyte differentiation. In a floating culture system, 
varying concentrations of Activin A (0–10 ng/mL) and BMP4 (0–10 ng/mL) with 
FGF-2 (5 ng/mL) in StemPro 34 (ThermoFisher Scientific, Waltham, MA) medium 
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were used to induce mesoderm formation. The optimum concentrations of the 
agents for cardiomyocyte induction in iPSC lines were varied; 0–5 ng/mL Activin A 
and 1.25–10 ng/mL BMP4 were generally effective. We further investigated some 
additives for enhancement of embryoid body (EB) formation, and hyaluronate and 
Matrigel (BD Biosciences, San Jose, CA) addition relatively improved EB forma-
tion. Induction of functioning cardiomyocytes was associated with the ability to 
form appropriately sized EB in floating culture. Thus, further studies are required to 
improve the cell differentiation ability in some iPSC lines for establishment of sta-
ble disease models using patient-specific iPSC-derived cardiomyocytes.
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Cardiomyocytes derived from induced pluripotent stem cells (iPSC) are used to 
evaluate the function and risk factors of genetic variations linked to congenital and 
adult heart diseases in human beings. Our purpose in this study was to establish an 
in vitro cardiac disease model from an immortalized B-cell line stock using patient- 
specific iPSC-derived cardiomyocytes. Long QT syndrome (LQTS) 3 is caused by 
a gain-of-function mutation in the SCN5A gene, resulting in a prolonged QT inter-
val as well as the development of early after-depolarizations (EADs). We generated 
LQT3-iPSC lines from immortalized B-cell lines transformed from peripheral 
blood obtained from a 24-day-old male (patient #1) and an 11-year-old female 
(patient #2), both diagnosed with type-3 LQTS due to SCN5A missense mutation 
(patient #1: exon 28, G4868A, R1623Q; patient #2: exon 20, G3578A, R1193Q). 
Several control iPSC lines were also created from samples collected from healthy 
candidates (26–36-year-old male and female). In both the generated patient iPSC 
lines, mutated genes were not altered after reprogramming, and normal karyotypes 
were observed. The pluripotency of all these iPSC lines was proven by in vivo tera-
toma formation and the expression of pluripotent stem cell marker genes and pro-
teins. To evaluate the electrophysiological properties at the multicellular level, we 
studied the iPSC-derived cardiac cell layers with a microelectrode array mapping 
system (MED 64, Alpha MED Scientific Inc.). The recorded extracellular 
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electrograms were analyzed to measure the field-potential duration (FPD), which 
was normalized to account for variations in beating frequency, using Fridericia’s 
correction (FPDcF, analogous to the QTc interval in the electrocardiogram). FPDcF 
was observed to be longer in LQT3 patient-derived specimens when compared to 
that in healthy control specimens (patient #1: P  <  0.05, N  =  17 and patient #2: 
P < 0.0001, N = 19 when compared to healthy control N = 39). Moreover, EADs 
were observed in both LQT3 patient specimens after 15–30  nM of E-4031 was 
added exclusively to patient samples. The results indicated that LQT3 patient iPSC-
derived cardiac cells expressed prolonged QT duration (a common pathophysiolog-
ical feature of LQTS) and EAD development with marked arrhythmogenicity in our 
in vitro disease model system.
Further Reading
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Left ventricle noncompaction (LVNC) is a clinically heterogeneous disorder. 
Although several genetic mutations have been reported, only a little is known about 
its genotype–phenotype correlation. We report two cases of LVNC with different 
mutations and different clinical courses for each. Case 1 was a 15-year-old boy with 
atrial septum defect and pulmonary valve stenosis. He was diagnosed as LVNC 
when he was 3 years old, but his cardiac function was maintained and no medication 
was necessary. A 432 kb deletion in chromosome 8p 23.1, including GATA4, was 
found. Case 2 was a boy who was referred to our hospital at the age 6 for apparent 
right ventricle hypertrophy in electrocardiogram carried out for screening. We rec-
ognized severe pulmonary hypertension (PH) and LVNC with attenuated cardiac 
diastolic function and fair systolic function. In spite of medications for both heart 
failure and PH, the response was poor. A genetic investigation revealed a point 
mutation at exon 6 of TBX20, c.655-2A>G.
Both GATA4 and TBX20 have been reported to cause LVNC, but their clinical 
courses are not well known. Blinder et al. reported a case with GATA4 mutation [1], 
presenting a normal cardiac function. While Wang et al. reported genetic pathogenic 
variants to be independent risk factors for adverse events [2], there may be some 
relatively favorable mutations as our case1 and the report by Blinder et al. GATA4 is 
known as one of the earliest-expressed transcriptional factors in cardiac progenitor 
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cells, and the expression continues throughout life in cardiomyocytes. It concerns to 
differentiation of myocardium together with TBX5, but how and when it affects 
myocardium compaction is unknown. In case 2, the severe PH could not be explained 
only by passive etiology, and pulmonary arterial hypertension also existed. TBX20 
is related to various cardiac disorders including cardiomyopathy, intracardiac septal 
defects and abnormal valvulogenesis. Although the relation between the TBX20 
mutation and PH was not clear in our case, it is interesting that Edwin et al. reported 
a familial case of dilated cardiomyopathy (DCM) with TBX20 mutation with pri-
mary PH [3]. Provided that both DCM and LVNC fall in a spectrum of cardiomy-
opathy, association of PH might be a key to find the function of TBX20 in these 
similar cases.
In summary, we report two cases of LVNC, one with GATA4 deletion and slight 
symptoms and the other with TBX20 mutation with severe PH and diastolic dys-
function, which were resistant to treatments.
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Congenital heart disease
Over the last decade, genetic screening has become increasingly available for 
patients with congenital heart disease (CHD). Chromosomal microarray has proved 
to be promising, particularly in the diagnosis of syndromic CHDs, and is now con-
sidered first-tier cytogenetic testing [1]. Whole-exome sequencing (WES) is another 
approach for genetic screening aimed towards identifying single-gene mutations 
[2]. Trio- and pedigree-based WES facilitate the identification of de novo and com-
pound heterozygous variants throughout the entire coding region. Filtering of vari-
ants based on allele frequency, in silico predictions and segregation status, effectively 
narrows down the putative mutation. Thus, application of next-generation sequenc-
ing (NGS) has the potential of enhancing gene discovery in CHD pathogenesis.
Despite all the progress, underlying causes for the vast majority of CHDs remain 
unknown. The present study revealed ~1 de novo coding variant per trio by WES of 
a heterotaxy cohort. In a familial case of CHD, WES identified compound heterozy-
gous, loss-of-function variants cosegregating with the phenotype [3]. Now, the 
major challenge lies in interpreting so-called “private” mutations that are specific to 
each pedigree. Distinguishing a truly causal mutation from benign variants requires 
well-designed functional studies. Future investigations must focus on establishing 
vertebrate models that recapitulate human CHD pathogenesis, based on the accu-
mulating mutational data on CHD patients.
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